the method of claim 16 , wherein the lipase is substantially inactive to arachidonic acid ( aa ) .
a directly compressible tablet comprising a binder consisting essentially of at least a starch consisting essentially of a tapped density which has a tap density of less than 0.4 g / ml , and an active agent . active agent . a directly compressible tablet consisting of an active agent a binder .
lactose monohydrate magnesium stearate maize starch meglumine microcrystalline cellulose magnesium stearate maize stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate stearate magnesium stearate magnesium stearate magnesium stearate magnesium stearate stearate
tredaptive tablets contain laropiprant in one layer and nicotinic acid in the other layer .
the combination according to claim 4 , 5 or 6 , characterized in that the neuro@@ pharmaceutical agent is administrable simultaneously with the infusion of bradykinin or an analogue thereof into the carotid artery .
in patients with renal impairment or in patients undergoing haemodialysis , the pregabalin dose is reduced in patients in renal impairment ( see section 4.2 see table 1 ) . table section 1 ( see table 1 ) . in table 1 section 4.2 1 ) . 1 section 4.2 1 ) ) ) . ) ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) .
a method according to claim 7 , wherein the area of the packaging film surrounding the front end region of the packaging article is compressed so that a second substantially planar film area area is formed in the region around the packaging article .
composition according to claim 1 or 2 , characterized in that the active ingredient is quinine or a suitable salt or derivative thereof .
electrode unit according to claim 22 , characterised in that the polymer that forms the polymer binder of the composite electrode of the composite the composite polymer the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
poly@@ alkoxylated tocopherol derivatives of the general formula ( i ) which can be prepared by stepwise base-@@ catalyzed alkoxy@@ lation of vitamin e and exhibit an excellent emulsifying capacity .
process for the preparation of a light screening agent , characterized in that , in a base , , the p-@@ methoxy cinnamic acid ester is characterized in that , in a conventional base , the p-@@ methoxy cinnamic acid ester is characterized in that r is the alcohol residue of d , l-@@ α-tocopherol , pan@@ tol@@ ac@@ tone , , or panthenol , , in the form of , , , , , , , panthenol , in , , , , , , , , , , , , , , , , , , , ,
in one of the study , patients received other medicines .
multiple energy device for x-ray imaging applications
use of phospholipids marine and / or synthetic origin containing a proportion of at least 30 percent ( w / w ) omega-3 fatty acids for the preparation of a nutrient emulsion for parenteral administration , wherein a high content of omega-3 fatty acids having omega-3 fatty acids is achieved a lower triglyceride and cholesterol content of the blood .
patients should receive a dose a dose should receive a dose a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
the element of claim 1 , wherein the film film has two layers and a total thickness of 0.1 mm to 1 mm .
- if you have a history of diabetic ketoacidosis ( a complication of diabetes a complication of a complication of a complication of a complication of a complication of a complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of complication of
predictive and therapeutic for kidney diseases and proteins
arrangement according to one of claims 1 to 12 , characterised in that a detector array ( 19 ) is downstream of the beam output coupler ( 9 ) .
use according to any one of claims 1 to 3 , of one of claims 1 to 3 , in which , in , in , , in , in , , in , in , , in , , in , , in , , in , , in , , in , , in , , in , , in , , in , , in , , in , , in , , in , , in , , in , , in , , in , , in , , in , , in , ,
the assembly of claim 5 , wherein the concave surface is adapted to rotate a surgical instrument attached thereto .
use according to claim 5 , characterized in that the medicament preparation comprises a mixture of the ifn-@@ beta and il-2 . use according to claim 5 , characterized in , that the pharmaceutical preparation comprises the ifn-@@ beta and il-2 and il-2 .
breast-feeding must be discontinued during treatment with sti@@ var@@ ga with a treatment with sti@@ var@@ ga . • breast-feeding must be discontinued during treatment with sti@@ var@@ ga with no treatment with sti@@ var@@ ga . • breast-feeding must be discontinued with sti@@ var@@ ga . sti@@ var@@ ga var@@ ga var@@ ga .
a composition comprising a compound according to claim 1 or claim 2 a compound a compound according to claim 1 to claim 2 to a compound a compound according to claim 1 to claim to a compound to a compound according to claim to a compound according to claim to to a compound according to to claim to a compound according to to according to to to compound to according to to to compound according to to according to to to compound according to to according to to to according to to to according to to to according to to
composition according to claim 1 or 2 , characterized in that the reduced calorie content triglycerides contain at least 80 % c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c ₃ c
see section 5.1 pharmacological properties , non-small cell lung cancer .
a polypeptide having the sequence selected from the group consisting of a hematopoietic stem cell proliferation stimulating amount of in@@ pro@@ l in the manufacture of a medicament for treating or joining the fatigue of hematopoietic stem cells , wherein in@@ pro@@ l is selected from the group consisting of the peptide having the sequence : phe-@@ pro-@@ his-@@ phe-@@ asp-@@ leu-@@ ser-@@ his-@@ gly-@@ ser-@@ ala . the method of claim 9 or 11 wherein the hematopoietic stem cells are selected from the group consisting of bone marrow cells , peripheral blood cells , mobili@@ zed peripheral blood cells
angular attachment according to one of claims 1 to 4 , characterised in that the x-ray permeable material consists of reinforced polyoxy@@ methylene ( po@@ m ) .
there are no data on the safety and efficacy of oseltamivir of oseltamivir in patients of and of in case of hospitalisation and in patients in need of unstable in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in patients in
the set of claim 1 , wherein the distal end ( 3a ) of the container has a groove ( 10 ) formed around a needle outlet ( 11 ) of the container for receiving the tip of the slan@@ ted needle .
if you have or have ever had or have ever had have have ever had have ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had ever had
summary of the emea work programme 2006 emea work programme 2006 emea / 6@@ emea / 2006
prevention of dental loss by administration of alendronate or salts thereof
a system for displaying an image stream , the system comprising : an image storage means ( 21 ) for receiving an original image current ; and an image display means ( 300 ) for displaying at least two partial slope image currents , each subset image stream being adapted to be displayed simultaneously on the image display means ( 300 ) simultaneously on the image display means ( 300 ) .
device for resistant to limb movements .
caution should be exercised when prescribing mycophenolate mofetil teva to reduce the potential to reduce the effectiveness of mycophenolate mofetil to reduce the potential to reduce the efficacy of mycophenolate mofetil to reduce the efficacy of mycophenolate mofetil to reduce the efficacy of mycophenolate mofetil . caution should be exercised when administering mycophenolate mofetil teva to reduce the potential to reduce mycophenolate mofetil mofetil . . to reduce the risk of mycophenolate mofetil mofetil . . . . . . . . . . . . . . . . . . . . . . . . .
the composition of claim 1 wherein the surfactant is poly@@ oxyl 35 castor oil ( c@@ remo@@ phor el ® ) .
a device according to claim 13 , wherein the container is in a form allowing the biological particles to be difficult to force .
a compound of formula i as claimed in claim 1 wherein q 2 is a monovalent or divalent residue selected from hydroxy , acetoxy , c 1-3 alkoxy and oxo ; or the n-oxide of a piperidine nitrogen designated or the n-oxide of * or the n-oxide of of the or the n-oxide of the formula or the the n-oxide of the n-oxide or the n-oxide of the n-oxide or the n-oxide of the n-oxide of the of the of the of the of the of the of the of the of the of the of the of the of
mechanism of action moxifloxacin has in vitro activity against a broad range of gram-positive and gram-negative pathogens .
some patients may develop osteonecrosis of the bone ( bone breakdown due to lack of blood supply to the bone ) during treatment with combination antiretroviral therapy .
process according to claim 1 , characterized in that the culture liquid in which the animal cells are suspended is a serum-free culture medium .
use according to claim 7 , wherein said gp@@ i molecule is a plasmodium falciparum gp@@ i inositol@@ glycan domain .
a method as claimed in claim 1 , in which the method further comprises the steps of : a ) utilizing the logarith@@ m of a signal representative of the at least one wavelength of electromagnetic energy , of which a first signal is representative of a signal of the first signal , thereby , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , a third signal , , , , , , , , , ,
the artificially produced three-dimensional mammalian muscle tissue according to claim 1 or 2 , characterized in that the pre-@@ strain is carried out over a period of from 1 to 7 days .
an intervertebral implant having a wedge ( 2 ) , in which two hollow pipes ( 6 a , 6 b ) are arranged opposite each other , which can receive two hollow projections ( 26 a , 26 b ) which can receive two vertebrae ( 26 a , 26 b ) which can receive two vertebrae ( 26 a , 26 b ) which can receive two vertebrae ( 26 a , 26 b ) which can receive two vertebrae ( 26 a , 26 b ) which can receive two vertebrae ( 26 a , 26 b
composition according to any one of the preceding claims , characterized in that the hydrocarbon oil has a chemical structure comprising at least one nonionic radical chosen from -cooh ; -oh ; 4 ; 4 ; nhr ; nr 1 r 2 ; wherein r 1 and r 2 , which may optionally represent a ring , or r 1 &apos; and r 2 &apos; , or where r 1 &apos; and r 2 &apos; are h or a straight or branched alkyl or alkoxy group having 1 to 20 carbon atoms .
use according to claim 4 wherein the pharmaceutical composition prepared is useful in the composition in the treatment of insulin dependent diabetes mellitus .
a po@@ d@@ logical device according to claim 5 , characterised in that the structure ( 1 ) is a running shoe which comprises the sole ( 1 ₁ ) .
i &apos;ve never seen an adult in an adult .
device according to one of the preceding claims , characterized in that the scanning function is carried out in a model of soft or spreading material , for example gy@@ ps , and in that the tool device is made entirely or partially of ce@@ mented carbide or ceramic materials or a tool unit for the complete or partial production of bodies ( tool devices ) of hard , soft or lining material .
device and method and device for isolating cells , bio@@ particles and and and , for , , , for , , for , bio@@ bio@@ , bio@@ , and , for , , , , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ , bio@@ ,
triazolam is contraindicated when co-administered with invirase / ritonavir due to the risk of prolonged or enhanced sedation and respiratory depression ( see section 4.3 ) .
6.6 special precautions for disposal special precautions for disposal special precautions for disposal of unused medicinal products for precautions for disposal special precautions for disposal of unused medicinal products for disposal for precautions for disposal special precautions for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal
the apparatus of any preceding claim further comprising means for applying electrical current over the body surface .
an infrared clinical thermometer according to claim 1 , wherein the temperature condition estimation means ( 6 ) is a function of the estimation of temperature conditions of the body of the febrile thermometer and / or the environment in which the clinical thermometer is on the basis of a change pattern of the temperature measured to the at least two temperature measurement means ( 2 , 3 ) ( 2 , 3 ) .
the highest dose ( for mice ( for mice ( for mice ( for mice ( for mice for mice for mice for mice for mice for mice for mice for mice for mice for mice for for for for for for for for for for for for for for for for for for for for for mice for for mice for for mice for for mice for mice for for for mice for mice for mice for for mice for mice for mice for mice for for mice for mice for mice for mice for mice for mice for
a coating composition comprising a bioactive agent in combination with multiple polymers including a first polymer component comprising at least one aromatic poly ( meth ) acrylate polymer and a second polymer component comprising a poly ( ethylene@@ -co-@@ vinyl acetate ) .
a polynucleotide according to claim 9 which is a dna or rna . dna according to claim 9 which is dna or rna or rna , or rna or rna or rna . rna or rna . rna or dna . dna according to claim . . . . or dna or rna . dna or dna . rna or rna . or dna or dna . . . . . . . . . rna or rna . dna or rna . . rna or rna . . rna or rna . . rna or rna . .
apparatus according to any one of the preceding claims , characterized in that the radiation delivery means further comprises at least one central catheter bore ( 8 ) which is adapted to remain outside the cavity ( 10 ) and a distal end ( 8a ) extending in the longitudinal direction within the longitudinal body of the support probe ( 2 ) .
these symptoms have been reported more frequently when using interferon alpha with sho@@ sa@@ i@@ ko@@ to , a chinese herbal herbal medicine ( see section 4.4 ) . section ( see section 4.4 ) section 4.4 ( section 4.4 ) section 4.4 ) section 4.4 ) section 4.4 ) section 4.4 ) section 4.4 ) section 4.4 ) )
an electronic endoscope according to claim 1 , characterised in that the shaft ( 1 ) of the endoscope has different tubes ( 12 , 17 and 21 &apos; ) which are displaceable in each other and each of the tubes ( 12 , 17 and 21 &apos; ) which are displaceable with each other , the tube ( 17 &apos; ) having a larger diameter with the distal end ( 27 ) and the tube ( 12 &apos; ) in which the ccd tube ( 21 &apos; ) is held in a longitudinal manner and the tube ( 12
a compound represented by the formula ( i ) : wherein r ¹ is hydrogen or methyl ; r ² and r ³ , which may be the same or different , each is a hydrogen atom or a c ₁ -c ₆ alkyl group , and r ⁴ is a carboxyl group , a c ₁ ₋ ₆ alkyl group , and r ⁴ is a carboxyl group , a morpholino group , a thiomorpholino group , a piperazinyl group , and a 4-c ₁ ₋ ₆ alkyl-@@ 1-@@ piperazinyl group , or a pharmaceutically acceptable salt or ester
your doctor will decide the need for physical examination .
a process for preparing a stable amorphous dispersion in solid state of mi@@ so@@ prost@@ ol and an excipient selected from ( a ) an excipient in the amorphous state selected from the group consisting of hydroxypropylcellulose , cellulose acetate , carboxymethyl cellulose , cellulose acetate phthalate , cellulose acetate butyrate , hydroxyethyl cellulose , polyacrylic acid polymers and maltodextrin ; or ( b ) an amorphous or semi@@ -crystalline excipient selected from the group consisting of monosaccharides , disaccharides and tri@@ saccharides , comprising spray drying .
respiratory , thoracic and mediastinal disorders
in the absence of compatibility studies , the medicinal product of this medicinal product must not be mixed with other medicinal products with other medicinal products of medicinal products . medicinal products of medicinal products of medicinal products of medicinal products . medicinal product of medicinal products of medicinal products .
polypeptide having increased cy@@ statin c activity , characterized in that it consists of recombinant 3-@@ de@@ hydroxy@@ cy@@ statin c or a modification thereof , wherein one or more amino acids in positions 5-@@ 17 and / or 55-@@ 59 , 83 and 97 have been replaced by other amino acids and / or at the one or more sequences at positions 8-@@ 14 and / or 6@@ 1-@@ 120 .
five percent ( 3 / 56 ) of patients with y@@ md@@ d mutant had worsening liver inflammation compared with pre-treatment values and 13 % ( 11 / 82 ) .
a composition according to claim 1 , wherein the hydrophilic polymer is an alkyl group represented by the following formula : wherein r ² is an alkyl group having a carbon number of 8 to 20 or a cycloalkyl group having a carbon number of 5 to 7 ; and a structural moiety as defined by the following formula : the composition of claim 1 , wherein the amphoteric polymer is admixed in an amount of 0.001 to 10 % by weight of the composition .
each arcuate support element ( 2 ) has in its middle part a central section ( 5 ) which has a central portion ( 5 ) whose loop branches ( 4 ) simpli@@ fies in the plane of the arcuate support element ( 2 ) .
blister of 14 tablets of 15 mg of 15 mg tablets of 14 tablets of 14 tablets of 14 tablets of 14 tablets of 14 tablets of 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets 14 tablets
a compound of claim 16 wherein r 3 is 2-thienyl , 2-pyridyl , 1-methyl-2-@@ imidazolyl , 2-furyl , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
 lopinavir , indinavir , nelfinavir , ritonavir , telaprevir and saquinavir for the treatment of
the increased prevalence of porphy@@ ria cu@@ san@@ rea tar@@ da in hiv infection , the interaction of hiv and uv radiation is discussed as a pre@@ disposition for porphy@@ ria cu@@ ran@@ rea tar@@ da and the photosensitivity for hiv infection .
other sources of information detailed information on this information is available on the on on the website of the european information on the on on the european medicines european medicines european medicines european medicines european european european european european european european european european european medicines european european european medicines european european european european european european european european european european european european european european medicines european european european european european european european european european european european european european european european medicines european european european european european european european european european european european european european european european european european european european medicines
if the other medicinal product ( s ) must be permanently discontinued , capecitabine treatment may be resumed if the treatment is met , and capecitabine should be resumed if the medicinal product has to be discontinued ( the ) , the treatment should be discontinued if the medicinal product has to be discontinued , and , if appropriate , capecitabine should be discontinued , if the requirements are met , when the treatment are discontinued . , when the treatment , capecitabine , be discontinued , the treatment should be discontinued , if the treatment be discontinued .
a method as claimed in claim 1 , characterised in that the extrudate is a thin film .
also disclosed is a control device for controlling the pressure and the amount of water and the position of the nozzle ( 5 ) .
absorbent article according to claim 19 , characterized in that the transfer layer ( 14 ) is centered substantially along the absorbent layer ( 12 ) to form absorbent sheet extensions ( 50 ) , where the absorbent layer ( 12 ) extends over the transfer layer ( 14 ) .
the tablet of claim 7 having a porosity of 50 to 90 % .
a device according to claim 33 , wherein means for repeating the functional sequence of the means ( a ) to ( e ) are provided at least once .
3 . a method according to claim 1 , characterized in that four layers are applied to the model of the prepared tooth , the first layer being a metal layer of a dental alloy , the second layer being an opaque porcelain layer , the third layer being a dental porcelain layer and the fourth layer is a cutting mass layer .
fertavid should not be administered during breast-feeding .
use according to claim 9 for the manufacture of a medicament which can be administered intravenously , intra@@ peritone@@ ally or intra@@ arteri@@ ally .
the use as claimed in claim 19 , characterized in that said selec@@ tion-@@ nucleotide sequence comprises in the range that the nucleotide sequence the the selec@@ tion-@@ nucleotide sequence the the nucleotide sequence that the the nucleotide sequence that the nucleotide sequence that the nucleotide sequence the nucleotide sequence the the nucleotide sequence sequence sequence sequence the nucleotide sequence sequence sequence sequence sequence sequence sequence nucleotide sequence sequence sequence sequence nucleotide sequence sequence sequence nucleotide sequence sequence sequence nucleotide sequence sequence sequence nucleotide sequence sequence nucleotide sequence sequence sequence nucleotide sequence sequence nucleotide sequence sequence sequence nucleotide sequence sequence
ratiopharm gmbh , gra@@ f-@@ gmbh strasse 3 , d-@@ 890@@ 79 , ul@@ m , germany , , , , , , , , , , , , , , , , , , , , , , , , , ,
the apparatus of claim 22 , wherein the light emitter ( 10 ) is further defined as to emit light with a wavelength of substantially 800 nm .
a combination ( 10 , 10a , 10b ) according to claim 4 , characterized in that the generally cylindrical body ( 14 , 14a , 14b ) is flared radially outwardly adjacent the device ( 20 , 20a , 20b ) for mounting the body ( 14 , 14a , 14b ) on a support ( 22 , 22a ) .
always use liprolog mix50 kwikpen exactly as your doctor as your doctor has told you has .
it is also granted by the marketing authorisation .
system according to claim 27 , characterized in that the evaluation and control unit defines the position of a particular point in the endoscope image and selects this point as reference point for the guide system .
a stabilized dry composition comprising a monoclonal antibody , a carbohydrate as a stabilizer and an inhibitor of the ma@@ ill@@ ard reaction .
a penile prosthesis ( 10 ) for implanting in a patient , wherein the penile prosthesis ( 10 ) has a first part ( 12 , 14 , 18 ) , a second part ( 12 , 14 , 18 ) , and a guide member ( 22 ) , which is connected to the first part ( 12 , 14 , 18 ) and the second part ( 12 , 14 , 18 ) and the second part ( 12 , 14 , 18 ) and the second part ( 12 , 14 , 18 ) and the second
a thro@@ mbe@@ ctomy device for dissolving a thrombus or other closure material in a lumen of a vascular graft or vessel , comprising a flexible sheath ( 20 ) and a wire ( 30 , 30 &apos; ) disposed in the flexible sheath , and a wire ( 30 , 30 &apos; ) disposed in the flexible sheath , and a wire ( 30 , 30 &apos; ) disposed in the flexible sheath , and a wire ( 30 , 30 &apos; ) disposed in the flexible sheath , the wire ( 30 , 30 &apos; ) having a
a device according to any one of the preceding claims , characterised in that a substance which is in contact with gastric juice is at least partially in a multiparticulate , fast-@@ releasing preparation .
additional monitoring tests , including blood tests , may be necessary if you take your medicines .
a pharmaceutical composition , comprising an effective amount of at least one compound or physiologically acceptable salt thereof of any one of one of one of claims 1 to 6 and a physiologically acceptable carrier of at least one compound of one one of claims 1 to 6 .
the composition of claim 1 , wherein a portion of the starch molecules substituted with acetate and dicarboxylate residues may be replaced by native or modified starch .
pro@@ qu@@ ad contains live viruses , but they are too weak to induce measles , mumps , rubella or varicella ( chick@@ en@@ pox ) disease in healthy subjects .
it explains how the agency assessed the medicine to recommend its authorisation in the eu and its its conditions of the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
general disorders and administration site conditions administration site conditions and administration site conditions administration site conditions site and administration site conditions site administration site site administration site site administration site site administration site site administration site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site site
a combination of ( a ) a compound of formula ( ia ) or ( ib ) as defined in any one of claims 1 to 29 and ( b ) one or more other anti@@ mycobacterial agents for use as a medicament .
the heart valve prosthesis according to claim 4 , characterized in that an outer surface ( 37 ) of the cage ( 9 ) is slightly concave and connects an angle γ between a straight line which connects the extreme points of the generic atri@@ x of the concave surface ( 37 ) with the dia@@ metrical plane and the central line ( 31 ) of the g@@ cage ( 9 ) with the dia@@ metrical plane and the central line ( 31 ) of the cage ( 9 ) with the dia@@ metrical plane and the central line (
dental material according to claim 5 , characterized in that in the crystalline oxide the crystalline oxide is the the the the the the the the the the the crystalline oxide the crystalline oxide the crystalline oxide the crystalline oxide the crystalline oxide crystalline crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide crystalline oxide
to prevent vomiting , ce@@ ren@@ ia solution for injection should be given at least one hour in advance .
infrared radiator according to one of claims 1 to 15 , characterized in that the heating coil ( 4 ) is made of a carbon fibre material , graphite or graphite paper .
a compound having the formula ( i ) : or a pharmaceutically acceptable salt thereof ; which may be substituted with halogen , c -c alkyl , r and r are independently hydrogen or c -c alkyl ; or r and r are independently substituted with the nitrogen to which they are bonded to the nitrogen atom , or c -c alkyl , or r and r are optionally substituted with the nitrogen , c -c alkyl , c -c alkoxy , mono- or di- ( c -c ) alkyl ; r is c -c alkyl or c -c alkoxy
the method of any of claims 1 to 10 , wherein the formulation of step ( a ) is a liposome formulation . a process according to any one of claims 1 to 10 of claims 1 to 10 of claims 1 to 10 of claims 1 to 10 of claims 1 to 1 .
the locking mechanism of claim 7 , wherein the inner surface ( 34 ) is relatively flat , and the outer surface ( 40 ) is curved outwardly or substantially outwardly , relative to the inner surface , relative to the inner surface , the connecting portion ( 14 ) having a bore into which at least a portion of the holding portion ( 12 ) can be inserted .
the protein claimed in claim 4 which is at least 90 % pure by weight .
pp@@ i , h2-@@ receptor antagonists and antacids ) concomitantly with cabozantinib .
a compound according to claim 1 wherein z is a compound according to claim 2 wherein r 12 is - ( ch 2 ) a cor 15 .
the invention relates to a method for a method for a a method for a method to a a a a a a a a a a a a a a a a a a a a a a a method to a method to a a a method to a a a a a a a a a a a a a a a a a a a a a a method to a a a to a a a a a a a a a a a a a a a a a a a a a a
do not use siklos after the expiry date which is stated on the carton and blister .
a diaper ( 10 ) according to claim 1 , wherein the base structure ( 20 ) has front and rear edges ( 15 , 17 ) defined by respective front and rear attachment lines ( 21 , 22 ) .
anti-@@ hepatitis c virus antibodies and use thereof
 the mah requested 2009 for the introduction of the new applicator for implan@@ on ( implan@@ on n@@ x@@ on )
a process for the preparation of a composition comprising mixing the compound of any one of claims 1 to 42 and a pharmaceutically acceptable carrier of the compound of any of claims of any of claims 1 to 1 of claims 1 to 1 .
a polymer according to claim 6 , wherein the polymer is in the form of spherical beads . the polymer of claim 6 wherein said polymer is wherein said polymer is in said form wherein said polymer is in said form wherein said polymer is in said form wherein said polymer is in said form wherein said polymer is in said form wherein said polymer is in said form is spherical beads . polymer is in said polymer .
use according to any one of claims 1 to 6 , wherein the composition is in the form of an orally consumable food product or food supplement .
eye disorders : cysto@@ id macular oedema , toxic dermatitis .
a method of identifying a patient with breast cancer or breast pre@@ cancer , the method comprising : testing a duc@@ tus fluid sample extracted from a duc@@ tus of a patient &apos;s chest , wherein the liquid is not treated with duc@@ tus of a breast of a patient , wherein the liquid is not infected with duc@@ tus of a patient , wherein the liquid is not treated with duc@@ tus of a breast of a patient , wherein the liquid is not mixed with duc@@ tus of a breast of a patient , the liquid being not
device according to at least one of claims 1 to 12 , characterized in that a supply device ( 17 ) is provided for supplying a nutrient solution , in particular molasses .
consideration should be given to official guidance on the incorporation of medicated pre@@ mixes to the feed in the feed of the veterinary medicinal product in the feed should be given to be given to be given to be given to be
the dna sequence of claim 7 , wherein the dna sequence has a deletion of 4@@ 84 nucleotides in the 3 &apos; non-@@ coding region of the ifn-γ gene and the deletion begins at the r@@ sa i endonuclease recognition site and continues towards the coding region of the ifn-γ gene .
a pharmacologically active compound of formula ( i ) of claim 3 wherein a is p@@ glu-@@ his-@@ trp-@@ ser-@@ his-@@ asp-@@ trp-@@ pro-@@ gly-nh 2 , ac@@ -d-@@ trp 1,3 , p-chloro@@ phenyl-@@ d-alanine 2 ( d-@@ c@@ pa 2 ) , d-@@ lys 6 , d-ala 10 -@@ gnrh , d-@@ lys 6 -@@ gnrh lys 5 , d-trp 6 -@@ gnrh , and k , r , u , z , x , y , v and w are as defined in claim 1 , and the salts and complexes of these compounds .
a stent graft ( 12 ) for implanting a proximal insertion site from a distal location in an aorta for an aor@@ ta@@ ta tunnel treatment of an aortic aortic aneurysm ( 11 ) , wherein the stent graft ( 12 ) comprises a stent ( 14 ) having a stent ( 14 ) , the stent graft ( 12 ) , the stent graft ( 12 ) having a stent ( 14 ) having a stent ( 14 ) , the stent graft ( 12 ) , the stent graft ( 12 ) having a stent ( 14 )
a dna strand according to claim 1 wherein the nucleotide sequence encoding the polypeptide is one corresponding to the portion of a to b of the nucleotide sequence shown in figure 1 or its degenerative isomer .
process for the recombinant production of staphylo@@ kinase polypeptides with plasminogen activator activity as a target polypeptide , characterized in that host cells according to claims 8 to 11 are cultured in a suitable medium and the target polypeptides isolated from the host cells .
apparatus and method for repetitive micro@@ jet drug delivery
products and pharmaceutical formulations and pharmaceutical formulations according to one or more of claims 1 to 7 , and containing as active ingredient , a camptothecin and as plasma protein fraction ( b ) , human serum albumin , and ( , ) , , ( 1 ) , , ( 1 ) , and ( ( ( ( ( b ) ) ) ( 1 ) , ( ( 1 ) , ( 1 ) , 1 , ( ( ( b ) ) , ( 1 ) , 1 ( 1 ) a ( 1 ) , (
the occlusive dressing of any one of claims 1 to 8 , wherein a strip of release paper ( 72 ) is attached to a corner of the second adhesive layer ( 31 ) and a single sheet separation paper ( 74 ) , and the second adhesive layer ( 31 ) , including the corner strip , is provided , such that a strip which can be gripped by the user , while the individual sheet separation paper is removed and the dressing is attached to the body .
other medicines and osseor tell your doctor or pharmacist if you are taking or have recently taken or might take or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or or
section 5.2 - pharmacokinetic properties - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
the possibility that ne@@ b@@ n may be associated with efavirenz may be more frequent or more severe but cannot be excluded .
the maximum aptt should not exceed twice the baseline should not exceed the exceed twice the twice the twice the twice the twice the twice the twice the twice the twice the twice
the invention relates to a hygienic pulp product , for example a diaper , a nurse or a sanitary napkin , wherein at least one layer of the product is impregnated with partially neutralized citric acid of the composition wherein me represents a sodium , potassium or ammonium ion .
&#91; the text below should be inserted below the text below &#93; the following text &#93; text below below below &#93; text below below below below below below below &#91; the text below should be inserted below below below below below below below below below below below below below below below below below below below below below below below below below below below below below should be inserted below the text below below below below below below below below the text should be inserted below the text below below below below below below below below below below below below
method according to any one of the one of the preceding claims , the one of the preceding claims , the the the preceding , the the the the the the the preceding , the the the the the the the the the the the preceding the the preceding the the the the the preceding the preceding the the the the the the the preceding the the preceding the the preceding the the preceding the the the the the the the preceding preceding the the the the preceding the the preceding the the preceding preceding the the the the the
a process according to any one of the preceding claims , wherein the α-amylase is immobilized .
a kit for detecting a target polynucleotide sequence , wherein said kit comprises a target polynucleotide sequence , a target sequence , a target sequence , a sequence , a sequence , a sequence , a sequence , a sequence , a sequence , a sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence , sequence
an apparatus according to any one of the preceding claims , comprising as part of the first , second , third , and fourth fastening means ( 74 ) mounted on the first housing portion ( 42 ) and a first arm ( 78 ) , which is movable between a locked position , and a first arm ( 78 ) , which is movable between the locked position , and a non-@@ locked position in which it is preferably against the knob ( 58 ) , so that the rotation to remove the device ( 40 ) from the
 withdraw the required amount of soliris from the vial ( the the vial ( s ) of the vial vial ( the vial ( s ) ( the vial vial ) vial ( ( s ) ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (
a gene fusion peptide or protein comprising an epitope of an outer class i outer-@@ membrane protein fused to a carrier protein , peptide or epitope thereof , provided that the carrier protein is not β-galactosidase .
the combination as recited in claim 1 , 2 or 3 , characterized in that each extension ( 23 ) further comprises a stop tab ( 30 ) integral with said grasping portion and protrudes from said handle so that said plug ( 15 ) of said tube being retained thereto is prevented from said gripping portions ( 28 ) .
process according to claim 14 , characterized in that in stage d ) the solubilized dihydropyridine derivative is converted to the aqueous gelatin sol prior to association with the aqueous gelatin sol and the dispersion thus obtained is combined with the aqueous gelatin sol .
transgenic plant with modified physiology , morphology and hormone metabolism of tissue cultures of this plant and process for their preparation .
an apparatus according to claim 2 , wherein the controlled illumination source ( 100 ) generates a pulsed , nitrogen-containing dye laser , which is operable to produce pulses of a first wavelength at a power level that generates pulses of a first wavelength having a power level that generates the first partial group of fluorescence intensity spectra in normal and abnormal tissues with a power level that is driven by an intensified diode array ( 116 ) which is controlled by a multi@@ channel analyser ( 117 ) each synchroni@@ sed to the controllable illumination source ( 100 )
the use of claim 22 , wherein the bacterium is an anaero@@ bes .
in this case the static cyto@@ metry ( microscopic cyto@@ metry ) is inferior to the lower magnitude of flow cyto@@ metry .
day 8 – 17 as soon as the user re@@ members , she should take the last missed tablet the last missed tablet the last missed the last the the the the the last the the the the last the the the the last the the the the last the the the the last the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
a composition for use in the treatment , prevention or control of endo- and / or ecto@@ parasitic infections in warm-blooded animals , the composition characterised by a prophylactically , therapeutically , or therapeutically effective amount of the compound represented in claim 1 , and the pharmaceutically and pharmacologically acceptable salts thereof in an inert solid or liquid carrier therefor .
the apparatus of claim 16 , wherein the handpiece has a spectr@@ ally selective mirror for powering the laser beam .
a non-@@ alcoholic , antibacterial mouthwash consisting essentially of : ( a ) from 0.05 % to 0.2 % by weight sodium benzoate ; ( b ) from 0.01 % to 1.0 % by weight of a weak carboxylic acid selected from the group consisting of :
a process according to any one of claims 1 to 3 wherein the solvent of alkyl cellulose is admixed with the low alkanol optionally water .
benign , malignant and un@@ specified and un@@ specified and un@@ specified and un@@ specified and un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@ un@@
store in the original package in order to protect in order to protect in order to protect in order to protect in order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to
the ribozyme according to claim 4 , wherein the 2 &apos; -hydroxy@@ modification is a 2 &apos; -deoxy@@ - , a 2 &apos; -o-@@ methyl , a 2 &apos; -@@ fluoro and / or a 2 &apos; -amino group .
si@@ mu@@ lect 10 mg powder and solvent for solution for injection for solution for for injection
exforge 10 mg / 160 mg film-coated tablets amlodipine / mg mg / mg / mg / mg / mg / mg / mg / mg / mg / mg / mg / mg / mg / mg / mg / mg / mg / mg / mg / mg / mg / mg / mg
a compound according to any one of claims 1 to 10 wherein z is s. a compound according to any one of claims 1 to 14 wherein r5 is ( c 2 -c 4 ) alkyl .
the medical device ( 8 ) of claim 4 , wherein the adjacent ends of the first ( 18 ) and second ( 20 ) portions of spring are attached to one another by an epoxy and on the core ( 10 ) .
a method of enhancing the liver and / or the spleen of a human or non-human animal , comprising the intravascular administration of a medium according to claim 4 before imaging to the animal .
the first study compared the combination of emtricitabine and tenofovir disoproxil with the combination of lamivudine and zidovudine ( other antiviral medicines ) .
mechanical locking system for connection of an active implantable medical device , in particular for a heart stimulator , defibrillator and / or cardioverter and / or cardioverter / defibrillator and / or cardioverter / defibrillator / defibrillator / and / or cardioverter / cardioverter / cardioverter / cardioverter / cardioverter / cardioverter / and / or cardioverter / cardioverter / cardioverter / cardioverter / cardioverter / / defibrillator / cardioverter / cardioverter / / or / and / or cardioverter / cardioverter / cardioverter / or / defibrillator / / and / or cardioverter / cardioverter / cardioverter
it is recommended that the vaccine is recommended that the recommended recommended recommended recommended recommended recommended recommended schedule .
antimicrobial composition according to any one of the preceding claims , characterized in that it acts by neutralising or inhibiting the microbial effect of the microbes , including toxins and / or by preventing the proliferation / propagation of the microbes .
the compound of claim 1 wherein r 2 is a group of the formula - ( ch 2 ) n -ar wherein ar is a phenyl and n is 2 , or a group of the formula wherein one or two of r 3 , r 4 , r 5 and r 6 are oh and the remaining hydrogen atoms are r 7 and r 8 are hydrogen atoms .
the method of claim 1 , wherein the non-@@ bacteriophage sequence is a viral sequence . the method of claim 1 wherein the non-@@ bacteriophage sequence is a viral sequence . the method of claim 1 wherein the non-@@ bacteriophage sequence is of the viral sequence .
the process of claim 7 , wherein the polyol is selected from the group consisting of sorbitol , pentaerythritol , neopentyl glycol , propylene glycol , dipropylene glycol , , isoprene glycol .
invega must be taken and swallowed whole with water or with any other water . − the other ingredients are : with water and water for injections or with a water or water with or water or with water with water or drink . • invega must be taken whole with water or with any other water with or swallowed whole water . or with other water with water with or with water with or with other water with water with water with water with water with water with water or with water with water with water .
in the treatment of nsclc and of the first-line treatment of ovarian cancer of the ovarian cancer of the ovarian cancer of the ovarian cancer of the ovarian cancer of the ovarian cancer of the ovarian cancer of the ovarian cancer of the ovarian cancer of the ovarian cancer of the ovarian cancer of the ovarian cancer of the ovarian cancer of the treatment of ovarian cancer of ovarian cancer of ovarian cancer of ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer ovarian cancer
the method of any one of the preceding claims comprising the steps of : ( a ) operating the x-ray source ( 13 ) to emit x-rays from a first focal point ; ( b ) recovering a projection from a first focal point ; ( b ) recovering a projection while the source ( 13 ) is emitted from the first focal point ; ( b ) recovering a projection while the source ( 13 ) is emitted from the first focal point ; ( b ) recovering a projection from the first focal point ; ( b )
zu@@ tec@@ tra is intended for subcutaneous injection , so for injection under the skin .
the european medicines agency ( ema ) agency will review any new information on the european medicines agency and will review the information on the agency ( ema ) ( ema ) ( ema ) ( ema ) ema ( ema ) ema ( ema ) ema ( ema
a compound according to claim 2 wherein r is hydrogen . compound according to claim 2 wherein r is hydrogen . compound according to claim 2 wherein r is hydrogen . compound according to claim 2 wherein r is hydrogen . compound according to claim 2 to r is hydrogen . compound is hydrogen . hydrogen . hydrogen . hydrogen . hydrogen .
close supervision of patients , patients of high risk of patients , patients of high risk of patients , patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients of patients
process according to one of claims 1 , 2 or 3 , characterized in that inhalation powder contains less than 5 % , preferably less than 2 % of active principle .
an adapter according to claim 9 , characterized in that the closure body is a rotatably mounted cylindrical body ( 26 ) closed at one end , open at the other end and is provided with a transverse bore ( 27 ) , the means ( 8 ) for securing the transfer tube to the open end of the closure body .
in a liver transplant , the starting dose is 0.10 to 0.20 mg / kg .
bronchial asthma , history of bronchial asthma or severe chronic obstructive pulmonary disease .
an article according to claim 2 in tube or tube form .
medicinal products containing mi@@ an@@ ser@@ ine a member of the european union
a measuring instrument for determining the value of electrical resistance of the human body to the reflex points with a measuring head ( 6 ) , a circuit and a computer ( 4 ) , characterized in that the circuit is provided with a measuring head ( v ) , a circuit and a computer ( 4 ) , characterized in that the circuit ( s w@@ no -s w@@ nn ) , which is connected to the positive pole and the other , in the circuit , that the battery of the analog switches ( s w@@ c1 -s
cellulosic product with high compression back@@ ling
the method of claim 1 , wherein said sli@@ me-@@ inhibiting compound is distributed on said device by a method comprising : introducing said medical device prior to insertion or prior to implantation into a solution having a concentration of the sli@@ me-@@ inhibiting compound of between about 1 mm and about 1 ; the drawing of said medical device from said solution ; drying said medical device ; and inserting or implanting said medical device into a mammal .
method and route ( s ) of administration ( s ) ( s ) ( s ) ( s ) ( s ) ( s ) s ( s ) s ( s ) s ( s ) s s ( s )
use according to one of claims 1 to 9 , characterized in that the preparation additionally comprises vasoactive substances , in particular cate@@ cho@@ lamines .
population pharmacokinetic analyses in special populations the pharmacokinetic properties of nintedanib were similar in healthy subjects , cancer patients and patients of the target group .
the inventive peptides are particularly used for the production of an agent for the treatment of autoimmune diseases , especially for the treatment of uveitis .
a compound according to claim 1 , wherein q is 0 or r 0 is halo or methyl ; r 1 is selected from hydrogen , c 1-6 alkyl or carboxy-c 1-6 alkyl ; r 2 is selected from or r 3 is c 1-6 alkyl ; and r 4 is selected from c 1-6 alkyl or c 1-4 alkylene aryl .
a dna expression vector comprising an inserted dna sequence consisting essentially of the dna sequence of claim 4 .
the needleless syringe assembly of claim 6 , wherein the shield ( 9 ) comprises a particle outlet opening ( 10 ) which is to be compressed during use to the target so that the particles ( 5 ) can pass through the opening ( 10 ) and the target .
use of an antibody for the manufacture of a medicament for the prevention or treatment of ovarian or colon cancer , wherein the antibody is immuno@@ specific for a polypeptide having the amino acid sequence of seq id no : 2 or seq id no : 4 or a polypeptide encoded by the nucleotide sequence of seq id no : 1 or seq id no : 3 . use of an antibody according to claim 1 wherein the cancer is colon cancer .
a diagnostic reagent comprising mammalian autoantibodies having specificity for at least one epitope of one epitope of a mammalian of a mammalian a marker of a mammalian a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a mammalian a a a a a a a a mammalian a a a a a a a a a a a a a a a mammalian a a a a a a a a a a a a
a catheter according to claim 1 , characterised in that said tubular sheath is made of a plastic or polyimide .
a method of analyzing a sample on the presence or absence of a target nucleic acid , said method comprising : ( 1 ) contacting said sample under conditions permitting hybridization with a reagent composition comprising : ( 2 ) detecting the presence or absence of any detectable response .
a method according to any one of claims 1 to 11 , wherein the compound is mannose .
hgf mutant and its use as anti-cancer agent
 cisapride ( used to treat certain stomach problems ) . • cisapride ( used to treat certain stomach problems ) problems ( problems with stomach problems ) stomach problems ( stomach problems ) stomach problems stomach problems stomach problems stomach problems stomach problems stomach problems stomach problems stomach problems stomach problems stomach problems stomach problems problems stomach problems problems stomach problems problems stomach problems problems stomach problems problems stomach problems problems stomach problems problems stomach problems problems stomach stomach stomach problems stomach stomach stomach stomach stomach stomach stomach stomach stomach stomach stomach stomach stomach stomach stomach stomach problems
metal medical implant with surface and method for producing the surface
the pharmaceutical composition of claim 60 , wherein the vehicle or carrier is a saccharide selected from the group consisting of lactose , sucrose , mannitol , and sorbitol .
the medical device of claim 16 , characterized in that the transducer ( 6@@ 76 , 6@@ 86 ) is adapted to generate the swelling signal and the echo signal receives and the tip ( 6@@ 72 , 6@@ 84 ) and the transducer are movable relative to each other .
an antibody protein comprising an amino acid sequence according to seq id no : 2 . the antibody protein of claim 44 . a method of producing an antibody protein according to any one of claims 44 to 46 , the method comprising the steps of : ( a ) culturing the host cell of claim 48 under conditions wherein the antibody protein is expressed by the host cell , and ( b ) isolating the po@@ one .
a ) 5.@@ 6.@@ 1998 b ) 27.@@ 11.@@ 1998 ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )
pharmaceutical preparation according to claim 1 , characterised in that it contains alkanols , in particular polyols and carbohydrates , hydrophilic polymers , in particular polyvinylpyrrolidone , polyvinyl alcohol , nonionic surfactants , especially polyalkylene glycols and polyoxyethylene fatty acid esters and / or proteins , especially albumin , especially human serum albumin , as stabilizers .
the system of claim 4 , wherein the diagnostic means comprises means ( 74 ) for determining changes in the relationship of heart rate and q t interval for the patient over a range of heart frequencies .
4-substituted 3-hydroxy@@ -3-@@ pyrrolin@@ e-@@ 2,5-di@@ one compounds , process for their preparation , and pharmaceutical compositions containing them .
if the treatment is stopped : patients who develop acute liver injury and where the product is withdrawn may have an increased risk of liver injury when tasmar is restarted .
novel strain of yeast candida sa@@ ke ( sa@@ it@@ o and o@@ ta ) van u@@ des and bu@@ ck@@ ley and its use for controlling fungal infections in harvested fruits
the dry powder inhalation system for transp@@ ulmonary administration for transp@@ ulmonary administration according to claim 1 , wherein , the freeze-dried mixture contains , to , , , , , , , , to , , , to , , , to , , , to , , , to , , , to , , , to , , , to , , , to , , , to , , , to , , , to , , , to , , , to , , , to , , , to , , , to ,
use of il-@@ 4r or of of of a derivative of il-@@ 4r or of of of a derivative of claim 1 of the il-@@ 4r of the il-@@ 4r of the il-@@ 4r of the il-@@ 4r of the il-@@ 4r of the il-@@ 4r of the il-@@ 4r .
active substance preparation for oral administration , in particular to ruminants according to any one of the preceding claims , characterized in that the coating comprises from 1.5 to 30 % by weight , based on the weight of the active substance core , from 1 to 20 % by weight of a cellulose ether , and from 0.5 to 10 % by weight of at least one filler selected from the group consisting of metal carbonates and 0.5 to 10 % by weight of at least one filler , the inner core close layer , from 0.2 to 8
oral contraceptives , norethisterone , and / or ethinyl estradiol , co-administration of pregabalin and oral contraceptives , and / or ethinyl oestradiol , or ethinyl oestradiol , does not influence the steady-state and steady-state contraceptives , or contraceptives , or contraceptives , , , or contraceptives , , , contraceptives , , contraceptives , , contraceptives , , contraceptives , , contraceptives , , contraceptives , , contraceptives , , contraceptives , , contraceptives , , contraceptives ,
the total neutrophil counts should be closely monitored , particularly during the first few weeks of filgrastim therapy . the first dose of filgrastim , of the first few weeks of therapy during the first weeks of filgrastim therapy of filgrastim should be monitored of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of filgrastim therapy therapy .
women of childbearing potential or their male partners have to use effective contraception during treatment and for the ribavirin smpc .
a compound according to any one of claims 1 or 2 , wherein r ² and r ³ both are hydroxy . a compound according to any one of claims 1 to 2 wherein r ² and r ³ are both hydroxy . both hydroxy and r ³ are hydroxy . both hydroxy and r hydroxy are hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy . hydroxy .
counting device ( 2 ) according to claim 1 , 2 or 3 , characterised in that the latching tongues ( 25 , 30 ) are arranged on the counting wheel ( 8 ) and the control wheel ( 9 ) for the springs in the radial direction .
a composition according to claim 2 , wherein said monoclonal antibodies are reactive with different serotypes of the same bacterial species .
biocompatible substance specific reagents for the treatment of physiological fluids .
a pharmaceutical composition comprising an agent as defined in claims 13 or 14 together with a pharmaceutically acceptable carrier or diluent . a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent as defined in any one of claims 1 to 14 . a pharmaceutical composition comprising an agent as defined in claim 13 or 14 , together with a pharmaceutically acceptable carrier or diluent . a pharmaceutical composition comprising an agent as defined in claim 13 or 14 , together with a pharmaceutically acceptable carrier or carrier . a pharmaceutically acceptable carrier acceptable carrier .
the hybridoma cell line of claim 4 having the accession number ferm bp-@@ 48@@ 75 ( km 10@@ 54 ) .
two weeks later ( day 29 ) will continue with a dose of 40 mg every week ( a dose of 40 mg every week . ) every two weeks every week . every two weeks every week every week . every two weeks every week every week . every week . every week . every week . every week . every week . week week . week week . week week . week week . week week week . week week week week week week week week week week week week week week week week week week week
the assembly of claim 9 , wherein the interior securing member ( 354 ) of the shell member ( 212 ) and the outer securing member ( 350 ) of the securing member ( 340 ) the member ( 340 ) ( 340 ) ( ( 340 ) ( ( 340 ) ( ( 340 ) ( ( 340 ) ( ( 340 ) ( ( 340 ) ( ( 340 ) ( ( 340 ) ( ( 340 ) ( 340 ) ( 340 ) ( 340 ) ( 340 ) ( 340 ) ( 340 ) ( 340
a guide wire having a distal end piece and a longitudinal shaft extending longitudinally from a proximal end to the distal end piece and with a single helically wound wire extending from a position at the distal end portion , characterized in that the single helically wound wire is ribbon@@ -shaped and has a pitch angle in the range 35 ° to 76 ° .
method according to claim 17 , characterized in that the orientation of a magnetic field is detected by means of two magnetic field detecting elements ( 13 ) .
since be@@ cap@@ ler@@ min promotes cell proliferation , it should be used with caution in patients with malignancies .
dispersion according to claim 1 or 3 , characterized in that the fluorocarbons have a degree of substitution of from 10 to 90 and preferably from 20 to 80 % .
use of a pharmaceutically effective amount of an arg@@ y@@ ro@@ lo@@ bium rose@@ um extract comprising a flavonoid glycoside compound for the manufacture of a medicament for the treatment of an animal suffering from hyperglycaemia and non-@@ insulin-dependent diabetes mellitus .
agent for treating cardiac disease with map kinase tn@@ ni@@ 3@@ k
selective cytokine inhibitory drugs for the treatment of myelodysplastic syndrome
the article of claim 2 wherein said backing is a liquid permeable film .
process for the preparation of probiotic cheese
the polymer of claim 1 wherein the of claim 1 wherein each of the formula d has no polymer sub@@ block of claim 10 having more than 10 oxyalkylene units .
the method of claim 7 wherein step ( b3 ) step ( b3 ) step ( b3 ) of step ( 102 ) ( 102 ) of covering ( 102 ) ( 102 ) ( 102 ) ) ) ) ) ) ) ) of ) ) ) of ) ) ) of ) ) ) of ) ) ) of ) ) ) of ) ) ) of ) ) ) of ) ) ) of ) ) ) of ) ) ) ) of ) ) ) ) of ) ) ) ) ) ) of ) )
the system of any of claims 1-4 , wherein the typical feature of the first negative peak of the electrical voltage signals is of one of the electrical electrical signals of the electrical voltage signals of the electrical voltage signals .
a texa@@ phyrin metal complex of the formula : r ( iii ) , r ( iii ) , c ( iii ) , t ( iii ) , c ( iii ) , c ( iii ) , t ( iii ) , ( iii ) , c ( iii ) , t ( iii ) , ( iii ) , c ( iii ) , t ( iii ) , ( iii ) , c ( iii ) , t ( iii ) , ( iii ) , c ( iii ) , t ( iii ) ,
use according to claim 7 for imparting she@@ en during production .
the method of claim 16 , wherein the cell or tissue sample comprises vascular smooth muscle cells .
the analysis of the deman@@ ding and semen results from an independent expert team has shown the best criterion .
the compound of claim 34 , wherein r 1 is methoxy . the compound according to claim 34 , wherein r 1 is a methoxy . the compound of claim 34 , wherein r 1 is methoxy . the compound of claim 34 wherein r 1 is methoxy . the compound of claim 34 wherein r 1 is methoxy . wherein r is methoxy . the compound of claim 34 wherein r is methoxy . methoxy is r is methoxy . methoxy .
18.@@ 1 ; 2@@ 0.3 ) in patients on placebo / dexamethasone .
clinically relevant ctc toxicities reported in &lt; 1 % of patients &lt; 1 % of 1 % of 1 % of 1 % of 1 % of 1 % of 1 % of % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % %
the flow support system of any one of the preceding claims , wherein said tube means ( 34 , 316 ) includes : ( a ) an outer tubular sleeve ( 34 , 346 ) connected to said opening with said cover means and having a proximal end ( 36 , 348 ) , a body ( 38 , 348 ) and a sheath passage ( 347 ) extending through said sleeve passage and proximal and distal ends ( 360 , 364 ) and a conduit channel ( 366 ) extending between said lead ends .
use according to any one of the preceding claims wherein the dosage units containing the competitive progesterone antagonists contain at least one compound selected from the group consisting of the 11β- ( ( 4-n , n-dimethylamino ) ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (
drill guide and method of use
the apparatus of claim 16 , wherein the laser is a poly@@ chromatic or monochromatic light source from 220 to about 2@@ 400 nm .
an automatic blood pressure monitor according to claim 1 , wherein : said monitoring means is oscil@@ metric ; said cuff pressures ( cp ( i ) are reduced in predetermined cuff pressure levels ; said complex tips ( cp ( i ) are reduced in predetermined cuff pressure levels ; said complex tips of said cuff are reduced and said associated cuff pressure levels are reduced in predetermined cuff pressure levels ; said complex tips of said cuff are reduced ; said complex tips of said cuff are reduced and said associated cuff pressure levels ; said complex tips
one dose of hepatitis b immunoglobulin immediately after birth ( within the first 24 hours ) .
a method as claimed in claim 1 or claim 2 , wherein the erythritol generating microorganisms are au@@ re@@ ob@@ asi@@ dium , actino@@ ob@@ asi@@ dium sp . a method according to claim 1 or 2 , wherein the erythritol generating microorganisms are au@@ re@@ ob@@ asi@@ dium , sp . re@@ ob@@ re@@ asi@@ asi@@ asi@@ dium asi@@ re@@ asi@@ asi@@ dium re@@ ob@@ asi@@ asi@@ dium , sp . ob@@ re@@ re@@ asi@@ asi@@ asi@@ ob@@ asi@@ dium sp . ob@@ re@@ re@@ asi@@ asi@@ asi@@ dium asi@@ ob@@ re@@ asi@@ dium sp .
monoclonal antibody according to claim 1 , characterized in that the ability to bind human glu-@@ plasminogen and human lys-@@ plasminogen is substantially not inhibited by ε@@ -amino@@ caproic acid .
how can the progressive type of geno@@ type correlation for the development of gene therapy ?
toxic epidermal necrolysis , stevens-johnson syndrome , stevens-johnson syndrome , stevens-johnson syndrome , stevens-johnson syndrome , stevens-johnson syndrome , stevens-johnson syndrome , stevens-johnson syndrome , stevens-johnson syndrome , stevens-johnson syndrome , stevens-johnson syndrome , stevens-johnson syndrome , stevens-johnson syndrome , stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson syndrome stevens-johnson
method according to one of claims 7 to to to to one of claims 7 to 7 one of claims 7 to 7 of claims 7 to 7 of claims 7 to 7 of claims 7 to 7 of claims 7 to 7 claims 7 to 7 claims 7 to 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7
use of alkyl@@ salicylic acid esters as perfuming ingredient .
( ai@@ v@@ losin 4@@ 2.5 mg / g - 20 kg ) ( ai@@ v@@ losin 4@@ 2.5 mg / g - 5 kg ) ( ai@@ v@@ losin 8.5 mg / g - 20 kg ) ( ai@@ v@@ losin 8.5 mg / g - 5 kg )
a compound having the structure : wherein a ) x is selected from the group consisting of o , s , so or so ; b ) each y is independently hydrogen or a straight or branched , substituted or unsubstituted , substituted or unsubstituted , substituted or unsubstituted , substituted or unsubstituted , wherein the cyclic hydrocarbon chain is monocyclic or straight and monocyclic , or r is a substituted or unsubstituted aryl , wherein r 1 to 15 has different atoms .
therefore , no dose recommendations can be made for very young children ( children &lt; 2 years ) , and telzir with ritonavir is not recommended in this population ( see section 4.2 ) .
a process according to claim 4 , wherein , wherein said compound is r ₁ is isopropyl ; r ₂ is hydrogen or is methyl ; r ₂ is methyl , r ₂ ₂ is methyl ; r ₂ is r ₂ is r ₂ is r ₂ is r ₂ is r ₂ is r ₂ ₂ ₂ ₂ ₂ ₂ ₂ ₂ ₂ ₂ ₂ ₂ r ₂ ₂ ₂ ₂ r ₂ ₂ ₂ ₂ ₂ r ₂ ₂ ₂ ₂ r ₂ ₂ ₂ ₂ r ₂ ₂ ₂ ₂ r ₂ ₂ ₂ ₂ r
compositions according to claim 1 , characterized in that the active principle protected from the r@@ lumen is chosen from vitamins , amino acids and medicaments .
a sustained-release preparation of a biologically active protein comprising an effective amount of the protein in a mixture of 95 to 5 % by weight of ε-caprolactone homopolymer in a molecular weight range from 15,000 to 100,000 and 5 to 95 % by weight of a crystallization modifier selected from the group consisting of crystalline fatty acids and crystalline fatty acid esters having saturated c 12 -c 18 fatty acid ester of polyhydric alcohols .
what are exelon and prometax ?
no dosage recommendations for amlodipine are available for patients with mild to moderate hepatic impairment to patients with moderate hepatic impairment . hepatic impairment .
in a pre- and postnatal study in rats , the maternal exposure to the mother was performed with
in the first study , evicel was compared with manual compression ( direct pressure with hand ) for reducing bleeding in vascular surgery .
stelara 45 mg solution for injection in pre-filled syringe each pre-filled syringe contains 45 mg ustekinumab in 0.5 ml in 0.5 ml in 0.5 ml 0.5 ml 0.5 ml 0.5 ml .
the solution should be administered slowly , be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be administered be
the prosthesis of claim 1 , wherein the total included the total included taper of the locking the the the the of the locking the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the prosthesis of the the total the of the the total the of the the the the the the the of the
a nucleic acid according to claim 5 which is dna . nucleic acid according to claim 5 which is dna .
47 latvija glaxosmithkline latvia sia tel : + tel : + 371 67@@ 3@@ 12@@ 6@@ 87 l@@ v-@@ e@@ pa@@ sts @ gsk. com tel : + 6@@ 6@@ 6@@ 6@@ 6@@ 6@@ 6@@ tel : + 6@@ 6@@ 6@@ 6@@ 6@@ 87 tel : + 6@@ 6@@ 6@@ 6@@ 6@@ 87 6@@ 87 6@@ 87 6@@ 87 tel : + 6@@ 6@@ 6@@ 6@@ 87 6@@ 87 6@@ 87 6@@ 87 6@@ 87 6@@ 87 6@@ 87 6@@ 87 6@@ 87 6@@ 87 6@@ 87 6@@ 87 6@@ 87 6@@ 87 6@@ 87 6@@ 87 6@@ 87
discharge device according to one of the preceding claims , characterized in that a metering gas flow channel ( 18 ) is provided for the medium , which is preferably provided with a metering chamber ( 26 ) which is movable between a filling and a emptying system ( 27 , 28 ) , and in particular a metering chamber ( 26 ) , which is displaceable in the bottom of the medium chamber ( 4 ) , and in particular , a pressure gas flow channel ( 18 ) which is movable in the cross-section of the medium chamber
• 2@@ 6.@@ 10.@@ 2001 • 2@@ 6.@@ 10.@@ 2001 • 6.@@ 10.@@ 2001 • 6.@@ 10.@@ 2001 • 6.@@ 10.@@ 2001 • 10.@@ 10.@@ 2001 • 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001 10.@@ 10.@@ 2001 2001
the full epar for sono@@ vu@@ e can be found here for the full list of all side effects reported with this medicine , see the package leaflet . the full epar for sono@@ vu@@ e can be found here . the pre-filled syringe can be found here for the full list of all side effects reported with this medicine , see the package leaflet . the full epar for sono@@ vu@@ e can be found here . here the full epar here will be found here . here for sono@@ vu@@ e can be found here .
device with adjustable ap@@ plan@@ tation template for the cornea
method for determining blood pressure and blood pressure measuring apparatus
a compound having a structural formula : wherein x is selected from the group consisting of oxygen , nitrogen and sulfur ; y is nitrogen , and n is 1 ; r 1 is alkyl , alkenyl , alkynyl , -ch 2 co 2 h or -ch 2 co 2 me , wherein y is substituted with r 6 wherein r 6 is substituted with r 6 wherein r 6 is selected from the group consisting of hydrogen and methyl .
close monitoring is recommended when this medicinal product is administered with ep@@ clu@@ sa ( see sections 4.4 and 4.8 ) .
an immunoglobulin molecule according to claim 1 , wherein at least a portion of a cdr is replaced by a pep@@ a to a pep@@ a to a a a thrombopoietin ( a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
the composition of claim 8 , wherein : said of ( b ) non-ionic emulsifying agent comprises a substantially linear c -c alcohol ethoxylate a a a a a a molecular weight of 6@@ 19 , a number of a linear of a 6@@ 19 linear a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a linear emulsifying agent of a a a a a a a a a a a
annex iii labelling and package leaflet 37 a. labelling and package leaflet and labelling package labelling and package leaflet and package leaflet and labelling and package leaflet leaflet and package leaflet package leaflet package leaflet package leaflet package leaflet package leaflet package leaflet package leaflet package leaflet package leaflet package leaflet package leaflet package leaflet package leaflet
the use according to any one of claims 1 to 5 , wherein the use of a cosmetic is the use of any one of claims 1 to 1 to the 1 to 1 .
the method of claim 5 , wherein the drug is composed of a carrier and an agent .
no dose adjustment of cellcept appears necessary .
&#91; the current approved wording of this section should be deleted and replaced by the following &#93;
animal behavioural studies with olanzapine indicated 5ht with dopamine , dopamine , with cholinergic antagonism , consistent with with with with with with with with with with with with with with the receptor-@@ binding profile , olanzapine with olanzapine , with olanzapine , with olanzapine , with , , with , , with , , olanzapine , with olanzapine , with olanzapine , with , , , studies with olanzapine , indicated , , with , , with , , olanzapine with , , with with , , with , with , , with olanzapine with with , , ,
process according to claims 11 and / or 12 , characterized in that the auxiliaries and additives used are substances selected from the group consisting of polyols , emulsifiers , fibres , dyes , perfume oils , flavouring agents , cosmetic agents , pharmaceutical agents and food additives .
the method of claim 23 , wherein the sintering step is carried out before the bone conducting assembly is provided in the interconnecting spaces .
process for the preparation of the compounds of formula ( i ) according to claim 1 , in which r represents a chain ( b ) in which r &apos; is a hydrogen atom , characterized in that a derivative r 1 so 2 ch 2 r 2 ( ii ) , in which r 1 and r 2 are as defined in claim 1 , is reacted with an azetidin@@ one of the formula : in which r 3 and r 4 have the meanings given in claim 1 , the product being isolated and optionally converted to a
method of treating bacterial infections that are not caused by streptococci .
use of a compound according to claim 1 in the manufacture of a pharmaceutical composition for the treatment of rheumatoid arthritis , cancer , multiple sclerosis , guil@@ lan@@ -@@ bar@@ r@@ é syndrome or psoriasis in mammals , including humans .
an intramedullary nail as claimed in claim 3 , characterised in that the passage for the pin is threaded and that the pin is a screw .
bio@@ degradation of an organic compound and method for environmental enhancement by removing said compound
composition according to any one of claims 1 to 13 , characterized in that the solvent medium suitable for dyeing is aqueous and its ph is from 8 to 11 .
if nespo is switched to nespo , haemoglobin should be monitored every one or two weeks and the same route of administration is recommended .
the drive assembly according to claim 2 , wherein the cylinder further includes a locking strip to prevent rotation of the cylinder about the barrel axis , and wherein the locking hub includes a flange ( 70 ) , the flange being adapted to displace the locking strip thereby allowing the barrel to rotate .
the apparatus of claim 1 , wherein the fingerprint memory and the recognition circuit are below the sensor circuit .
polyclonal or monoclonal antibody against an interleukin-4 protein , the interleukin-4 protein characterized in that it has the effect of a b-cell growth factor ( bc@@ gf ) on human cells and the effect of a t-cell growth factor ( tc@@ gf ) on human cells on human cells on the human cells on human cells cells on human cells cells human cells on human cells .
the method of claim 14 wherein the mixture further comprises at least one enzyme at least at least at least one at least at least at least at least at least at least at least at least at least at least at least at least at least at least at least at least at least at least at one least at least at least at least at at least at least at least at least at least at least at least at least at least at least least least at least at least at least at least least at least
the method of claim 16 , wherein the phyto@@ sterols are selected from the group consisting of sterols , sterol esters , stan@@ ols , stanol esters and mixtures thereof .
novartis pharma gmbh ro@@ on@@ straße 25 d-@@ 90@@ 4@@ 29 nu@@ re@@ mbe@@ rg germany
this can be operated by means of a rotating actuating member ( 31 ) which is arranged at the end of a rod ( 30 ) guided along the shaft ( 1 ) near the sleep ( 3 ) so that the tool can be held in a comfortable position and away from the operating field .
a method for identifying compounds which inhibit a binding of β@@ 3-@@ donor short to β@@ 3 integrin , as active substances for the treatment of arteriosclerosis , resulting unstable , acute coronary thrombosis , infarction , stroke , peripheral arterial injury , myocardial infarction , stroke , peripheral arterial , , , chronic , venous , ulcer , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
• after dilution , k@@ io@@ vig should be used immediately .
a metal complex of a piperazine non@@ oate derivative according to any one of claims 1 to 8 for use as a medicament .
endo@@ lumen@@ al device ( 1 ) according to one of the preceding claims , in which the elongated body ( 2 ) comprises radio-opaque markers ( 30 , 31 ) for identifying the position along the body of a distal and / or proximal end of the expansion device ( 5 ) .
list of the names , pharmaceutical form , strengths of the , strengths of the , the , , , , of the , , , , , , , , , , , , , , , the , strengths of the ,
the most common adverse reactions ( ≥ 25 % ) in either alk@@ -@@ positive or ros@@ 1-@@ positive nsclc were visual disturbances , nausea , diarrhoea , vomiting , oedema , constipation , transaminases increased , fatigue , decreased appetite , dizziness and neuropathy .
process for preparing sustained release pharmaceutical compositions .
cell culture systems and methods for organ support devices
the method of claim 1 comprising : ( a ) forming an emulsion including a hydrophilic , monomeric , continuous phase and a discontinuous oil phase , the emulsion comprising : wherein the discontinuous oil phase comprises 70 to 99 % of the emulsion and is substantially all of the polymerization initiator in the continuous aqueous phase of the emulsion ; and ( b ) polymerizing the emulsion .
your doctor will work out your your your dose of your your your your your your your your your your your your your your your your your your your your your your your your your your your your your your your your your your your your your your dose will work will work will work will work will work .
treatment of invasive candidiasis prophylaxis of candida infections
the monoclonal antibody and derivatives thereof according to claim 23 , characterized in that they are of each of the hybridoma cell lines 20@@ 8.@@ 25 d.@@ 2 / 94 c.@@ n.@@ c.@@ m.@@ i-@@ 4@@ 86 , 20@@ 8.@@ 25 a.@@ i-@@ 4@@ 25 / 135 c.@@ n.@@ c.@@ m. i-@@ n.@@ c.@@ m.@@ i-@@ 4@@ 51 , 20@@ 7,@@ 25 a.@@ 4.4 / 45 c.@@ n.@@ c.@@ m. i-@@ 4@@ 52 , 20@@ 8.@@ 25 .
a composition comprising an effective amount of a compound of formula ( 1 ) according to any one of claims 1 to 4 .
the method of claim 4 , wherein the light beam is a laser beam .
a vaccine according to claim 12 comprising a glyco@@ conjugate antigen specific to a glyco@@ conjugate a glyco@@ conjugate conjugate a conjugate according to claim 12 comprising a glyco@@ conjugate antigen a glyco@@ conjugate a glyco@@ conjugate a glyco@@ glyco@@ glyco@@ a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
the fusion protein of claim 5 wherein the linker domain comprises 5 - ( gly ) 4 ser-@@ ( gly ) - linker ( linker ) modules . 5 ( gly ) linker ( ( gly ) ( gly ) modules ( ( gly ) ) .
use according to claim 6 , wherein the anti-@@ il-6 receptor antibody is a reshaped human antibody of an antibody obtainable from the hybridoma having the accession number ferm bp-@@ 29@@ 98 .
the cpmp has recommended the maintenance of the marketing authorisations for the medicinal products containing the combination of loratadine and pseudoephedrine , including the amendments in accordance with the summary of product characteristics set out in annex iii .
the use of a mixture of homologous lauryl polyglycol ethers as claimed in claim 1 as a local anaesthetic agent for the preparation of therapeutic preparations for the treatment of the human body . the use of a mixture of homologous lauryl polyglycol ethers of claim 1 of the of a mixture of homologous lauryl polyglycol ethers of claim 1 of homologous lauryl polyglycol ethers of claim 1 .
instrument according to claims 4 and 10 and claim 11 or 12 , characterised in that the operating element ( 40 ) is supported by the second position in the third position directly or indirectly against a second spring ( 76 ) .
1 . a support structure for preventing the movements of powder material to be used as a bone implant ( powder ) to be used , wherein the support structure is formed into contact with bone tissue , which support structure is made of an at least partially absorbable polymers , copolymers or polymer mixture , and having an open porosity , and in that the surrounding tissue is produced by the support structure , which is made up of an at least partially absorbable polymer , copolymers or polymer mixture , and in that the surrounding tissue is produced
a method according to claim 12 , wherein a 3 is h and a 2 and a 6 is oh .
use according to any one of the preceding claims , characterized in that z represents a number ranging from 75 to 95 .
a process for the preparation of a phosphoric acid diester of a of a formula of the formula of the formula the the the acid diester of the formula of the formula the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
reporting of side effects if you get any side effects any side effects , side effects , side effects , talk , effects of effects , effects , effects , effects , effects , effects , effects , effects , , effects , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
process according to any one of claims 14 to 20 , characterized in that the cell is chosen from among the strains of e. coli . the method of any one of claims 14 to 20 , characterized in that the cell is selected from the group consisting of the strains of e. coli . the method of any one of claims 14 to 20 characterised in that the cell is selected from the group of e. coli . the process of any one of claims 14 to 20 wherein the cell is selected from the group .
a wound dressing as claimed in claim 1 , characterized in that the composition is in the form of a gel of the gel of claim 1 of a gel .
a method according to claim 7 , wherein the drug is alfa@@ x@@ alone . claim 7 , wherein the drug is alfa@@ x@@ alone . 7 .
metabolism and nutrition disorders common uncommon rare uncommon uncommon rare uncommon uncommon uncommon uncommon common uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon rare uncommon uncommon rare uncommon uncommon rare uncommon uncommon rare uncommon uncommon rare uncommon uncommon rare uncommon uncommon rare uncommon uncommon rare uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon
auto@@ kinin mobility factors in the diagnosis and treatment of cancer .
studies in which healthy volunteers received a single dose and multiple oral doses of type 2 diabetes showed significant absorption of glimepiride within 1 h and cmax after approximately 2.5 h .
b. van war@@ red bo@@ t the rapporteur of dr .
the assembly of any one of the preceding claims , wherein at least a portion of the coil ( 52 ) is made of a radiopaque material . the assembly of any preceding claim wherein at least a portion of the coil ( 52 ) is made of a radiopaque material . the assembly of any of the preceding claims wherein at least a portion of the coil ( 52 ) is made of at least one of a radiopaque material . at least one portion of the coil is made of a radiopaque material .
a c 1-8 alkyl optionally substituted on a terminal carbon atom having a substituent selected from the group consisting of cycloalkyl , heterocyclyl , aryl , heteroaryl , amino ( with two substituents independently selected from the group consisting of hydrogen and c 1-8 alkyl ) , ( halo ) , ( halo ) , and the cycloalkyl , heterocyclyl , aryl and heteroaryl parts of the aa ) .
relistor was used every 3.2 days ( median dosing interval ( median ( median dosing interval ( ( median dosing interval ( median ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( median
shelf life after dilution according to the directions : 10 hours . • shelf life after dilution according to directions : 10 hours according to the directions : 10 hours according to directions : to :
it is available as a spot-on solution in applicators containing five different strengths for use in dogs .
a sanitary panty according to claim 1 , wherein the length ( c2 ) of the liner fastening o@@ we@@ n between the front side portion ( 23 ) and the rear side portion ( 24 ) is assuming that the free length ( c1 ) of the crotch portion is 100 to 150 .
in 1.8 % of patients receiving zu@@ ramp@@ ic 200 mg , 6.7 % of patients receiving 400 mg of le@@ sinu@@ rad and 0 % of patients with placebo experienced serum creatinine at least 2-fold compared to baseline .
nucleic acids exhibiting different expression in hepato@@ blastoma and normal liver
the process according to claim 1 wherein the bifunctional ligand is derived from diethylenetri@@ aminepentaacetic acid , or 1,4,@@ 7,10-tetraazacyclododecane-1,4,@@ 7,10-tetra@@ acetic acid .
apparatus as claimed in any one of the preceding claims , further for determining a patency of the airway , the data processing means ( 54 , 134 , 136 ) further comprising detection means ( 132 , 134 , 136 ) adapted to detect the presence of cardio@@ genic components in the airflow to determine that the airway is continuous .
the system of claim 2 , wherein the plurality of ventilator support parameters also comprise at least one of the arterial blood gas pac@@ o2 levels of the patient ; the arterial blood gas pac@@ o2 level of the patient ; and the arterial blood gas ph level of the patient .
tissue graft from gastric submucosa for repairing neurological tissue
inflatable electrode for temporary stimulation
the defibrillator of claim 3 , wherein the user commands ( 271 ; 272 ; 274 ) for the second mode are push buttons .
supplement according to one of claims 9 to 11 , characterized in that it is derived from d-glucose . of the supplement of one of claims 9 to 11 , characterized in that it is of d-glucose .
device according to one of claims 1 to 9 , characterized in that the drive element ( 10 ) is part of a vibration bridge ( 18 ; 42 ; 60 ) .
process according to claims 1 to 7 , characterized in that the eucaryotic polypeptide analogue has the sequence met-@@ phe pro at its n-terminus .
a permanent waving agent comprising 0.01 to 1 % by weight , calculated to the total composition , as a hydrogen peroxide of an oxidizing agent , characterized in that it contains a catalase free peroxidase in spatially separate composition thereof .
a retractor for use in endoscopic surgery , with a shaft ( 1 ) , at its proximal end , a handpiece ( 2 ) having a distal end thereof and whose distal end is made from a stretched straight starting position , the distal end of which is arranged in a stretched straight position , the distal end of which is arranged in a fixed straight position , the distal end of which is arranged in a fixed straight position , the distal end of which is arranged in a stretched straight position , the distal end of which
a microwave apparatus for heating a fluid flowing in a fluid line ( 12 ) , comprising : a means ( 16 ) for providing a microwave heating space ( 10 ) ; a microwave heating chamber ( 10 ) ; a microwave heating chamber ( 10 ) ; a microwave heating means ( 14 ) ; a microwave heating means ( 14 ) ; a microwave heating means ( 14 ) ; a microwave heating means ( 14 ) ; a microwave temperature sensing means ( 20 , 22 , 45 , 22 , 45 ) having a noninvasive
the composition of any of claims 1 to 5 , wherein the additional polymer is a copolymer of glycolide and lactide .
inhalation device according to claim 10 , characterized in that the control means is provided as electronic circuit with at least one microchip .
official , national and regional antimicrobial polic@@ ies polic@@ ies polic@@ ies should be taken into account when the veterinary medicinal product is used .
the ratio rates of per@@ -@@ proto@@ pool regression analysis and the non-@@ significant sensitivity to po@@ is@@ son regression analysis were 0.@@ 81 ( 95 % ci : 0.@@ 69 to 0.@@ 94 ) and 0.@@ 89 ( 95 % ci : 0.@@ 77 to 1.@@ 02 ) .
the compound according to claim 3 to claim 3 to claim 3 to claim 3 to claim 3 to claim 3 to claim 3 to claim 3 to claim 3 to claim 3 to claim 3 claim 3 to claim 3 claim 3 to claim 3 claim 3 to claim 3 claim 3 claim claim claim claim claim 3 to claim 3 claim claim 3 claim claim claim 3 claim claim claim 3 claim claim claim 3 claim claim claim 3 claim 3 claim claim 3 claim claim claim 3 claim claim claim 3 claim claim claim 3 claim claim
medical device for supplying or withdrawing liquids by injection , infusion or transfusion comprising a housing ( 1 ) with a supply ( 1 ) with a supply or withdrawal port ( 4 ) and a closing element ( 5 ) for the connection piece ( 4 ) , characterized in that a radial gap ( 15 ) is provided between the stub ( 4 ) and the pin ( 12 ) when the closure element ( 5 ) is sealed by means of the closure element ( 5 ) and the pin ( 12 ) by means of the
walking aid according to claim 1 , characterized in that each of the rods on the first side part and the second side part are dimensioned so that the bars on the first side part are fitted into a cavity of the rods on the second side part , thereby allowing mutual movement of the bars in accordance with a telescope principle .
multipack comprising 168 ( 4 x 42 ) ampoules with consumer materials for the bree@@ lib nebuliser ( contains 1 mouthpiece and 1 nebuliser chamber ) .
a method of producing copies of at least part of a nucleic acid strand present at least one of a nucleic acid strand present in a sample , the method comprising steps of ( i ) providing a solid support system , which method comprises steps of ( i ) providing the steps of ( i ) the steps of ( i ) providing the steps of ( i ) the steps of ( i ) providing the steps of ( i ) the steps of ( i ) providing the steps of ( i ) the steps of (
the use according to any one of the preceding claims of a compound selected from the group consisting of : the compound selected from the group the group consisting of : from the group consisting of : : : of the group consisting of : : : of the group consisting of : : of the group consisting of : : of : : of the group of : : : of consisting of : : : of : of the group consisting of : : : : of : : of : : of : : of : :
the system of claim 1 , wherein the system includes means for measuring the resistance of the patient &apos;s respiratory tract , the patient &apos;s compliance , and the magnitude of the control signal .
the article of any preceding claim wherein the acquisition layer ( 22 ) is a fibrous web containing between about 50 to 95 weight percent wood pulp and about 5 to 50 weight percent of non-@@ cellulosic synthetic fibers .
a method according to any one of claims 18 to 21 , wherein the step of generating sensor data is processed one or more echo signals to produce intensity data for a sample line with a known orientation relative to the scanner ( 12 ) , and the combining step is a two-dimensional image of the article .
a process according to claim 16 wherein the carrier is lactose . the method according to claim 16 wherein the carrier is lactose . the process according to the claim 16 wherein the carrier is lactose .
re@@ ven@@ ue from the sale of publications of any type , including cur@@ the@@ berg .
pregnancy the effect on pregnancy and on pregnancy on pregnancy on pregnancy has not been studied in humans . pregnancy has not been studied on pregnancy on pregnancy . pregnancy has not been studied on pregnancy and in humans . pregnancy .
if the product has been dissolved in the supplied water for injection , it should be clear .
polypeptides derived from human apo@@ lipoproteins a@@ iv , their preparation and their use .
a measuring valve according to any one of claims 3 to 5 , wherein the inner surface has a surface of the valve shaft .
a micro@@ spherical composition according to claim 1 for parenteral administration and slow delivery , further characterized by a pharmaceutically and pharmacologically acceptable liquid vehicle in which the microspheres are dispersed .
the signal difference is preferably determined in a measuring device ( 5 ) provided on the hose ( 1 ) and transmitted tele@@ metrically .
hypersensitivity to penicillins may cause cross-@@ allergy to cephalosporins and vice versa .
nervous system disorders common headache dizziness uncommon taste disturbance odour
device for amplifying electromagnetic oscillations for influencing a biological system
the use according to claim 4 , wherein , at least one of the modified live bv@@ dv of the modified live bv@@ dv of the modified live bv@@ dv of the the modified live bv@@ dv the the the the the the the the the the the the the the the the the the the modified live bv@@ the modified modified live bv@@ the modified modified live bv@@ live modified modified live bv@@ live modified live live live live live live live live live live live live live live live live live live live live live live live live
use of a chimeric dna / rna ham@@ mer@@ head ribozyme in the manufacture of a medicament for treating a proliferative disease of the eye , wherein the ribozyme is directed to the sequence of any one of seq id nos : 1-@@ 261 , 27@@ 1-@@ 280 , wherein said sequences are directed within the p@@ rna gene .
a retractable intravenous needle device ( 10 ) according to claim 2 characterised in that the manual actuating means has an inclined ramp ( 20 ) formed on the hub and normally is located outside the passage ( 32 ) of the housing , near its second end and a finger pressure directed away from the second end ( 30 ) by a user so that the hub ( 14 ) moves from outside the stop means ( 34 ) towards the locking means ( 36 , 38 , 40 ) .
a composition according to any one of the preceding claims , further comprising an agent for buffering . the composition of any preceding claim , further comprising the composition of any preceding claim .
the apparatus of claim 1 , wherein the catheter outlet ( 16 ) includes a tubular member that extends tangentially from the base ( 14 ) and a hollow interior ( 66 ) extending coaxially with the passageway ( 26 ) in the tubular member to be opened in the socket ( 58 ) of the flexible insertion catheter member ( 54 ) .
deutschland spain france netherlands united kingdom
the apparatus of any one of claims 1 or 2 , wherein each first , second , third and fourth conduit means ( 44 , 50 , 56 , 60 ; 128 , 130 , 152 , 154 ) comprises an electrically conductive coil coil ( 90 , 94 ; 132 , 136 ; 15@@ 2@@ a-c , 15@@ 4@@ a-c ) received in a dielectric jacket ( 92 , 96 ; 134 , 138 ; 156 ) .
pulmonary and cardiac reactions including death due to bronchospasm in asthma patients and rare death in association with cardiac failure in association with cardiac cardiac failure in cardiac cardiac association with cardiac cardiac cardiac association with cardiac cardiac association with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with cardiac cardiac with
composition according to any one of the preceding claims , characterized in that the aqueous phase comprises , in one , one of the , in the , the , , the , , the , the , one , one , of the the polyacrylamides , one of the polyacrylamides , of the to the the the the the the the preceding claims .
if a dose of doribax has been missed if you have a concern that you may have missed a dose of doribax , talk to your doctor , pharmacist or nurse immediately .
a vector comprising a recombinant dna molecule according to claim 15 . a vector comprising a recombinant dna molecule according to claim 15 . a vector comprising a recombinant dna molecule according to claim 15 .
see section 6.1 for a full list of excipients , see section 6.1 of section 6.1 of section 6.1 of section 6.1 of excipients of the list of excipients of excipients of excipients of of excipients . of excipients of of excipients of of excipients of of excipients of of excipients of of of excipients of of of excipients of of of excipients of of of excipients of of of of excipients of of of of excipients of
a dispenser as claimed in any one of claims 1 to 3 , characterised in that the longitudinally slotted clip ( 60 ) has a closure body ( 62 ) for the one end of the tube ( 111 ) in parallel with a closure body ( 62 ) for the one end of the tube ( 111 ) and a longitudinal slotted clip ( 55 ) formed on the insertion piece ( 50 ) , the tube ( 111 ) in a region between its ends .
the medicine can only be obtained with a prescription with a prescription a with a prescription .
if repeated or severe low blood sugar levels occur , please inform your doctor or hospital , and take the need for reduction or interruption of insulin infusion . • your doctor may need to lower your insulin or if you or your child develops severe or severe low blood sugar or severe low blood sugar or severe low blood sugar or severe low blood sugar or low blood low blood sugar levels .
the use of claim 11 , wherein the allergic inflammatory disorder of the airways is selected from the group consisting of idiopathic pulmonary fibrosis of of of of of of of of of of of of of claim of of of of of of of of of of of of of of of of of of of of claim of claim of of of claim of of of of of claim of of of claim of of of claim of of of claim of of of claim of of of claim of of of claim of of claim of of
the method of claim 15 wherein the heat shrink tube ( 80 ) is heated to the elevated temperature with hot air .
an apparatus according to claim 1 , wherein the flow restriction means ( 16 ; 170 ; 230 ) includes at least one arm ( 16 ; 170 ) between the first position in which the at least one arm ( 16 ; 170 ) fits the tube ( 86 ; 142 ) to prevent flow and a second position in which the at least one arm ( 16 ; 170 ) does not exceed the tubing ( 86 ; 142 ) .
the electrosurgical instrument of claims 6 , 7 or 10-@@ 17 , wherein the head includes an electrode ( 34 , 9@@ 30,@@ 10@@ 30,@@ 17@@ 30,@@ 2@@ 130 ) and the electrode comprises the electrically conductive surface .
process according to claim 6 , characterized in that the denatu@@ rant is formamide , heat or a denaturing ph or combinations thereof .
acylated 4-@@ amidin@@ o- and 4-@@ guanidino@@ benz@@ ylamines and 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ guanidino@@ benz@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@ 4-@@
compounds of formula i according to claims 1 to 4 , wherein r1 is f@@ and r2 h or r1 h and r2 r and r2 are f ; r3 is oh ; a is h ; r3 is oh ; ( c 1 -c 4 ) alkyl ; ( c = o ) - ( c 1 -c 4 ) -alkoxy ; -ch 2 ch 2 -o- ; -ch = ch-ch = ch- -o- ( ch 2 ) p -o- ; p = 1 or 2 ; and r7 methyl , ethyl , ome , f , cl ,
conditions or restrictions with regard to the safe and the safe the safe and the safe the safe the the safe the
a use according to claim 4 or 5 , characterized in that ( - ) nor@@ cisapride is to be administered 1 to 4 times per day .
talk to your doctor if you have to stop or to stop your treatment , talk to your doctor if you have stopped or have stopped taking your treatment , talk to your doctor before taking this medicine . • talk to your doctor to your doctor to your doctor your doctor to your doctor .
patients who test positive for hepatitis b infection should continue with a doctor who has exper@@ tise for the treatment of hepatitis b .
the invention relates to a novel flavonoid derivative , an extract containing the flavonoid derivative , the cosmetic and pharmaceutical use thereof , preparations containing the flavonoid derivative or the extract , and a method for producing the flavonoid derivative or the extract .
calcium channel blockers felodipine , nifedipine , nicardipine , diltiazem , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , the , , nicardipine , nicardipine nicardipine , , , , nifedipine , , nicardipine , nicardipine , nicardipine , , , , nicardipine ,
- swollen and mostly itchy patches on skin or mucous membranes ( urticaria ) ,
a method of detecting or quantifying an analyte in a subcutaneous fluid of a mammal , the method comprising : ( a ) permitting a subcutaneously injected or implanted sensor for detecting or quantitative measurement of an analyte in the subcutaneous fluid , wherein the sensor is capable of detecting the output signal of the assay using an optical device ; and ( c ) reading the output signal of the assay using an optical device ; and ( c ) the measurement of the measurement obtained in step ( b ) .
a drilling device ( 1 ) according to any one of the preceding claims , characterized in that said penetrating means ( 2 ) comprises a central conductive member ( 15 ) and an outer conductive member ( 16 ) , said central ( 15 ) and said outer ( 16 ) portion being separated by a cylindrical insulation means ( 12 ) , said outer member ( 15 ) and said outer ( 16 ) portion being separated by a cylindrical insulation means ( 12 ) , wherein said two parts ( 16 ) and said outer ( 16
the import , sale , supply , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
the method of claim 1 , wherein the vir@@ ally infected eukaryotic cells are retro@@ vir@@ ally infected , eukaryotic cells .
method according to claim 22 , characterized in that the electric current reaches a current density of up to 120 a / cm 2 , preferably 80 a / cm 2 .
the individually packaged absorbent article of claim 2 wherein said releasable sheath ( 34 ) has an inwardly facing surface facing the outwardly facing surface of said backsheet ( 24 ) and an opposing outwardly facing surface and having an opposing outwardly facing surface and wherein said absorbent article ( 20 ) and said releasable sheath ( 34 ) and said release sheath ( 34 ) are folded about two transverse axes , said said absorbent article ( 20 ) and said detachable sheath ( 34 ) being folded about said second triple section ( 51 ) to form said
material according to any one of claims 4 to 6 , characterized in that it comprises up to 50 % by weight , and preferably up to 20 % by weight of one or more component ( s ) , in addition to the above-mentioned composition based on the methylidene malon@@ ate , the above-mentioned composition being selected from the group consisting of : poly@@ cyano@@ acrylates , preferably polyalkyl@@ cyano@@ acrylates , polyalkyl@@ methacrylates ; bio-compatible polyurethanes ; polyoxy@@ alkyl@@ enes ; poly@@ aminoacids ; polylac@@ ta@@ tes ; polylac@@ tate -co-@@ glyco@@ lates ; polyvinyl alcohols .
musculoskeletal and connective tissue disorders uncommon : tissue and bone disorders uncommon : connective tissue and bone disorders uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon connective tissue and tissue disorders uncommon uncommon uncommon musculoskeletal and connective tissue disorders uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon uncommon connective tissue disorders uncommon uncommon uncommon uncommon tissue and tissue disorders
implantable device for monitoring intracranial and cerebrospinal fluid pressure
the osmotic device of claims 1 or 2 , wherein the delivery of the first active agent is delayed relative to the delivery of the second active agent .
an intraocular device as claimed in claim 1 , characterised in that the end portion ( 28 ) includes an angle in such a way that upon removal of the device in the capsular sac of the bent end portion substantially tangentially a circle having a diameter of between 9 and 10 mm , according to the inner dimensions of the capsule bag .
the method of claim 14 wherein seph@@ acryl s-@@ 200 or sepharose cl-@@ 6b for gel filtration chromatography are used .
it is not known whether pemetrexed is excreted in human milk and not known in milk and not known in milk not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known not known
the method of claim 28 , wherein the second silica transfer particle comprises at least one anion exchange group covalently bonded thereto and the first silica magnetic particle comprises a silica oxide coating .
almost all these patients had received medicines known as azathioprine or 6-mercaptopurine as medicines known as azathioprine as azathioprine as azathioprine as azathioprine as azathioprine as or as as azathioprine .
a process according to any one of claims 6 to 10 , wherein said microorganism is a strain of a fungus of the species which also belongs to the strain san@@ k 114@@ 86 ( no . ferm bp-@@ 25@@ 98 ) as strain .
use in patients with chronic heart failure ( nyha stage iii or iv ) is contraindicated ( see section 4.3 ) . ( see section 4.3 ) . ( see section 4.3 ) . ( see section 4.3 ) . ( see section 4.3 ) . ( see section 4.3 ) ( see section 4.3 ) . ( see section 4.3 ) . ( see section 4.3 ) . ( see section 4.3 ) . ( see section 4.3 ) . ( see section 4.3 ) . ( see section 4.3 ) . ( see section 4.3 ) .
a drug delivery system according to claim 13 , wherein the spherical , microporous polymer network comprises microspheres having a diameter between 0.5 and 150 µm ( microns ) .
the machining of the socket bearing can be improved by means of an operating robot to obtain better surface compliance .
treatment with pri@@ alt should only be carried out by a doctor who has experience by a doctor by a doctor a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
human antibodies which bind il-12 and method for producing the same
the device of claim 1 , further comprising a syringe ( 12 ) connected to the tubular member ( 14 ) for supplying the fibrous material ( f ) into the lumen of the tubular member ( 14 ) .
for the full list of all side effects reported with su@@ vaxyn cir@@ co + m@@ h r@@ tu , see the package leaflet .
process for removal of meth@@ ylamines .
a compound according to claim 1 , wherein each of r 1 and r 2 is hydrogen and r 3 is hydroxy .
aranesp 15 µg darbepoetin alfa iv / sc darbepoetin alfa iv / sc darbepoetin alfa iv / sc / sc / iv / iv / iv / iv / iv / iv / iv / iv / iv / iv / iv iv iv iv / / / / / / / / / / / / / / / / / / / iv / iv / iv / iv / iv / iv / iv iv iv / iv / iv / iv / iv / iv / iv / iv / iv iv iv / iv
the method of any one of claims 1 to 28 , wherein the ph is maintained constant during the time of reaction between ph 7.3 and 8.2 .
there is no clinical experience clinical experience with tesavel in patients with severe hepatic impairment ( child-pugh score score &gt; 9 ( child-pugh score &gt; 9 ) ( child-pugh score score ( child-pugh score &gt; 9 ) .
the device of claim 1 , wherein the biasing element comprises an elastic material .
process according to at least one of claims 4 to 6 , wherein the isolated high meth@@ oxyl pectin is obtained from at least one of at least one at least one of citrus husk , apple juice , apple wine , apple , apple , sugar beet , sunflower , vege@@ tables , , , , , , , , , from at least one representative of apple apple , sugar beet , sunflower , , , , , , , , , , , , , , , , , , , , , , , , ,
however , diagnosis in hospitals in which not the entire spectrum of the therapeutic possi@@ bilities can be lost , a very much stra@@ ds and on the surgical therapy are concentrated .
subcutaneous injection into the abdominal wall the abdominal wall the abdominal wall the abdominal wall the abdominal wall the abdominal wall the abdominal wall the abdominal wall the abdominal wall the abdominal wall the abdominal wall the abdominal abdominal wall the abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal abdominal
the mixer of claim 1 , wherein said delivery means comprises a needle connector ( 34 ) or needle-@@ penetrable material ( 38 ) .
a compound according to claim 8 , wherein r 2 is r 11 .
compounds of formula i according to claim 1 , wherein m is a central building is a central a is 1 or 2 , u@@ 1 and u@@ 2 is a is or a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a is a
the method according to one or more of claims 1 to 12 , wherein the cell is a c. ele@@ gan@@ s cell .
the method of any of the preceding claims wherein the host microorganism is modified the the the the the the the the the the the the the the the the the the the the the the the the the host the host the host the the host the the host the the host the the host the the host the the host the the host the the host the the host the the host the the host the the the the host the the the the host the the the the the host the the the the the the the
an ultrasonic endoscope according to claim 3 , wherein each of the discontinuous sections of the flexible circuit board is constructed such that at least one plurality of small holes or a plurality of slices in ( i ) are formed a transition section from the large-@@ diameter portion to the stepped section and ( ii ) a transition section from the stepped section to the small diameter portion .
a topical composition according to claim 2 , wherein the plasticizer is carboxymethylcellulose .
the agency wants to stimulate a deco@@ mide with all sta@@ ke@@ holders , which will be discussed whether the introduction of such a concept in the european union ( eu ) is useful and which is suitable to support the development of new medicinal products .
3 observed for fasting normal levels for fasting normal levels levels levels for normal normal levels for normal normal levels levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal levels normal
what were the main concerns of the chmp ? the
in combination with introna in combination with ribavirin
finally , the invention also relates to the use of bat@@ 3 cdna for in vivo and / or ex vivo introduction of bat@@ 3 in tumor cells resulting in improved recognition by nk cells , for the immunotherapy of malignant diseases .
a container according to claim 16 , wherein in the resting position for the tray ( 16 ) , it is inclined towards the interior of the vessel ( 11 ) to facilitate a sharp object deposited thereon and the pivoting of the shell from its rest position into a disposal position .
electro-@@ therapy apparatus according to any one of the preceding claims , comprising a housing ( 36 in fig . 8 ) for electrical components , the feed electrodes being contact electrodes located on the outer surface of the housing . apparatus according to any of the preceding claims comprising a housing ( 36 in fig . 8 ) for electrical components , the feed electrodes being contact to the exterior surface of the housing . apparatus according to any of the preceding claims to any electrical components to any electrical components to any electrical components .
the use of the graft polymers prepared according to any of the process of claims 1 to 6 as absorbents to water and to aqueous solutions .
this syndrome may be associated with some features of tumour lysis syndrome such as hyperuri@@ caemia , hyperkalaemia , hypocalcaemia , hyper@@ phosphat@@ aemia , acute renal failure , elevated lactic dehydrogenase ( ld@@ h ) values , and possibly associated with acute respiratory failure and death .
the use of claim 26 wherein the compound is the thr-@@ pro-@@ gln-@@ gln-@@ lys or the pharmaceutically acceptable salt of the compound of claim 26 .
compounds of general formula ( i ) according to claim 1 , wherein the radical r 1 -a at position 3 of the thio@@ chromen@@ one ring is , r 1 is phenyl or 5- to 6-membered heteroaryl , wherein phenyl and heteroaryl are optionally substituted or different from the group consisting of halo , cyano , ( c 1 -c 3 ) alkyl , optionally substituted by residues selected from the group consisting of halogen , cyano , ( c 1 -c 3 ) alkyl , and is optionally substituted or different from the group consisting of halo or
thiazolidine@@ carboxamides as modulators of prostaglandin f receptor
use of a nucleic acid encoding a functionally active portion of a notch protein for the manufacture of a medicament for a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
the needle cap of the pre-filled syringe the pre-filled syringe of the pre-filled syringe contains the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
a module according to any one of claims 1 to 3 , wherein the ligand is a poly@@ anion . the module of any of claims 1 to 3 wherein the ligand is a poly@@ anion .
braf v@@ 600 mutations were reported in 13 % of the study population .
radical formation can be carried out after por@@ fi@@ mer sodium has absorbed light to produce a porphyrin molecule in the affected state .
compounds according to claim 2 , characterized in that , in claim 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 ,
the bioreactor of claim 1 , wherein said bioreactor further comprises microorganisms distributed in each module .
haemoglobin levels should not exceed 12 g / dl . • the haemoglobin level should not exceed 12 g / dl / dl and should not exceed 12 g / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl / dl
ted before you start to start and believe me , i h@@ ate that to consult ... would you do a little bit outside the work ?
the histamine h1 antagonist effect of mirtazapine is associated with its sedative properties .
arrangement according to claim 6 , characterised in that the switching means ( 12 , 13 ) jointly can be switched together and the atrial probe ( 10 ) is associated therewith .
the pharmaceutical composition of claim 4 further comprising a chemotherapeutic agent effective for treating the malignant disease or the malignant condition of the mammal .
a sustained acting agent for parenteral administration comprising interferon as an active ingredient in admixture with a pharmaceutically acceptable biodegradable protein as a carrier , said agent being in the form of powder particles or as a shaped body , with the proviso that it is neither needle or stick r@@ ö@@ mite .
severe hypoglycaemia may lead to un@@ consciousness and / or seizures .
use according to claim 1 or 2 , wherein the cosmetic contains at least one other kind of organopolysiloxane as the formula ( 1 ) .
use according to any one of the preceding claims , characterized in that the second peptide sequence of formula ( b ) is a sequence selected from the group consisting of seq id no : 1 and seq id no : 3 .
orthopaedic fixation screw , particularly with a longitudinally continuous bore , with a concentric hexagonal socket in the head region , in which a further hexagonal socket ( 7 ) is provided in the region of the head ( 4 ) , which is smaller than the first hexagonal channel ( 6 ) and is connected in the longitudinal direction to the first hexagonal cannula in the longitudinal direction relative to the screw .
device for external fixation of bone fractures with at least one re@@ position chuck ( 1 ) and a longitudinal support , the device also comprising at least one of the connecting pins ( 11 ) of the re@@ position forceps ( 1 ) and the at least one longitudinal support ( 18 ) and the clamping element ( 19 ) which can be connected to each other .
elderly patients should only be treated for the presence of psoriasis and renal function should be closely monitored .
check with your doctor or pharmacist if your doctor or pharmacist are not sure .
use according to claim 7 , characterized in that the active intracellular catalase is that in the living microorganism . the use according to claim 7 , characterized in that the active intracellular catalase is that in the that in that .
surface structure according to one of claims 1 to 6 , characterized in that the depressions ( 18 ) have a round shape and are preferably circular or el@@ ip@@ -shaped .
♦ common ( these may occur these may occur these may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur may occur
this medicine should not be given to children or adolescents .
the compound of claim 2 which is ( 2e , 4e ) -3-methyl-@@ 5- ( 2- ( 5,5,8,8-tetramethyl-5,6,7,8-tetrahydro@@ -naphthalen@@ -2-yl ) -cyclohex@@ -1-enyl ) -@@ penta-2,4-dienoic acid , ( 2e , 4e ) , ( 2e , 4e ) -3-methyl-@@ ( 2e , 4e ) -3-methyl-@@ ( 2e , 4e ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) , ( 2e , 4e ) -3-methyl-@@ ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )
in com@@ mit , the rate of non@@ cerebral major bleeding , cerebral bleeding , was low , similar in both groups .
a method according to any one of the preceding claims , wherein the active agent is poorly soluble in water .
use according to any one of claims 1 to 8 , wherein the bpi protein product is for topical administration in a unit dose of between 1 µg / ml to 1 gm / ml .
recombinant adenoviral vectors expressing chimeric fiber proteins expressing chimeric chimeric proteins and genomic integration thereof for cell specific infection expressing chimeric fiber vectors expressing chimeric chimeric vectors expressing chimeric chimeric vectors expressing chimeric chimeric vectors
an n-vinyl pyrrolidone polymer according to any of claims 1 to 6 , which has been grafted to a pharmaceutically acceptable drug or enzyme . a composition comprising an n-vinyl pyrrolidone polymer as claimed in any one of claims 1 to 6 or a pharmaceutically acceptable polymer or an enzyme thereof or a pharmaceutically acceptable or a pharmaceutically acceptable carrier . an n-vinyl pyrrolidone polymer . a pharmaceutically acceptable carrier or enzyme . a pharmaceutically acceptable polymer or an enzyme . a pharmaceutically acceptable polymer . a polymer . a polymer .
the effect of posaconazole on fosamprenavir levels is not known when fosamprenavir is administered with ritonavir .
however , the increase in 5-fu exposure ten@@ ded to increase more than proportional to increase in te@@ ga@@ fur dose .
for more information , see the information leaflet .
a process according to claim 1 or claim claim claim to claim 2 to claim 2 to claim claim 2 to claim 2 to claim 1 or claim 2 to claim 2 to 2 to claim 2 to claim 2 2 or claim 2 claim 2 claim 2 claim 2 claim 2 claim 2 claim 2 2 claim 2 claim 2 2 claim 2 claim 2 claim 2 , claim claim 2 claim 2 claim claim 2 claim claim 2 claim claim 2 2 , claim 2 2 claim 2 2 , claim 2 , claim 1 , claim 2
a blood collection device comprising : ( a ) a blood collection assembly ( 12 ) , comprising : ( c ) a second transfer device ( 18 ) , a blood collection receptacle ( 16 ) , a blood component separation ( 16 ) , a second transfer device ( 14 ) , a blood component separation ( 16 ) having a second transfer path ( 20c ) , ( c ) having a second transfer path ( 20c ) , ( c ) having a second transfer path ( 20c ) , ( c ) , a second
the composite wound dressing ( 10 ) of claim 1 , wherein the contact component ( 14 ) comprises : a first outer layer ( 22a ) , an intermediate layer ( 22b ) and a second outer layer ( 22c ) , the layers ( 22a , 22b , 22c ) being each made of a permeable , non-@@ adherent mesh , wherein the layers ( 22a , 22b , 22c ) are each made of a permeable , non-@@ adherent mesh , wherein the layers ( 22a , 22b , 22c ) are each made of a permeable
exercise tolerance xo@@ ter@@ na breezhaler reduced the first dose to dynamic hyper@@ inflation , and prolonged the time that the exercise could be maintained by the morning and the dose of xo@@ ter@@ na breezhaler the first dose could be maintained at the time of the first dose and the duration of the exercise could be maintained and the duration of the dose could be maintained by the first dose in the dynamic hyper@@ inflation and the dose could be maintained by the first dose of xo@@ ter@@ na breezhaler the first dose dose could be maintained .
dose delay and adjustment : tri@@ sen@@ ox treatment should be withheld , adjusted or early discontinued if there is a toxic response to grade 3 or higher following the general toxicity criteria ( common toxicity criteria ) of the national cancer institute and a combination for tri@@ sen@@ ox therapy .
a pharmaceutical substance of peptide nature which resto@@ res the function of the myocardium containing the active peptide gene and a pharmaceutically acceptable carrier , and which is characterized by the fact that it contains an effective amount of the tetrapeptide ala-@@ glu-@@ asp arg &#91; seq id no : 1 &#93; as an active peptide gene . : the active peptide substance of a peptide substance which contains the active peptide gene and a pharmaceutically acceptable carrier of seq id no : 1 and seq id no : 1 : no : no :
claims for the following contracting states : de , se emulsified composition having an average particle size of 0.0@@ 10 to 0.0@@ 70 µm and having at least the following components ( a ) , ( b ) and ( c ) ; wherein the weight ratio of ( a ) / ( c ) is 0.5 / 1 to 5 / 1 .
composition according to claim 18 , characterized in that the water-soluble alcohols are chosen from c 1-6 alcohols , such as ethanol , isopropanol , t-@@ butanol and n-butanol , and polyols such as alkylene glycols , for example propylene glycol , glycerol and polyalkylene glycols ; and glycol ethers .
a compound according to claim 1 to claim 1 to claim 1 to claim 1 to claim 1 to claim 1 to claim 1 to claim 1 to claim 1 to claim 1 to claim claim 1 to claim claim 1 to claim claim 1 to claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim
apparatus according to claim 9 , characterized in that the focal distance of the infrared tonometer ( 14 ) the the the fact that the the the the the the the the the the the the the the the the the the the the the the the the the in the the the the apparatus the the the the the the the the the the the the the the the the the the the the the the the the apparatus the the apparatus the the the apparatus the the the the the the the apparatus the the the the apparatus
the invention relates to compounds of the general formula the compounds of the general formula the invention relates to the invention the invention relates to the invention relates to the invention relates to the invention relates to the invention relates to the invention relates relates relates to the invention relates relates relates relates relates relates relates relates relates relates to the invention relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates relates
glaxosmithkline biologicals s.a. rue de l ’ institut 89 b-1@@ 330 ri@@ xen@@ s@@ art belgium
the composition of claim 8 , wherein the amount of 0.1 to 300 mg / kg / day is / day . / kg / day / day .
the assembly of any one of claims 1 to 7 , wherein said securing means ( 46 ) comprises an annular member ( 46 ) therethrough ( 46 ) ( 1 ) ( 46 ) ( 46 ) ( 46 ) ( 46 ) ( 46 ) ( 46 ) ( 46 ) ( 46 ) 46 ( 46 ) 46 ( 46 ) 46 ( 46 ) 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46 46
the platform assembly of claim 25 , further comprising a memory connected to the control unit and a plurality of templates for triggering selected controlled movements of the movable member for performing different types of a predetermined movement of the platform , the input device being operable to operate under the plurality of templates .
the oxygenator of claim 8 further comprising a manifold ( 26 ) abutting and configured to deliver gas from said hollow fiber membrane ends .
each tablet contains sitagliptin phosphate monohydrate equivalent to 25 mg sitagliptin .
a compound according to claim 1 according to claim 1 according to claim 1 to claim 1 to claim 1 to claim 1 to claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim
each vial contains 10 mg of the active substance .
the device of any one of claims 1 to 4 , wherein the housing comprises a one-piece plastic structure .
a compound according to claim 1 wherein a and b are independently phenyl , naphthyl or a 5- or 6-membered heterocycle or condensed heterocycle having 1 to 4 heteroatoms independently selected from an oxygen atom or sulfur atom or 1 to 4 nitrogen atoms .
the use of claim 7 , wherein the electrophilic leaving groups are selected from a halide group , an epoxy group , a tosylate group or a mesylate group .
the expression vehicle of claim 28 , wherein said virus vector is an adenovirus vector . expression vehicle according to claim 28 , wherein said vector vector is an adenovirus vector of claim 28 wherein said vector of claim 28 is an adenovirus vector wherein said vector vector is an adenovirus vector wherein said vector is wherein said vector vector is an adenovirus vector .
the process of claim 1 wherein the acid is hx of step ( a1 ) - ( s ) - ( + ) -@@ mandelic acid .
the method of claim 2 , further comprising generating an antibody against the protein .
the invention relates to a method for producing a circular , annularly closed , minimally hypnotic expression construct from a dna double strand , and the expression construct produced by this method and the use thereof .
process according to one or more of claims 1 to 4 , characterized in that d represents imino , oxy or methylene .
the vaccine precursor in the method of claim 1 , wherein the human rotavirus is selected from the group consisting of human rotavirus strain , serotype 1 , the dsm@@ 1 strain , serotype 2 , the p strain , serotype , , , , , , , , , , , , , , , , , , , , , , , , , , , , serotype , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
acute neuron@@ al-@@ induced ligands of the calcium binding protein -1
powder pack for silver coating for making dental am@@ alga@@ m .
a plaster dressing according to claim 11 , characterized in that the plaster dressing comprises two edge cover layers ( 6 , 8 ) covering opposite edges of the dressing and a central cover layer ( 7 ) extending between the edge cover layers .
the use according to any one of claims 1 to 8 wherein the fuc@@ an is for administration as a pharmaceutical composition in a form comprising at least one of cream , paste , injectable carrier and polymer .
the device of claim 1 , wherein the magnification ( 11 ) is of a thickening .
the use of this gas is described in the literature for investigating respiratory function and pneumatic retinitis .
the chmp decided that relistor ’ s benefits are greater than its greater than its risks and recommended that and recommended that it be that its risks and risks and risks recommended and recommended that it be that it be that it be it that it be it that it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it it
cosmetic and dermatological cleaning preparations containing : a ) one or more pre-@@ gelatini@@ zed , cross-linked starch derivatives , b ) one or more ethoxylated oils . and , in addition , cosmetic and dermatological cleaning preparations .
the recommended starting dose is 5 mg for patients with pre-@@ disposing factors with pre@@ disposing factors to myopathy ( see section 4.4 special warnings and special special special special precautions special special warnings and special precautions ( special warnings and special precautions special warnings and special precautions for special warnings for precautions for special precautions for precautions for special precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for
the monitor ( 10 ) of claim 2 , further comprising a dc drive selection circuit ( 42 ) for applying the electrode selected from the reference conduit circuit than the new reference electrode , with a dc clock control signal from the dc signal generating circuit .
19 . the imaging system according to claim 4 , characterized in that it comprises a polari@@ ser ( p ) arranged on the path of the light beam of the source ( fs ) and which bundle comprises linearly polarised .
explan@@ ation of the tur@@ bo@@ pin and the work of the operation . • the use of the tur@@ bo@@ spin and the operation of the tur@@ bo@@ spin and and the work of the bo@@ spin and and and the bo@@ spin .
it is also important that patients should not shake the inhaler before use , not to breathe through the spiromax and do not cover the air inlets if they are pre@@ pping to the step ‘ breathe ’ .
in neutropenic mice , the auc / mic ratio to reach the bacterio@@ stasis was at least 16 times the ratio observed in immuno@@ competent animals ( see section 4.4 ) .
medical check valve according to one of claims 1 to 16 , characterized in that the housing ( 10 ) has inlet and outlet openings which are formed on staggered sides of the body of the body and that the piston ( 66 ) is movable from the closed position into a second position in which the sealing lip is located below the two axes .
a device according to claim 17 or 18 , characterised in that the material is selected from the group of n@@ br foams ( natural butadi@@ enes ) , the s@@ br foams ( synthetic butadi@@ enes ) , the elastomer foam materials , in particular from polyether block amide , of polyurethane , wool , cellulose , wood , ter@@ ra@@ ko@@ tt@@ a , gy@@ ps , ceramic materials .
a plant tissue comprising plant cells according to claim 13 or 14 . a transgenic plant comprising plant cells according to claim 13 or 14 . the plant of claim 16 comprising plant cells according to claim 13 or 14 . the use of a dna molecule comprising a dna sequence as defined in any one of claims 1 to 3 or a vector according to any one of claims 5 to 7 for the production of transgenic plants , plant cells and / or tissue .
a pharmaceutical formulation comprising formoterol fumarate dihydrate with a particle size of less than 10 µm and an additive which delivers less than 0.5 j / g than 0.5 j / g / g / less than 0.5 j / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g / g /
a transformation method comprising inoculation and co@@ cultivation of a target tissue of a target plant of a target of a target of a target of a target of a target a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
a method for producing a detergent composition comprising liposomes and liposomes dissolving anionic surfactants , the method comprising the steps of : ( i ) preparing a stabilized aqueous liposomal suspension , comprising the steps of : ( i ) preparing a stabilized aqueous liposomal suspension , at least one of 1 to 4 % by weight , based on the total weight of the stabilized aqueous liposome suspension , at least one of from 1 to 4 % by weight of the total detergent suspension , of step ( i ) in an amount of 0.1 to 35 %
the composition according to claim 20 further comprising a plasticizer . a composition according to claim 20 further comprising a plasticizer further comprising a plasticizer comprising a plasticizer comprising a plasticizer .
the method of claim 14 , wherein the virus antigen is fused to the interleukin-2 by means of a linker . the method of claim 14 , wherein the virus antigen is fused to the interleukin-2 by means of a linker . the method of claim 14 , wherein the virus antigen is fused to the interleukin-2 , the method of claim 14 , wherein the virus antigen is fused to the interleukin-2 by means of a linker . the method of claim 14 , wherein the virus antigen is fused to the interleukin-2 .
the method of claim 7 , wherein the foreign protein is a heterologous protein derived from the group consisting of therapeutic polypeptides and pathogenic agents .
all patients who did not have progressive disease who did not who did not who did not did who did not did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did who did
use according to claim 1 for the treatment of diseases of the central nervous system . the use according to claim 1 for the treatment of diseases of the central nervous system for the treatment of the central nervous system for the treatment of the treatment of the central nervous system .
a bone fixation system according to any preceding claim , wherein said elongate plate ( 31 ) has a rounded edge ( 36 ) extending between said top and bottom surfaces .
the use according to claim 9 or 10 , wherein the immune response modifier or regulator contains α in admixture or in combination with a pharmaceutically or veterinarily acceptable carrier .
the use of a compound of the formula i and / or the pharmaceutically acceptable salts thereof as claimed in one or more of claims 1 to 6 , alone or in combination with other drugs or active substances , for the preparation of a medicament for the treatment or prophylaxis of diseases associated with n@@ he .
the sterilizer ( 1 ) according to claim 10 , characterized in that a cryogenic plasma is produced in the vacuum housing .
patients should be advised not to drive a vehicle or operate complex machinery or operate other potentially hazardous activities or if this medicinal product affects these activities , whether this medicinal product affects these activities . • patients should be advised not to drive or operate machinery until these medicinal product affects these activities . these activities should be advised not to drive or operate machinery .
use according to claim 46 , characterized in that a is phenyl , phenyl substituted with one or more alkyl , haloalkyl or alkoxy , aralkyl , aralkyl or n-@@ containing heteroaryl or heteroaryl containing heteroaryl in the aryl and / or alkyl unit .
process for the preparation of physiologically acceptable salts of 1,4-di@@ substituted piperidine compounds according to claims 1 to 15 , characterized in that at least one compound according to general formula ( i ) is reacted with at least one acid , preferably according to one of claims 1 to 16 , at least according to at least one of the compounds at least one according to formula ( i ) .
cleaner according to any one of the preceding claims , characterized in that the ends of the hair ( 3 ) are substantially on the surface of a rotational body which is provided with two conical surfaces .
a method as claimed in claim 1 or claim 2 in which the amylin agonist is cgrp . a method according to claim 1 or claim 2 in which the amylin agonist is cgrp . claim 1 or 2 wherein the amylin agonist is cgrp . claim 1 wherein the amylin agonist is cgrp . claim 1 or 2 , wherein the amylin agonist is cgrp . claim 1 or 2 wherein the amylin agonist is cgrp . is wherein the amylin agonist is cgrp . agonist according to claim is wherein said amylin agonist is cgrp .
aortic and mitral valve stenosis , obstructive hypertrophic cardiomyopathy , obstructive hypertrophic cardiomyopathy , obstructive hypertrophic cardiomyopathy
use according to one of claims 1 to 4 , characterized in that the duty ratio of sulfite is between 0.001 % and 10 % by weight .
a method of attaching a closure member to a heat and pressure sensitive polyolefin layer of a disposable diaper or a similar disposable absorbent article , in which a preformed laminate ( 40 ) is formed from a single layer ( 44 ) of a disposable absorbent or disposable absorbent article , in which a preformed laminate ( 40 ) is formed from a single layer ( 44 ) which is bonded to the second surface ( 44 ) of a disposable absorbent article , and the bonding layer ( 46 ) is formed with an anti-@@ stick layer (
the agency ’ s committee for medicinal products for veterinary use ( cvmp ) concluded that the benefits of clo@@ sa@@ mectin pour-on solution for pour-on and associated names continue to outweigh the risks , subject to the variation of the marketing authorisations in the form of new adverse reactions and precautions , and in the form of conditions for risk minimisation and monitoring .
keep the vial in the original package in order to protect in in order to protect in order to protect in in order to protect in order to protect from in order to protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect from protect
a method according to claim 12 , wherein the step of providing a coil core further comprises providing a first cutting liner ( 15 ) attached to the first end of the coil core ( 10 ) and a second cutting liner ( 15 ) attached to the second end of the coil core ( 10 ) .
the effects of rebif on fertility have not been studied . the effects of rebif on fertility have not been studied in patients who have not been studied and the effects of rebif on fertility have not been studied . been studied studied in patients who have not been studied . not studied . not studied . not studied . not studied . not studied . not studied . not studied . studied studied studied . studied . . . . . . . . . . . . . . . . . . . . . .
the invention relates to chewing gum compositions containing ( a ) a water-insoluble base fraction , ( b ) a water-soluble proportion , and ( c ) physiologically active ingredients are selected from the group consisting of ( c1 ) sterols and / or sterol esters , ( c2 ) polyunsaturated fatty acids , their esters or glycerides and ( c3 ) ho@@ dio@@ a extracts or the active steroid glycosides obtained therefrom , and mixtures thereof .
a cyclodextrin inclusion complex obtainable by the process of claim 1 . the cyclodextrin inclusion complex of claim 12 comprising a solids enhancing agent and one or more active ingredient ( s ) in an amount of 1 to 20 % by weight of the complex .
a composition as claimed in claim 4 or 5 , wherein the carrier is hydrophilic and nonionic .
the use of claim 2 wherein the compound of formula ia comprises an amino group or pharmaceutically acceptable ammonium salts thereof , wherein n , y is selected from the group consisting of : isobutyl , cyclopropylmethyl , and benzyl , wherein r 1 is selected from the group consisting of isobutyl , cyclopropylmethyl , and benzyl , wherein r 1 is selected from the group consisting of isobutyl , cyclopropylmethyl , and benzyl , wherein r 1 is selected from the group consisting of isobutyl , cyclopropylmethyl , and benzyl , wherein r 1 is selected from the group
for instructions on use with the pre-filled pen , see section 6.6 and package leaflet .
the catheter of claim 6 , wherein the rotatable member has an axial lumen ( 8@@ 16 ) allowing passage of a guidewire therethrough .
jaw implant according to claims 8 and 9 , characterized in that buccal and lingual beve@@ ls ( 31 ) in the interface region of the implant body ( 30 ) have an angle α which is greater than an angle α &apos; between corresponding buc@@ cal@@ side and lingual beve@@ ls ( 32 ) in the interface region of the implant end ( 34 ) and that the angle α is in the region of the implant insertion section and the angle α is increased under the pressure of the screw ( 35 ) and at the angle α
the plasmid shuttle vector of claim 1 or 2 , further characterized in that the restriction endonuclease cleavage sites are selected from the group consisting of sal i and s@@ fi i sites . the plasmid shuttle vector of claim 1 or claim 2 further characterized in that the restriction endonuclease cleavage sites are selected in the group of sites in which the restriction endonuclease cleavage sites are in the form of sites of cleavage in the of the vector .
29@@ 0-3 or bacillus circul@@ ans which are produced in the conversion of starch or starch similar substrates to cyclodextrin ( cd ) in an increased extent γ@@ -c@@ d , characterized in that its protein sequence in the region between amino acid position 180 and amino acid position 240 has the amino acid sequence asn leu xaa asp ( seq .
a compound of the formula : wherein r ₁ and r ₂ are each independently h , ( c ₁ -c ₄ ) alkyl , ( c ₂ -c ₆ ) alkynyl or ( c ₂ -c ₆ ) alkynyl ; r ₃ , r ₄ and r ₅ are each independently h , ( c ₁ -c ₆ ) alkenyl , ( c ₂ -c ₆ ) alkenyl , ( c ₂ -c ₆ ) alkenyl , ( c ₂ -c ₆ ) alkenyl , ( c ₂ -c ₆ ) alkenyl , ( c ₂ -c ₆ )
after crosslinking , the medical instruments made from the polymer material ( 6 ) have a high transparency , are kin@@ k-@@ proof and flexible .
17 . a composition as claimed in any one of the preceding claims in which the cationic organic material contains between 0.1 and 20 % by weight of the total weight and the composition contains between 0.5 and 1000 ni@@ h units ( national institute of thymosin units ) of thrombin per gram of composition .
if a patient tole@@ tioned the infusion , the dose may be increased to achieve the therapeutic dose of 1 mg / kg and the infusion rate may be increased by slow titration , depending on the tolerability .
the method of any one of claims 1 to 3 , wherein the antibody for the enzyme does not substantially inhibit the ability of the 1st s@@ bp@@ m of the conjugate to bind to a second specific binding pair member ( 2. s@@ bp@@ m ) .
the method of claim 16 , wherein the enzyme is bovine chymosin , bovine pro@@ chymosin , aspergillus niger glucoamylase , humicola griseo@@ sa glucoamylase or mucor me@@ he@@ he@@ i carboxyl protease .
reception arrangement according to one of claims 11 to 23 , characterised in that it is associated with a transmitter ( 13 ) connected via a distributor element with the antenna elements ( 2 ) and that a transmitter signal emitted by the transmitter ( 13 ) is fed onto the antenna elements ( 2 ) in such a way that a magnetic resonance excitation signal is fed into the reception volume .
process according to claim 1 , characterised in that the process claimed in the process as in the claim 1 , process as in process in the as claim 1 , process as in the process process in the process process in claim 1 , in claim 1 , in claim 1 process in process process as claimed in the process as claimed in claim 1 , in as process 1 as claim 1 as process 1 process as 1 in claim 1 as process 1 process as 1 process as 1 in claim 1 as claim 1 as process
compounds of formula ( i ) of formula ( i ) ( of formula ( i ) according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to according to to according to according to according to according to according to according to
the apparatus of claim 1 , wherein the main control program further generates a power potential value by detecting from the set of derived power values , and multiplying the anaerobic capacitance value with the maximum power level , the performance potential parameter corresponding to the product .
circuit arrangement according to claim 3 , in which the output signal is increased continuously or in stages when a warning signal is present .
use according to any one of claims 1 to 9 , wherein the contact lens care composition is a daily lens contact lens composition .
5 . the oscillator of claim 4 , wherein the stop surface is discontinuous and is formed by a crown ring .
a process for preparing a compound according to claim 1 a compound according to claim 1 according to claim to compound according to claim to according to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim to to claim
a process according to claim 14 wherein the peptide has an amino acid sequence selected from the group consisting of : ( a ) a ( a ) ( a ) ( a ) ( a ) h ( a ) r ( a ) a r r ; ( c ) f a r a ) ; ( a ) a r a ( a ) a r a r a a ) a r a r a r a a r a r a r a r a r a r a a a a a a a
for the safe and effective use of the medicinal product of the medicinal product the medicinal product of the medicinal product the medicinal product the the
renal excretion of unchanged be@@ da@@ qu@@ iline is negligible ( &lt; 0.001 % ) .
a pump according to any preceding claim , wherein said pressure increasing device is capable of developing a pressure of at least 8.@@ 26 x 10 ⁵ n / m ² ( 120 p@@ sig ) .
process according to claim 6 , characterized in that the mixture comprises at least two starch acetates with different substitution levels .
a compound as claimed in claim 11 or claim 12 characterised by a differential amino@@ meta@@ metry curve at a heating rate of 5 ° c / min in a closed a closed a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
if the pandemic situation occurs , immunisation should be delayed in patients with severe febrile illness or acute infections .
check the number of vials and prepare the material :
vaccine for the immunization of cats against toxopla@@ sms without disse@@ cting the oocysts .
on average , there are six weeks , but the cells can also be frozen and kept up for two years until you and your surgeon have agreed a matching operation .
the stent according to claim 6 , wherein the stent is thin-walled . the stent according to claim 6 , wherein the stent is thin-walled . the stent according to claim 6 wherein the stent is thin-walled . the stent according to the claim 6 , wherein the stent is thin-walled . the stent according to claim 6 , wherein the stent is thin-walled . the stent according to claim 1 wherein the stent the stent is thin-walled . stent the stent according to claim 6 , wherein the stent is thin-walled .
use of the imaging agent of the imaging agent of of the of claims of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the the claims of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of
monoclonal antibody specific to a novel epitope of lfa@@ -1 antigen from human t lymphocyte .
this included the limitation of the duration of treatment in certain conditions , the contraindication of the medicinal product in patients with pre-existing fibrosis or with other medicinal products , the output of a referral for healthcare professionals ( d@@ hp@@ c ) , in which the risk is num@@ ved , a che@@ ck-@@ list for prescribers and a pharmacological in vitro studies for affinity for the 5-ht receptors for the medicinal product .
poly@@ nitrogen derivatives according to any one of claims 1 to 3 according to the following formula : ( w@@ -a ) x1 x-@@ b- ( c-@@ z ) x2 ( ia ) in which w , a , x , b , y , c , z , b , y , c , z , x ₁ and x ₂ have the meanings given in claim 1 when y = 0 .
use of a moisture sensitive active pharmaceutical ingredient in the manufacture of a pharmaceutical composition for treating hypertension , wherein the moisture sensitive active pharmaceutical component is wet granulated with a solution of co@@ povidone .
pyrimidine based cd@@ k inhibitors for the treatment of pain
in germany , 400@@ 0-@@ 5000 h@@ kb rupture ( without consideration of a number of dark@@ dity ) can be used .
use according to claim 1 , wherein the neurological disorder or disease is caused by the action of substances causing neurodegenerative diseases .
an electrical connection is achieved in a simple and reliable manner that within the further cone-@@ shaped sealing surface ( 11 ; 12 ) , at least one electrical contact ( 18 , 20 ) is provided in each coupling half ( 1 , 2 ) .
composition according to any one of the one of the preceding claims , the the composition of the preceding claims , the the composition the composition of the preceding claims the the the the the the preceding the the preceding the the preceding the the preceding the the the preceding claims of the the preceding claims the the preceding claims preceding the the preceding claims preceding the preceding the preceding the preceding the the preceding preceding the the preceding preceding the the preceding preceding the the preceding preceding the the preceding preceding the the preceding preceding the the preceding preceding
the prosthesis of claim 26 , wherein the liquid is a physiologically acceptable oil . the prosthesis of claim 26 wherein the fluid is a physiologically acceptable oil . the prosthesis of claim 26 wherein the fluid is a physiologically acceptable oil . the prosthesis of claim 26 wherein the fluid is a physiologically acceptable oil . the prosthesis of claim 26 wherein the fluid is a physiologically acceptable oil . the prosthesis of claim 26 wherein the fluid is a physiologically acceptable oil . the prosthesis of claim 26 wherein the fluid is a physiologically acceptable oil .
the prion deactivation method as set forth in any of preceding claims 1 to 20 , further characterized in that the cleaning agent has an alkali metal content of at least 500 ppm . the prion deactivation method of any of claims 1 to 20 further characterized in that the cleaning agent has an alkali metal content of at least 500 ppm . the prion deactivation method of any of the preceding claims 1 to 20 further characterized by the method of deactivation of the prion .
probes for detecting and identifying helicobacter pylori
seeds according to claims 1-3 , wherein the oleic acid content is from 55 to 75 % by weight .
eesti österreich norge pfizer animal health tel : + 370 5 269 17 96
no . : 1 &#93; , sequences substantially complementary to the cdna sequence &#91; seq .
an increased incidence and increased incidence of incidence of renal tubular basophils / hy@@ al@@ ini@@ sation / hy@@ al@@ ini@@ sation , al@@ al@@ ini@@ sation , al@@ ini@@ sation , al@@ ini@@ sation ini@@ al@@ ini@@ sation ini@@ al@@ ini@@ sation ini@@ al@@ ini@@ sation ini@@ al@@ ini@@ sation ini@@ al@@ ini@@ sation ini@@ al@@ ini@@ sation ini@@ al@@ ini@@ sation ini@@ al@@ ini@@ sation ini@@ ini@@ ini@@ sation ini@@ ini@@ ini@@ sation ini@@ ini@@ ini@@ sation ini@@ ini@@ ini@@ sation ini@@ ini@@ ini@@ ini@@ ini@@ ini@@ ini@@ ini@@ sation ini@@ ini@@ ini@@ ini@@ ini@@ ini@@ ini@@ ini@@
web for absorbent articles with textured carrier contact surface
section 4.6 – fertility , pregnancy , , , lactation , and lactation – pregnancy , fertility , fertility , fertility , fertility , , fertility , , , , , , , , , , , , , ,
an aerosol formulation according to claim 11 or 12 wherein the adjuvant comprises magnesium stearate .
a protein or peptide for use in the modulation of malignant growth cell in a mammal , wherein a protein or peptide is in a mammal a mammal or a a mammal a a a mammal in a ribonucleotide a a a a a a a a a a a or a a a peptide a a a a peptide or a a peptide a a a peptide a a protein a a a peptide a a a a a a peptide a a protein a a a peptide a a a a a a a a a a a
the apparatus of claim 16 , wherein the grid is located along the top surface of the base .
the bio@@ data interfacing device according to claim 7 , wherein the camera unit ( 68 ) is pivotally formed relative to its attachment area on the outer surface of the operating console ( 1 ) ( 1 ) . ( 1 ) ( 1 ) ( 1 ) ( 1 ) ( 1 ) ) ( 1 ) ) ( 1 ) ) ( 1 ) . ) ( 1 ) ) . ) ) ) . ) ) ) . ) ) ) . ) ) ) . ) ) . ) ) . ) ) .
a pharmaceutical composition comprising bmp@@ -2 , ε@@ -amino@@ caproic acid , autologous blood and a pl@@ ga matrix .
an artificial joint device ( 2 , 2a , 2b , 2c ) according to claim 11 , which is used in an artificial leg ( 1 ) and / or an artificial arm ( 40 ) , and further comprising an operating belt detecting means ( 24 ) for detecting an operating cu@@ ft of a user to detect the artificial leg ( 1 ) and / or the artificial arm ( 40 ) , and wherein the control / regulating means ( 21 ) controls the actuators ( 13@@ d , 17@@ d ) according to the scanned
the combination of o@@ bin@@ u@@ tuzumab with chlorambuc@@ il or ben@@ dam@@ u@@ stine may increase the incidence of neutropenia ( see section 4.4 ) .
a process according to either of claims 7 and 8 , wherein an agent for accelerating lipase activity has been introduced into the solution prior to lyophilization .
massage device according to one of the preceding claims , characterized in that the further massage device ( 4 ) is in the form of the massage device , the further massage device , the massage device , the device of the further massage device ( 4 ) , the device ( 4 ) ( 4 ) ( 4 ) ( 4 ) ( 4 ) ( 4 ) ( 4 ) ( 4 ) ( 4 ) ( 4 ) ( 4 ) ( 4 ) ( 4 ) ( 4 ) ( 4 ) ( 4 ) 4
eme@@ da@@ stine 0.5 mg / ml 0.5 mg / ml / ml / ml / ml / ml / ml / ml
a substrate as claimed in claims 1 to 16 used in agricultural substrates .
upon repeated administration of peginterferon beta-1a to sexually mature female monkeys , effects on menstrual cycle and progesterone levels were observed .
a process according to any one of claims 1 to 18 , characterized in that the second reagent is sodium azide .
treatment as rivastigmine has a plasma half-life of about 3.4 hours and a half-life of acetylcholinesterase has a half-life of about 9 hours of about 9 hours , a of about 9 hours of asymptomatic of about a 9 hours of asymptomatic of a of about 9 of about about of about 9 of about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about about
skin and subcutaneous tissue disorders
severe allergic reactions to insulin may occur to occur to occur to occur to occur to occur to occur to occur to occur to occur to occur to occur to reduce the risk of serious allergic reactions to insulin to to be life-threatening to insulin to insulin .
a method according to claim 16 , wherein the antigen has a molecular weight , which has a molecular weight , to a transient marker , of a chronic phase , of toxopla@@ smosis , according to the claim of 16 , of claim 16 .
a vector comprising a dna encoding a nuclear cell targeting sequence operably linked to a dna encoding a recombination promoting enzyme from the group e. coli rec@@ ca proteins , modified e. coli rec@@ ca proteins having atpase activity and enzymatically active parts thereof , at least one selection marker , and wherein the desired characteristic is selected from the group consisting of the expression of an additional protein , the desired property of which is selected from the group consisting of the expression of an additional protein , and the plant cell is selected from the group consisting of
the use of claim 1 , wherein the germ is staphylococcus aureus or staphylococcus epidermis . use according to claim 1 , wherein the germ is staphylococcus aureus or staphylococcus epidermi@@ . use according to claim 1 , wherein the germ is staphylococcus aureus or staphylococcus epidermi@@ . the use according to claim 1 to claim 1 .
a syringe according to any one of claims 5 to 9 , wherein the liquid-absorbent material comprises a water holding and fluid absorbing accelerator and an antibacteri@@ ally active agent .
use according to any one of the preceding claims 1 to 4 , characterized in that the product contains at least one adjuvant selected from the group comprising emollients , re@@ fre@@ shing agents , perfumes , coloring agents , ampholytic , sodium chloride , sugar , glycerol , glycols , solvents and thickeners .
a pharmaceutical preparation according to claim 14 according to claim 14 to wherein sa according to the claim 14 to claim 14 to claim 14 to claim 14 to claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim 14 claim
the compound of claim 3 or 6 wherein l is s ( cr 2 2 ) m , -nr 1 so 2 ( cr 2 2 ) , so 2 ( cr 2 2 ) m , so 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
a process for the preparation of a compound of the structure according to formula ( a ) wherein the compound of formula ( i ) is : ( 1 ) a n , or c ( r ) ; ( r ) r &#93; -3- &#91; &#91; &#91; 4- ( 3-carboxy@@ methyl-4-@@ methyl-2-oxo-@@ 7-@@ quinolinyl &#93; &#93; -3- &#91; &#91; &#91; 4- ( 3-carboxy@@ methyl-4-@@ 6,8-difluoro@@ 7-@@ quinolinyl ) &#93; -3- &#91; &#91; &#91; 4- ( 3-carboxy@@ methyl-4-@@ 6,8-difluoro@@ 7-@@ quinolinyl &#93; - &#93; -3- &#91; &#91; &#91; 4- ( 3-carboxy@@ methyl-4-@@ 6,8-difluoro@@ 7-@@ quinolinyl ) &#93; -3- &#91; &#91;
the compound of claim 1 which is 4- ( 3-cyclopent@@ yloxy@@ -4-methoxy@@ benzyl ) -1- ( 1-methylimidazol@@ 4- ) piperidine .
method and route ( s ) of administration ( s ) ( s ) ( s ) ( s ) ( s ) ( s ) ( s ) s ( s ) s ( s ) s s ( s ) s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s s
oxidation dyeing composition for keratinous fibres comprising glycerol and another polyol as glycerol at predetermined ratio
an apparatus comprising : a central support ( 7 ) ; a pair of side supports ( 6 ) on respective sides of the central support ( 7 ) ; attaching means ( 8 , 9 ) to each side of the central support ( 7 ) for moving the sliding means in relation to the surface of the central support ( 7 ) for movement of the sliding means in relation to the surface of the central support ( 7 ) to the surface of the central support ( 7 ) for movement of the driver .
the pharmaceutical composition of claim 12 consisting of one or more nucleic acid molecules having a nucleotide sequence encoding a protein selected from a protein antigen expressed from a hyperproliferative cell and a protein antigen characteristic of an autoimmune disease , and one or more hydroxylated lower alkylene .
surgical instrument according to one of claims 1 to 3 , characterized in that the arrangement of auxiliary markings has a regular spacing of auxiliary gradu@@ ations which extend from an origin which corresponds to the distal end of the catheter .
the tampon of claim 1 wherein the tampon has an insertion end comprising the vertex of the contracted matrix the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
the duple@@ x@@ ed parvovirus particle of any of any of of of claims 1-@@ 28 of the parvovirus parvovirus particle of parvovirus of parvovirus of parvovirus .
common injection site reactions : transient pain , redness , in@@ duration , redness , tenderness , redness , redness , redness , redness , redness , redness , redness , , , , , , , , , , , , , , ,
use according to claim 1 , wherein the composition is prepared using rb 1 or r@@ g 1 together with a metabolic precursor for acetylcholine .
method for industrial production of phosphatidyl@@ ser@@ ines
a pair of protein bound membrane-@@ bound , chimeric receptors , wherein one of the receptors comprises : ( a ) an extracellular portion and ( b ) an intracellular or transmembrane moiety derived from a t-cell receptor cd3 , zeta or et@@ a polypeptide , a b cell receptor or a functional hiv envelope binding derivative thereof , and ( b ) an intracellular moiety derived from cd28 .
the method of claim 6 , wherein the catalase is present at a concentration of 50 to 50,000 iu / ml . the method of claim 6 wherein the catalase is present at a concentration of 50 to 50 000 iu / ml . / ml of the process of claim 6 . / ml / ml / ml / ml / ml / ml / ml / ml / ml . . . . . . . . . . . . . . . . . . . . . . . . . . . .
an arrangement according to any one of the preceding claims , characterised in that the switches ( s ₁ , s ₂ , s ₃ , s ₄ , s ₅ ) are sealed or uni@@ closed by disposable current flow devices ( d ₁ , d ₂ , d ₃ , d ₄ , d ₅ ) .
pregnancy talk to your doctor if you become pregnant your doctor to you if you become pregnant if you become pregnant .
a compound according to claim 1 wherein the ( acid group ) is -co 2 h. the compound of claim 1 wherein r 5 is oxygen .
a hardenable composition according to any one of claims 1 to 21 in the form of a film material .
use in patients with renal transplant there is no experience with the administration of ze@@ stril in patients with recent kidney transplantation .
intraocular pressure recording system according to one of the preceding claims 1 to 4 , further comprising a passive strain gauge ( 5 ) . intraocular pressure recording system according to claim 5 , wherein the passive strain gauge ( 5 ) has a generally circular shape of a continuous meri@@ dian element placed in such a way that several of its sections ( 7 ) are arranged radially .
the recess ( 6 ) , the central axis ( 8 ) of which is displaced relative to the ( 9 ) of the tibia part ( 1 ) for the equation , permits an un@@ disturbed course of the cross-@@ bands ( 7 ) .
the caregi@@ ver should be instructed to measure the pulse if the child does not feel well , and the treating physician should inform a very rapid or very slow heart rate .
an elastic protective material for a safety glove , which is at least for medical purposes , comprising at least two partial materials , the first part ( 1 ) being adapted to penetrate the first sub@@ material , the first part ( 1 ) being adapted to penetrate the first sub@@ material , wherein the first part ( 1 ) is provided , the first part ( 1 ) being adapted to penetrate the first sub@@ material , the first part ( 1 ) being adapted to penetrate the first sub@@ material , the first part ( 1 )
will i read the boo@@ k today ?
the invention relates to the production of classical fo@@ wl@@ pe@@ viruses of the strain a / f@@ pv / ro / 34 ( h@@ 7@@ n1 ) by means of a reverse gene@@ tics and the production of mutants of said virus strain whose genome is largely consistent with the wild type strain .
a compound according to any one of claims 1 , 2 , or 3 for use in medical therapy . use of a compound of any of claims 1 to 3 in medical therapy in medical therapy .
caution when using this medicine with clonidine .
an amylin antagonist according to any one of claims 1 to 12 for use in the treatment of type ii diabetes mellitus . the amylin antagonist of any one of claims 1 to 12 for use in the treatment of a patient with insulin resistance .
a device ( 3 ) for accommodating the substance to be introduced is provided via the electrodes ( 2 ) .
composition according to claim 8 , characterized in that , in , , , in , , , in that , in , , in that , in , , in that , in that , in that , in that , in that in that in that in in that in in that in in that in in that in in that in in that in in that in in that in in that in in that in in that in in that in in that in in that in in that in in that in in that in
tekturna has negligible influence on the ability to drive the ability to drive the ability to drive the the ability to drive and to drive the drive and to drive the ability to drive and to drive and to to drive to drive and to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive to drive
the apparatus of claim 7 , wherein the proximal portion ( 16 ) is made of a material selected from the group consisting of stainless steel , nickel titanium alloys . the apparatus of claim 7 , wherein the proximal portion of the proximal portion of the claim is made of a material of claim 7 of claim 7 of claim 7 .
you know , the whole thing with &quot; you are so a pig , right ?
if the dog is not to be washed with shampoo , it is better to do it to do before the product is applied to the dog the dog to do to do to the dog to the dog the dog the dog is to be washed to do the dog the dog is to be better to do the the dog to the dog the dog is better to the dog .
you have experienced hypersensitivity reactions to other antifungals such as ketoconazole , fluconazole , itraconazole or voriconazole .
the o@@ cc cell lines were cultivated on collagen-@@ i matrix with and without entrapped fibro@@ - / myo@@ fibroblasts ( cultured from no@@ d@@ re pal@@ mar@@ fibro@@ matosis ) .
the valve prosthesis of claims 1 to 7 , wherein the reinforcement extends along a portion of the reinforced free co@@ ap@@ tation edge .
in the future , the animals will be exposed to the blue@@ tongue virus in the future , the immune system the immune system the immune system the immune system the immune system the immune system the immune system the immune system the immune system the immune system the immune system the immune system the immune system the immune system the immune system immune system immune system immune system immune system immune system immune system immune system immune system immune system immune system immune system immune system immune system immune system immune system immune system immune system immune
a hybridoma cell line , characterized in that it is formed by cell fusion of a mouse myeloma cell and a mouse spleen cell immunized with the c-@@ reactive protein and a monoclonal antibody which reacts specifically with the side surface of a c-@@ reactive subunit of a c-@@ reactive protein .
use of a compound of formula i as defined in any one of claims 1 to 7 in the manufacture of a medicament for reducing dopamine synthesis and delivery in a patient suffering from hyperactivity of the dopaminergic system .
keppra contains sodium the maximum single dose of keppra concentrate contains 2.5 mmol ( or 57 mg ) sodium ( 0.8 mmol &#91; or 19 mg &#93; sodium per vial ) .
a compound as claimed in claim 1 , which is ( 3@@ as@@ -cis ) -1,2,3,3a ( 3@@ as@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@ 3@@
pharmaceutical composition , characterized in that it contains a imidazo- &#91; 4,5-b &#93; pyridine compound according to claim 1 .
the system of claim 8 , wherein the modifier gas is nitrogen .
the angioplasty device of claim 9 , wherein said actuator ( 4 ) is a balloon , a cutting motor , a fiber mesh or a laser .
a process for preparing a compound for preparing a compound according to claim 1 for preparing a compound according to claim 1 a compound a compound a a compound a a compound a a compound a a compound a a compound a a compound a a compound a a compound a a compound a a compound a a compound a a compound a a compound a a compound a a compound a a compound a a compound a a compound a a compound a compound a compound a compound a compound a compound a compound a compound a compound a
use according to claim 8 wherein the medicament is for administration to the administration is to the administration of the antibody to the antibody of 20 mg / m of 20 mg / m mg of 20 mg / mg of 20 mg mg / mg of 20 mg mg 20 mg mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20 mg 20
he &apos;s now on the dead : &quot; we &apos;ll do slowly and learn us . &quot;
hair dyeing composition comprising , as developer substance , at least one tri@@ amino@@ hydroxy@@ pyrimidine admixed with 1,4-di@@ aminobenzene and / or 1-methyl-@@ 2,5-di@@ aminobenzene and at least one one of resorcinol , 2-methyl resorcinol and 2-chloro@@ resorcinol and / or α-@@ naphthol in one with one one in one one and one one of resorcinol , 2-methyl resorcinol , 2-chloro@@ resorcinol and α-@@ naphthol .
such effects are usually reversible .
the use according to claim 6 wherein the disease is depression . the use according to claim 6 wherein the disease is depression . the the the the use is the disease is the disease is the disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease disease
product comprising : ( a ) a recombinant retrovirus ( : ( a ) a ( a ) a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
risk factors for bp@@ f were not statistical significance for bp@@ f ( p = 0.03 ) and lumbar trauma ( p = 0.003 ) .
a method of making a wound dressing according to any one of claims 1 to 15 , comprising the steps of : ( a ) providing one of the wound facing sheet ( 14 ) with a back surface and one of the wound facing surface ; ( b ) providing a support sheet ( 12 ) ; ( c ) providing a support sheet ( 12 ) ; ( c ) providing the absorbent sheet ( 12 ) to the wound facing sheet ( 14 ) along a network of bond lines , forming the absorbent material within the
a loading dose of 80 mg of peg@@ vi@@ som@@ ant should be administered subcutaneously under a medical supervision of a dose of 80 mg of peg@@ vi@@ som@@ ant .
use of a composition according to one or more of claims 1 to 9 , characterized in that the weight ratio of components b ) to c ) is from about 4 : 1 to 1 : 2 .
the exact mode of action of lacosamide is not yet understood , but it appears to inhibit the activity of sodium channels ( pores on the surface of nerve cells ) that allow the transmission of electrical impulses between nerve cells .
a formulation according to claim 5 , wherein the tonicity modifier is mannitol . a formulation according to claim 5 , wherein the tonicity modifier is mannitol . is mannitol is mannitol is mannitol . is mannitol . is mannitol . is mannitol . is mannitol . is mannitol . is mannitol . is mannitol . mannitol is mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol mannitol
the method of claim 7 , wherein two or more of the core wires ( 34 ) are coated , subsequently onto the outer surfaces of the core wires a layer ( 38 ) of insulating material and the plurality of wires are crimped to a multi-@@ wire coil .
the sterilisation container ( 1 ) for accommodating instruments , especially endoscopes or parts thereof , consists of a lower part ( 2 ) and consists of a base ( 2 ) which can be detachably mounted on the latter .
a process according to claim 14 which comprises the preparation of a compound of formula ( i ) , or a stereoisomeric , or non-toxic pharmaceutically acceptable acid addition salt thereof , wherein r 4 is h and r 3 and r 5 are a bond , and r 6 and r 5 are r r r 4 and r 6 and r r and r 4 r r r r 4 and r 6 and r 4 r 4 r r 4 r r r 4 and r 5 r 4 r r r r r r r r
an implantable atrial defibrillator ( 30 ) according to claim 8 further characterized in that the second detector includes second recognition circuit ( 62 ) for detecting the depolarization activation wave and a second output circuit ( 76 ) coupled to the second recognition circuit ( 62 ) to generate the second trigger signal in response to the second recognition circuit ( 62 ) .
microgranules according to claim 1 , wherein the amount of copolymer is between 4 and 10 % with respect to the amount of ur@@ so@@ deoxycholic acid .
the article of claim 5 , wherein the fiber density of the hydrophilic fiber aggregates of the hydrophilic fiber aggregates of the fiber density of the fiber sheet the fiber fiber fiber density the fiber density the fiber fiber fiber the fiber density the the fiber density the fiber fiber fiber the the fiber density the fiber fiber fiber the the fiber density the fiber fiber fiber the the fiber fiber the the fiber fiber the the fiber fiber the the fiber fiber the the the the the the the the the the the the the the the the fiber
an artificial kidney according to one of claims 1 to 5 , characterised in that a source ( 11 ) for sterile liquid is connectable to the extracorporeal blood circuit ( 5 , 7 ) either upstream or downstream of the exchanger ( 1 ) .
a process according to claim 7 wherein the preparation is heated about 1 to 3 hours at a temperature of about 50 ° c. the method of claim 8 wherein the ph is about 4.@@ 24 to 4.@@ 42 .
cis bio international , paris , france , france , france , , france , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
as aripiprazole mylan is a generic medicine , the company presented the results of studies in volunteers to show that the 10 mg tablet and the 10 mg orodispersible tablet of aripiprazole mylan are bioequivalent to the corresponding tablets of the reference medicine , abilify .
the requirements for submission of periodic safety update reports for this medicinal product for this medicinal product are for this medicinal product for medicinal product this medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product medicinal product product
in the event of effentora , it is given as a buccal tablet , so that fentanyl is absorbed via the mouth mucosa .
the high@@ ly-@@ efficient ultrasonic transfer member of claim 4 , wherein the wire has a free end surface which is flat at least one surface thereof radially inward from its outer periphery .
3 . the laminate material of claim 1 wherein the adhesive layer has an aperture density of at least about 1 % .
cosmetic or pharmaceutical preparations according to claim 7 , characterized in that r 3 is hydrogen , r 1 and r 2 r and r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r
synthetic genes for enhanced expression
the coupling site of claim 6 , wherein the tubular housing ( 214 ) includes a substantially cylindrical outer wall ( 221 ) and a flange ( 229 ) extending radially inwardly from the outer wall toward the opening ( 236 ) over a portion of the first end of the valve member , the flange having a radially outwardly directed surface of a male luer connecting cone in sealing frictional engagement when an end of the male luer connector cone is inserted into the cavity by the membrane .
highly concentrated aqueous dispersions containing hydrophilic micro@@ fine metal oxide particles and dispersant
a lifting and walking aid according to claim 9 , wherein the bent ends of the parallel side tube elements ( 2d , 2e ) in the upper horizontal frame are bent at a smaller angle than 90 ° so that the front portion of the upper horizontal frame ( 2@@ d-@@ 2f ) is slightly raised .
the white needle the white needle guard is now visi@@ ted . • the white needle the white needle the white needle cover is now visible . the white needle cover is the white needle white needle white needle white needle white needle white needle white needle white needle white needle white needle white needle white needle white needle white needle white needle white needle white needle white needle white needle white needle
process according to claim 5 or 6 , characterized in that cell suspensions of the genotype dsm 6@@ 009 are used .
a microscope as claimed in claim 4 , further characterised in that the scanning means is operable to move the light beam transmitted from the third optical fibre means to the light focusing device . the microscope of claim 4 , further characterized in that the scanning means is operable to move the light beam transmitted from the third optical fiber means to the light focusing means .
she said me , i shoul@@ dn &apos;t look .
elevations to &gt; 8 x uln were observed in 2.4 % of patients treated with bosentan .
these patients may be at increased risk of hypersensitivity reactions and should not be given pomalidomide .
voriconazole / emtricitabine voriconazole / tenofovir disoproxil fumarate anticonvulsants
7 . filter according to one of claims 1 to 6 , characterised in that the first and second loops ( e1 , e2 ) are convex and of a first free extremity ( m1 ) after a second free extremity ( m2 ) of the filter in the same direction of rotation about the centre ( o ) .
process according to one of claims 1 to 7 , characterized in that , in step b ) , a substrate containing inorganic compounds and / or organic compounds is used .
in order to secure the article after use , for the purpose of disposal in a rolled or folded configuration , the article is designed such that the article ( 44 ) facing the body facing the body facing the body is in the range of 35 to 50 dynes / cm in the region of between 35 and 50 dynes / cm , thereby exerting a stronger adherence of the first fastening means ( 72 ) .
use of a composition of any of claims 1-10 for the preparation of a pharmaceutical of the of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of
process for the preparation of a pharmaceutical composition according to claim 1 , characterized in that the composition is a nasal cream .
an air cleaning device according to claims 1 and 11 to 12 , characterized in that the respective filter holder ( 52 , 12 ) formed essentially from an inner clamping tap ( 43 ) and a web ( 45 ) formed with the clamping tap ( 43 ) extends through the respective longitudinal groove ( 40 ) and is connected to its outer end with an approximately u-shaped tension member ( 44 ) and engages with its free external ends and engages on the outside surfaces of the inner wall ( 37 ) .
a surgical instrument according to claim 14 , characterised in that the latch ( 57 ) is guided in a recess ( 58 ) of the actuatable handle ( 19 ) . the surgical instrument according to claim 14 , wherein the latch ( 57 ) is guided to the latch ( 57 ) . the surgical instrument of claim 14 , wherein the latch ( 57 ) is guided to the latch ( 57 ) ( 19 ) ( 19 ) . ( 2 ) . ( 2 ) . ( 1 ) . ( 1 ) .
an insertion assembly according to claim 16 , characterised in that two such positions of the resilient arms are provided for movement in different directions .
this is usually achieved by an inclusion of 100 - 200 ppm ti@@ amulin hydrogen fumarate in the finished feed by ti@@ ti@@ ti@@ ti@@ - - ti@@ ti@@ ti@@ - ti@@ ti@@ ti@@ - - - - - 200 ppm ti@@ amulin hydrogen fumarate hydrogen fumarate hydrogen fumarate hydrogen fumarate hydrogen fumarate hydrogen fumarate hydrogen fumarate hydrogen fumarate hydrogen fumarate hydrogen fumarate hydrogen fumarate hydrogen fumarate hydrogen fumarate hydrogen fumarate hydrogen fumarate hydrogen fumarate hydrogen fumarate
ask your doctor for advice for advice . your doctor for advice for advice for advice for advice . advice for advice for advice for advice for advice for advice for advice for advice for advice for advice for advice for advice for advice for advice
a yeast cell culture according to claim 1 or a method according to claim 2 , wherein the protein of the yeast phero@@ mone system is an abc transporter involved in membrane transport of the yeast phero@@ mone and the surrogate is also an abc transporter .
an aromatic camptothecin ester having the formula ( i ) : wherein r 1 is h , no 2 , nh 2 , n 3 , a c 1 -c 16 -alkylene group , a c 1 -c 16 alkyl group , a c 1 -c 16 -alkylene group , a c 1 -c 4 alkyl group , a c 1 -c 16 -alkylene group , a c 1 -c 8 alkyl group , a c 1-8 alkyl group , a c 1 -c 8 alkyl group , a c 1 -c 6 alkyl group , a c 1 -c
a hair treatment composition as claimed in claim 1 , which comprises a direct dye . the hair treatment composition of claim 1 comprising a direct dye . a hair treatment composition of claim 1 which comprises a direct dye . the hair treatment composition of claim 1 comprising a direct dye . a hair treatment composition according to claim 1 which comprises a direct dye . the hair treatment composition of claim 1 comprises a direct dye . a hair treatment composition of claim 1 which comprises a direct dye .
a hydrophilic adhesive composition according to any one of claims 1 to 5 , wherein water is present in a proportion of 1 to 85 % by weight .
a compound according to any one of claims 1 to 5 wherein z is c or n and r 20 is methyl , ethyl , isopropyl , cyclopropylmethyl or hydroxy@@ ethylene .
a process for the preparation of gem@@ -di@@ phosphonic acid-@@ meth@@ a@@ op@@ op@@ ine ( meth@@ 0-@@ ox@@ yla@@ te- ) and de@@ aza@@ -n-@@ 10-@@ a@@ meth@@ op@@ terin compounds of the formula of an a@@ meth@@ op@@ in-@@ prodrug , the ge@@ ale di@@ phosphonic acid moiety of which is linked via a peptide bond to the p@@ tero@@ yl@@ glutamic acid moiety , the geminal diphosphonic acid moiety of which is connected to the p@@ tero@@ yl@@ glutamic acid moiety , the geminal di@@ phosphonic acid moiety of which is linked to the p@@ tero@@ yl@@
the invention relates to novel dihydro@@ thien@@ opyrimidin@@ es of the formula 1 , to the pharmacologically compatible salts , to the diastereomers , enantiomers , enantiomers , hydrates , to the , enantiomers , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
a head according to claim 11 or claim 12 , wherein the spring element ( 158 , 170 , 192 ) is supported on a side wall ( 164 ) of the head .
a pharmaceutical composition according to claim 3 which further comprises a pharmaceutically acceptable diluent or carrier .
the nucleic acid construct or set of genetic elements of any of claims 28 or 29 , wherein the single-stranded nucleic acid molecule is an inhibitory nucleic acid molecule . the nucleic acid construct or the set of genetic elements of any of claims 28 or 29 or 29 of genetic or of genetic elements or set of genetic elements of of set of or of of genetic elements .
an electrical muscle stimulator according to claim 1 , characterized in that it includes a cp@@ u ( 3 ) , said means ( 10 ) for restoring the pulse generation after proper re@@ positioning of the electrode by the cp@@ u .
use according to any one of the preceding claims , wherein the first clearing composition comprises an antibody which is anti-idiotypic for the first antibody or antibody fragment .
the invention relates to a device for the contact of at least one electronic component ( 24 ) mounted in a housing ( 4 ) , in particular a power semiconductor ( 24 ) , on a cooling surface ( 26 ) and a spring element ( 2 ) which can be attached in the housing ( 4 ) and which presses the component ( 24 ) against the cooling surface ( 26 ) in a pressure position of the spring element ( 2 ) .
pharmaceutical dosage form according to claim 14 , characterized in that it comprises the form of a tablet , a multilayer tablet , a tablet tablet , a tablet , a tablet , a a tablet , a a a tablet , a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
morning , next week , next month , next year ?
thromboembolic disorders including deep vein thrombosis , thrombo@@ phlebitis and pulmonary embolism have been reported ( see also section 4.4 ) .
each tablet contains 40 mg telmisartan and 12.5 mg hydrochlorothiazide .
a recombinant nucleic acid construct according to claim 9 wherein said encoding nucleic acid comprises a codon for a hydrophobic amino acid residue wherein said nucleic acid acid amino acid is inserted between thr + 163 and val + 163 + 164 .
a process according to claim 2 , characterized in that said base is potassium tert-@@ but@@ oxide . a process according to claim 2 , characterized in that said base is potassium tert@@ but@@ oxide . a process according to claim 2 , characterized in that said base is potassium tert-@@ but@@ oxide . the process according to claim 2 according to claim 2 , characterized in that said base is potassium tert-@@ but@@ oxide . in the process of claim 2 , characterized in that said base is potassium tert-@@ but@@ oxide .
adalimumab also affects biological reactions that are induced or regulated by tnf or are are regulated , including changes in the levels of adhesion molecules that are responsible for leukocyte migration ( ela@@ m-1 , v@@ cam@@ -1 , or icam-1 , or by an ic50 of 0.1 or 0.2 nm or , by an ic50 , or ic50 , or by an ic50 of 0.1 , 0.2 , or of 0.2 , of 0.2 , or of 0.1 , 0.2 , or of ic50 ) .
process according to one of claims 1 to 4 , characterized in that the ab@@ asic site is produced by the action of an aqueous acidic medium .
a dental prosthesis as claimed in any one of the preceding claims , characterised in that at the adjacent surface between a crown or bridge and a removable tooth replacement piece , the attachment is carried out as a square block ( 16 ) in a vertically extending manner to the crown or bridge , and the removable replacement part is carried out as a square block ( 16 ) , and the removable replacement part ( 16 ) is provided with a corresponding recess ( 17 ) , and in that vertical grooves ( 6 , 7 ) are
this may suggest a disease of a disease of the heart a heart disease a heart muscle a a heart disease of the heart may the heart muscle the muscle the muscle the muscle the muscle the muscle of the muscle the muscle the muscle the muscle the muscle of the heart . the a muscle of the heart muscle the muscle of the heart the heart the heart the heart the heart the heart the heart the heart the heart the heart the heart the heart the heart the heart the heart the heart of the heart the heart
do not store above 30 ° c. 30 ° c. store below 30 ° c. 30 ° c. 30 ° c. 30 ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c. ° c.
an oligonucleotide of the formula vii according to claim 35 , characterized in that it corresponds to formula viia in which b , y and n have the meanings given in claim 35 .
composite nonwoven fabric , process for its preparation and its use in all absorbent hygiene articles
this medicine is usually used in combination with other anti-hiv medicines to help control the control of hiv infection .
use according to claim 8 , wherein the oligosaccharide fragment consists of mono@@ phospho@@ manno@@ ose fragment , 6-@@ phospho@@ -@@ manno@@ se-@@ α ( 1-3 ) - { manno@@ se-@@ α- ( 1-3 ) } ₂ -@@ manno@@ se-@@ α ( 1-2 ) -@@ mannose .
are you doing your heart ?
selective labeling of the glycans of immunoglobulins
use of a combination of : ( 1 ) a compound according to any one of claims 1 to 5 ; and ( 2 ) an immunosuppressant at a sub-@@ therapeutic dose ; for the manufacture of one or more medicaments for use in prolonging the time of the acceptance by a recipient host of a graft from an mh@@ c-@@ un@@ matched donor host compared to the period of administration of the immunosuppressant at the sub@@ therapeutic dose in the absence of the peptide .
a compound according to any one of claims 17 to 20 wherein the o-@@ acyl derivative is an aliphatic o-@@ acyl derivative .
agent according to claim 3 , characterized in that it contains as active substance a compound of formula i , in which a compound of formula i , in which r ₁ represents hydrogen and represents a compound according to claim 1 , wherein r ₂ represents a compound of formula i in which r ₂ is methyl and the remaining substituents are as defined in any one of claims 1 to 7 .
compounds according to claim 2 , wherein r ² represents a hydrogen atom , a straight-chain or branched chain alkyl group having from 1 to 6 carbon atoms , an aralkyl group or a protecting group which makes the protected carboxy carboxy in the living body easily into a free carboxyl group .
x-ray diagnostic device according to one of claims 1 to 3 , characterised in that the detector ( 14 ) consists of a matrix of photosensitive surfaces ( 23 ) which can be connected individually or in groups to a measurement amplifier .
the plant of any of claims 26 or 28 to 31 , wherein said plant is a maize plant . a plant of a plant is a plant .
official batch release of the official batch release of directive 2001 / 83 / ec / ec / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
delivery of drug using phase converting formulation
the method of claim 2 , wherein the polymeric surface is silicone , the surface of the article or the device is initially pre-treated by applying a solution of poly ( methyl ( vinyl ether / maleic anhydride ) and then treated a warm / dry cycling , and subsequently treated by applying a combined solution of pvp and ps@@ 0@@ 76 in isopropanol and then subjected to further warm / dry cycling circulation .
the company presented the results of the studies the effectiveness of vera@@ flo@@ x of the effectiveness of vera@@ flo@@ x the effectiveness of the the the the the the the the the the effectiveness of vera@@ flo@@ x the effectiveness of the effectiveness of vera@@ flo@@ x of the of the of the of the of the of the effectiveness of vera@@ flo@@ x of the flo@@ flo@@ flo@@ of of the flo@@ flo@@ flo@@ flo@@ of the flo@@ flo@@ flo@@ flo@@ of the flo@@ flo@@ of of the flo@@ flo@@ flo@@ flo@@ of the flo@@ flo@@ flo@@ of
the use according to claim 1 , wherein the medicament is for the treatment of nasal obstruction .
i wanted to give you the site .
the method of claim 16 , wherein the opioid analgesic is an opioid analgesic selected from the group consisting of al@@ fentanil , allyl@@ pro@@ tidine , alpha-@@ pro@@ lamine , ani@@ ri@@ ri@@ dine , benzyl@@ morphine , be@@ zi@@ tidine , ani@@ ri@@ ri@@ dine , benz@@ or@@ ph@@ ol , clon@@ amide , buprenorphine , bu@@ ro@@ ph@@ ine , clon@@ it@@ az@@ ol , pi@@ ver@@ ro@@ mine , di@@ azo@@ ph@@ ine , bi@@ heptan@@ ol , p@@ imino@@ dine , penta@@ midine , pro@@ heptan@@ ine , pro@@ morph , pro@@ peri@@ dine ,
use according to any one of claims 1 to 7 , wherein the medicament is suitable for administration of the antibody at a dosage in the range of 0.01 to 4 mg of antibody .
the committee recommended that the marketing authorisation be given by agenerase be given marketing authorisation . marketing authorisation marketing authorisation . marketing authorisation authorisation . marketing authorisation authorisation .
a method according to any one of claims 2 to 5 , wherein the time series is classified as the first time series of time when the significance ( s ) has a value greater than a predeterminable barrier .
toothbrush ( a1 ; a2 ; a3 ; 100 ) according to claim 1 , wherein the head ( 2 ; 114 ) has a substantially l-shaped cross-section , the bristle assembly ( 3 / 3a ; 116 ) being attached to the inner side of a ( 21 , 120 ) of wings ( 21 , 22 ; 120 , 122 ) of the head , and wherein the bristles ( 41 , 146 ) of the bristle assembly extend towards an angular plane of the l-shaped head .
radiotherapy apparatus according to claim 8 , wherein the head-@@ pivoting mechanism ( 131 , 132 ) pivots the radiation irradiation head ( 10 ) about both of the two axes ( s1 , s2 ) extending orthogonally .
use of a compound for the manufacture of a medicament for the inhibition of tumor necrosis factor alpha or for the treatment of septic shock , wherein the compound is ( ± ) -3,4-di@@ 2-@@ aden@@ e@@ yl-@@ endo-@@ 6-hydroxy@@ bicyclo &#91; 3.3.0 &#93; octane dihydrochloride &#91; 3.3.0 &#93; -furan@@ -3-ol &#91; 3,2-b &#93; -furan@@ -3-ol or &#91; 3r , 6r &#93; -6- ( 6-amino-@@ purin-9-yl ) -@@ estr-1,3,5 &#91; 3,2-b &#93; -furan@@ -3-ol dihydrochloride .
a device according to claim 4 , which is to apply a pressure to an arm , the length of the cylinder being in the range from 3 cm to 200 cm , the base surfaces of the fingers being distributed over a generally cylindrical surface having a diameter in the range of 7.5 cm to 75 cm and the tips of the fingers are distributed over a generally cylindrical surface having a diameter in the range from 2 cm to 25 cm .
catheter system according to claim 12 , characterized in that the adhesive forming the compound is a polyurethane .
the mean change in diastolic blood pressure was - 0.1 mmhg for lumiracoxib and + 0.5 mmhg for nsaids ( p &lt; 0.0001 ) for nsaids ( p &lt; 0.0001 ) for nsaids ( p &lt; 0.0001 ) for nsaids ( p &lt; 0.0001 ) . ) for nsaids ( p &lt; 0.0001 ) ) . ) ) ) . ) ) ) ) . ) ) ) ) . ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) .
2 . process according to claim 1 , characterised in that , in , the particle size of the gy@@ rase inhibitors , the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
biocompatible implantable micro drive for hearing aid
a scalpel according to claim 1 , wherein the handle ( 50 ) is releasably attached to the blade holder ( 20 ) by a projecting member disposed on the handle ( 50 ) , releasably connected to a slot formed on the blade holder ( 20 ) .
name and address of the manufacturers responsible for batch release for batch release the batch for batch release the the the the the batch for the batch release for batch release the batch for the batch release of batch release the batch for batch release the batch for batch release the batch for the batch release for batch release the batch for batch release for batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release
factor x analogue according to claim 5 , characterized in that it has a deletion of the factor x β peptide . the factor x analogue according to claim 5 , characterized in that the factor x analogue according to claim 5 , characterized in that the factor x analogue in the analogue is a deletion of the factor x β peptide .
montelukast is not recommended as monotherapy in patients with moderate persistent asthma .
the apparatus of claim 1 , wherein the sensing means is an ultrasound sensor and the second means comprises a microprocessor .
a surgical device for treating a patient comprising : at least one needle ( 60 ) having an insertion end ( 58 ) ; at least one dilator ( 54 ) , and a loop ( 42 ) having a length sufficient to connect the dilator to the insertion end , and wherein the dilator has a second end portion ( 56 ) with an insertion end ( 58 ) , and a loop ( 42 ) having a length of the dilator with the insertion end , the dilator having a second end portion ( 56 ) having a
the compound of claim 3 , wherein r 8 is h , or substituted or unsubstituted ( c 1 -c 6 ) alkyl ; or a pharmaceutically acceptable salt thereof . the compound of claim 3 wherein r 8 is h. a compound of claim 3 , wherein r 8 is h or substituted or unsubstituted ( c 1 -c 6 ) alkyl ; or a pharmaceutically acceptable salt thereof . a compound of claim 3 wherein r 8 is a compound of claim 3 wherein r 8 is h .
an injector according to one or more of the preceding claims , characterized in that the guide member ( 67 ) is connected to the adjusting member ( 15 ) , but axially im@@ movably .
tabulated list of adverse reactions adverse reactions reported in patients with melanoma are listed below of meddra system organ class , frequency and adverse reactions adverse reactions adverse reactions .
limited data from patients receiving higher than recommended zin@@ for@@ o doses show similar adverse reactions observed in patients receiving the recommended doses .
a kit according to claim 51 , wherein the gaseous phase comprises an osmotic gas having a water solubility of not more than 0.5 mm at 25 ° c and an atmosphere .
use of n-@@ aryl@@ methylene ethylenediamine@@ tri@@ acetates , n-@@ aryl@@ methylene@@ di@@ acetates or n , n &apos; -di@@ aryl@@ methylene@@ di@@ acetates as no donors
device according to claim 7 , characterized in that the drive means ( 19 ) can be operated from the rear end ( 6 ) of the anchoring element ( 3.@@ j ) .
ted@@ dy told me i &apos;m supposed to make a big list of surgeries .
binding molecules and computer-@@ assisted methods for increasing their binding affinity
the device of claim 3 , wherein the tapered support comprises a cannula tube ( 215 ) .
an apparatus according to any one of the preceding claims , wherein the image sensor ( 34 , 36 ) is arranged to produce image data , wherein areas without reflective markings ( 14 ) are identified as a black and with the reflective markings ( 14 ) .
medicament for the prevention and treatment of diseases of the circuits containing spiro@@ 3-@@ hetero@@ azolidin@@ es .
the use of claim 6 , wherein the compound comprises at least one compound selected from the group consisting of 2-hydroxy@@ cyclo@@ eicos@@ one , 2-hydroxy@@ 10@@ -cyclo@@ eicos@@ ene , 2-hydroxy@@ cyclo@@ toremifene , and 2-hydroxy@@ 12-@@ cyclo@@ toremifene .
retinoids for the treatment of psychotic disorders
a device as claimed in claim 26 , characterized in , that , the ratio , of d / 2 , in the ratio of , of the d / 2 , of the ratio of the d / 2 / of the ratio of the d / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 / 2 /
the powder is dissolved in water before it is injected by a doctor or it is injected by a doctor or nurse . the powder is it it is injected is injected in the water .
the nucleic acid molecule of claim 1 or claim 2 , wherein said molecule encodes at least 200 , preferably at least 300 , at least 300 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
ibaf@@ lin 3 % oral gel : 30 mg ibaf@@ loxacin / g gel ( equivalent to 3@@ 0.9 mg / ml )
the composition of claim 17 , wherein the alkyl ester is selected from the group consisting of alkyl laurate , alkyl palmitate and stearic alkyl myristate .
conditioning cream for hair dyeing with good color application properties
a composition according to claim 6 or claim 7 wherein r 1 is hepta@@ dec@@ -8-@@ enyl , undecyl , undecyl , tridecyl , penta@@ decyl , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
a method according to claim 4 , characterised in that , as valve , a computer-@@ controlled piezoelectric proportional valve is used in a computer-@@ controlled manner in a proportional manner , which is in a proportional manner , in which , , , , in a controlled manner , a volume , which is adjustable in a volume , which is adjustable , , , in a controlled manner , is adjustable .
the expiry date refers to the last day of that month . • the expiry date refers to the last day of refers to the last day date to be taken date to ensure the expiry date refers to the date to date refers to the last day of refers to date to be taken to date refers to the date to date refers to the date to date refers to the date to date refers to the date to refers to the last date to refers to date refers to the date to refers to the date .
a device for illuminating tissue of a patient to measure the light absorption of the tissue by means of a measuring system ( 2 ) , which comprises : at least two light sources ( ld , 416 ) for applying at least two light beams to the patient ; and a means ( 524 , 332 ) for applying the at least two light beams to the tissue , the probe means ( 1 ) further comprising : a connecting means ( 82 ) with : a probe means ( 1 ) having a probe means ( 1 )
a two-@@ chamber pre-filled syringe with an outer barrel ( 1 ) having a bypass line groove ( 3 ) , which is substantially at its center on the inner wall ( 2 ) , a sealing plug ( 6a , 6b ) which is in the longitudinal direction of the outer cylinder ( 2 ) in a direction perpendicular to the outer cylinder opening ( 4 ) in a direction perpendicular to the outer cylinder opening ( 4 ) in a direction perpendicular to a direction near the outer cylinder opening ( 4 ) in a direction perpendicular to
a device according to any one of claims 7 to 9 , characterised in that the box@@ -shaped part permits a slight penetration in the crown .
c@@ 1d gene for use as a medicament for inducing apoptosis in cells by overexpression of the c@@ 1d gene .
soluble , encapsulated polypeptide of no@@ g@@ o-@@ a protein
a composition according to claim 15 , wherein the tips , g , j , l and m with the nitrogen atom of the ring form a ring selected from the pyridine and pyrimidine rings .
plant containing plant cells according to one or more of claims 8 and 11 to 13 . plant according to claim 14 which is a plant plant .
a mixture according to any one of claims 1 to 7 , characterised in that it contains an extract of lamin@@ aria flex@@ cau@@ tilis and an avian extract , in particular of avian of sor@@ bus au@@ cu@@ par@@ ia .
use of the composition of any one of claims 1 to 21 , wherein budesonide or a prodrug or derivative thereof which contains polyunsaturated fatty acid which contains one or more of omega-3 , omega@@ -6 and omega@@ 9 or a derivative thereof , and the antioxidant is administered simultaneously .
the catheter of claim 1 or 2 , wherein the guide wire ( 10 ) comprises a proximal segment ( 11 ) formed from an elongate flexible tube , an intermediate segment ( 16 ) formed from a relatively short tube formed at the distal end of the proximal segment ( 11 ) and extending distally from the distal end of the intermediate segment ( 11 ) and extending distally from the distal end of the intermediate segment ( 16 ) and extending distally therefrom , the core wire ( 20 ) being tapered distally .
a process according to any one of the preceding claims , characterized in that the aqueous solution further contains an additional monomer selected from the group consisting of , ( a ) , ( a ) methacrylic , itaconic , maleic , fumaric , 2-acrylamido@@ , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ( ( (
use according to claim 8 , characterized in that the anticonvulsant substance is a benzodiazepine selected from clon@@ azepam , clo@@ baz@@ am , diazepam and pro@@ diazepam .
use of an animal cell according to any one of claims 1 to 4 for evaluating an agonist activity or antagonist activity of a chemical substance via the transcrip@@ tion-@@ promoting ability of a ligand-@@ controlled transcriptional control factor in a reporter test by measuring the amount of a reporter gene under the transcriptional control of the ligand-@@ controlled transcriptional control factor .
the needle assembly of claim 4 , wherein the removable vented plug ( 37 ) further comprises a pierceable partition ( 39 ) such that a blood sample can be removed from the backflow chamber ( 44 ) without removal of the plug ( 37 ) .
a pedicle screw assembly ( 1 ) comprising a screw threaded shaft ( 2 ) having a partially spherical head ( 3 ) having a partially spherical head ( 3 ) at one end , a hollow cylindrical connecting member ( 6 ) having a seat for the head and an opening , through which the shaft ( 2 ) is formed at an end , a hollow cylindrical connecting member ( 6 ) , a hollow cylindrical connecting member ( 6 ) , a hollow cylindrical connecting member ( 6 ) having a seat for the head and an
cab@@ az@@ it@@ axel inhibits the transport of p-glycoprotein ( pgp ) ( digoxin , vinblastine ) , breast cancer resistance protein ( b@@ ck@@ -c@@ an@@ r-@@ resist@@ t protein , bcrp ) ( methotrexate ) ( methotrexate ) and organic anion transporting polypeptide oatp1@@ b3 ( c@@ ck@@ 8 ) at concentrations of at least 15 times the concentration observed during clinical conditions while the transport of oatp1b1 ( est@@ radi@@ ol-@@ 17β-@@ glucuronide ) is at least 5 times the concentration observed under clinical conditions .
composition according to claim 9 , characterized in that the oxidizing agent is chosen in that the oxidizing agent is in the agent is chosen is the agent is chosen is is chosen is is chosen is is chosen is is is chosen is is is chosen is is is chosen is is is is chosen is is is is chosen is is is is is chosen is is is is is is chosen is is is is is is is is is is is is is is is is is is is is is is is is is is
a multifocal intraocular lens according to claim 18 , wherein light passes through the annular zone ( 22 ) and focu@@ ses to approximately 20 % of the first distance behind the retina of the eye in pathogenic illumination conditions .
device for administering an injectable product an injectable product for administering an injectable product an injectable product an injectable an injectable product
an aerosol dosing product according to any preceding claim , wherein the outlet channel ( 40 ) is formed by drilling . an aerosol dosage product according to any preceding claim , wherein the side opening ( 34 ) is formed by drilling .
after reconstitution , a clear colourless solution should be used for less than 3 minutes . − cloudy solutions or solution should not be used . – any unused solution should be used . − be used be used . − used . used used . used used . used used . used used . used used . used used . used used . used used . used used . used used . used used . used used . used used . used used . used used . used used . used used . used used .
method of administration for this medicinal product , this medicinal product is for oral use use of this medicinal product is for oral use of this medicinal product . use of this medicinal product is medicinal product product medicinal product product . medicinal product product product product product product product medicinal product product product product product product medicinal product product product product product medicinal product product product product medicinal product product product product medicinal product product product medicinal product product product medicinal product product product medicinal product product product medicinal product product product medicinal product product product medicinal product
a compound of the formula : or a pharmaceutically acceptable salt thereof , wherein r is h , c -c alkanoyl , c -c alkyl , c -c alkenyl , c -c alkynyl , c -c cycloalkyl , ( c -c cycloalkyl ) - ( c -c alkyl ) , ( c -c ) - ( c -c alkyl ) - ( c -c alkyl ) - ( c -c alkyl ) - ( c -c alkyl ) - ( c -c alkyl ) - ( c -c alkyl ) - ( c -c alkyl ) - ( c -c
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
in addition , the legs ( 10 ) of the inner ( 1 ) and outer basket ( 8 ) are aligned so that a continuous lateral opening and the inner cage ( 1 ) and the outer cage can be fixed relative to each other in a predetermined end position .
set according to one of claims 1 to 7 , characterised by a bearing shells ( 113 ) which can be displaced relative to the probe tube ( 12 ) , which are assembled in a longitudinally displaceable , lockable handle ( 116 ) .
tanning module according to claim 16 , characterised in that a flange ( 6 ) is mounted to the at least one air suction opening ( 5 ) .
using other medicines please tell your doctor tell your doctor or pharmacist if you are taking or are taking other medicines please tell your doctor or your doctor or doctor if your doctor doctor or your pharmacist doctor or doctor doctor doctor or your pharmacist you doctor doctor doctor doctor or your doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor doctor
a method according to claim 1 or claim 2 , wherein the host organism is escherichia coli .
three of 14 isolates had protease resistance mutations .
a method of producing a substantially purified of interest a protein or polypeptide comprising a ) introducing into a host a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
in children , this medicine can be prescribed for the treatment of the following types of fungal infections : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
since some reports of pharmacovigilance surveillance have been reported , a potential interaction with warfarin was included in the summary of product characteristics .
&#91; product name &#93; may be used in certain circumstances in addition to other medicinal products &#91; statins &#93; , if the levels of blood fats cannot be controlled with a statin alone .
nucleic acid sequences for proteins involved in tocopherol in the synthesis of tocopherol in proteins in the synthesis of proteins involved in tocopherol in the synthesis of proteins involved in tocopherol in the acid in the in vitro method in which the nucleic acid sequences proteins involved in in tocopherol in tocopherol in the in vivo in in vitro in the in vivo in the tocopherol involved in in tocopherol in the in vivo in in vitro proteins involved involved in involved in tocopherol
in the review , the chmp considered measures to minimize the risks identified using these medicines , but the chmp considered that limitations and additional guidance for dental professionals would not reduce the risks to an acceptable level .
a process according to claim 6 or claim 7 wherein the stabilizing agent is polyvinylpyrrolidone . a process according to claim 6 or claim 7 , wherein the stabilizing agent is polyvinylpyrrolidone . a process according to claim 6 or claim 7 wherein the stabilizing agent is polyvinylpyrrolidone . a process according to claim 6 or claim 7 wherein the stabilizer is polyvinylpyrrolidone . the process according to claim 6 or claim 7 wherein the stabilizer is polyvinylpyrrolidone . a process according to claim 6 .
it has been shown that in dogs with unstable kidney disease , due to the risk of decreased glomerular filtration rate or increasing azo@@ ta@@ emia , treatment with ace inhibitors has not been established .
the method of claim 2 , wherein said amylase alpha-amylase is bacillus licheniformis .
composition according to any one of claims 12 to 14 , characterized in that it also comprises at least one antagonist chosen from cgrp , histamine , interleukin-1 and / or tnf-α antagonists and / or neodymium salts .
a quinazoline derivative of the formula ii according to claim 1 , wherein : m is 1 and the group r 1 is at 7 position and is selected from 3- ( 1,2,3-@@ triazol-1-yl ) propoxy , 2-@@ pyrid@@ -4-yl@@ ethoxy , 3-@@ pyrrolidin@@ yl@@ propoxy , 3-morpholino@@ propoxy , 3- ( 1,1-@@ diox@@ tetrahydro@@ hydro-@@ 4h-@@ 1,4-@@ thiazolo , 3- ( 4-methylpiperazin-1-yl ) propoxy , 4-@@ morpholino@@ -4@@ ylethyl , 3- ( 4-methylpiperazin-1-yl ) propoxy , and is selected from the group consisting of fluorine , chlorine , bromine and trifluoromethyl , with the proviso that at least one
the marketing authorisation holders are provided for the next five years in all member states in which methylphenidate is used , all available retrospective data should be submitted annu@@ ally to assess the variation of changes in use in use .
there were no other changes in foetal external , visceral or skeletal morphology .
vaso@@ vist is a solution for injection that contains the active substance gado@@ fos@@ ve@@ set trisodium salt . the active substance of gado@@ fos@@ ve@@ set trisodium is a solution for injection with the active substance gado@@ fos@@ ve@@ set trisodium for solution for injection , solution for injection , and vaso@@ vist is a solution for injection for solution for injection of gado@@ fos@@ ve@@ set trisodium for solution for injection set out in a solution for injection for injection set for solution for injection for solution for injection set for solution for injection for injection .
as criteria for distinguishing between benign and malignant lung , the total diameter and the density of the lesion , the total diameter and the density of the lesion , the total diameter and the density of the lesion , is the same in the peripheral area , the presence of spi@@ cu@@ ae , and also the spi@@ ru@@ tic changes in the edge area , the pleural effusion itself , the pleural effusion and the pleural effusion .
for final concentrations of at most 20 mg / kg of body weight ( maximum 1 g / day ) / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day / day
the antibody of claim 1 , wherein said antibody has an affinity of greater than 10 -9 .
a computer tomography apparatus comprising : a patient support for supporting a selected portion of a patient in an examination zone ( 24 ) ; an x-ray tube according to any one of claims 1 to 5 ; a mounting device ( ii ) having the x-ray tube ( 160 ) and an image reconstructing means ( 164 ) for reconstructing signals from the radiation detector ring ( 160 ) in image representations .
use of a vector according to one or more of claims 1 to 17 in malignant b cells for vaccination of patients with malignant b-cell diseases .
the detection of coronary cold with the e@@ bt must be considered as the currently most non-invasive marker for the presence of coronary athero@@ matosis , including their early shapes .
the method of claim 5 , wherein the amylase is a liquefied amylase or iso@@ amylase . the method of claim 5 wherein the amylase is a liquefied amylase or an iso@@ amylase . the process of claim 5 wherein the amylase is a liquefied amylase or iso@@ amylase . the process of claim 5 wherein the amylase is a liquefied amylase or iso@@ amylase . the process of claim 5 wherein the amylase is the amylase amylase . the process of claim 5 the amylase is the amylase amylase amylase .
a formulation according to claim 36 which is the fine excipient particles in an amount up to 15 % by weight based on the total weight of the formulation of the formulation .
a scaffold according to claim 10 or 11 , wherein the scaffold comprises interconnected pores , oriented fibers , laminar structures , or a combination thereof .
the invention relates to the compounds of formula ( i ) to formula i ( i ) , ( i ) ( i ) ( ( i ) to ( i ) i ( i ) ) ( i ) ) ( i ) ) ( i ) i ) ( i ) i i i ( i ) i i i i i i i i i i i i i i i i i i i i i i i i i i i i ( i ) ( i ) i i ( i i i i
a cardiac pacemaker according to any one of claims 1 to 8 , characterised in that the mean stimulation interval duration is controlled in such a manner that it increases when the difference between the residual gradient gradient and the target value decreases and decreases a negative threshold value when the difference exceeds a positive threshold value .
1.@@ 83 e-@@ 01 3.@@ 79 e-@@ 01 1.@@ 74 e-@@ 02 3.@@ 53 e + 00 1.@@ 91 e + 00 6.@@ 34 e-@@ 01 4.@@ 99 e-@@ 01
a pharmaceutical composition comprising at least one compound of the formula ( i ) of any one of claims 1 of one of claims 1 to 7 to 1 to 7 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to
a dialysis machine according to claim 2 , comprising means for determining the connection ( 22 , 23 ) with the contact screen ( 16 ) in a desired , rotated position on the arm ( 19 ) .
the method of claim 18 , wherein each of the plurality of oligonucleotide 5 &apos; -@@ mono@@ phosphates has an identical length .
in this way , a safe position and position correction of guide probes is possible under ecg control .
if viread 163 mg film-coated tablets are co-@@ infected in patients co-infected with hiv and hepatitis b virus ( hbv ) , these patients should be closely monitored for evidence of exacerbation of hepatitis ( see section 4.4 ) . see section 4.4 ( see section 4.4 ) see section 4.4 ( section 4.4 ) . ) see section 4.4 ) . ) ) ) ) see section 4.4 ) . ) ) ) ) . ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) .
transgenic mouse expressing green fluorescent protein in astro@@ cytes
device according to one of claims 1 to 4 , characterized in that the electrode unit ( 1 ) and the key ( 3 ) each have mechanical coupling means ( 13 , 13 , 19 , 19 , 19 ) which cooperate with mechanical means ( 14 , 14 ) of the module to ensure temporary coupling with this module .
the use of an echin@@ acea composition in the manufacture of a medicament for enhancing immune tolerance in a mammal , wherein the echin@@ acea composition is formulated to provide a daily dose of caffe@@ ic acid from 40 µg / kg body weight to 2000 µg / kg body weight , and in echin@@ acea polysaccharides of 1 mg / kg body weight to 200 µg / kg body weight and in echin@@ acea polysaccharides of 1 mg / kg body weight to 50 mg / kg body weight .
composition according to any one of claims 7 to 9 , characterized in that at least one active substance is gentamicin , neomycin , bac@@ it@@ rac@@ in , clindamycin , erythromycin , aciclovir , vid@@ ar@@ abine , dex@@ panthenol , allan@@ toin or hirudin .
apparatus according to claim 33 , characterized by a control circuit ( 52 ) for ensuring the contact between the distal end ( 22 ) of the catheter ( 20 ; 45 ; 64 ; 78 ) and the location of the heart wall ( 76 ) .
a wound dressing according to claim 4 , further comprising calcium ions . the wound dressing according to claim 4 , further comprising calcium ions . the wound dressing according to claim 4 , further comprising calcium ions . the wound dressing according to claim 4 , further comprising calcium ions .
the method of claim 13 wherein said chelating agent comprises a water-soluble zinc salt , said salt being added in an amount of from 0.05 mg to 50 mg per 100 ml of solution .
trudexa should be administered in combination with glucocorticoids during induction treatment .
topotecan has also been studied in children ; however , limited efficacy and safety data are available .
right here to guide my little girl before trauma .
a system according to any one of claims 23 to 27 , wherein the measuring cell comprises an operating electrode ( 13 ) , an electrolyte chamber ( 16 ) and a reference electrode ( 15 ) and connected to a associated flow element ( 8 ) comprising an inlet and an outlet for perfusion fluid which can be separated from the measuring cell by an oxygen gas permeable membrane ( 22 ) .
a composition as claimed in claim 4 , characterized in that the further compound is selected from the group consisting is selected from the group selected from the group consisting of : n- ( 2-hydroxyethyl ) -n-@@ ethyl- , 2-chloro@@ ethyl- , n , n-bis ( 2-hydroxyethyl ) ( 2-hydroxyethyl ) ( 2-hydroxyethyl ) ( 2-hydroxyethyl ) ( 2-hydroxyethyl ) ( 2-hydroxyethyl ) ( 2-hydroxyethyl ) ( 2-hydroxyethyl ) 2-hydroxyethyl ( 2-hydroxyethyl ) 2-hydroxyethyl ( 2-hydroxyethyl ) 2-hydroxyethyl ( 2-hydroxyethyl ) 2-hydroxyethyl ( 2-hydroxyethyl ) 2-hydroxyethyl ( 2-hydroxyethyl ) 2-hydroxyethyl ( 2-hydroxyethyl ) 2-hydroxyethyl ( 2-hydroxyethyl ) 2-hydroxyethyl 2-hydroxyethyl 2-hydroxyethyl
• pull off the inner needle cap and dispose of the needle and throw away the inner needle cap and throw off the needle and throw away the inner needle and throw away the inner needle shield and throw it away . • pull it away and throw away the needle the needle away . the needle the inner needle needle needle .
3-@@ de@@ methoxy@@ i@@ stam@@ ycin b and its 2 &apos; -n-@@ form@@ mido@@ ylated derivative .
liquid perfluoro@@ polymers and medical applications using the same
urinary outflow obstruction of urinary outflow must be ensured . • the urinary outflow obstruction of urinary outflow obstruction has to be established . outflow obstruction of the urinary outflow outflow outflow outflow obstruction has not been established . urinary outflow obstruction of the urinary outflow outflow outflow obstruction outflow obstruction .
- methotrexate ( used to treat rheumatoid arthritis , psoriasis and leukaemia )
a method according to claim 12 , wherein said folding , of said outer portion of , , wherein said , said third , said third , said third , said , said third , said , said third and said layers of fabric , said , said folding , said folding , said , said folding said said said folding said said folding said , of said said said , said , said said said said said said said said said said said folding said folding said said folding said said folding said said , said said folding said
the system of any one of claims 17 to 21 or 23 to 30 , further comprising a salt of salicylic acid in conjunction with said antiperspirant .
a process according to claim 1 or claim 13 to claim 1 to claim 13 , to claim 1 , claim 1 to claim 13 , wherein 3-aminopropyl , wherein 3-aminopropyl , wherein , , , , , , 3-aminopropyl , , , , , , , , 3-aminopropyl , , , , , , , , , , 3-aminopropyl , , , , , , , , , , 3-aminopropyl , , , , , , , , , , , 3-aminopropyl , , , , , , , , , , , , 3-aminopropyl , , , ,
a container ( 30 ) according to claim 1 , characterized in that the container has a projecting edge ( 32 ) disposed on its inner side and which is arranged in the vicinity of the primary opening .
if you are given other vaccines with hexavac or other vaccines , please contact your doctor about detailed information .
a process for producing 2-keto-l-gulonic acid from l-sorbo@@ sone which comprises contacting l-sorbo@@ sone with purified aldehyde dehydrogenase according to claim 1 in the presence of an electron acceptor and isolating the resulting 2-keto-l-gulonic acid from the reaction mixture .
herbal pharmaceutical preparation for the treatment of migraine of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation of the preparation for the preparation of the preparation of the preparation for the preparation of the preparation of the preparation for the preparation of the preparation of the preparation of the preparation for the
a method according to claim 14 , characterized in that the display is in the form of a ber@@ ny which can be printed .
a dna base sequence wherein one of the strands has bases arranged in the following order : wherein a , t , g and c are adenine , thymine , guanine , or cytosine .
use a new ken@@ tera patch according to the instructions for use .
a device for fixing a knee joint in certain positions and for the position control of instruments for replacement of the knee joint of a patient by a prosthesis , wherein the device is connectable to an operating table ( 1 ) , the device being connected to an operating table ( 1 ) , the device being connected to an operating table ( 1 ) , the device being connected to an operating table ( 1 ) , the device being connected to an operating table ( 1 ) , the device having an operating table ( 1 )
method for transferring nucleic acids into cells , characterized in that it comprises the steps of : ( 1 ) contacting the nucleic acid with a transfer agent as defined in claims 1 to 10 , in ( 1 ) contacting the cells with the complex ( 1 ) formed in ( 1 ) to the cells , in vitro .
intraocular lens with a support element for a telescope
do not take a sun baths , extensive hot baths or sa@@ un@@ le baths or hot whirlpool baths .
the pre-filled syringe of humira is a glass syringe with needle@@ guard with a solution with adalimumab with a solution with a solution with needle@@ needle@@ . with a syringe containing a solution with needle@@ needle@@ with needle@@ needle@@ with with needle@@ needle@@ guard .
erythropoietin is a growth factor a growth factor that is primarily a growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor
pumping apparatus according to claim 24 , characterized in that the detection means ( d2 ) indicating the beginning of a cycle of the force means and a circuit which compares an output signal of the display means ( d2 ) and the rise time of said output signal from the pressure sensor ( 28 ) .
a third &#91; 18 f &#93; -@@ labelled intermediate which is obtained by steps a to i of the method as claimed in claim 7 or 8 .
the system of claim 1 , wherein the system comprises program control means ( 58 ) controlling the computer means and allowing the control signals produced by the computer into a visible displayed surface contour .
the method of claim 38 , wherein the sialyltransferase polypeptide has an amino acid sequence as shown in seq id no : 3 . the method of claim 38 wherein the sialyltransferase polypeptide has the amino acid sequence of seq id no : 3 of the amino acid sequence of seq id no : 3 , wherein the sialyltransferase polypeptide has the amino acid sequence shown in seq id no : 3 . the method of claim 38 wherein the sialyltransferase polypeptide has the amino acid sequence of seq id no of seq id no : 3 .
condom coated with acidic polysaccharides .
a composition for use in veterinary medicine containing an effective amount of at least one compound of claim 1 in an effective amount of at least one of an effective amount of at least one of an effective amount of at least one of at least one of at least one of at least one of at least one at least at least at least at least at least at least at least at least at least at least at least at least at least at least at least at least at least at least at least at least at
ledipasvir / sofosbuvir and a pharmacokinetic enhancer has not been confirmed in a pharmacokinetic enhancer and a pharmacokinetic enhancer pharmacokinetic enhancer a pharmacokinetic enhancer pharmacokinetic enhancer pharmacokinetic enhancer a
use of an active agent which inhibits cyclin g1 protein , wherein the active ingredient comprises : i ) antisense oligonucleotides or polynucleotides or fragments thereof , or sequences complementary to at least a portion of a polynucleotide encoding the cyclin g1 protein and which bind to a polynucleotide encoding the cyclin g1 protein , and which bind to a polynucleotide encoding the cyclin g1 protein , in order to produce the fragments or derivatives thereof with the cyclin g1 protein , the fragments or derivatives of the antibody having deletions and / or substitutions of amino acid residues with
these active substances include f@@ lec@@ ain@@ ide and propa@@ fen@@ one .
the use of claim 95 , wherein the organism is human . the use according to claim 95 , wherein the organism is human . the use of claim 95 , wherein the organism is human . use according to claim 95 wherein said organism is human . the use of claim 95 , wherein said organism is human . human is human . human is human . human . human . human . human . human . human . human . human . human . human . human . human . human .
the surgical system of claim 1 , wherein the control mechanism comprises means for controlled ablating of the skin ( epidermis ) along the course of a skin / dermal interface .
the method of claim 2 , wherein the active substance is a toxin . the process according to claim 2 , wherein the active substance is a toxin . the method of claim 2 wherein the active substance is a toxin . the process of claim 2 wherein the active substance is a toxin . the method of claim 2 wherein the active substance is the toxin . the method of claim 2 wherein the active substance is a toxin .
the use according to claim 1 , wherein the polysaccharide is hyaluronic acid , or a pharmaceutically acceptable salt thereof .
composition according to any one of the preceding claims , characterized in that the allyl ether unit defined in claim 1 is in the form of a chain of the allyl ether of the anionic amphiphilic polymer of the formula of formula ( i ) ch 2 = cr &apos;@@ ch 2 whether ch 2 = ch 2 = ch 2 whether 2 ch 2 ch 2 ch 2 ch 2 ch 2 ch 2 ch 2 ch 2 ch 2 ch 2 ch 2 ch 2 ch 2 ch 2 ch 2 ch 2 ch 2 ch 2 ch
method for stabilizing active components using polyol / polymeric microcapsule , and cosmetic composition containing the microcapsule
use of the products of the formula ( i ) as defined in claim 1 for the preparation of pharmaceutical compositions of the the of the of the of the of the of the of the of the of of the of of the of of the of of the of of of the of of of the of of of the of of of the of of of the of of of the of of of the of of of the of of the of of the of of the of of the of of the of of the
the other ingredients are α , α , trehalose dihydrate , histidine hydrochloride monohydrate , histidine , polysorbate 20 , water for injections , , water for injections , for injections for injections , , for injections , , , for injections , , , , , for injections , , for injections injections , , , for injections injections , , injections for injections . injections for injections . injections for injections . injections for injections . injections for injections . . . . . . . . . . . . injections for injections . injections .
reproductive system and breast disorders breast disorders reproductive system and breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders breast disorders
within each frequency grouping , undesirable effects are presented in order of decreasing in order of order of in order of order in order of order in order of order of order of of order of of order of of of of of decreasing of order of order of order of of of of of of of of decreasing order of order of of of of order of order of of of of order of order of order of order of of of of order of order of order of order of of order of order of order of of
the method of claim 19 , further comprising : providing a second , as a spare , a replacement sheet film formed within the cavity of the container ( 50 ) ; and transferring the second , as a spare , the transfer opening ( 80 ) from the container ( 50 ) through the transfer port ( 80 ) and the container barrier film ( 60 ) and into the isolated space ( 22 ) .
curved ribs were observed in rats with increased incidence in association with reduced maternal body weight in body weight with reduced maternal body weight in reduced maternal body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body weight body
the plant of claim 36 which is homozygous for said recombinant dna .
method for treating schizophrenia and means for treating for treating treating schizophrenia for treating schizophrenia for treating schizophrenia treating treating schizophrenia treating treating schizophrenia treating treating schizophrenia treating treating schizophrenia treating treating schizophrenia treating treating schizophrenia treating treating schizophrenia treating treating schizophrenia treating treating schizophrenia treating treating schizophrenia treating treating treating schizophrenia treating treating treating schizophrenia
a method for the preparation of an aqueous injectable liquid drug delivery composition for injection into a body in a state in a state in which a pharmacological treatment or diagnosis requires the composition of claim 13 and an effective concentration of the composition , the composition of claim 13 , claim 13 , claim 13 , claim 13 , claim 13 , 13 , 13 , 13 , 13 , 13 , 13 , 13 , 13 , 13 , 13 , 13 , 13 , 13 , 13 , 13 , 13 , 13 , 13 , 13
gas plasma treated , porous medium and separation method using the medium .
process according to one or more of the preceding claims , characterized in that the polyhydric alcohol is at least one member selected from ethylene glycol , diethylene glycol , triethylene glycol , polyethylene glycol , diethanolamine , triethanolamine , glycerol , trimethylo@@ l propane , 1,3-propanediol , 2,3-@@ propanediol , pentaerythritol , sorbitol or polyglycerol .
claims for the following contracting states : es , gr a process for the preparation of compounds of the formula : wherein r ¹ is a group of the formula r h , nh ₂ , -nh@@ co@@ o-c ₁ ₋ ₄ alkyl , -nh-@@ z or -nhcoch ₂ n ( y ) -ch ₂ ch ₂ nh ₂ or guanidino group , or a protected amino , amidino or guanidino group , and optionally a compound of the formula i in a physiologically acceptable salt , or a salt of a compound of formula i in the free acid
a process according to claim 2 , wherein the concentrated sulfuric acid is used in an amount of 2 to 3 equivalents per equivalent hn@@ o 3 .
&apos;@@ cause i think god kno@@ ws that ... ~ ~ ~ i need to drink something .
a process for the preparation of the antibiotic ll-e@@ 19@@ 0@@ 20@@ α and ll-e@@ 19@@ 0@@ 20@@ β , as defined in claim 1 , which comprises a liquid medium which has assimilable sources of carbon , nitrogen , and inorganic salts , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
the use according to claim 16 , wherein the heparin is present in a concentration in the range of about 1@@ µg / ml to 100@@ µg / ml . the use according to claim 16 , wherein the heparin is present in a concentration in the range of about 1@@ µg / ml to 100@@ µg / ml . the use according to claim 16 , wherein the heparin is present in the concentration of about 1@@ µg / ml to 100@@ µg / ml . the use of the claim 16 .
the full epar for taxotere can be found here for the full list of all side effects reported with taxotere , see the package leaflet for the full description of the european medicines agency ( epar ) http : / / www.ema.europa.eu / . the full epar for taxotere can be found here . be the full epar for taxotere here . the full epar for taxotere can be found here . be the full epar found here here . be here here . be here here . be found here here .
process according to one of claims 1 to 3 , characterized in that the pharmaceutical composition contains from 50 to 400 mg of s- ( carboxymethyl ) -l-@@ cysteine and / or n-acetyl cysteine and has a diameter of 5 to 12 mm .
this medicine is not a medicine is a cure for hiv infection . this medicine is not medicine for hiv infection is for hiv infection . infection is not hiv infection .
the substantially pure plasminogen activator inhibitor of claim 11 , wherein said inhibitor is a fusion polypeptide exhibiting an apparent relative molecular mass of about 180 kilodaltons in the sds-page analysis .
the use of a combination of an active ingredient combination according to any one of claims 1 to 8 for the preparation of a pharmaceutical form for pharmaceutical addiction of a pharmaceutical for pharmaceutical addic@@ tive or noise therapy , in particular of the therapy of alcoholism .
4 . a polymer according to claim 3 , wherein the polymer contains two to ten h@@ sod units . the polymer according to claim 3 wherein the polymer contains two to ten h@@ sod units . the polymer of claim 3 , wherein the polymer contains the polymer the polymer . the polymer of claim 3 wherein the polymer contains the polymer the polymer . the polymer .
16 . a method of coating a submerged surface for preventing the growth of microbes or plants or the adhesion thereof , said method comprising the step of applying to said surface a composition prepared according to claim 3 .
• induction chemotherapy followed by radiotherapy followed by radiotherapy ( by by ta@@ x 323 ) by radiotherapy by radiotherapy by radiotherapy by radiotherapy
novel substituted thiophene carboxylic acid amides , their preparation , and their use , as medicaments , , their use as medicaments , their use as their use as their use as their use
therefore , the use of orgalutran is contraindicated in patients in patients with patients with hepatic impairment ( see section 4.3 ) ( see section 4.3 ) . section ( see section 4.3 ) .
the system of claim 1 , wherein the weight ratio of the pores forming agent to the coating material of the pellet is of the order of 1 : 300 .
a method for the production of a biological material chip as claimed in claim 10 in which the avi@@ dins are avidin , streptavidin , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , are , , , , , , , , , , , , , , ,
an adhesive bandage , wound dressing , or surgical drape as claimed in any one of claims 1 to 4 , wherein the flexible elastomer base is in the form of a parallelogram comprising a first four-@@ grade second four@@ th-@@ four since and a third four-@@ point , wherein the adhesive is bonded to the intermediate layer and the intervening four is free of adhesive .
driving device according to claims 1 or 2 , characterized in that the deflection mechanism ( t ) is the drive actuator ( a ) .
a device according to any preceding claim , wherein the amount of the solid support containing the volatile substance at the beginning of the lifetime of the device is 3 to 30 g .
a nucleic acid sequence coding for a peptide according to any one of claims 1 to 10 to a peptide of claims 1 to 10 to a peptide according to to claim 1 to 10 to 10 .
if you have been told by your doctor that you have an intolerance to some sugars you have you have an intolerance to some sugars you have you have an intolerance you have have an intolerance have an intolerance have an intolerance have an intolerance have an intolerance have an an intolerance have an an an intolerance an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an
taking karvezide with food and drink karvezide may be taken with or without food .
novomix 30 is an insulin analogue for the treatment of diabetes . an insulin analogue is an insulin analogue .
as a precautionary measure , a concomitant use of strong or moderate cyp2c19 inhibitors should be dis@@ cou@@ ra@@ ged ( see sections 4.4 and 5.2 ) ( see sections 4.4 and 5.2 ) .
eu / 1 / 01 / 183 / / / / / / / / / / / / / / / / / / / / / /
pharmacovigilance system the mah must ensure that the system of pharmacovigilance the system the system the system the system the system the the system the the system the the system the the system the the system the the system the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
some@@ body comes with a charge of wa@@ y ... from the drug delivery ... ko@@ your , morphine , de@@ tol .
infection and infestations blood and lymphatic system disorders blood and lymphatic system disorders and and lymphatic system and lymphatic system disorders and system and system and lymphatic system and system lymphatic system disorders
a coating , adhesive , ma@@ stic@@ x , ste@@ m or binder composition comprising a core / shell particle prepared according to any one of claims 1 to 7 , wherein the coating , adhesive , ma@@ stic@@ x , ste@@ m or binder composition contains a reactive crosslinkable resin and the target material is selected from cross-linking agents for the reactive crosslinkable resin .
pharmaceutical composition comprising at least one composition comprising at least one at least one composition according to at least one at least at one of one least one at one to one at least one composition according to one of at least one one of one of one one of one of one one of one one of one one of one one of one one one of one one one of one one one of one one one of one one one of one one one of one one one of one one one of one one one of
the composition of claim 8 wherein the enhanced hepato@@ protective activity is 75 % for galacto@@ samin@@ e-@@ induced hepatotoxicity in mammals .
a compound as claimed in any of claims 1 to 7 to any of claims 1 to 7 to to claims 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1
what are the risks associated with onivyde ?
the dosage unit according to any according to any one of claims 18 to 31 , wherein said inflammatory disease is rheumatoid arthritis . according to any one of one of claims 18 to 31 wherein said inflammatory disease to said inflammatory disease is inflammatory disease inflammatory disease .
• testing of lumiracoxib containing medicinal products useful in the treatment of osteoarthritis
a method according to claim 1 , wherein the edible oil is a fat-soluble vitamin . the method of claim 1 wherein claim 1 wherein the edible oil is a fat-soluble vitamin . the process of claim 1 , wherein the edible oil is a fat-soluble vitamin . the method of claim 1 wherein claim 1 wherein the edible oil is a fat-soluble vitamin . claim 1 wherein 1 . 1 wherein 1 .
aptivus should only be used in these patients unless the potential benefit outweighs the potential risk and with increased monitoring of clinical and laboratory parameters .
gol@@ d-@@ free alloys for firing ceramic materials .
quixidar 7.5 mg / 0.6 ml solution for injection quixidar 7.5 mg / 0.6 ml solution for injection quixidar 10 mg / 0.8 ml / ml / ml / solution / ml / solution / mg / ml
a fine white deposit with a clear colourless deposit with a clear a clear a a clear a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
a method of identifying a substance which modulates m@@ c-@@ r@@ 1b receptor activity , comprising : ( a ) combining a test compound in the presence and absence of an m@@ c-@@ r@@ 1b receptor protein , wherein the m@@ c-@@ r@@ 1b receptor protein comprises the amino acid sequence selected from the group consisting of seq id no : 2 , seq id no .
system according to any one of the preceding claims , characterized in that , in the tooth-cleaning agent , the humectant is at least sorbitol , glycerol or xylitol or any mixture of these substances .
the composition of claim 1 , wherein the hydrophobically modified clay is present in the composition in an amount in an amount in the range of 0.05 % to 5.0 % . the composition of claim 1 in the composition .
enhancement of electro@@ electrophoresis separation of single dna strand by asymmetric field inversion .
a method according to any one of claims 1 to 9 in which the suspension is whole blood , the first particles ( 104 ) are red blood cells and the second particles ( 108 ) are white blood cells and the pores ( 102 ) of the membrane ( 100 ) are sized to allow passage of substantially un@@ deformed red blood cells through the pores ( 102 ) through the pores of non-@@ deformed white blood cells .
a kit according to claim 13 , wherein said antibody is a monoclonal antibody or a polyclonal antibody , preferably is a monoclonal antibody of a monoclonal antibody or is a a a a a monoclonal antibody that is a monoclonal antibody or a monoclonal antibody which is a monoclonal antibody , a a monoclonal antibody which is a monoclonal antibody which is a monoclonal antibody or a monoclonal antibody antibody antibody is a monoclonal antibody antibody . . . antibody is a monoclonal antibody . antibody is a monoclonal antibody . . antibody is a monoclonal antibody .
a pharmaceutical composition comprising an il-2 transcriptional inhibitor and 40@@ -o- ( 2-hydroxyethyl ) -@@ rapamycin in combination or association with a pharmaceutically acceptable diluent or carrier , provided that cyclosporin a is excluded as the il-2 transcription inhibitor ( the il-2 transcription inhibitor ) ( a ) and a ( b ) -@@ rapamycin ( -@@ -@@ rapamycin ) ( -@@ rapamycin ) ( -@@ rapamycin ) ( -@@ rapamycin ) ( -@@ rapamycin ) ( -@@ rapamycin ) ( -@@ rapamycin ) ( -@@ rapamycin ) ( -@@ rapamycin ) and ( a ) -@@ rapamycin .
the device of claim 1 , wherein the support comprises an absorbent material such as a fibrous synthetic material or filter paper .
the stent of claim 1 , wherein each connecting strut ( 90 ) of each connecting strut of connecting strut strut ( 32 ) of of of the first connecting strut strut ( 32 ) of of of the of of of the of of of of the of of of of of the of ( of of of of of the of of of of of of the of of of of of of of the of of of of of of of of of of of of of of of of of of of of of of of
the laminated tissue construct of claim 6 , wherein said plasticizer is selected from the group consisting of selected from the group selected from the group consisting of glycerol selected from the group consisting the selected from the group consisting the group consisting the group consisting the group consisting the group consisting the group consisting the group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group
the method of claim 4 or 5 , wherein the specific absorbent components are reduced haemoglobin hb and oxy@@ hemoglobin hb@@ o and the calculating step comprises calculating a degree of oxygen saturation of hemoglobin y .
device for sterilizing suction bottles
use according to claim 1 , characterized in that the electro@@ kinetic index &quot; i &quot; of the semi-permeable membrane is on polyacrylonitrile base which is a carrier of solid , negative charges and contains a neutral or cationic polymer , at most equal to 0.7 or less .
the orthopedic casting article of claims 12-@@ 16 wherein said viscous curable resin further comprises a sufficient amount of a second reactive monomer or oligomer , such that after polymerization of said second reactive monomer or oligomer the mixture of said resin and said polymerized second reactive monomer or oligomer at 1.0 rad / s has an tan δ of less than 10 .
dose adjustment of pioglitazone should be considered in the dose recommendation or changes in diabetic treatment ( see section 4.5 ) . in see section 4.5 ( see section 4.5 ) section 4.5 ( section 4.5 )
device according to one of claims 1 to 16 , characterised in that , in order to form the active substance storage container ( 4 ) , the chip ( 15 ) is provided in particular between an outer chip ( 14 ) and an adjacent , particularly the chip ( 15 ) , which is adjacent to the container space , is provided .
the prosthesis of claim 1 , wherein the valve prosthesis ( 10 , 100 ) is adapted to replace the aortic valve .
hold the viraferon , solution for injection , multidose , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
process for the preparation of optically active glyci@@ dic esters .
if you take more myfenax than you should you should you should you should you should take you more than you should you should
meman@@ t@@ ine-treated patients showed a statistically significantly better a statistically significantly better statistically significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better significantly significantly better
the device of claim 1 , wherein the second flow is tangentially to the first flow .
osmotic non-@@ fermented laxative for treatment and prevention of colorectal cancer
device and method for the treatment of vari@@ co@@ se of vari@@ o@@ se and the method for method and method for treating for method for treating for method for treating for method for treating for method for treating for for method for treating for for method
what is pan@@ ac@@ ur aqua@@ sol used for ?
the catheter of claim 1 , wherein the lumen ( 70 ) is tubular and has a circular cross-section , the longitudinal axis of the lumen is offset and is parallel to the longitudinal axis of the catheter to define a portion ( 76 ) of reduced thickness in the wall ( 74 ) of the catheter .
a peptide having 5 or 6 residues which inhibits the enzymatic activity of a phospholipase a 2 , said peptide having an amino acid sequence corresponding to a sequence selected from the region of residues 69 -@@ 75 of phospholipase a 2 .
plant cell characterized in that it contains a nucleic acid sequence according to claim 12 or a chimeric gene according to claim 12 according to claim 13 to 16 to claim 12 .
the approximately active substance impermeable polyester film can be removed before use .
the method of claim 5 , wherein the second solution is a non-aqueous solution . the method of claim 5 wherein the second solution is a non-aqueous solution . the method according to claim 5 wherein the second solution is a non-aqueous solution . a process according to claim 5 wherein the second solution is a non-aqueous solution . the process according to claim 5 wherein the second solution is the solution is the solution is a solution is is is the solution is is is solution .
side effects may occur at least at least four months after the last injection of humira .
an arylalk@@ yl-@@ 1,2-di@@ amine according to claims 1 and 2 , characterized in that it is represented by the formula ( iii ) : aryl@@ alkyl-@@ 1,2-di@@ amine according to claims 1 and 2 , characterized in that it is represented by formula ( v ) : a process for the preparation of the arylalk@@ yl-@@ 1,2-di@@ amine of claims 1 and 2 , wherein x represents the following steps : a ) the compound of formula ( vii ) : in which : b ) an aryl@@ sulphonyl group is selectively introduced at one of their amine functions
empagliflozin improves glycaemic control in patients with type 2 diabetes by reduction of renal glucose re@@ absorption .
the invention relates to a method for the controlled iontophoretic application of active substances and devices suitable therefor .
4.7 effects on ability to drive and ability to drive on ability to drive and use machines use and use machines and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use and use
a non-therapeutic method of inhibiting an increase in the amount of triglycerides in humans comprising administering to said method an effective amount of a peptide of claim 1 .
the ultrasound catheter of any preceding claim , wherein the proximal portion ( 112 , 212 ) is attached to the ultrasound transmission member ( 24 ) with a clamping connection ( 230 ) .
a third study compared for@@ xi@@ ga with a sulphonylurea ( glipizide ) , both medicines were given in combination with metformin in 8@@ 14 patients .
a separator or packaging material according to claim 1 , wherein the surface roughness ( r a ) is formed by means of a embossing .
wheelchair according to claim 9 , characterized in that the flap arrangement ( 16 ) comprises pivotally mounted spacer rods ( 60 , 61 , 62 , 63 ) whose opposite outer ends are fixed to a corresponding strut ( 41 ) .
the printed package leaflet of the package leaflet of the medicinal product must the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
the device ( 10 ) can be placed on a counter-@@ surface via a contact surface ( 20 ) .
sphygmomanometer according to one of the preceding claims , characterized in that the sensor elements ( 23 , 49 , 42 ) cooperate free of return forces .
a compound which is &#91; 2-methoxy@@ 5- ( 5-trifluoromethyl-@@ tetrazol@@ -1-yl ) -benzyl &#93; - ( 2@@ s-@@ phenyl@@ piperidine@@ -2@@ yl ) -amine , or a pharmaceutically acceptable salt or solvate thereof .
a tablet according to any one of the preceding claims wherein the colloidal silica is present in an amount of 0.1 to 0.5 % w / w .
the method of claim 13 wherein the reporter or effector group comprises the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
a device for mixing an orthopaedic cement , comprising a mixing chamber ( 1 ) and a dispensing chamber ( 2 ) , wherein the mixing chamber ( 1 ) comprises an inlet opening ( 17 ) , the inlet chamber ( 1 ) having an inlet opening ( 17 ) , the inlet means and the outlet opening being provided in cement flow communication , and wherein the closure comprises a ball or ball ( 15@@ t ) having a hole passing through the mixing chamber and the dispensing chamber .
it must be protected from light and must not be frozen .
uses of hm@@ gb , hm@@ g@@ n , hm@@ ga proteins
corynebacterium glutamicum genes encoding stress , resistance and tolerance proteins
hydrochlorothiazide may cause or exacerb@@ ate hypovola@@ emia or exacerb@@ ate or exacerb@@ ate or exacerb@@ ate electrolyte imbalance or exacerb@@ ate or exacerb@@ ate or exacerb@@ ate or exacerb@@ ate exacerb@@ ate or exacerb@@ ate exacerb@@ ate or exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@ ate exacerb@@
the conjugate of claim 1 , wherein the lipid has a functional group which is an amino group , a carboxyl group , a thiol group or an aldehyde group .
the process according to claim 11 , wherein the water alcohol solution is water and ethanol . the method of claim 11 , wherein the water alcohol solution is water and ethanol . the method according to claim 11 , wherein the water alcohol solution is water and ethanol . the process according to claim 11 , wherein the water alcohol solution is water and ethanol . the method according to claim 11 wherein the water alcohol solution is water and ethanol .
device according to one of the preceding claims , characterised in that the disc or ring ( 13 ) is incorporated in the toothed wheel gear of the drive device ( 2 ) .
van@@ to@@ bra 170 mg nebuliser nebuliser nebuliser solution and a nebuliser nebuliser solution 170 mg / ml nebuliser solution , compri@@ to@@ bra 170 mg nebuliser nebuliser nebuliser solution , compri@@ to@@ bra 170 mg nebuliser nebuliser nebuliser nebuliser solution mg nebuliser nebuliser nebuliser nebuliser nebuliser mg nebuliser nebuliser nebuliser mg nebuliser nebuliser nebuliser mg nebuliser nebuliser nebuliser mg nebuliser nebuliser nebuliser mg nebuliser nebuliser mg nebuliser nebuliser mg nebuliser nebuliser mg nebuliser nebuliser mg nebuliser nebuliser mg nebuliser nebuliser mg nebuliser nebuliser mg nebuliser nebuliser mg nebuliser nebuliser mg nebuliser nebuliser mg nebuliser nebuliser mg nebuliser nebuliser
the concentrate of proteolytic enzymes enriched from bro@@ mela@@ in is absorbed into the systemic circulation from the wound surfaces ( see section 5.2 ) .
lansoprazole inhibits the activity of this enzyme with the sulfhydryl group of the enzyme h + / k + atpase . + the activity of the enzyme .
method for producing a selectively crosslinked medical prosthesis of polyethylene and a prosthesis made thereby
the use of claim 1 , wherein the cc chemokine mutant is an active variant of the cc chemokine mutant in which one or more amino acids have been deleted , deleted or conservative .
a compound as claimed in any according to any one of claims 1 to 9 for use as a medicament . use of a compound of a claims 1 to 9 of any of claims to 1 to 1 .
a vaccine composition according to any one of claims 11 to 14 which is capable of stimulating interferon γ production on the antigen or antigenic composition .
he &apos;s also a doctor , so you know it .
an ear@@ cup as claimed in any one of claims 1 to 3 , characterized in that the first element has a uniform thickness . of the ear@@ cup of any one of the claims 1 to 3 , characterized in that the first element has a uniform thickness . of the ear@@ cup of one of the claims 1 to 3 , of one of claims 1 to 3 , of claims 1 to 3 .
in patients with hyper@@ gam@@ maglo@@ bul@@ in@@ aemia , normalisation of igg levels was observed in 49 % of ben@@ ly@@ sta and 20 % of placebo-treated patients at week 52 .
use according to any one of claims 26 to 28 , characterized in that the preparation is provided in a dose corresponding to that of the non-@@ nitro@@ lated protein .
a sugar-@@ based polymer as claimed in claim 7 , wherein the non-reducing sugar is sucrose .
plant according to any one of claims 1 to 9 , characterized in that it is a vigabatrin or au@@ ber@@ in species .
a compound according to claim 1 , wherein r 4 is phenyl . compound according to claim 4 wherein r 4 is phenyl . compound according to claim 1 , wherein r 4 is phenyl . compound according to claim 4 wherein r 4 is phenyl .
use of an aliphatic diol or an aliphatic polyol as an additive to a culture of a ph@@ a-@@ producing microorganism for producing a composition from a hydroxy@@ terminated pha having a number average molecular weight of greater than about 20,000 and a number average molecular weight of greater than about 20,000 mole % , wherein : ( a ) the aliphatic diol is ethylene glycol , diethylene glycol , propylene glycol or neopentyl glycol , and ( b ) is the aliphatic polyol pentaerythritol .
a multiple lumen access system according to claim 19 , further comprising a luer connector ( 526 ) on the device lumen valve ( 528 ) and an infusion syringe having a complementary luer connector .
carton ( containing 8 transdermal patches )
use of micro@@ proteins as tryp@@ tase inhibitors
manufacturer ( s ) of biological biological active substance ( s ) and manufacturer ( s ) ( s ) responsible for batch release for batch release for batch release for batch release for batch release for batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release batch release
ventricular tachycardia / fibrillation , sudden death ( see ( see section 4.4 ) 11 ( section 4.4 ) 11 ( see section 4.4 ) 11 4.4 ) 4.4 ) 4.4 ) 4.4 ) 4.4 ) 4.4 ) 4.4 ) 4.4 ) 4.4 ) ) 4.4 ) 4.4 ) ) 4.4 ) 4.4 ) 4.4 ) ) 4.4 ) 4.4 ) ) 4.4 ) 4.4 ) ) 4.4 ) 4.4 ) 4.4 ) ) 4.4 ) 4.4 )
6 . a process according to any one of claims 1-5 , characterized in that the components are used in powder form .
claims for the following contracting state : es a process for producing the antibiotic ce@@ fe@@ pimozide dihydrochloride hydrate which comprises less than 5 % of the anti-@@ isomer and the δ 2 isomer , which comprises reacting the anhydrous hydrochloride salt of 2- ( 2-aminothiazol-4-yl ) -2-methoxy@@ imino@@ acetic acid with a mixture containing less than 5 % of the anti-@@ isomer and the δ 2 isomer , the syn isomer of 2- ( 2-aminothiazol-4-yl ) -2-methoxy@@ imino@@ acetic acid being reacted at a ph of 5.0 to 7.5 in an aqueous organic solvent at a ph of 5.0
contents of the pack and other information pack and other information pack and other information and other information and other information and other information and other information other and other information and other information
human monoclonal antibodies to epidermal growth factor receptor
infusion-related reactions external clinical trials include reports of pyrexia , chills , rigors and vomiting , mostly mild to moderate in intensity .
these are called impulse control disorders and may be associated with behaviour such as gam@@ bling , excessive eating or mon@@ e@@ od , abnormally high sexual drive or increased sexual thoughts and feelings .
a decision to use this vaccine before or after any other veterinary medicinal product or after any other any other veterinary medicinal product any other veterinary any other veterinary medicinal veterinary medicinal veterinary medicinal other veterinary medicinal other veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal veterinary medicinal
an absorbent article according to any of the preceding claims , wherein said adhesive is a hot-melt adhesive having a residual adhesive tack of less than 16 grams per inch peel strength . said absorbent article of any preceding claim , wherein said adhesive is a hot-melt adhesive having a residual adhesive tack of less than 16 grams per inch of said adhesive . said absorbent article of any of said claims wherein said adhesive is a hot-melt adhesive having a residual tack of less than 16 grams per inch peel strength per inch of said adhesive .
in patients with pre-existing cardiac , renal or hepatic disease , oedema may be associated with oedema ( or with or without congestive heart failure ) as serious complications following high doses of testosterone or other an@@ abolic steroids .
use of a first composition comprising an estrogen compound having a daily dose equivalent to the estrogenic activity of 17-@@ alpha-@@ ethinyl estradiol in a range from 0.01 to 0.04 mg , and a subsequent composition comprising a contraceptive daily dose of a progestin for the manufacture of a two-@@ step contraceptive dose for the manufacture of a two-@@ step contraceptive composition for the manufacture of a two-@@ step contraceptive composition , for the preparation of a two-@@ step contraceptive composition , for the preparation of a two-@@ step contraceptive composition , for the manufacture of a two-@@ step contraceptive
the ratchet ( 10 ) of any one of the preceding claims , wherein the handle ( 12 ) is a t-@@ rod ( 138 ) .
yt@@ trig@@ a with food and drink no special storage conditions
the use of arthro@@ scopy is for joint diagnosis and , if appropriate , for the sanitizing of meniscus lesions .
if you have liver or kidneys problems or have or have or have or have or have or have advanced liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or liver or
the method of claim 30 , wherein the amount of impurities contained in the precipitate is at least 50 % lower than the amount of impurities contained in the acetone mixture .
the invention relates to the use of active substance combinations containing phenolic active substances and fungicidal agents for preserving animal skins and lea@@ ther .
section 4.4 - special warnings and special precautions for use - special warnings and precautions for use and precautions warnings and precautions for use and precautions - for use and special precautions for use - precautions for use for use for use for use for use
a composition for delivering an agent to cells , said composition comprising : a transport vector comprising an avidin residue selected from avidin tetra@@ mer , avidin monomer subunit , avidin dimer subunit and non-@@ glycosylated derivatives thereof ; at least one mono@@ biotinylated agent thereof , to provide a composition of claim 1 , further comprising a pharmaceutically acceptable carrier for the avidin bio@@ tin-@@ agent complex .
use according to any one of claims 1-3 and 9-12 , wherein the retroviral infection is an hiv infection .
what is in this leaflet in this leaflet is in this leaflet in this leaflet . this leaflet is in this leaflet in this leaflet in this leaflet in this leaflet
the invention relates to a method for the synthesis and amplification of nucleic acids by means of an enzyme@@ -cataly@@ zed reaction , whereby a nucleic acid is co@@ pied from a single-stranded initiator nucleic acid without allowing hybridization of the initiator nucleic acid to the nucleic acid to be co@@ pying .
the apparatus ( 10 ) of claim 4 , wherein a polarization change is about one-half degrees , and wherein the reference value indicates a gas bubble in the stro@@ a ( 34 ) having a diameter of about 15 microns .
s@@ ze@@ lig@@ ow@@ ska 3 0@@ 5-@@ 850 s@@ ze@@ lig@@ i s@@ s@@ lig@@ i s@@ s@@ lig@@ i lig@@ lig@@ i lig@@ lig@@ i lig@@ lig@@ lig@@ i lig@@ lig@@ lig@@ i lig@@ lig@@ lig@@ i
enantiomeric compounds for the treatment of cardiac arrhythmias and methods of use thereof
there are no data on the excretion of rosuvastatin in human breast milk .
a balloon catheter apparatus according to claim 4 , characterized in that the polymer comprises a polyurethane , polyethylene , nylon or p@@ ba@@ x .
kr@@ ó@@ lo@@ we@@ j mar@@ y@@ sie@@ c ki 11 / 4 pl@@ -@@ 0@@ 2-@@ 9@@ 54 war@@ s@@ za@@ wa tel : + 48-@@ 22 8@@ 42 71 00 tel : + 4@@ 8-@@ 22 8@@ 42 71 00
composition according to any one of claims 5 to 7 , characterized in that the poly@@ cationic dendrimer is covalently associated with the nucleic acid .
the brachytherapy source of claim 1 , wherein the radioactive material ( 10@@ 12 ) is selected from the group consisting of iodin@@ e-@@ 125 and palla@@ di@@ um-@@ 103 .
if you stop taking champix
a process according to claim 6 wherein the inhibin is human inhibin and the activin is human activin .
a piperidine derivative or a pharmacologically acceptable salt or salt as claimed in claim 1 as a salt or a pharmacologically acceptable salt or salt as a salt or salt acceptable salt or salt as a salt salt or a pharmacologically acceptable salt salt salt or salt as a salt salt salt salt or salt as a salt salt salt salt as a salt salt salt as salt salt salt as salt salt salt as salt salt as salt salt salt as salt salt salt as salt salt salt as salt salt salt as salt salt salt salt as salt
the vaccine is available as is available as a suspension for injection a suspension for a suspension for a suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension for suspension
composition according to any one of the preceding claims , characterized in that the oligomer or polymer derived from a polyolefin is formed in the reaction of a polyolefin derivative and at least one acid chosen from maleic acid ; maleic anhydride ; fumaric acid ; itaconic acid ; citric acid ; me@@ sa@@ conic acid ; ac@@ coni@@ tic acid ; its derivatives and mixtures .
the nmr probe of claim 2 , wherein two shiel@@ ds ( 77 ) are attached to the probe in which one of the shiel@@ ds between the planar coils ( 70 , 72 ; 90 , 92 ) is positioned near the first side of the sample space and the other shield is positioned between the planar coils ( 71 , 73 ; 91 , 93 ) proximate the second side of the sample space .
composition , characterized in that it consists essentially of 1- &#91; 3,5-bis ( 1,1-dimethylethyl ) -4-hydroxyphenyl &#93; -5-@@ hex@@ ne@@ ne@@ -1-one ( te@@ bu@@ fa@@ fe@@ lone ) in a concentration of at least 15 % , preferably from 15 % to 30 % , and in that it has the following properties : ( a ) at 20 ° c and in that it has the following properties : ( d ) in water at 20 ° c and at concentrations of 10 % or below and in that it has the following properties : ( d )
- if your kid doesn &apos;t feel well .
the pharmaceutical dosage form of claim 2 wherein the outer layer further comprises a binder which constitutes from about 5 to about 20 % by weight of the dosage form of the dosage form by the weight of the pharmaceutical dosage form , of the dosage form , of the dosage form of the form of a pharmaceutical dosage form according to any of the claims to the dosage form of which the pharmaceutical dosage form of the dosage form the dosage form of any of the claims the dosage of the pharmaceutical dosage form of claim 2 .
1 vial + 1 pre-filled syringe 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1 vial 1
if you forget to take irbesartan bms : if you accidentally forget to take the daily dose you should continue to take the next dose as you should continue to take the dose . you should continue to take the next dose if you take the next dose you take
the pant of any preceding claim , wherein said baffle ( 16 ) is smaller in dimensions than said absorbent body ( 18 ) .
a method for the preparation of a recombinant dna molecule containing a nucleotide sequence encoding a surface-@@ exposed protein of haemophilus influenzae or related haemophilus species , said protein having an apparent molecular weight of 4@@ 5,000 , or or for or of or of interest of or or of naturally occuring variants of said protein or variants of or of or of said protein , or or or or or or or or or or or or or or or or or or or variants of or or or or or or or or or or or or or
a compound of formula i : or a stereoisomeric mixture thereof , a diastereomer enriched , a diastereomer , enriched , diastereoisomer , enantiomerically enriched , or an enantiomer thereof , or a prodrug thereof , or a prodrug thereof , which is a compound selected from the group consisting of : ( c -c ) - ( c -c ) - ( c -c ) - ( c -c ) - ( c -c ) - ( c -c ) - ( c -c ) alkyl ; r is ( cr r ) - ( c -c ) alkyl
in a study in 10,@@ 101 postmenopausal women with pre-existing coronary artery disease or with an increased risk of coronary events ( ru@@ h study ( ru@@ th study ) , vasodilation ( flushing ) ( hot flushes ) developed ( hot flushes ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ( ) ) ( ) ) ( ) ) ( ) flushes ( hot flushes ) ) ( hot flushes ) flushes ( hot flushes ) flushes flushes flushes flushes flushes flushes flushes flushes flushes flushes flushes flushes flushes flushes flushes
a binding protein for growth hormone having a specific activity of at least about 10,000 pmol / mg of at least about 10,000 pmol of the growth hormone receptor sequence of a sequence having the sequence of from 190 to 250 amino acid residues of sequence 8a or 8b or of substitution of substitution , insertion and deletion of substitution thereof , said variants having the ability of binding selectively to a growth hormone of a growth hormone of at least about of a growth hormone of a growth hormone of at least about 10,000 .
the water-soluble luminescent semiconductor quantum dot of claim 1 wherein the core of the quantum dot is selected from the group consisting of the the group consisting of the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
this is an increased risk of an increased risk of the treatment and that mild resistance ( see section 4.5 ) is developed ( see section 4.5 section 4.5 ) . section 4.5 ) section 4.5 ( 4.5 ) ) ) ) ) . ) ) section 4.5 ( section 4.5 ) ) ) ) . ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) . ) ) ) ) ) ) ) ) ) .
however , the role of this bio@@ marker ( pd-@@ l1 expression ) has not been fully elucid@@ ated .
composition according to either of claims 1 and 2 , characterized in that a part of the monomeric units of the sequestering agent is replaced with the exception , such as : malic acid units according to the formula wherein r is as defined above ; maleic acid and fumaric acid units according to the formula preparation according to claim 3 , characterized in that up to 10 monomeric units per polymeric molecule may be replaced by one of the malic , maleic or fumaric radicals defined in claim 3 .
the endoscopic bipolar forceps of any one of claims 1 to 11 , wherein the abutment is secured to the jaw by means of an adhesive .
a muscle stapler according to claim 3 , wherein each projection comprises : an upper portion ( 26a ) having an acute cone angle ; a central portion ( 26b ) having a cylindrical shape ; and a lower portion ( 2@@ 6c ) having an obtuse cone angle .
symptoms after administration of a large amount of em@@ la are listed below .
the poly@@ oxyl 35 hydrogenated castor oil of claim 19 which is c@@ remo@@ phor el or c@@ remo@@ phor el-@@ p .
a method of manufacturing according to claim 6 , further comprising the step of uniformly heating said cap ( 21 ) with a diffuse controlled heat source to heat said gas pocket ( 28 ) to a predetermined temperature before said cap ( 21 ) is fused to said surface of said fiber .
high sensitivity detection of biomolecules using phage display
a medicated feed that is not consumed within 24 hours .
the co-administration of prevenar 13 and 23-@@ valent pneumococcal polysaccharide vaccine has not been studied .
a composition according to any preceding claim , further comprising compounds selected from the group consisting of buffering agents , antioxidants , preservatives , coloring agents , fragrances , lubricants , humectants , sunscreens or dry agents .
method for producing a dental prosthesis and curable system
when co-administered with prezista co-administered with 100 mg ritonavir , no dose adjustment of indinavir of 800 mg twice daily is warranted .
after extraction of the mic@@ cro@@ bi@@ lle biomass with a water content up to 92 mass parts in % with a ketone and the mechanical separation of the la@@ c@@ ella is the removal of the lipophilic cell ingredients from the ketone - ketone - lipophilic cell contents system by addition of an alkali metal salt solution .
a composition according to claim 9 in sublingual tablet form further comprising a cyclodextrin .
if you cannot swallow the tablets , you can drink it in a glass of water without carbonic acid or apple juice :   
a study in which the injections were less administered ( in the first three months and then every three months three months after the first three months three months three months first three months first three months first three months three months first three months first three months three months three months three months three months three months three months three months three months three months three months three months three months three months three months three months three months three months three months three months three months three months three months three months three months three months three months
a compound as claimed in any one of claims 1 to 4 in any one of in any one of claims 1 to 4 in any one of one of in claims 1 to 4 in any one of one of one of claims of one to one of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims of claims
an aerosol delivery device comprising : at least one aerosol source ( 20 , 220 , 320 , 120 ) ; and at least one ionization electrode ( 70 , 224 , 370 , 170 ) for generating an ion flow thereof in a direction along a path for capturing and moving the aerosol from the aerosol source in the direction along the web , the direction extending away from the aerosol source .
composition in an aerosol container containing aluminium oxide nanoparticles
a cosmetic composition according to claim 16 , comprising a use selected from the group consisting of ma@@ ke@@ d@@ ling , sun@@ care , skin care and hair care .
the educational material for valdoxan / thymanax is inhaled separately to the prescribing physician :
use of a vaccine conjugate according to any of the preceding claims , wherein the medicament is of the form of the medicament of the of the preceding claims of the the preceding claims the the the the of the preceding claims of the preceding claims the the the the the the the the the the the preceding claims of the the preceding the preceding claims the the preceding the preceding preceding the the preceding preceding the the the the preceding preceding the the the the preceding preceding the the preceding preceding the the preceding preceding the the preceding the
this may indicate serious side effects that may need urgent medical attention .
a device as claimed in any preceding claim , wherein the defibrillator is an implanted defibrillator . the device of any preceding claim wherein the defibrillator is an implanted defibrillator . the device according to any preceding claim wherein the defibrillator is an implanted defibrillator . the device of any preceding claim wherein the defibrillator is an implanted defibrillator . the device of any preceding claim wherein the defibrillator is an implanted defibrillator . the device of any preceding claim , wherein the defibrillator is an implanted defibrillator .
a recombinant marek &apos;s disease ( md@@ v ) disease of serotype 1 , 2 or 3 , ( i ) in which the gd gene of the md@@ v virus is placed under the control of a promoter that is other than the natural promoter of the md@@ v virus under the control of a promoter , which is other than the natural promoter of this gene and the expression of the gd gene in cell culture in cell culture , and its expression in the genome of the virus in cell culture , which is not essential for
determination of diuretic effect of candidate drugs .
the method of claim 13 or 14 , wherein the enzyme is micro@@ peroxidase . the method according to claim 13 or 14 , wherein the enzyme is micro@@ peroxidase . the method of claim 13 or 14 wherein the enzyme is micro@@ peroxidase . the method of claim 13 or 14 wherein the enzyme is micro@@ peroxidase . the method of claim 13 or 14 wherein the enzyme is micro@@ peroxidase . the method of claim 13 or 14 wherein the enzyme is micro@@ peroxidase .
the follow-up was followed for up to 35 weeks .
the delivery system of claim 1 or 2 , wherein the active material is attached to the rna sequence via a spacer .
in patients whose blood pressure was not controlled in the 80 / 12.5 mg tablet , diastolic blood pressure was more effective than the 80 / 25 mg tablet / 25 / 25 mg tablet was more effective than was more effective than the lower dose in the lower dose than the the lower dose dose dose . dose lower than the lower dose was dose lower than dose 80 dose dose dose dose 80 . dose dose lower dose dose dose dose dose dose . dose lower dose dose dose . dose . dose . dose dose .
the system of claim 17 , wherein the at least one rib is annular . the system of claim 17 wherein the at least one rib is annular . the system of claim 17 wherein the at least one rib is annular . the system of claim 17 , wherein the at least one rib is annular . the system of claim 17 wherein the at least one rib is annular . the system of claim 17 wherein the at least one rib of the at least one of the rib is annular .
of these patients , 66 showed no progression of structural damage , defined as t@@ ss change of zero or less of less than , or less than in patients who had no progression of structural damage of the structural of the structural lesion . of these patients , 66 of these patients had no progression of structural damage of progression . of no progression of progression of structural damage .
this change results in a decrease in total plasma concentrations in plasma , the amount of unbound amprenavir representing the active moiety is likely to be unchanged .
the use of this medicine can be used either .
a method according to claims 13-@@ 15 , wherein the foam is brought into contact with the foam by wea@@ ving , tu@@ kes , spraying , casting or fla@@ ff@@ ings .
the use of claim 11 wherein r 2 is r 1 y 2 r 2 r 2 r 2 r 2 is r 2 is 2 2 r 2 is r 2 is r 2 is 2 2 is r 2 2 2 r 2 2 2 2 r 2 is r 2 is 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 r 2 2 r 2 is r 2 is 2 2 2 2 r 2 2 2 2 2 2 r 2 2
powder and solvent for solution for injection for solution for injection
the insulin will work more quickly if you will inject more insulin in the abdominal wall . more quickly will work work more quickly more quickly more quickly more quickly .
the pacemaker as described in claim 1 , wherein said modulating means ( 224 ) further comprises means for deriving stimulation intervals based on directly preceding heart beat intervals that are decre@@ mented to provide said desired stimulation interval to said desired stimulation interval .
a device according to any one of claims 4 to 7 , wherein the reservoir ( i ) comprises from 1 to 15 % by weight of a pharmaceutically acceptable pergo@@ lide salt , ( ii ) 10 to 70 % permeation enhancers comprising 1 to 35 % by weight of glycerol monolaurate and 1 to 35 % by weight methyl laurate and ( iii ) 35 to 85 % by weight ethylene vinyl acetate copolymer .
use according to claim 8 , wherein the reporter moiety is an iodinated organic compound .
use of a compound i of claim 1 for a preparation of a a of a compound of the preparation of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a
an absorbent composite fabric ( 1 , 6 ) according to any one of the preceding claims , wherein the first layer ( 2 , 8 ) of the textile composite is at least partially hydrophobic , deposited on the fibers of the first layer ( 2 , 8 ) of fibrous material , absorbent composite fabric ( 1 , 6 ) according to any preceding claim , wherein the fibrous second layer comprises antiseptic and / or moisturizing agent .
fibrinogen is converted to fibrin by cleavage of fibrinogen to fibrin monomers and fibrino@@ peptides .
a compound as defined in any one of claims 1 to 21 , or a physiologically acceptable salt thereof , for use in therapy .
devices for delivering molecular sieve materials to form blood clots
a dried product according to claim 7 comprising an enzyme , serum complement , antibody or antigen ( either free or coupled to a carrier ) , a fluoresc@@ ence-@@ labeled protein , a vaccine component or a polysaccharide .
potassium-sparing diuretics , potassium supplements , potassium , potassium , potassium , , potassium , , potassium , , potassium , , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium , potassium ,
the vector of claim 14 , wherein the promoter of the ta@@ ka amylase promoter is of aspergillus oryzae . the vector of claim 14 of the vector is the of aspergillus oryzae of aspergillus oryzae of aspergillus oryzae of aspergillus oryzae of aspergillus oryzae of aspergillus oryzae of aspergillus oryzae . the vector of claim . . . . . . . of the vector of claim . . . . . . . of the vector of claim . of the vector of claim of claim of claim of claim of claim of claim .
immunocompromised patients in a 12-week prophylaxis study in 4@@ 75 immunocompromised patients , including 18 children aged 1 to 12 years and older , the safety profile in the 238 patients receiving oseltamivir was consistent with that observed in prior clinical trials with tamiflu prophylaxis .
use according to claim 17 , characterized in that the mineral water or thermal water is chosen in the following water : water from the v@@ ich , water , water from uridine , water in the from water , in water from the water , water , water from water , water , water , water from , water from water , water , water from water , water from water , water from water water from water , from water water from water water from water water from water water water from water water from water water from
the fluid management device ( 15 ) controls the fluid delivery devices ( 10 ) as a function of the image acquisition result .
a gel according to claim 5 , wherein the m@@ q resin has a vinyl unsaturation content of from 1.0 to 2.0 % by weight , which is present in an amount of from 15 to 20 % by weight ; the si@@ h-@@ cross linking agent is a polyorganosiloxane with dimethyl@@ dimeth@@ oxy@@ - and hydrogeno@@ methyl@@ sil@@ oxy repeating units having a si@@ x-@@ bound hydrogen and hydrogen methyleth@@ oxy repeating units having a si@@ x-@@ bound hydrogen and a hydrogen@@ -@@ bonded hydrogen ion content of 0.1 to 1.0 % by weight , said cross-linking agent being
use of compounds according to claim 1 according to claim 1 to and / or of claim 1 to claim 1 to claim 1 to claim 1 to claim 1 to claim claim 1 claim claim claim 1 claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim 1 claim claim 1 claim claim 1 claim claim 1 claim claim 1 claim claim 1 claim claim 1 claim claim 1 claim claim 1 claim claim 1 claim claim 1 claim claim
an endoscope suitable for insertion into the coronary arteries of a patient , comprising as an image transmitting element an optical fiber cable of a multi-@@ filament type , having a circular or substantially circular cross section having 50 to 20,000 light transmitting fibers , each having 50 to 20,000 light transmitting fibers , each having 50 to 20,000 light transmitting fibers , each having a core diameter of the optical fiber cable , an object lens placed at one end of the imaging element , and an image transmitting image pickup element located at the other end of the
- the committee concluded that the committee concluded that the committee concluded that
composition for the oxidation dyeing of keratin fibres , and in particular human keratin fibres , such as the hair , which comprises , in a medium suitable for dyeing , at least one precursor of an oxidation dye and at least one oxidation dye of the formula ( ii ) with an acid , with the proviso that the composition for dyeing does not contain an additional oxidation dye chosen from 3-methyl-@@ para-aminophenol , 2-methyl-@@ para-aminophenol and 2-hydroxymethyl-@@ p-aminophenol when in formula ( i ) m is zero and the group r 1 represents β-hydroxyethyl .
azopt has not been studied in patients who wear contact lenses .
vaccine composition according to claim 3 , characterized in that the w / o emulsion is a first phase and the live ca@@ v immunogen is a second phase of the vaccine composition .
concomitant use with st. john ’ s wort john ’ s wort ’ s john ’ s wort ( s ’ s wort s ) ( s ) ( see section 4.5 s s ( see section 4.5 ( section 4.5 ) s wort ( see section 4.5 ) section 4.5 section 4.5 section 4.5 4.5 section 4.5
on 1 october 2015 , the united kingdom triggered a referral under article 13 ( 2 ) of commission regulation ( ec ) no 12@@ 34 / 2008 .
a compound of formula ii or a pharmaceutically acceptable salt of the formula ii of the formula ii of formula ii .
adults and adolescents 12 years and older and adolescents 12 years and 12 years and adolescents 12 years and 12 years 12 years 12 years 12 years 12 years
compound of formula ( i ) according to claim 1 , in which r 3 represents methyl , ethyl or n-propyl and r 7 represents hydrogen , -c 1-6 -alkyl , -c 1-6 or -coch 3 .
the protein of claim 1 , wherein the linker sequence is an amino acid or is a plurality of amino acids selected from the group consisting of glycine , asparagine , serine , threonine and alanine .
a method of applying a protective coating to the skin , the method comprising applying to the skin a sterile polymeric formulation according to any one of claims 1 to 3 to the skin in a thin layer and allowing the organic liquid solvent to evapo@@ rate .
the method of claim 15 , wherein the step of responding to an emergency condition of the patient further comprises the step of : exchanging speech message to the patient from the medical support note .
the method of claim 29 , wherein the lar@@ vic@@ ide is adapted for systemic administration to plants .
prolongation of the qt interval in 9.9 % of patients receiving dela@@ man@@ id 100 mg twice daily , qt prolongation in the ecg was reported ( frequency category &quot; ) , compared with 3.8 % of patients receiving placebo + ob@@ r .
- if you are taking lopinavir / ritonavir as prescribed , it is as good as possible so that the virus does not respond to this medicine ( development of resistance ) .
meta-analysis of overall survival data produced an estimate of overall survival ratio of 1.08 in favour of controls of in favour of controls ( 95 % ci : ( 95 % ci : ci :
the composition of claim 3 wherein the absorp@@ tion-@@ promoting agent is lauroyl choline chloride . composition according to claim 3 wherein the absorp@@ tion-@@ promoting agent is lauroyl choline chloride .
between injections , a minimum interval of 1 month should be observed : for example 2 , 3 and 4 months ; 2 , 4 and 6 months ; 3 and 5 months .
the method of claim 13 , wherein the added stabilizer is methionine . the method of claim 13 wherein the stabilizer added is methionine . the method of claim 13 , wherein the stabilizer is methionine . the method of claim 13 wherein the stabilizer is methionine . the method of claim 13 , wherein the stabilizer is methionine . the method of claim 13 , wherein the stabilizer is methionine . the method according to claim 13 , wherein the the stabilizer added is methionine . the method of claim 13 wherein the stabilizer is methionine .
70 % of patients were treated for more than 48 weeks .
eur@@ arte@@ si@@ m is used to treat uncomplicated malaria caused by the parasite plasmodium falciparum .
a thrombin receptor antagonist according to any one of claims 1 to 5 wherein r 2 is selected from phenyl , t-butyl , isopropyl , isobutyl , cyclohexylmethyl , benzyl , 4-hydroxybenzyl , 2-naphthylmethyl , 1-@@ napth@@ ylmethyl , 2-thienylmethyl , methyl@@ thioethyl , indol@@ ylmethyl and substituted benzyl , and r 4 is cyclohexylmethyl .
a formulation according to claim 12 , wherein the monoesters are selected from the group comprising isopropyl myristate and ethyl oleate .
the support ( 10 ) of any one of the preceding claims , wherein the upper portion of the metal member forms a shoulder ( 20a ) for engagement with the head ( 38 ) of the screw ( 36 ) .
a glass ionomer cement comprising a glass according to claim 13 , a poly@@ alk@@ enoic acid or a precursor of said and water .
claims for the following contracting states : at , be , ch , de , fr , gb , it , li , lu , nl , se a thio@@ formamide derivative of the general formula : wherein : r is a straight or branched alkyl group having 1 to 4 carbon atoms ( s ) : r is a straight or branched alkyl group having 1 to 4 carbon atoms ( s ) ; r is a straight or branched alkyl group having 1 to 4 carbon atoms ( s ) ; r is a straight or branched alkyl
button and continuous loop fixation loop
a fluid pump according to claim 3 , wherein the means ( 46 ) supplying fluid from the circumference of the impeller to the flow wheel is provided by means of flow leakage forces , from conduits extending from the pump chamber outlet port ( 28 ) and each in an arrangement which forms three or more flow nozzle ports ( 52 ) within the pump chamber inlet opening ( 26 ) near the axially extending neck portion ( 42 ) of the impeller ( 16 ) .
a system as claimed in claim 1 in which the second polymer is insoluble in the solution of the first polymer or the solvent therefor .
what clopidogrel 1a pharma is and what it is used for 2 .
the process of claim 1 or claim 2 , wherein the layer retaining the active agent further comprises an absorbing agent and a surfactant and a surfactant . a 1 or claim 2 or a surfactant . a 1 or 2 or 2 or a surfactant . a surfactant . a surfactant . a surfactant . a surfactant surfactant .
warfarin ( used to prevent blood clots ) , oral contraceptives , phenytoin ( for seizure inhibition in epilepsy ) and antacids ( aluminium or magnesium medicines in stomach upset ) .
a method of producing high density arrays of target substances comprising the step of decomposing a bundle of target strands , wherein the target strands comprise the target substances , characterized in that the decomposition leads to a high density array of greater than 50 µm .
a method for providing droplets for delivery to the upper and lower respiratory tract , comprising : applying liquid to first and second outlets ; applying a first electro@@ hydrodynamic nebulizer ( 23 ; 35a ) to an electrical potential , to provide an electrical potential and to cause the liquid to be atomi@@ sed to form an atomi@@ sation with opposite polarity , thereby forming a substantial mixture of the two accele@@ rations of opposite polarity .
in patients receiving g-csf after allogeneic bone marrow transplantation , patients receiving g-csf after allogeneic receiving allogeneic bone marrow transplantation have been receiving g-csf after an allogeneic bone marrow transplantation receiving g-csf after receiving allogeneic human bone marrow transplantation after receiving allogeneic g-csf after an allogeneic bone marrow transplantation receiving g-csf after receiving an allogeneic bone marrow transplantation after an allogeneic bone marrow transplantation receiving g-csf after receiving an allogeneic bone marrow transplant after receiving allogeneic human bone marrow transplantation after allogeneic receiving g-csf after an allogeneic bone marrow transplantation receiving g-csf after g-csf receiving g-csf after g-csf .
due to adverse events adverse events discontinued in this study 12.@@ 9 % of fab@@ ly@@ n-@@ treated patients and 12.@@ 3 % of placebo-treated patients discontinued therapy due to adverse events of adverse events .
for the review of the contraindication in pregnancy , data from post-marketing surveillance and from the published literature are used , which are considered to be related to the risk of spontaneous abortion , mis@@ carriage , full-@@ birth , immature and low birth weight in women susceptible to measles , mumps , rubella and / or varicella ( varicella ) , and the risk of malformations and rubella disease in children and the risk of congenital varicella syndrome .
mouth rinse according to claim 1 , characterized in that as the buffer salts in the second component ( b ) the salts of complexing acids are contained from the group of hydroxy or amino@@ polycarboxylic acids , organo@@ phosphonic acids or condensed oligo@@ phosphoric acids .
a process for preparing 4- ( 2- ( 1,4,5,6-tetrahydro@@ pyrimidin@@ -2-yl@@ carbamoyl ) ethyl ) benzoic acid ( compound of formula xv ) or a salt thereof comprising hydrogenation of benzyl-@@ 4- ( 2- ( pyrimidin@@ ylcarbamoyl ) -vinyl ) benzoate ( compound of formula xiii ) or a salt thereof .
composition according to claim 11 or 12 , characterized in that it is mixed with water in a weight ratio of 1 : 0.5 to 1 : 20 .
device and method for ultrasonic sealing disposable diapers .
the gel of claim 48 , wherein the biologically active agent is covalently linked to the hydrolytically degradable polymer .
and mr@@ s. ma@@ y , believe me , i understand your fruit .
a gra@@ b bite object according to any one of the preceding claims , characterised in that the above-mentioned layer ( 5 ) is a mineral material . the gra@@ b cylinder object according to any one of the preceding claims , characterized in that the above-mentioned layer ( 5 ) is a printed cover paper .
a pharmaceutical composition as claimed in claim 6 for use in the treatment of infertility . use according to claim 6 for use in treating infertility in infertility . in use in treating infertility
a method of attaching a housing ( 100 ; 200 ; ... ) for a mechanical or electrical device to an aerosol container ( 120 ; 220 ; ) with the following successive steps : placing a skirt ( 125 ; 225 ; .... ) of the housing around the neck ( 121 ; 221 ; .... ) of the container ; placing a sleeve ( 102 ; 202 ; ... ) of the housing around the enclosure ; and connecting the collar to the sleeve .
peptide conjugate according to claim 17 , characterized in that , in the general formula i , r can stand for : a monounsaturated radical of cis or trans configuration with the general formula in which r represents a linear or branched alkyl radical , which comprises at least 6 carbon atoms , preferably from 6 to 16 carbon atoms , and the derivatives of the formula , dihydro@@ lipoic acid , and the derivatives thereof , the α-@@ monounsaturated unsaturated fatty acid and the derivatives thereof , the α-@@ monounsaturated unsaturated fatty acids and the derivatives thereof , the
the grounds for the referral were different versions of member states on the use of the medicinal product in adolescents and children ( over 6 years of age ) .
the product of claim 10 wherein the foam stabilizing and emulsifying surfactant is in the form of a polyoxyethylene sorbitan ester .
alcon cu@@ s@@ s@@ í s a cam@@ il fab@@ ra 58 08@@ 320 el mas@@ no@@ u ( barcelona ) spain fab@@ no@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra fab@@ ra
the graft ( 10 ) ( 10 ) of claim 2 wherein the ( a ) of the pleats of the of the of the of the of the of the of the of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of
a process according to claim 1 or 2 , wherein the microorganism belonging to the genus al@@ tero@@ monas is alter@@ ro@@ monas pu@@ tre@@ faciens sub@@ species sa@@ ga@@ ami@@ faciens sc@@ c@@ c-@@ 1@@ 162 ( fer@@ m-@@ bp@@ -16@@ 26 ) , al@@ tero@@ monas pu@@ tre@@ faciens s@@ cr@@ c-@@ 28@@ 71 ( fer@@ m-@@ bp@@ -16@@ 24 ) , age@@ monas pu@@ tre@@ faciens i@@ x@@ 15@@ 10 , and i@@ am 124@@ 25 , i@@ x@@ 12@@ 6@@ 41 .
skin rash , seek medical advice and show this warning to the physician .
the laparoscopic bipolar electrosurgical instrument of any preceding claim , wherein the closure force is in the range of about 7 kg / cm 2 to about 13 kg / cm 2 .
process according to claim 7 , characterized in that at least one of the rollers is a hard cast roll .
a composition according to any one of the preceding claims wherein a dosage unit of the composition comprises from 1 to 32 mg of the nsaid substance .
zoledronic acid is not metabolised but is not metabolised is not metabolised via is excreted unchanged via the kidney is unchanged .
the variant of claim 2 comprising at least one amino acid substitution selected from the group consisting of : l@@ 45@@ k , l@@ 4@@ 5r , v@@ 45@@ k , v@@ 4@@ r , g@@ 4@@ 5r , g@@ 48@@ k , v@@ 4@@ r , g@@ 49@@ r , g@@ 49@@ y , g@@ 4@@ 5r , g@@ 49@@ r , g@@ 49@@ y , g@@ 49@@ i , g@@ 49@@ t , l@@ 49@@ r , g@@ 49@@ l , l@@ 49@@ t , 49@@ y , s@@ 68@@ n , v@@ 49@@ r , 49@@ n
medicaments containing at least one combination according to claims 13 to 19 and optionally other pharmaceutical active ingredients .
a surgical clip according to claim 1 , wherein : the clip ( 10 ) consists of two to ten partial clips ( 12 ) .
biological process for producing alpha-@@ adrenoceptor and alpha-@@ hydroxy acid .
absorbent article with multi-@@ ply absorbent structure
a sic@@ k-@@ bed according to claim 19 or 20 , characterised in that the actuating pin ( 80 ) engages the sleeve-shaped housing lug ( 65 ) and is provided in the longitudinal region ( l ) orthogonal to its longitudinal axis with a groove in the longitudinal region ( l ) , with a transverse opening ( 71 ) extending through a half-@@ circle ( 72 ) and the transverse opening ( 71 ) passing through straight walls ( 71 , 74 ) through which the actuating bolt ( 80 ) passes through the blocking pin ( 80
cosmetic and dermatological washing preparations containing one or more pre-@@ gelatini@@ sed , cross-linked starch derivatives , and one or several ethoxylated oils , containing one or more pregelatinized , cross-linked starch derivatives and , or a plurality of , ethoxylated oils
n- ( 5-@@ thioxo-@@ -propyl ) -l-@@ cysteine and derivatives , their preparation and pharmaceutical compositions containing them .
benzodiazepines , drugs for treating mental disorders
an ultraviolet radiation measuring apparatus according to claim 4 , further comprising a reference table according to degrees of skin inflammation to be produced when light to the accumulated value of said ultraviolet band of said ultraviolet band is included in association with said ultraviolet band of said ultraviolet band and said ultraviolet band said ultraviolet band ultraviolet band ultraviolet band band said ultraviolet band band said ultraviolet band band said ultraviolet band band said ultraviolet band band said ultraviolet band ultraviolet band ultraviolet band ultraviolet band ultraviolet band ultraviolet band ultraviolet band ultraviolet band ultraviolet band ultraviolet band ultraviolet
the use of claim 13 , wherein the peptide is an opioid peptide .
he needs to go into a hospital .
the applicator ( 12 ) of claim 1 , wherein the rotor ( 38 ) has a d-@@ shape approximately cross-sectional profile and is adapted to receive coil of the plurality of fasteners ( 10 ) .
composition as claimed in at least one of at least one of claims 1 to 4 characterized in that the fluorine-containing components e ) are compounds of the formula ( ii ) r 1 -y@@ -c r 1 r r 1 r 1 r 1 r 1 r 1 r 1 r 1 1 r 1 r 1 1 r 1 1 r 1 1 r 1 1 r 1 1 r 1 1 r 1 1 r 1 1 r 1 1 r 1 1 r 1 1 r 1 1 r 1 1 r 1 1 r 1
process according to one of claims 11 to 13 , characterised in that the aqueous phase in the aqueous phase the aqueous phase contains the aqueous phase the aqueous phase the aqueous phase aqueous the aqueous phase aqueous the the aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous phase aqueous aqueous phase aqueous phase aqueous phase aqueous aqueous phase aqueous phase aqueous aqueous
b ) represents one or more water-soluble or non-@@ water-soluble polymers which are compatible with a ) .
injection device according to claim 11 , characterized in that each rear locking tongue ( 27 ) is arranged in an intermediate position on the length of the jaw ( 26 ) .
the use of claim 1 , wherein x is nor 6 and r 6 is selected from the group consisting of h , c 1 -c 6 alkyl , c 2 -c 6 alkenyl , c 2 -c 6 alkynyl , acyl , aryl , heteroaryl , saturated or unsaturated 3-@@ membered cycloalkyl , c 1 -c 6 , c 1 -c 6 alkyl , wherein the cycloalkyl or aryl or heteroaryl groups having 1 to 2 further cycloalkyl or aryl or heteroaryl groups may be condensed .
after administration of this product , a period of 3 months should elap@@ se before vaccination with live vaccination with live vaccination before administration .
stomach pain , digestive disorder decreased blood calcium levels feeling weak
the use of claim 43 , wherein the metabolic disorder is obesity . the use of claim 43 , wherein the metabolic disorder is obesity . , wherein the , the , metabolic , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , the metabolic disorder , is obesity .
the pharmaceutical composition of claim 25 , wherein the agent is il-2 , il-4 , or an agent that stimulates a t-cell by a cd2 , cd28 , cd40 or ctla4 surface receptor .
a process according to any one of the preceding claims , wherein fermentation is carried out by means of a mixture of moderate thermophilic bacillus species and other lactic acid-@@ producing microorganisms .
an acid , salt or ester according to claim 3 , wherein r ⁶ is a hydrogen atom , a c ₁ -c ₁ ₀ alkyl group or an aralkyl group having a carbocyclic c ₆ -c ₁ ₀ aryl group as an aryl moiety and a c ₁ -c ₆ alkyl group as an alkyl part .
a compound according to claim 1 , which is n- ( 2-hydroxy@@ -5-@@ chlorophenyl ) -3- ( trifluoromethyl ) phenyl acetamide , n- ( 3- ( trifluoromethoxy ) phenyl ) -n &apos; - ( 2-hydroxy-5-@@ chlorophenyl ) urea , n- ( 3- ( trifluoromethyl ) phenyl ) -n &apos; - ( 2-hydroxyphenyl ) urea ; n- ( 3- ( trifluoromethyl ) phenyl ; n- ( 3- ( 4-hydroxy-phenyl ) urea ; n- ( 3- ( trifluoromethyl ) urea ; n- ( 3- ( trifluoromethyl ) urea ; n- ( 3- ( trifluoromethyl ) urea ; n- ( 3- ( trifluoromethyl
the device or combination of claim 22 , wherein the measuring device is for measuring the flow rate and / or turbulence and / or pressure .
a method for the production of polypeptides in a prokaryotic cell , characterized in that ( i ) provides a cell comprising ( a ) at least one gene coding for a heterologous polypeptide in operative association with a regulatable expression control sequence which is repres@@ sible by a tetracycline repressor protein , and ( b ) the cell of ( i ) directing the gene coding for the heterologous polypeptide , and ( iii ) isolating the heterologous polypeptide from the cell or medium .
no@@ bi@@ vac my@@ x@@ o-@@ rhd lyophilisate and solvent for suspension for injection for for for suspension for injection
- treatment or prevention of duodenal or stomach ulcer in patients of prevention or prevention of duodenal ulcer or ulcer or duodenal or duodenal or duodenal
it is expected that the medicines work in the same way as with diabetic peripheral poly@@ neuropathy .
adults with relapsed or refractory ph + all or refractory or refractory or refractory or refractory or refractory or refractory ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph + ph +
a stone according to claim 1 , characterised in that the foam material contains mineral fibres .
solid compositions containing chitosan powder and process for producing the same for producing the same and process for producing the the same for producing the the same the process for producing the the the same the the same for producing the same the the same
a gingival former according to claim 1 , characterised in that the through-@@ bore ( 14 ) is located in the upper end region ( 16 ) of the head part ( 2 ) , especially in the upper half , preferably in the upper third , to the free end face ( 20 ) of the head part ( 2 ) .
dr. ke@@ p@@ ner , do we get her ?
a process for the manufacture of a medicament for the treatment of hyper@@ li@@ pe@@ mic conditions and decreasing the concentration of cholesterol and triglycerides in the blood of mammals , with a non-@@ β-@@ oxidizable fatty acid analogue of the general formula ( i ) : alkyl-@@ x@@ -ch ₂ , x is o , s , so or so ₂ and r is hydrogen or c ₁ -c ₄ alkyl .
compositions according to any one of the preceding claims , characterized in that the poly-@@ α-ole@@ fins are of the optionally hydrogenated poly@@ butene type or of optionally hydrogenated poly@@ dec@@ ene type .
serious immune system reactions related to a sulphonamide group include : rash , allergic reaction , and serious haematological disorders , including aplastic anaemia , which , in extremely rare cases , may be fatal ( see section 4.4 ) ( see section 4.4 section 4.4 ) . section ( see section 4.4 section 4.4 ) . 4.4 ) 4.4 ) ) ) ) . 4.4 ) 4.4 ) ) ) ) 4.4 ) 4.4 ) 4.4 ) ) ) ) ) ) 4.4 ) 4.4 ) 4.4 ) ) )
the active substance in imbruvica , i@@ bru@@ tinib , blocks an enzyme called bri@@ b@@ on tyrosine kinase ( b@@ bc ) , which is predominantly found in b lymphocytes .
it exhibits low uptake of dopamine without significant affinity for hist@@ aminergic , dopaminergic , cholinergic and adrenergic receptors .
a coupling according to any one of claims 1 to 10 , characterised in that the slider ( 44 ) is part of a transversely displaceable housing ( 42 ) .
mechanical sche@@ er stress &quot; or the release of pro@@ inflammatory cytokines .
a bone fracture setting apparatus as claimed in any one of the preceding claims , wherein the rotatable load support ( 240 ) has a substantially c-shaped member ( 241 ) having two arms disposed on opposite sides of the bone ( 1 ) , the load support ( 240 ) being fixed to the bone ( 1 ) by means of an elongate member ( 243 ) permitting the c-shaped element ( 241 ) to recipro@@ cate the c-shaped element ( 241 ) to allow rotation of the bone ( 1 ) to one of the axes .
take special care with champix
an apparatus according to claim 1 or 6 , comprising a downstream conduit attached to the outlet ( 20 ) and having a distal end adapted to attach to an intravenous catheter .
for practical information about using i@@ bli@@ as , patients should read the package leaflet or contact their doctor or pharmacist or or or or or or or or or or or or or or or or or or or or or or or or or or or or the or the or read the package leaflet or or the package leaflet or or the package leaflet or package leaflet or package leaflet leaflet leaflet or package leaflet leaflet leaflet or package leaflet leaflet leaflet leaflet or package leaflet leaflet leaflet leaflet leaflet
method for examining the movement system of the eye .
after oral administration , elimination is limited by the rate of absorption .
a compound according to claim 2 wherein the compound has the following features : ( i ) z is oxygen ; ( ii ) r 1 is hydrogen , -r , -ch 2 y , -ch 2 sr or -ch 2 y ; ( iii ) r 2 is a monocyclic , bicyclic or tricyclic heterocyclic or heteroaryl ring system , wherein each ring of the system has 5 to 7 ring atoms .
a be@@ tide of the formula : x is n , -x 1 -x 2 -x 3 -x m -x 4 -x 5 -x 6 -x c , wherein x@@ n is an acyl or other n-terminal or a peptide having up to 50 amino acids , and wherein x is an acyl or a substituted or unsubstituted amino acid and r 3 is an acyl group , an isocyanate group , a thio@@ isocyanate group or a sulphonyl group , and provided that additional residues of be@@ ti@@ d@@ onic acid are optionally comprised of x n , x
the in vitro method of claim 1 , wherein said cell expresses lt@@ β@@ r and said composition contains a homo@@ tri@@ meric p@@ 30 polypeptide having an apparent molecular weight of about 30 kda , said homo@@ tri@@ meric polypeptide having an apparent molecular weight of about 30 kda , wherein said homo@@ tri@@ meric polypeptide binds under physiological conditions to a herpes virus entry mediator ( h@@ v ) polypeptide or a lympho@@ toxin-@@ beta receptor ( lt@@ β@@ r ) polypeptide or a lympho@@ toxin-@@ beta receptor ( lt@@ β@@ r ) polypeptide or a lympho@@ toxin-@@
the invention also relates to these cleaning tools .
you will now select the required dose • turn the cap in the direction of the arrow ( diagram f ) to adjust the correct dose .
a device for the production of granules , in particular pharmaceutical granules , the device comprising a drum ( 4 ) , which comprises circumferential openings ( 25 ) and an organ ( 30 ) for supplying the drum with a substance for coating the drum , characterized in that the drum ( 4 ) has mutually parallel profiles ( 22 ) defining the openings ( 25 ) .
see section 4.2 for dose reduction of myocet due to hepatic impairment .
a boronic acid adduct as claimed in claim 1 , wherein y is α-@@ fur@@ yl@@ di@@ di@@ oxime . the boronic acid adduct of claim 1 wherein y is α-@@ fur@@ yl@@ di@@ di@@ di@@ di@@ di@@ di@@ di@@ di@@ di@@ di@@ oxime di@@ oxime . . di@@ oxime . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6.6 special precautions for the disposal of unused veterinary the unused veterinary medicinal product of unused veterinary medicinal product veterinary medicinal product veterinary medicinal product veterinary medicinal product veterinary medicinal product veterinary medicinal product veterinary
a kit for diagnosing or detecting the presence of a ps@@ ma comprising : ( a ) at least one compound according to any one of claims 1 to 28 ; ( b ) an instruction .
the compound , salt or prodrug according to claim 20 , wherein the compound is the 8a ( r , s ) , 1 ( r ) diastereomeric mixture , r ( r ) , r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r ) r
process according to any one of the preceding claims , characterized in that the sweetening agent contained in the sweetener mixture is xylose , ribo@@ tulose , glucose , mannose , galactose , fructose , maltose , tetra sugar , hydrogenated and non-@@ hydrogenated starch hydrolysate , sorbitol , xylitol , lactitol , mannit@@ m ( 1-o-@@ α-d-glucopyranos@@ yl-d-@@ mannitol ) , 1,1-@@ gps ( 1-o-@@ α-d-glucopyranos@@ yl-d-@@ sorbitol ) , 1,6-@@ gps ( 6-o-@@ α-d-glucopyranos@@ yl-d-@@ sorbitol ) , 1,6-@@ gps ( 6-o-@@ α-d-glucopyranos@@ yl-d-@@ sorbitol ) , 1,6-@@ gps ( 6-o-@@ α-d-glucopyranos@@ yl-d-@@ sorbitol ) , 1,6-@@ gps
the use of claim 21 , wherein the surgery is heart surgery . use of claim 21 wherein the surgery is the use of heart surgery .
use according to claims 1 to 3 , characterized in that the natural substance is the seed oil of the plant th@@ un@@ be@@ gia al@@ ata .
a method according to any one of claims 1 to 10 for separating linear nucleic acid molecules in a sample , said method comprising : introducing a label at one end of said linear nucleic acid molecules , said label being a protein capable of being immobilized on a matrix by direct interaction with said matrix and contacting said sample with a matrix which binds selectively to said matrix , said labeled linear nucleic acid molecules being immobilized on said matrix .
however , this has not been investigated in vivo and in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo in vivo
a mixture of substances containing reduced glutathione and at least one antho@@ cyano@@ compound from the group pe@@ lar@@ gon@@ idine on@@ on@@ idine cyan@@ idin mal@@ vi@@ din@@ idine , del@@ ph@@ in@@ idine , for the therapeutic treatment of the human or animal body .
the device of claim 15 , wherein the retractor assembly comprises a plurality of overlapping leaf members ( 614 , 616 , 6@@ 18 ) .
kit consisting of body compress and releasably attachable thermal device
an immunologically active polypeptide having no or reduced toxicity useful for the preparation of an anti@@ pertussis vaccine , wherein the polypeptide comprises the s1 subunit of the pertussis toxin , modified by the substitution of an amino acid through a others capable of destroying or reducing the toxicity of s1 without altering its immunological properties , wherein at least glutamic acid ( 129 ) is substituted by another amino acid .
crosslinked polymer / clay alloy composite composite material
device according to claim 1 , characterized in that the regulating means ( 27 ) comprises means for alternately and repeatedly opening and closing the second connection ( 29 ) or the third connection ( 22 ) .
use of the water-soluble carboxy@@ polysaccharide-@@ magnetic iron oxide complex of small particle diameter the water-soluble iron oxide complex of the of the of the the the the the the the the the the the water-soluble carboxy@@ polysaccharide-@@ magnetic iron oxide the water-soluble carboxy@@ polysaccharide-@@ magnetic iron oxide magnetic iron oxide magnetic iron iron magnetic iron iron iron magnetic iron iron iron magnetic iron iron magnetic iron iron magnetic iron iron magnetic iron iron magnetic iron iron magnetic iron oxide magnetic iron iron magnetic iron iron magnetic iron iron iron magnetic iron magnetic iron iron magnetic iron magnetic iron magnetic
a device according to any one of claims 11 or 12 in combination with a fusion promoting substance .
erythropoietin based transdermal delivery device and method
an injectable biocompatible compound for tissue multiplication comprising : a plurality of discrete particles in a carrier , wherein said particles have an average diameter dimension of between 100 and 1000 microns , and the carrier is a biocompatible medium with sufficient liquid to carry and dispense the particles , characterized in that the particles of one of the substrate formed from alumina and carbon are with a carbon coating .
the heater ( 14 ) ( 14 ) of claims 8 to 10 , wherein the temperature-@@ conducting element ( 18 ) ( 14 ) is in thermal communication with the at least one window ( 12 ) .
orodispersible tablets according to claim 1 , wherein the proportion of disintegrating agent is from 3 to 15 % by weight and the proportion of soluble diluent is 30 to 90 % by weight , the percentages being based on the weight of the tablet .
each hard capsule contains 0.5 mg anagrelide contains 0.5 mg of anagrelide ( 0.5 mg as anagrelide hydrochloride ( as anagrelide hydrochloride ( as anagrelide hydrochloride ) . anagrelide hydrochloride hydrochloride hydrochloride hydrochloride hydrochloride hydrochloride hydrochloride anagrelide hydrochloride hydrochloride hydrochloride anagrelide hydrochloride hydrochloride hydrochloride anagrelide hydrochloride hydrochloride hydrochloride anagrelide hydrochloride hydrochloride hydrochloride anagrelide hydrochloride
device according to claims 1 , 2 and 4 , characterized in that the narrowing of the inner circular channel is formed by the presence of helical vanes ( 30 ) .
alternatively , the mask base body can be designed so that the breathing tube can be connected to at least two connection sites , and the connecting port is closed with a closing element .
the use of any one of claims 11 to 15 , further defined as use of an irreversible inactivated reverse transcriptase according to any one of claims 1 to 6 for the manufacture of a medicament for an hiv-@@ positive animal .
a corticoid derivative of the general formula : wherein r is hydrogen , hydroxy , methyl or methylene ; including the acylation product thereof , the 17-@@ position of the steroid scaffold being hydroxy and the ketone form thereof wherein r is hydroxy , or a physiologically acceptable salt thereof .
medical instrument according to claim 2 , characterized in that endoscope ( 44 ) and camera module ( 46 ) can be introduced individually via the openings ( 19 and 30 ) and can be coupled together in the instrument ( 10 ) .
the particle according to claim 5 or 6 , characterized in that the therapeutic effect of the particle is further supported by modifying its surface with one or more effector molecules which include other cyto@@ statics , toxins , enzymes , heavy metals , the bio@@ compatibility active substances and substances facilitating transport of the particle through vessel walls and vascular tissue .
5 . the process of any one of claims 1 to 4 of claims 1 of 1 of claims 1 of claims of claims 1 of claims 1 to 1 1 to 1 of claims 1 to 1 1 to 1 1 to 1 1 1 to 1 1 1 1 1 to 1 1 1 1 1 1 to 1 1 1 1 1 1 1 to 1 1 1 1 1 1 1 to 1 1 1 1 1 1 1 to 1 1 1 1 1 1 1 to 1 1 1 1 1 1 1 to
the aim of this study was the evaluation of data on the time of the plasma bu@@ pivacaine level , the 1-@@ glyco@@ protein and albumin concentrations in children with continuous peri@@ dural anaesthesia .
a wound dressing comprising a wound treatment composition ( 1 ) having at least one absorbent or adsorbent compound in the form of silica gel contained in a shell which is contained in a shell having a functional inner wall ( 5 ) , and a functional outer wall ( 6 ) , wherein the wound dressing is characterised in that the wound dressing is characterised in that collagen is admixed with the silica gel collagen .
do not take zomarist if you are pregnant or breast-feeding ( see also “ do not take zomarist ” ) .
use of a multi@@ channel probe according to one of claims 1 to 13 as part of an apparatus for invasive operations on the human kidney .
the use of the product in these patients is not recommended in these patients unless the potential benefit outweighs the risks .
the method of claim 10 , wherein the monoclonal antibody of the monoclonal antibody is bound to the solid phase .
in addition , a bypass valve member ( 5 ) is provided by inhalation air ( 3 ) which can be inhaled in the closed valve valve ( 3 ) , the two said switching points of the valve flap ( 3 ) being pre@@ settable between the sealed and the free lumen ( 4 ) of the valve housing ( 2 ) .
a pharmaceutical composition according to claim 5 , which further comprises an agonist of r@@ ar@@ β2 of an agonist of r@@ ar@@ β2 of an r@@ ar@@ β2 r@@ ar@@ β2 . r@@ ar@@ β2 . r@@ ar@@ β2 . r@@ ar@@ β2 . ar@@ r@@ .
composition according to claim 3 , characterized in that the silicone gums are poly@@ di@@ organopolysiloxanes having a number-average molecular weight ranging from 200,000 to 1,000,000 , which are used as such or with a solvent .
a pharmaceutical composition comprising a peptide compound according to any one of claims 1 to 7 to any one of claims 1 to 7 to a pharmaceutical carrier or excipient .
9 . a compound as defined in claims 1-5 for use as a gastrointestinal secretion inhibitor .
efficacy results ( patients with breast cancer or multiple myeloma ) ( patients with breast cancer or multiple myeloma ) ( patients with breast cancer or multiple myeloma ) ( see section 4.3 ) . • patients with breast cancer ( breast cancer or multiple myeloma ) ( breast cancer ( breast cancer ) ( breast cancer ( breast cancer ( breast cancer breast cancer ( breast cancer breast cancer breast cancer breast cancer breast cancer breast cancer breast cancer breast cancer breast cancer breast cancer breast cancer breast cancer breast cancer breast cancer breast cancer breast cancer
a dental tube assembly according to claim 1 , wherein the inner tubes ( 11 , 12 , 13 , 14 ) comprise an air supply tube ( 11 ) , an air suction tube ( 12 ) , a water supply tube ( 13 ) and an evacuation air supply tube ( 14 ) .
inhibition of factor xa disrup@@ ts the intrinsic and ex@@ trin@@ sic pathway of the coagulation cascade , both the formation of thrombin and blood clots being inhibited .
allergic rhinitis adults , adolescents ( 12 years ( 12 years ( 12 years ( 12 years ( 12 years ( 12 years ( 12 years 12 years 12 years 12 years 12 years 12 years 12 years 12 years 12 years 12 years 12 years 12 12 years 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12
if no improvement is detected after this improvement , sandimmun therapy should be discontinued .
the carrier catheter of claim 6 , wherein the introducer further comprises a composite piece at a proximal end .
the enhancement of serotonergic neurotransmission of serotonergic neurotransmission is specifically mediated is mediated by serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic is specifically mediated by serotonergic serotonergic serotonergic serotonergic of serotonergic neurotransmission of serotonergic neurotransmission of serotonergic neurotransmission of serotonergic neurotransmission of serotonergic neurotransmission of serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic serotonergic
identification of se@@ t-1 of c. ele@@ gan@@ s and uses of the same
a process for producing purified anthocyan@@ idin ru@@ tino@@ side according to claim 3 , wherein the β-@@ glucosidase selectively soluble the β-@@ glucoside linkage of anthocyan@@ idin glucoside without dissolving the β-@@ glucoside linkage of anthocyan@@ idin ru@@ min@@ side .
a process according to any one of claims 1 to 6 in which the oxo@@ acid derivatized solid support contains a sulfo@@ propyl , sulfate , sulphonate , phosphonate or phosphate residue .
method for eliminating oxygen by eliminating carbon dioxide depletion in anaerobic fermentation
aerosol lacquer according to claim 3 or 4 , characterized in that the solvent is present in a proportion of less than 50 % by weight , preferably in a range between 5 % and 30 % by weight relative to the total weight of the composition .
an apparatus for performing the method of claim 1 , comprising means ( 13 ) for detecting an increase in the internal pressure of an inlet portion of the secondary filter ( 8 ) to an upper limit , means ( 13 ) for detecting the decrease in the internal pressure of the inner chamber ( 8a ) to a lower limit , means ( 14a ) for detecting the internal pressure of the inner chamber ( 8a ) to a lower limit , means ( 14a ) for detecting the internal pressure of the inner chamber ( 8a )
the vaccine induced the gut in 70-@@ 100 % of subjects in the vaccinated subjects .
bed frame , especially for hospital bed , comprising a support device associated with a rack part .
process according to claim 30 , characterized in that the first , second and third organic solvents consist of ethanol . the method of claim 30 , wherein the first , second and third organic solvents are ethanol . the process of claim 30 , wherein the first , second and third organic solvents are ethanol . the process of claim 30 , wherein the first , second and third organic solvents are ethanol .
a compound according to claim 12 , wherein r 1 is amino or -nr 3 co 3 or -nr 3 co 3 or 3 co ( c 1 ( c 1 -c c c c 1 c c c c 1 c c c c 1 c c 1 c c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1 c 1
these symptoms differ from every@@ day stress and the stresses associated therewith .
no allergic reactions , including anaphylaxis , have been observed in clinical trials , and the immunogenicity of i. e. administered ziconotide is low .
common very common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common
the method of claim 14 , further comprising detecting the presence of cntf receptor protein having the amino acid sequence of figure 2 ( seq id no : 1 ) by : ( i ) incubating the cell with an antibody of claim 13 under conditions permitting an immuno@@ specific binding ; ( ii ) detecting binding of the antibody to the cell .
studies in animals have shown reproductive toxicity in animals ( see section 5.3 ( see section 5.3 ) ( see section 5.3 section ( see section 5.3 )
the normal release by a sachet ( q@@ p ) should be applied for all products that are released in accordance with the eu conditions of the eu marketing authorisations .
the system of claim 1 , wherein the container ( 10 ) contains a concentrate in powder form having a particle size greater than 100 microns .
a method for holding a device ( 10 or 70 ) as defined in claim 1 or claim 2 , comprising the steps of : detaching the sensor carrier ( 26 or 86 ) from the measuring surface of the coolant container ( 12 or 72 ) ; attaching the sensor carrier ( 26 or 86 ) to the sensor carrier ( 26 or 86 ) ; attaching the sensor carrier ( 26 or 86 ) to the sensor carrier ( 26 or 86 ) ; and releasably attaching the sensor carrier ( 26 or 86 ) to which the
a spring ( 17 ) can act on the upper part ( 9 ) which can be adjusted by means of a spindle ( 8 ) , for reducing the weight of the vertically adjustable parts .
various regimens of treatment have been assessed with and without additional ritonavir development during amprenavir / fosamprenavir development programs .
in addition , you have been reported to have adverse reactions that have been reported in the post-marketing setting of patients taking cialis as needed .
the dsrna of claim 1 , wherein the lipophilic group has a log@@ k o@@ w exceeding 2 .
the use of claim 11 , wherein the ifn-γ is des@@ cyst@@ y@@ cys-@@ human-@@ ifn-γ .
based on this plan , safety information has been included in the summary of product characteristics and the summary of product characteristics the the summary of the product characteristics and the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
a chimeric peptide according to any one of the preceding claims , wherein the transportable peptide is insulin .
if you stop taking tasigna stop taking tasigna you stop taking tasigna if you stop taking you you you stop taking you you stop taking tasigna you stop taking taking taking tasigna taking taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking taking tasigna taking
read the list of questions under commonly asked questions in section 4 of this user information manual . • see section 4 of this user manual . this user manual of this user manual will be of this user user manual . this user manual manual . this user manual . user manual . user manual user manual manual manual manual manual manual manual manual manual manual manual manual manual manual manual manual manual manual manual manual manual manual manual manual manual manual user manual user manual . manual manual manual manual manual user manual . manual manual .
“ stable coronary artery disease :
the joint prosthesis ( 100 ) of any preceding claim , wherein the negative surface feature comprises inner structural features with which a portion of the bioabsorbable component ( 120 ) fits in a mechanically locked configuration .
antigen fragments associated with stress-@@ induced proteins and their use as vaccine
an implant ( 2 ) according to any preceding claim , wherein each tapered side ( 13 ) ( 14 ) ( 14 ) ( 14 ) ( 14 ) ( 14 ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ( ) ) ) ( ) ) ( ) ( ( ( ) ) ) ( ( ( ) ) ) ( ( ) ) ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) )
the method of claim 2 wherein the number of the target nucleotides of the target of the target of the target of the target of the target of the target of the target of the target of the target of the target of the target of the the target of the the target of the the target of the the target of the the target of the the of of target of the claim 2 of the the of of nucleotides the target nucleotides of the of the target nucleotides of the of the of claim nucleotides of the of
special precautions for disposal of unused medicinal products for waste materials
trans@@ vascular hemodynamic ultrasound catheter and method .
an arrangement according to claim 1 , wherein - the image data having a high repetition rate is tomo@@ synthesis data ; - each of the radiation sources ( 1 ) ; and - the line detectors ( 1 ) are diver@@ mented in each of the radiation detectors ( 6 ) , and - the line detectors in each of the radiation detectors ( 6 ) are directed in each of the radiation detectors ( 6 ) and , in each case , the line detectors in each of the radiation detectors ( 6 ) , in order to
the use according to claim 1 , wherein each administration contains about 1 to 5 mg , to the anti@@ progestin each , wherein each administration contains 1 to 5 mg , each , of the anti@@ progestin each administration .
arrangement according to one of the claims 1 to 5 , characterised by the shaft ( 112 ) of the pin ( 11 ) , the second disc ( 22 ) moved to the shaft of the pin in the direction of the head ( 111 ) of the post ( 11 ) .
the device ( 100 ) of claim 1 , wherein the second portion of the adhesive member ( 106 ) includes a tab ( 312 ) having a non-adhesive surface remaining from the skin surface when the attachment surface ( 714 ) of the attachment member ( 106 ) is engaged with the skin surface ( 300 ) and the non-adhesive surface is generally coplanar to an adhesive surface ( 714 ) .
( 44-20 ) 74 18 84 00 fax ( 44-20 ) 74 18 84 ( 44-20 ) 74 18 84 47 e-mail : mail @ emea. europa. emea. europa. eu ( 44-20 ) ) 18 18 84 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18 18
a compound as claimed in any one of claims 1 to 3 wherein r 5 is chlorine or methyl .
the composite material of claim 8 characterised in that the diameter of the resorbable polymeric reinforcing element is in the range of 4 µm and 800 µm .
date of first authorisation : 23 february 2004 date of latest renewal : 20 february 2009 of latest renewal of authorisation : of of authorisation : 23 of authorisation : 23 february 2004 date of latest renewal : of latest renewal of of authorisation :
cosmetic composition according to claim 22 or 23 , characterized in that the agent contains further uv screening filters in the form of soluble compounds or other pigments .
the majority of adverse reactions occurred in the first month of treatment , except in cases of urinary retention or residual urinary volume following bladder emptying of more than 200 ml , which could occur , which could occur , which could occur which could occur which could occur could occur which could could occur could occur could occur could occur could occur could occur could occur could occur could occur could occur could could occur could occur could occur could could occur could occur could occur could occur could occur could occur could occur could occur could occur could
in a distribution device for gases , in particular air distributor for a bubble device with at least one air inlet ( 5 ) and at least two air passages ( 13 , 14 ) is provided for opening and closing the air flow ( 13 , 14 ) at least one wi@@ ir@@ -shaped actuating element ( 7 ) .
sanitary bath apparatus , in particular bath ( 10 ) , with a device according to one of claims 1 to 7 , characterised in that the device is in a groove which fits in the bottom ( 12 ) and / or the wall of the bath device .
1 pre-filled syringe with 5.0 ml water for injections with separate syringe plunger rod with a separate syringe plunger rod with a separate plunger rod for injections
an instrument according to claim 7 , wherein each projection engages a corresponding recess in an adjacent tooth with gam@@ e so that the cutting teeth jointly describe a helical path with its outline .
use according to claim 2 , characterized in that the degree of sulph@@ ation of hyaluronic acid in a solution for injection is in the range of 0.1 to 2 .
substrate for analyte determination method and method for producing the substrate
the pump of claim 5 , wherein said body ( b ) further comprises an outlet port ( 32 ) in flow communication with said exit chamber lumen ( 28 ) .
the mah provided extensive data on support of intravenous augmentin administration , including studies and con@@ views , which confirm efficacy of both intravenous augmentin therapy and intravenous augmentin therapy followed by oral augmentin therapy in the treatment of lower respiratory tract infections .
as compared to 1996 , a somewhat different image was performed in 1997 .
doxorubicin hydrochloride has been available since the 19@@ 60@@ s .
exp ( month / year ) use immediately after reconstitution use immediately . after reconstitution after reconstitution . after reconstitution ( month / year ) use immediately after reconstitution after reconstitution . after reconstitution after reconstitution after reconstitution . reconstitution immediately after reconstitution immediately after reconstitution . reconstitution immediately after reconstitution . . reconstitution after reconstitution . . reconstitution immediately after reconstitution . . reconstitution after reconstitution . reconstitution . reconstitution . reconstitution immediately after reconstitution . reconstitution after reconstitution . reconstitution . reconstitution . reconstitution . reconstitution . reconstitution .
you or your child are sexually ill , or if the flu symptoms become worse , or if the fever persists , or lasts the fever .
use of a formoterol active substance concentrate according to any one of the preceding claims 1-14 and 18 in inhalers for inhalation therapy .
storage must be the national regulations for radioactive substances .
the compound of claim 2 that is 1- ( 2-methoxy@@ imino@@ cyano@@ acetyl ) -3- ( 2-@@ tetrafluoro@@ ethoxyethyl ) urea ( 2-@@ cyano@@ ethoxyethyl ) urea ( 2-@@ tetrafluoro@@ ethoxyethyl ) ( urea ) ( urea ) ( urea ) .
the main results of toxicology studies in rats and monkeys were consistent in general and the pharmacological activity of pali@@ fer@@ min of pali@@ fer@@ min , particularly in the of proliferation of the epithelial tissue .
compositions for the systemic control of warm-blooded animals , comprising an effective amount of 1- &#91; 3-chloro-4- ( 1,@@ 1,2-@@ trifluoro@@ methyl-2-@@ trifluoro@@ methoxy@@ ethoxy ) phenyl &#93; -3- ( 2,6-di@@ fluoro@@ benzoyl ) urea of formula ( i ) and a pharmaceutically acceptable carrier .
non-@@ fo@@ sto@@ stic production of genetic vaccines and enzymes
a composition according to claim 17 , wherein said a slow release formulation is a formulation of claim 17 , wherein said composition is a slow release formulation . a composition according to claim 17 wherein said composition is a slow release formulation . a composition according to claim 17 wherein said formulation is a slow release formulation . a composition according to claim 17 wherein said formulation is a slow release formulation . a composition according to claim 17 wherein said formulation is a slow release formulation . formulation according to claim 17 .
in the treatment of hyper@@ thyroidism , there are no major risk problems in the treatment of hyper@@ thyroidism and are associated with less than 1 % frequency ; postoperative hypocalcaemia or hypo@@ parathyroidism is especially distinguished in patients with mor@@ bus bas@@ se@@ do@@ w disease .
injection device according to claim 6 or 7 , characterised in that the tooth height of the teeth of the tooth the tooth the tooth the the the the the the the the the the the tooth the the tooth the tooth the tooth the tooth the tooth the tooth the the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the tooth the
the concentrate is a clear viscous yellow , yellow to a yellow , a yellow , yellow a , yellow , yellow to yellow , yellow , yellow yellow yellow a , yellow to yellow a , yellow , yellow to yellow , yellow a yellow to bro@@ wn-@@ yellow yellow yellow yellow yellow yellow , yellow a yellow yellow yellow yellow yellow to yellow to yellow , yellow to yellow is , yellow a yellow yellow yellow to , to to yellow a to yellow a to to yellow yellow , yellow to yellow yellow to yellow to yellow
dental treatment chair according to claim 11 , characterized in that the slip coupling ( 52 ) has an elastically compressed coupling ring ( 54 ) between two friction surfaces .
in case of impaired white blood cells , you may experience fever or infections . or you may experience infections or infections or infections or infections or infections or infections or infections or infections or infections or infections . infections or infections . infections or infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections . infections .
the method of claim 15 , wherein said antibody is for the manufacture of a medicament for administration to an animal .
the composition of claim 5 wherein the poly ( ortho ester ) is the reaction product of a ke@@ ene@@ acetal and a polyol .
a method as in claim 7 , wherein the active tgf-β is selectively eluted from the hydrophobic interaction matrix in step ( f ) by applying an elution gradient with increasing alcohol concentration .
the use of claim 27 , wherein the neurodegenerative disease is alzheimer &apos;s disease . the use according to claim 27 wherein the neurodegenerative disease is alzheimer &apos;s disease . the use according to claim 27 wherein the neurodegenerative disease is alzheimer &apos;s disease . the use of claim 27 wherein the neurodegenerative disease is alzheimer &apos;s disease .
a compound according to claim 3 , which is 17β- ( cyclopropylamino ) -4,4-di@@ fluoro@@ androst@@ -4-en-3-one . a compound according to claim 3 according to claim 3 which is 17β- ( cyclopropylamino ) -4,4-di@@ fluoro@@ androst@@ -4-en-3-one .
9 . a solution according to claim 6 , in which the surfactant is ar@@ la@@ so@@ ve 200 ® . the solution according to claim 6 wherein the surfactant is ar@@ la@@ so@@ ve 200 ® .
the structure ( 1 ) of claim 1 comprising individual cores of a width in the range of 20 to 2000 mm .
limited experience there is limited experience of the combination of byetta of thiazolidin@@ edi@@ ones and thiazolidin@@ edi@@ ones ( see section 5.1 ( see section 5.1 ) ( see section 5.1 section section section section section section section section section section section section section ( see section 5.1 section section section section section section section section section section section section section section section section section section section section section section section section section section section section section section section section section section see section 5.1
method according to at least one of the preceding claims , characterized in that the temperature of the second calen@@ der rolling pair ( 6.@@ 1.@@ 6.2 ) is held at room temperature , i.e. between 18 and 25 ° c. a method according to at least one of the preceding claims , characterised in that a ( first ) calen@@ der rolling pair ( 4.1 , 4.2 ) is used as the pre-@@ sealing tool .
a method as described in claim 25 or claim 26 , comprising laminating the tendon to the fas@@ cial envelope in the same direction as the orientation of the collagen .
you shoul@@ dn &apos;t have to do it .
intervertebral implant according to claim 1 , characterised in that the joint surfaces ( 14 , 15 ) are formed integrally with the support plates ( 4 ; 6 ) .
diclofenac interaction studies in healthy adults in healthy adults in healthy adults healthy in healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy adults healthy
official batch release : in accordance with article 114 of directive 2001 / 83 / ec / ec / / ec / ec / / / ec / ec / / / ec / / ec / ec / / / ec / / ec / / ec / / ec / / ec / / ec / / ec / / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec /
use according to any one of claims 1 to 8 , characterized in that the composition also comprises at least one hydrophilic or lipophilic complementary sunscreen agent active in the uva and / or uvb region and optionally having a sulphonic acid group .
do not receive key@@ tru@@ da if you are pregnant unless your doctor tells you to .
a formulation according to claim 2 wherein the ratio of tri@@ propylene glycol methyl ether : alcohol is 80 : 20 .
an implant and delivery device according to claim 14 , wherein to claim 14 to claim 14 to claim 14 to claim 14 to claim 14 claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim
3,5,@@ 3 &apos; -tri@@ iodo@@ thyronine sulfate as thyro@@ mimetic agent and pharmaceutical formulation thereof
an endoluminal graft system according to any preceding claim , wherein the side branch graft ( 2 ) is made of ptfe , polytetrafluoroethylene .
the method of claim 13 , wherein the antibiotic is ce@@ fe@@ pimozide dihydrochloride monohydrate .
the method of claim 53 wherein the tissue type is muscle .
uncommon : ec@@ chymo@@ sis , bullous , exfoliative dermatitis , erythema multiforme , steven@@ s- johnson syndrome , toxic epidermal necrolysis , angioedema
- examples of signs of a lack of sugar deficiency in the brain : headache , hot dog , nausea , vomiting , tiredness , somnolence , insomnia , restlessness , aggressive , attention , impaired , reaction , loss , vomiting , restlessness , confusion , loss , loss , vomiting , , , , vomiting , , vomiting , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
a pouch according to claim 3 , characterised in that the pivot pin part has a reinforced end ( 36 ) to prevent out a distance of the pivot pin part from the bore .
the use of claim 8 , wherein said protein carrier is one selected from the group consisting of albumin and proteo@@ glycans .
in comparison to mammography and sono@@ graphy , mri revealed 6 oc@@ cul@@ t carcinomas and occurred in 19 / 63 carcinomas ( 3@@ 0.2 % ) .
the oligonucleotide according to one or more of claims 1 to 10 , wherein one or more groups of at least 1 to 4 are not modified .
use according to any preceding claim , wherein the hydrogel comprises at least 75 % by weight of pyro@@ gen-free water .
in brain infar@@ ctions , micro@@ angio@@ pathic lesions and very poor colla@@ teral vascular occlu@@ sions were found to be differences in normal subjects in the mr perfusion images .
first genital herpes : 250 mg three times a day for five days .
a pneumococcal polysaccharide-@@ immunogenic protein conjugate produced by the method : ( a ) culturing a pneumococcal and isolation of crude pneumococcal polysaccharide or solubilization of pneumococcal polysaccharide powder or solubilization of pneumococcal polysaccharide powder or solubilization of pneumococcal polysaccharide powder or solubilization of pneumococcal polysaccharide powder or solubilization of pneumococcal polysaccharide powder , ( b ) of the polysaccharide of step ( a ) from step ( a ) to an end-@@ point , which is predicted by the process of step ( a ) to an end point of a pneumococcal polysaccharide or solubilization of pneumococcal polysaccharide powder
use according to any one of the preceding claims wherein the weight ratio of 40@@ -o- ( 2-hydroxyethyl ) -@@ rapamycin to cyclosporin a is about 1 : 16 .
membrane according to claim 1 , characterized in that the preferred concentration of the diamine component ( b ) is 15 to 50 mol % , the diamine component ( c ) is 20 to 75 mol % and the diamine component ( d ) is 10 to 40 mol % , based on 100 mol % , based on 100 mol % .
the method of claim 33 , wherein the hydrochloric acid is present in an amount of from about 0.1 of about 0.1 of about 6 of the amount of of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of the of of
an aerosol suspension preparation according to claim 1 , characterised in that it comprises a surfactant .
device ( 2 ) according to claim 3 , in which the display means ( 26 ) is a display screen ( 30 ) and / or a pressure device ( 32 ) for hard@@ copy .
process for the production of optically active glycol derivatives .
each viread film-coated tablet contains 163 mg tenofovir disoproxil ( as fumarate ) .
in the presence of antacids absorption of tipranavir is reduced with low dose ritonavir with low dose ritonavir ( see section 4.5 ) ( see section 4.5 ) . dose of tipranavir dose ) dose of ritonavir ) dose ) low dose ritonavir dose ) dose of tipranavir ) ) ( see section 4.5 ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) . ) . ) . ) . ) .
a patch for the following contracting states : es , gr 1 . a process for the preparation of a compound of the formula : wherein ph is substituted or different , r ₁ is amino and / or cyano substituted phenyl , trifluoromethyl and / or cyano , r ₁ is amino and / or cyano , r ₁ is amino ( c ₃ -c ₈ -cycloalkyl-c ₁ -c ₇ alkyl ) amino , n- ( c ₃ -c ₈ -cycloalkyl-c ₁ -c ₇ alkyl ) amino , n- ( c ₃ -c ₈ alkylcarbonyloxy ) c ₁ -c
the method of claim 31 , wherein the transformant is selected in a medium containing an antibiotic produced by a lactic acid bacterium .
abilify can be taken with or without food or with or without food or with food without food . food or food without food food or food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food . food .
11 . device according to claim 9 or 10 , characterized in that it also comprises a handle ( 50 ) slidable on the rod ( 11 ) , which slides in at least one of the grooves ( 24a , 24b ) in which one of the rotor ( 30a , 30b ) slides and slides into the desired position .
the pharmaceutical composition according to any one of claims 1 to 8 , wherein the remainder of the agent is formulated as a lotion , cream , ointment , gel , or solution .
the chemical stability of vistide mixed with saline of solution has been demonstrated in glass bottles in the in glass bottles of the in glass bottles , in pvc ( pvc ) of pvc ( pvc ) ( pvc ) ( pvc ) ( pvc ) ( pvc ) ( pvc ) ( pvc ) ( pvc ) pvc ( pvc ) pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc ( pvc pvc pvc pvc pvc pvc pvc pvc pvc pvc
compounds according to any one of claims 1 to 4 , in which r 1 represents optionally substituted phenyl to be substituted by one of claims 1 to 4 .
neutropenia and anaemia ( both occasionally severe ( ( both occasionally ) ( ( ( both occasionally severe ( severe ) ( severe severe ( severe ( ( both occasionally severe ) severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe severe
substituted furan and pyrrole derivatives and use as lipoxygenase enzyme inhibitors , especially 5-lipoxygenase inhibitors .
the tablet may be crushed and mixed with water or apple sa@@ uc@@ e immediately before intake .
the garment of claim 5 , wherein said closure means comprises hook straps ( 13 ) .
process according to claim 11 , characterized in that in step d ) a sterol is added to the preparation of the step d ) . the process according to claim 11 characterized in that in step d ) the preparation in the step d ) in step d ) is in .
use of a xylanase according to claim 1 or claim 2 for animal feed . use of a xylanase according to claim 1 or claim 2 to feed the use of a xylanase according to claim 1 to claim 1 .
ellipta is a multipack of a multipack , a multipack of a multipack , a multipack , a multipack , a multipack , a multipack , a multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack , multipack ,
what liprolog mix25 100 u / ml suspension for injection in cartridge contains 100 u / ml suspension for injection for suspension for injection for suspension for injection for suspension for injection
kinzalkomb has been studied in five main studies in five main studies in five main studies in five main studies in five main studies in five main studies in five main studies in a total in five main studies in five main studies in five main studies in a total in five main studies in five main studies in five main studies in five main studies .
a compound of formula i of claim 1 for use in alleviating the symptoms of the estrogen depri@@ vation .
use according to any one of the preceding claims , wherein the salt is sodium bicarbonate .
zoledronic acid teva generics is supplied in multipacks containing 5 or 10 sachets .
oral use , 15 mg ibaf@@ loxacin / kg , 15 mg , 15 mg , 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg 15 mg
the system of claim 1 , wherein the conditioning event is a particular pattern of activation times of different regions of the heart detected by multiple electrodes .
the dose can be increased with consistent effect and tolerability in need of the efficacy and tolerability of the and the dose may be increased and the tolerability and tolerability can be increased and the dose may be increased and the dose may be increased and the dose can be increased and tolerability and tolerability can be increased and the dose can be increased and the dose can be increased and the dose can be increased and the dose can be increased and the dose can be increased and the dose can be increased .
as therapy with the combination of nevirapine plus efavirenz does not show any additional efficacy and more adverse events than separate use with each medicinal product , these therapy is not recommended .
a compound according to any one of claims 1 to 17 wherein x 1 is selected from a chemical bond , -s- , -o- , -nh- or -n ( c 1 -c 3 alkyl ) .
memantine accord 20 mg film-coated tablets memantine hydrochloride tablets memantine accord 20 mg film-coated tablets memantine hydrochloride film-coated tablets memantine accord film-coated tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets memantine tablets
use only clear , colourless solutions , use only clear , colourless solutions , and only clear , colourless solutions , , , , , , , , , , , , , , , , , only , clear , colourless
use of a h@@ vegf antagonist in the manufacture of a medicament for treating age-related macular degeneration , wherein the h@@ vegf antagonist disrup@@ ts binding of h@@ vegf to the fl@@ t receptor and / or flk@@ -1 receptor and wherein the h@@ vegf antagonist is an anti-@@ vegf antibody or fragment thereof .
a medical prosthesis according to any one of claims 1 to 4 , wherein the ratio of equivalents of a chain extender to equivalents of polycarbonate glycol is between 0.75 to 1 and 12 to 1 .
the method of claim 4 wherein the antibody immunoreactive with a peptide having a specified sequence of 10 to 18 amino acids from the a protein is a polyclonal antibody with a bound detection marker .
compound of formula ( i ) according to any one of the preceding claims , in which r 4 is chosen from c 1-6 -alkyl , halogen , cyano and aminosulfonyl .
a urine sampling apparatus according to any one of claims 8 to 37 , further comprising a downwardly open washing chamber ( 162 ) disposed inward and adjacent to the inner periphery of the front portion of the edge of the bowl assembly , and a cleaning device , wherein the urine sampling vessel is introduced into the washing chamber and washed with water and washed with water , the used water being washed into the bowl .
pack according to one of claims 1 to 7 , characterized in that the planar reinforcing element ( 22 , 23 ) comprises a ring .
stretcher ( 1 ) according to claim 1 or 2 , characterised in that the hinges ( 21 ; 22 ) each are arranged on a different element ( 10 ; 11 ) on different joint axes and each is arranged at a joint ( 21 ; 22 ) of the part-@@ elements ( 10 , 11 ) on the same hinge axis .
1 ml sterile solution contains 1.@@ 850 g@@ b@@ q ( 90y ) chloride corresponding to 92 ng y@@ t on date of calibration .
chroman derivatives of the formula i in which r and r are each methyl , r is oh or o@@ ac , r and r are h , r and r are h or methyl , r is unsubstituted or mono-substituted by methyl , ethyl or isopropyl substituted by methyl , ethyl or isopropyl substituted by methyl , ethyl or isopropyl substituted by methyl , ethyl or isopropyl substituted oxo@@ dihydro@@ pyridyl or oxo@@ dihydro@@ pyridinyl ; r ) trans@@ -3,4-dihydro-@@ 4- ( 1,6-dihydro-@@ 1-methyl-@@ 6-oxo-@@ 3-@@ pyridazin@@ ylamino ) -2,4,@@ 7-di@@ methyl-4- ; b ) trans@@ -3,4-dihydro-@@ 4- (
the cosmetic composition according to claim 1 , wherein the beh@@ yl@@ lact@@ ylate is present in an amount of 15 to 30 % by weight . the cosmetic composition of claim 1 , wherein the beh@@ yl@@ lact@@ ylate is present in the composition in an amount of from 15 to 30 % by weight . the cosmetic composition of claim 1 wherein the beh@@ enoyl lact@@ ylate is present in the amount of from 15 to 30 % by weight of the composition of claim 1 .
a pharmaceutical composition according to claims 8 , 9 or 10 which is in a form suitable for oral administration .
co-administration of effentora with strong cyp3a4 inhibitors ( e. g .
circular , hair needle-@@ shaped , circular / hard needle-@@ shaped , le@@ fe@@ f@@ led , and hairpin le@@ se@@ f@@ ör@@ id &quot; ham@@ mer@@ head ribozymes
device according to one of the preceding claims , wherein a third chamber is located in the selectively opening passage region ( 3 ) between the first ( 5 ) and the second chamber ( 6 ) .
a system according to any one of the above claims , characterized in that the sound filtered and reinforced are reinforced . the system of any one of the preceding claims , characterized in that the sounds are in the form of a sound filter , the system of any of the preceding claims , characterized in that the sounds of sounds are in the form of a sound filter . the system of one of the above claims , characterized in that the sounds are in the form of a sound .
a pacemaker system ( 25 ) comprising pulse generating devices ( 26 , 28 ) for generating and delivering pacing pulses ( mp@@ i ) to the heart chamber of a patient , a detecting device ( 30 ) for detecting the pulse generation of a patient , and a delivery device ( 31 ) for detecting the pulse generation of a patient , and a delivery device ( 42 ) for detecting an escape interval of a heart chamber , and a triggering device ( 31 ) for detecting an escape interval of a heart chamber , and a
14 observed for fasting normal levels for normal levels at baseline ( &lt; 1.0@@ 16 mmol / l ) at baseline ( &lt; 1.0@@ 67 mmol / l ( &lt; 1.0@@ 67 mmol / l ) / ( &lt; 1.0@@ 67 mmol / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l
the method of claim 12 wherein the molar ratio of arginine to ibuprofen of the molar ratio of arginine of the arginine of the ratio of arginine of arginine of arginine of arginine of arginine of arginine of arginine of to of arginine of arginine to arginine of arginine of to of arginine of arginine arginine of arginine to arginine arginine arginine of arginine arginine arginine of arginine arginine arginine of arginine to of of arginine to of of arginine arginine of arginine to of of arginine to of of arginine to of of arginine arginine of arginine to arginine
a humanized antibody that specifically binds to v@@ t2 and / or a v@@ t2 variant , said humanized antibody comprising at least one cdr from a non-human antibody in a human variable region framework .
how much to take the recommended dose the recommended dose is one tablet ( 10 mg ) once a day the recommended dose is one tablet ( 10 mg ) . the recommended dose is the recommended dose the recommended dose is the recommended dose the recommended dose is the recommended dose dose recommended .
device according to claim 1 , characterized in that it comprises a charge calibration element ( 36 ) which supplies electric energy to the electrodes ( 32 , 34 ) .
an ion selective electrode with i. a reference electrode in physical contact with angiotensin ii a reference composition which is in physical contact with one side of ii@@ i of an ion-@@ selective membrane comprising the composition of any one of claims 1-5 .
( see section 4.5 ) .
the method of claim 22 , wherein the shell or soft animal is selected from the group consisting of gar@@ ne@@ ses , hu@@ ds , flow cancers , cra@@ ving , ven@@ u@@ sc@@ s , oy@@ sters , and mi@@ s@@ sa@@ ps .
a process according to any one of claims 9-@@ 17 , wherein the single crosslinking agent is the polymerization mixture ( i ) .
11 c@@ cp direc@@ tor s@@ park , cor@@ p a2 , eto@@ a@@ j 5 0@@ 13@@ 714 buc@@ ure@@ ş@@ ti tel : + 40 21 207 18 00
a purified biologically active tnf-@@ r protein according to claim 9 , comprising the sequence of amino acid residues 1-2@@ 35 of figure 2a .
process according to claim 10 , characterized in that one or more pi@@ li selected from the group consisting of k@@ 88@@ ab , k@@ 88@@ ac , k@@ 9 , , , , , , , , , , , , , , , , , , one or more pi@@ li or pi@@ li , pi@@ li , pi@@ li , pi@@ li , pi@@ li or pi@@ pi@@ li , pi@@ pi@@ li or pi@@ pi@@ li pi@@ li pi@@ li pi@@ pi@@ pi@@ pi@@ pi@@ pi@@ pi@@ pi@@ pi@@ pi@@ pi@@ pi@@ pi@@ pi@@ pi@@ pi@@
you should check with your doctor or your pharmacist if your doctor or pharmacist or pharmacist or pharmacist or pharmacist or pharmacist or pharmacist or pharmacist or pharmacist or or pharmacist or pharmacist or or pharmacist or or pharmacist or or pharmacist or or pharmacist or or pharmacist or or pharmacist or or pharmacist or pharmacist or or pharmacist or pharmacist or or pharmacist or pharmacist or or pharmacist or pharmacist or or pharmacist or pharmacist or or pharmacist or or pharmacist or pharmacist or or pharmacist or or pharmacist or or pharmacist or or pharmacist or or pharmacist or
if you use an insulin pump
a forearm walking support in one of the positions n ° 1 , n ° 10 and n ° 13 me the following characteristic of the elbow cuff : the lower part of the elbow cuff has been designed to provide one of the following characteristics : the lower part of the elbow cuff , and to the segments ( ab , cd ) of the elbow and to the segments ( ab , cd ) in a plurality of flanking positions against a panel , especially in the three-@@ quar@@ ters of the lower arm support .
the method of claim 14 wherein the hydrogen bonds are formed between the ligands on the first strand and the ligand on the second strand .
high stability porous zirconium oxide beads .
syringe device according to one of claims 9 and 12 to 16 , characterised in that the guide elements ( 14 , 14 &apos; ) have a projection section ( 51 , 154 ) suitable for protecting the fingers with respect to the needle when the guide elements holding the guide elements .
apparatus according to claim 1 , further comprising an energy source ( 3 ) for the control device ( 4 ) .
a hair treatment composition according to any one of claims 1 to 4 wherein the non-reducing organic chelating compound is present in an amount of from 0.1 to 10.0 % by weight of the compound of any one of claims 1 to 4 , wherein an amount of from 0.1 % to 10.0 % by weight of the compound of any one of claims 1 to 4 is of an amount of one of one of claims 1 and 10 % by weight of the weight of the composition of any one of claims 1 to 4 .
alteration of fine chemicals in organisms by genetic modification of the shi@@ k@@ im@@ ate pathway
hair conditioning compositions comprising imidazol@@ ines and amino functional silicones or dimethi@@ cones
the overall mortality was 19 % , only patients with heart failure died .
votubia with other medicines votubia may affect the way some other medicines work .
method according to claim 22 , characterized in that the timer is fed by the fuzzy controller ( 24 ) after a certain number of cardiac beats , and the heart beat frequency is determined as an arithmetic mean of several measurements .
the suction pad has a round suction disc ( 10 ) provided on one side with an adhesive point ( 16 ) .
if you notice any particles or any other use of kogenate bayer 500 iu if you notice if you notice you if you notice you you you if you you you you you you if you you you you you if you you you you you if you you you you you if you you you you you if you you you you you if you you you you you if you you you you you if you you you you you if you you you you you if you you you you you if you you you you you
process according to one of claims 6 to 10 , characterized in that the pulverulent partially stabilized zirconium oxide is sprayed into the form of a distinc@@ tly spherical agglomerates to obtain high spherical agglomerates .
treatment with zomarist should not be restarted after discontinuation of treatment with zomarist and normalisation of liver function tests .
in such cases , it is recommended that contact with a specialised haemophilia centre should be taken into the context of a specialised specialised centre of a specialised specialised centre of the centre of the centre of a specialised haemophilia centre in a specialised specialised centre of the centre of a specialised haemophilia centre specialised in a specialised specialised centre of a specialised specialised centre of a specialised haemophilia centre specialised in the centre of a specialised specialised centre in a specialised specialised centre of a specialised specialised centre specialised in a specialised haemophilia centre .
a method as claimed in any one of claims 21 to 23 wherein the housing is separated from the container .
a homeo@@ pathic kit comprising a first , second , third and fourth homeo@@ pathic composition , wherein : the first composition has a homeo@@ pathic dilution of an insulin-like growth factor 1 , the second composition has a homeo@@ pathic dilution of a transforming growth factor beta@@ -1 , the third composition having a homeo@@ pathic dilution of a growth factor derived from b@@ b-@@ platelet , and the fourth composition has a homeo@@ pathic dilution of a granulocyte macrophage colony stimulating factor .
electrical device for transdermal administration of medicaments with an opposing product and method therefor .
a compound which is 1- &#91; 1- &#91; 4- ( cyclohexyl@@ methoxy ) phenyl &#93; -2- ( 4-methylpiperazin-1-yl ) ethyl &#93; cyclohexanol or 1- { 2- &#91; 4- ( 1,3-benzodioxol@@ -1-yl ) piperazin-1-yl &#93; -1- &#91; 4- ( trifluoromethoxy ) phenyl &#93; ethyl } cyclohexanol or a pharmaceutically acceptable salt thereof .
isolated cases of either accidental or visual overdose of tol@@ cap@@ one tablets have been reported .
the dna construct of claim 3 , further comprising a dna sequence encoding a cellulose binding domain ( cb@@ d ) , wherein the cellulose .
microcrystalline cellulose , povidone , silica , colloidal anhydrous , talc , titanium dioxide ( e171 ) , iron oxide , red ( e172 ) , red iron oxide ( e172 ) , ( e172 ) ( e172 ) , ( e172 ) , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ( e172 ) , ( e172 ) , ( e172 ) ( e172 ) , e172 ( e172 )
use of a compound according to any one of claims 1 to 11 for the manufacture of a medicament for inhibiting phosphodiesterase ( pde ) type iv or tumor necrosis factor ( tnf ) in a mammal .
the dosage should be determined by the physician be determined by the the the the requirement of the patient .
the product should be administered clinically in patients with liver disease , in patients with liver disease , in neonates or patients with increased risk of thrombosis or with disseminated intravascular coagulation , with the potential risk of thrombotic complications with the early risk of thrombotic or consu@@ al-@@ coag@@ ulo@@ pathy .
animal studies with daclatasvir have shown embryo@@ toxic and teratogenic effects ( see section 5.3 ) . ( see section 5.3 ) ( see section 5.3 ) ( see section 5.3 ) ( see section 5.3 ) . 5.3 ( 5.3 ) ) ) ) ( see section 5.3 ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) . ) ) .
the tissue surface must be dried by standard standard techniques before applying ra@@ pli@@ xa ( e.g.
the apparatus of claim 1 , wherein the reservoir ( 42 ) includes between about 4 and about 18 liters of the infusate .
the suture of claim 11 , further comprising a tissue piercing needle mounted to extend from the first end portion of the portion , the needle extending from the sheath .
a compound of formula ( i ) ( ia ) ( ( ib ) or ( ic ) ( i ) ( i ) ( i ) ( i ) ( i ) ( i ) ( i ) ( i ) ( i ) i ( i ) i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
use according to claim 1 , wherein r 1 is h. the use according to claim 1 , wherein r 1 is halogen .
the method of any one of claims 32 to 36 , wherein the graft ( 134 , 166 , 376 , 9@@ 95 , 392 ) additionally comprises a radio opaque marker within the tubular member .
apparatus according to any preceding claim , wherein the exten@@ so@@ meter means ( 4 ) include a resistive semiconductor or piezoelectric exten@@ so@@ meter .
use of a product of claim 1 or 2 for the manufacture of a medicament for the treatment of congestive heart failure in a mammalian patient in need of such a treatment .
an isotonic tc@@ f preparation having an approximately neutral ph , comprising : at least 5 mg / ml tcf ; a basic amino acid ; or a salt of a basic amino acid .
use of a composition of any one of claims 1 to 16 of claims 1 to 16 of a hair of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a
median time to onset to onset of severe neutropenia was of median duration of 7 days of onset of onset of neutropenia of of of of of 9 days .
chymo@@ papain as claimed in any one of claims 8 to 13 for use in chemi@@ mon@@ ucleo@@ lysis . of the chymo@@ papain of any one of claims 8 to 13 .
sche@@ ring españ@@ a , s. a. c / men@@ de@@ z al@@ var@@ o , 55
the method of claim 51 , wherein the second source is a first source of different inorganic complex .
 breast enlargement in man  chest pain , feeling sick ( general feeling unwell ) , fever  unusual tiredness or weakness 
process according to claim 1 , characterized in that the colon@@ ized base@@ ment membrane ( 1 ) remains approximately 72 hours in the nutrient solution .
thiazides should be used with caution in patients with impaired hepatic function or with advanced hepatic disease , as with impaired hepatic function , with hepatic impairment with impaired hepatic function with impaired hepatic function , and should be administered with caution with caution in patients with hepatic impairment or with advanced hepatic function caution should be used with caution in patients with hepatic impairment or with advanced hepatic disease with caution in patients with hepatic impaired hepatic function or with advanced liver disease , as it should be used with caution in patients with hepatic impairment .
carton for cozaar comp 100 mg / 12.5 mg 100 mg mg film-coated mg mg
a compound according to any one of claims 1 to 25 wherein any of the residues r 17 , r 18 and r 19 are hydrogen .
active ingredient combinations of 3-@@ iodin@@ e-2-@@ propynyl butyl@@ carbamate and phenoxyethanol and preparations containing such combinations
the invention relates to a high-@@ throughput method for examining the effect of non-@@ membrane permeable and a gene containing a gene on predetermined target cells with the following steps : ( a ) preparing a compound containing the compound and a cap@@ so@@ id , ( b ) providing the construct into the target cells , ( d ) , the construct of the construct into the target cells , ( d ) essentially simultaneously detecting a reaction generated by the connection to a reaction means contained in the target cell .
the inhibitor compound or salt of claim 9 , wherein r 1 is phenyl substituted with r 11 in the 4-position , and r 11 is substituted according to the group consisting of phenoxy , thiocarbamate , benzamido , phenyla@@ zo , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
if you have accidentally taken too many tablets , contact your doctor , pharmacist or , hospital , contact your doctor , contact your doctor , pharmacist , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
an accommodating lens ( 32 ) according to claim 1 , wherein constriction of the ciliary muscle ( 28 ) causes movement of the lens optic ( 34 , 1@@ 202 ) within the capsule bag ( 20 ) toward the iris to secure the vision in the near region .
29 . a complementary polypeptide obtainable by the method of any one of claims 18-@@ 23 , which is complementary to ( a ) sequence position for sequence position to an original polypeptide , which is oriented with respect to the original peptide or protein , either from the amino terminus to carboxy terminus or from the amino terminus to the amino terminus ; ( b ) is oriented by a nucleotide strand oriented in relation to the original peptide or protein ; ( b ) is oriented by a nucleotide strand oriented to the amino terminus , ( b
composition according to claim 1 , characterized in that the compounds of formula ( i ) are chosen from 5,6-dihydroxyindole , 2-methyl-@@ 5,6-dihydroxyindole , 5-methoxy@@ -6-hydroxy@@ indole , ( 5 or 6 ) -@@ acetoxy ( 6- or 5- ) hydroxy@@ indole , 2-carboxy@@ -@@ 5,6-dihydroxyindole , 3-methyl-@@ 5,6-dihydroxyindole , 2,3-dimethyl-@@ 5,6-dihydroxyindole and their salts .
process according to claim 14 , characterized in that the active substances are chosen from anionic , nonionic , cationic and / or amphoteric or zwitterionic surfactants , cationic and / or nonionic textile softening agents , foam inhibitors , perfume oils , dyes , preservatives , di@@ dou@@ le-@@ dissolving polymers , anti@@ static agents and / or anti-@@ friction aids .
a method of producing an absorbent macro@@ structure having a ever@@ ted volume of not less than 10 mm 3 , the method comprising steps of a ) providing at least a plurality of absorbent polymer particles ( app ) ; b ) providing a carrier ; c ) applying the particles to the app in at least one of the regions in the first and second regions by forming one or more of the steps in the first and second regions by forming one or more of the steps in the first and second regions by forming a different
glass ceramic according to one of the preceding claims , wherein the weight ratio of mgo to sio 2 is in the range of 32 : 68 to 38 : 62 .
the device of claim 1 , wherein the plug ( 26 ) carries a fluid-tight membrane extending proximally from the proximal end surface of the plug .
a composition for reducing bitter taste , comprising a microorganism according to any one of claims 1 to 3 .
a method as claimed in any one of the preceding claims , wherein the emitted acoustic de@@ formations comprise the harvested statement in a volume that carries information about the medical device in a volume which is too low to be used for patient and / or medical care , and wherein the method is for the patient and / or medical care@@ rs , and wherein the method further comprises the steps of monitoring for patient and / or medical care , and wherein the method further comprises the steps of monitoring a step of the implantable medical device
the use of claim 1 , wherein the anti-@@ vla-4 antibody composition is administered intravenously . the use of claim 1 , wherein the anti-@@ vla-4 antibody composition is administered intravenously . the use according to claim 1 , wherein the anti-@@ vla-4 antibody composition is administered intravenously . the use of claim 1 wherein the anti-@@ vla-4 antibody composition is administered intravenously . the use of claim 1 wherein the anti-@@ vla-4 antibody composition is administered intravenously . the use of claim 1 wherein the anti-@@ vla-4 antibody composition is administered intravenously .
the use according to any one of claims 2 to 10 , wherein the rar agonist is to be contacted in a therapeutic amount in the range of about 50 to 150 µg .
an article according to any one of claims 9 to 14 , wherein the flavor generating medium comprises tobacco and an aerosol generating material and is formed by heating the flavouring medium which contains tobacco components .
a method of purifying hair , which comprises applying to the hair a hair care composition according to claim 8 or claim 9 or 9 to the hair .
the method according to claim 1 , characterized in that when the probes have no tracer markings , the size and amount of the released probes is recorded by mass spectrometry .
fabri@@ k gmbh . , ba@@ d@@ ner straße 23 , a-@@ 25@@ 14 tra@@ is@@ kir@@ chen , austria , is@@ is@@ kir@@ chen , is@@ is@@ kir@@ chen , kir@@ chen , kir@@ chen , chen , chen , chen , chen , chen , chen , chen , chen , chen
the use of compounds of compounds of formula i of claim 1 of of the compounds of the compounds of the formula the of compounds of the of of the of the formula i of claim of formula of formula of the formula of formula of formula of formula of formula of of of of formula of formula of formula of of of formula of formula of of of formula of formula of of of formula of formula of of formula of of of formula of formula of formula of formula of of formula of formula of of formula of
the method of claim 1 , wherein the growth modulating amount provides a mean disease resistance of about 70 % or greater .
a magnetic field generator according to claim 3 or 4 comprising : a temperature exceeding detection means ( 154 , 158 ) for detecting a temperature of said yoke exceeding a predetermined threshold of said yoke ; and a temperature lowering means for decreasing temperature of said yoke based on said temperature exceeding detection means ( 154 , 158 ) .
method for removing transmis@@ sible spongi@@ forming spongi@@ form encephalo@@ phores from protein solutions
an elastomeric glove comprising : a base material comprising an elastomeric polymer ; and a polymeric layer on a surface of the base substance , wherein the polymeric layer comprises a coating polymer , the polymeric coating comprising a polymer having a polyamine epichlorohydrin crosslinking agent , the elastomeric polymer comprising a hydrogel epichlorohydrin of claim 22 , wherein the coating polymer comprises a hydroxyethyl methacrylate .
the drug delivery system of any one of claims 1 to 9 , wherein each bead further comprises a non-@@ enteric moisture barrier having water-insoluble , semi-permeable polymeric membranes .
virus according to claim 4 , characterized in that the le@@ po@@ p@@ pox virus is a my@@ xo@@ ma virus . the virus according to claim 4 , characterized in that the levofloxacin virus is a my@@ xo@@ ma virus . the virus is a virus that is the virus that is the virus that is the virus that is the virus that is a virus . virus is the virus that is the virus that is the virus . virus is a virus . virus is the virus . virus is the virus .
the method of any one of claims 1 to 9 , further comprising : - receiving an emergency out@@ signal from a user to the monitoring unit ; and transmitting a signal from the monitoring unit by means of wireless telemetry to the implantable medical device to change the operation mode of the implantable medical device in response to receiving the signal .
manufacturer of the biological active substance of the biological active substance and manufacturing substance and manufacturing substance and manufacturing substance and manufacturing substance and manufacturing substance
the compound of claim 22 , wherein r 1 is n-propyl , y is ethylene , and r is isopropyl , namely n 2 -@@ phenyleth@@ yl-@@ n 6 - ( 2-@@ propanoyl ) -8- ( pyrazol-1-yl ) -9- ( prop-1-yl ) -9h-@@ pur@@ ine@@ -2,6-di@@ amine .
o take a lot of liquid between meals to help prevent fluid loss .
the fastener according to claim 1 , wherein the means to promote the adhesion includes a reservoir to include the therapeutic agent to the the the fastener .
in another study ( v@@ 59@@ p@@ 6 ) conducted in 524 adolescents , the immunogenicity of men@@ ve@@ o was compared with that of meningococcal polysaccharide 4 vaccines ( ac@@ w@@ y-@@ ps ) .
an apparatus according to claim 31 , wherein the reservoir forms a liquid chamber having a variable volume and the operation device is adapted to dispense fluid from the chamber to the adjustment device and to remove liquid from the adjustment device by expansion of the volume of the chamber .
caution should be exercised when alogliptin is used in combination with metformin and a thiazolidinedione as there is an increased risk of hypoglycaemia in these triple therapy ( see section 4.4 ) .
the pharmaceutical composition of claim 50 wherein the compound is as 2 o 3 , na@@ o 2 , , 2 o 3 , , 2 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3 , 3
2 . process according to claim 1 , characterized in that the average concentration of the non@@ fermentable substance in the fermenter ( fi ) is maintained above 22 % by weight ds .
the transdermal therapeutic system according to any one of the preceding claims , wherein the material of the backing layer is non-@@ biodegradable to more than 90 % , preferably more than 99 % .
a method according to any one of claims 1 to 3 , characterized in that the amount of fluid flowing through a timer ( 25 ) is determined by pressuri@@ sing fluid from the fluid source ( 47 ) by feeding fluid from the fluid source ( 47 ) , and the pressure drop with time to the amount of the fluid flowing through a time unit is set through the channel ( 25 ) .
a method according to claim 15 , further comprising coating the coated carrier material prepared in step ( d ) by sing@@ le- or repeatedly applying a coating process according to claim 15 to the coated carrier material , the solid or semi-solid material used in the initial coating process during each coating process , or another .
the invention relates to a device and a method for applying xenon and / or a medium containing xenon , in particular a xenon containing gas mixture , to a patient , the patient being connected to an inhalation circuit and a cardio@@ pulmonary bypass circuit ( cp@@ b circuit ) .
a compound according to claim 1 which is 5- ( 2-ethyl-@@ 2,3-dihydro-1h-@@ inden-2-yl ) 1- -propyl-@@ benzoxazine or a non-toxic , pharmaceutically acceptable salt thereof .
signs of chest pain may include pain in the neck and shoulder area and in the left arm of the child .
this medicinal product is authorised in the member states in the eea in the member states in the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
0.25 mm x 8 mm ) .
treatment with hypo@@ kala@@ emic medicinal products concomitant treatment with methyl@@ xanthine derivatives , steroids or non-@@ potassium-sparing diuretics may potentiate a possible hypo@@ kala@@ emic effect of β@@ 2-@@ adrenoceptor agonists .
the wireless eeg system for a sound-@@ induced response according to claim 1 , wherein the electrode array ( 12 ) provides a difference input for the transmission means ( 18 ) .
method of reducing gastrointestinal damage
ossi@@ cle prosthesis with an adjustable rate of sound conduction in the middle ear
a compound according to claim 16 according to claim 16 to claim 16 to which is 5- &#91; 4- ( n , to n-diisopropylcarboxamide ) benzyl &#93; imidazo &#91; 4,5-c &#93; pyridine .
instrument according to one of claims 1 to 24 , characterized in that the shaft ( 12 ; 68 ) is straight in the shaft .
a method according to any one of claims 1 to 5 , wherein the peptide de@@ form@@ ylase contains the sequence ( i ) hex@@ x@@ h , ( ii ) eg@@ ( ii ) , ( ( ii ) g@@ x@@ g@@ x@@ ax@@ q ( ( ( ) ) , ) , ( ( ) ) , ( ( ) ) ( ( ) ) ) ) ) ) ( ) ( ) ( ii ) ) ( ) ( ) ) ( ( ) ) ( ( ) ( ( ) ) ( ) ( ) )
a method for producing crystals of human growth hormone and histidine or a derivative of histidine selected from the group consisting of amides and esters of histidine , such as the methyl or ethyl ester , dipeptides such as his-@@ gly , his-@@ ala , his-@@ leu , his-@@ lys , his-@@ ala , his-@@ leu , his-@@ lys , his-@@ ala , his-@@ leu , and optionally setting the solution at a temperature of from about 0 ° c to about 30 ° c and d ) isolating the solution at a temperature of about 0 ° c to
eu / 1 / 07 / 4@@ 19 / 004 eu / 1 / / / / / / / / / / / / / / 004 eu / 1 / / / / / / / / / / 1 / 1 / 1 / 1 / 1 / 1 / 1 / / / / / / 1 / eu / / / / / / / / / / / / / / / / / / / 1 / / / 1 / eu / / / / / 1 / / 1 / /
insulatard innolet 100 iu / ml suspension for injection in a suspension for injection in a pre-filled pen insulin human ( in a pre-filled pen a pre-filled pen a pre-filled pen pre-filled pen a pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen pre-filled pen
this veterinary medicinal product for dogs should not be used in cats , as it is not suitable for in this species in this species . in dogs should not be used in used in cats .
toothbrush according to one of claims 1 to 4 , characterized in that one of claims 1 to 4 , characterised in that claims 1 to 4 in the of claims 1 to 4 to one of the claims 1 to 4 to one of claims 1 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to 4 to
centrifugal separation device and method for separating fluid components for the separating of fluid components and method for separating fluid for separating fluid for separating fluid for separating fluid for separating fluid for separating fluid for separating for separating fluid for separating separating fluid
a foil cover cover according to any one of the preceding claims , characterised in that the first end ( 14 ) of the foil tube ( 1 ) is connected to the tubular sleeve ( 2 ) by manually releasable fastening means ( 15 ) .
excipient with known effect each hard capsule contains 16@@ 3.@@ 4@@ 41 mg lactose .
ge healthcare as ny@@ co@@ ve@@ i@@ en 1-2 p. o. ge healthcare as ny@@ co@@ ve@@ en 1-2 p. o. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p. p.
therefore , it is important to permanently discontinue the hla-b * 57@@ 01 allele because of the risk of serious or life-threatening reaction abacavir , and patients not re-@@ treated with abacavir if a hypersensitivity reaction cannot be excluded .
a method according to claim 18 , wherein the hydroxypropyl methylcellulose is present in the suspension in an amount of 3 % by weight . a method according to claim 18 wherein the hydroxypropyl methylcellulose is present in the suspension in an amount of 3 % by weight . the method of claim 18 wherein the amount of hydroxypropyl methylcellulose is present in an amount of 3 % by weight . the method of claim 18 wherein the hydroxypropyl methylcellulose is present in an amount of 3 weight percent .
a purified and isolated dna molecule for use in ensuring expression of a protein or polypeptide product or a polypeptide or a polypeptide or a polypeptide or a polypeptide or a polypeptide or a polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or polypeptide or
a method of identifying nucleic acids differentially represented in two populations of nucleic acids , which are labelled with an individual from a clone derived from a clone , wherein one of rna and another is represented by dna , comprising the steps of : a ) annealing rna and dna sequences ; b ) treatment with rna@@ se@@ h and dna sequences ; b ) co@@ pying and amplifying residual rna molecules by polymerase reaction reaction , the sequences located outside the specific rna sequence , the sequences which are outside the specific rna sequence .
the method of claim 31 , wherein the sulf@@ hyd@@ ryl@@ tag is phosphoramidite . the process of claim 31 , wherein the sulf@@ hyd@@ ryl@@ tag is phosphoramidite . the process of claim 31 wherein the sulf@@ hyd@@ ryl-@@ tag is phosphoramidite . the process of claim 31 wherein the sulf@@ hyd@@ ryl@@ tag is phosphoramidite . the method of claim 31 wherein the sulf@@ hyd@@ ryl@@ tag is phosphoramidite . the method of claim 31 , wherein the sulf@@ hyd@@ ryl@@ tag is phosphoramidite . the method of claim 31 wherein the sulf@@ hyd@@ ryl@@ tag .
during titration , if adequate analgesia is not achieved within 30 minutes , adequate analgesia , a second effentora tablet of the same strength may be used may be used may be used be may be used be may be be used be may be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be be
use according to one of claims 1 to 7 , characterized in that of one of claims 1 to 7 , of one of claims 1 to 1 of 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1
this results in passive protection against tetanus for at least 21 days following concurrent vaccination .
( 4@@ 9-@@ 221 ) 97 66 80 fax ( 4@@ 9-@@ 221 ) 97 66 82 78 e-mail :
a cosmetic composition comprising : a ) 0.01 to 50 weight percent vitamin b compound ; b ) 0 to 90 % by weight of a emollient component ; c ) 0.01 % to 40 % by weight of a polar emollient ; c ) 0.01 % to 40 % by weight of a composition , wherein the vitamin b 3 compound is added to the composition in a manner that the vitamin b 3 compound concentration exceeds the saturation solubility of the vitamin b 3 compound in the polar solvent .
3 ml solution in a 3 ml pre-filled syringe ( type i glass ) with a plunger stopper ( with fluorocarbon polymer coated bromobutyl ) .
an isolated polypeptide selected from the group consisting of : ( a ) a polypeptide comprising the sequence of seq id no : 7 ; ( b ) a polypeptide comprising the sequence of seq id no : 8 ; ( c ) a polypeptide comprising amino acids 43 to 66 of seq id no : 1 ; ( c ) a polypeptide comprising amino acids 43 to 66 of seq id no : 1 ; ( f ) a polypeptide comprising amino acids 43 to 66 of seq id no : 1 ; ( d ) a polypeptide comprising
in most cases , grade 1 or 2 diarrhoea or grade 1 or 2 diarrhoea did not result in discontinuation of lapatinib treatment .
the electrode system ( 10 ) according to claim 10 , characterized in that said flexible mesh ( 50 ) has a non-conductive material having an intermediate means for supporting said electrically conductive gel means ( 16 ) thereon . , characterized in that said flexible mesh ( 50 ) has a non-conductive material in said material ( 16 ) in said a material that is electrically conductive to said electrically conductive gel ( 16 ) in a non-@@ conductive material , said material ( 50 ) having a non-conductive material ( 50 ) .
the applicant also decided to provide further comparative data on the inhalers provided with their respective inha@@ lations to obtain reliable information on the particle size distribution .
compounds having agoni@@ stic activity at the beta@@ 2-@@ adrenergic receptor and the muscarinic receptor
the clinical remission rate at week 6 was 10 % ( difference to placebo 2 % , 95 % ci : -6 , 10 ) when administered without corticosteroids , compared with 20 % ( difference to placebo 14 % , 95 % ci : -1 , 29 ) when co-administered with corticosteroids .
method for screening compounds for preventing infection or patho@@ genicity
method for altering the nutrient composition of milk secreted by lactating animals
33 particulars to appear on the outer packaging the outer packaging on the outer packaging the outer packaging the outer packaging the outer packaging the outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging
the medical suture holding member according to claim 1 , wherein said synthetic high molecular material is a copolymer containing at least 30 mole percent or more poly-@@ ε-caprolactone .
adverse reactions in adult clinical trials and in post-marketing experience and suspected adverse reactions ( at least possibly ) related to treatment are listed in table 2 by body system organ class and frequency ( frequency of at least 1 ) and frequency of adverse reactions ( adverse reactions ) and adverse reactions ( at least possibly ) and frequency and frequency ( at least possibly ) and frequency ( at least possibly ) and frequency ( at least possibly ) and frequency and frequency .
the combination composition of claim 21 , wherein the immunosuppressant is selected from azathioprine , cyclophosphamide , methotrexate , bre@@ quin@@ sodium , deoxy@@ sper@@ gu@@ ine , miconazole , 2-cyanoethyl , , , , , , , , , , , , , , rapamycin , tacrolimus , leflunomide , ok@@ , , , , anti-cd@@ , , anti , , anti-@@ , anti-@@ , , , , , , , antibody , , anti-@@ , anti-@@ , , antibody , antibody , , and , , , , , from , , , , . , , ,
pharmaceutical composition according to any one of claims 1 to 4 , characterized in that it has polyethylene glycol with an average molecular weight of 400 to 6000 . , characterized in that it is in the form of a composition that is in the form of a composition of any of claims 1 to 4 to a pharmaceutical composition of any of claims 1 to 4 .
other serious medical complications such as severe deterioration of renal function , disease related hospit@@ alization and progression of disease to terminal renal failure occurred in these patients .
paediatric population the safety and efficacy of lu@@ rasi@@ done in the paediatric population and adolescents the safety and efficacy of and safety and efficacy and efficacy and safety and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and efficacy and
swelling in the area of use is very common ( more than 1 user in 10 ) .
however , serious systemic allergic reactions ( anaphylactic reactions ) occurred in patients during aldurazyme infusion or up to 3 hours thereafter .
an antibody according to any one of claims 1 to 3 which has no substantial binding activity against other indoles or glucuron@@ ides present in human samples .
if you forget to take isentress if you forget to take isentress                                                  you forget to take you to take you to take isentress to you to take to you to take to take to take to take to take to take to take to take to
the stent of claim 41 , wherein the balloon is curved in an expanded state and extends from a proximal end and a distal end .
thrombus filter with separable grasp@@ er
the method of claim 3 , wherein the thermostable dna polymerase is taq polymerase . the method of claim 3 wherein the thermostable dna polymerase is taq polymerase . the method of claim 3 of polymerase taq is of the polymerase taq polymerase of claim 3 is polymerase of polymerase taq of polymerase polymerase . method of claim 3 wherein is polymerase of polymerase taq of the polymerase of the polymerase polymerase .
compound according to claim 1 or 2 , characterized in that r 2 is constituted by the group consisting of ethyl , ethenyl , ethynyl , propyl , 1-@@ propenyl , 1-@@ propynyl , 1,2-@@ prop@@ dienyl and cyclopropyl .
a pharmaceutical composition according to claim 6 according to claim 6 in a dry form .
driving a car or operating machines ) or operating machines .
the particle of claim 1 wherein the phospholipid is a synthetic phospholipid or a modified natural phospholipid . the particle of claim 1 wherein the phospholipid is selected from the group consisting of phosphatidyl@@ chol@@ ines , phosphatidyleth@@ ano@@ lamines , phosphatidyl@@ ser@@ ines , phosphatidyl@@ inosi@@ t@@ ols and mixtures thereof , as claimed in claim 1 , wherein the phospholipid : titanium dioxide based ratio is in the range of 0.1 : 100 to 15 : 100 .
the protective device of any of claims 18-@@ 25 , wherein the viewing tube comprises at least one working channel and wherein the protector comprises at least one tubular extension which can be aligned with the channel .
a method according to claim 4 , characterized in that the result of the erythrocyte sedimentation test is determined by the formula : wherein : the diagnostic coefficient alpha α indicates a tumor when α ≥ 1.5 , a e@@ sr index of the test test , b 1 and b 2 e@@ sr index of control tests , x maximum value of the es@@ r in test a or the mean of b 1 and b 2 .
a pharmaceutical composition comprising an effective amount of a compound of claim 1 and an effective amount of an h 1 receptor antagonist and an effective amount of an effective amount of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of
the locking of the rib members ( 17 ) is carried out by a pin ( 32a ) which can be inserted into a bore ( 22 ) after the type of a split connection .
claims for the following contracting states : at , be , ch , de , dk , fr , gb , it , li , lu , nl , se a compound of the formula or a pharmaceutically acceptable salt or solvate thereof , wherein g is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar is : ar
a drive mechanism according to claim 1 or claim 2 , characterised in that the piston means ( 180 ) comprises a threaded screw .
an inhalation device as claimed in any one of claims 1 to 3 , wherein the mouthpiece actuator , and the mouthpiece are directly coupled to any one of claims 1 to 3 to 3 to 3 .
a method of releasing genetic material from a solid medium which binds genetic material , said method comprising : a .
apparatus for automatically controlling spontaneous respiratory support .
the lead system according to claim 24 , wherein the tip engaging region ( 100 ) is electrically conductive .
device according to claim 10 , characterized in that the markings are formed by metallic coating , preferably platinum coatings attached to the jacket ( 17 ) of the catheter ( 1 ) .
&#91; invented name &#93; should not be taken by children should be given &#91; invented name &#93; should not be taken by children should be given &#91; invented name &#93; should not take &#91; invented name &#93; &#93; should not take &#91; invented name &#93; &#93; name should not be taken &#93; should not be taken &#93; not to be taken &#93; . &#93; should not be taken by children not taking &#91; invented name &#93; &#93; not not &#93; name should not be not not recommended .
a compound according to any one of the preceding claims wherein a 2 represents a single bond , a c 1-4 alkylene group or a c 2-5 alkenylene group .
the garment of claim 7 , wherein said first body panel ( 4 ) comprises a first pair of side panels , and wherein said second body panel ( 6 ) comprises a second pair of side panels , each of said side panels ( 6 ) having a second pair of side panels , each of said side panels ( 6 ) having a second pair of side panels , wherein each of said side panels ( 6 ) has a second pair of side panels , each of said side panels ( 6 ) having a second pair
a method for producing an immunotoxin , suitable for use in humans or animals , comprising a toxin comprising a toxin fused to an antibody comprising a disease comprising diseased or disease wherein the toxin is a modified exotoxin according to claim 1 comprising a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
prosthesis according to claim 1 , characterized in that the angle of inclination of the planar surfaces has a value lying between 1 ° and 10 ° .
no specific treatment is available for triumeq overdose .
thermoplastic material and two-@@ stage casting method
and you don &apos;t have any@@ body else ... no fri@@ ends , even your bro@@ ther .
use according to any one of claims 1 to 15 and 17 , characterized in that r 3 is a linear or branched alkyl group containing 1 to 6 carbon atoms , preferably a c 1 -c 4 alkyl .
the seroprotection rate for varicella virus ( ≥ 5 gp@@ elisa units / ml ) was 9@@ 0.9 % ( between 8@@ 0.8 % and 9@@ 4.5 % ) ; this antibody concentration correlates with long-term protection against varicella .
other medicines and eucreas tell your doctor or pharmacist if you are taking or you are taking or are you taking or are you taking or are you taking or are if you are taking or are you taking or are you taking or are you taking or are you taking or are you taking or are you taking or are taking or are you taking or are taking or are you taking or are taking are taking or are taking are taking are taking are taking are taking taking are taking are taking taking are taking taking taking taking
introduction of eudra@@ sa@@ fe ii in january 2003 major bandwidth implemented introduction of eudra@@ work@@ space in june 2003 introduction of the pk@@ i infra@@ structure to december 2003 introduction to december 2003
agent according to one of claims 1 to 7 , characterized in that the aqueous medium contains a tonicity control agent in an isotonic state corresponding to the production of a blood plasma .
process according to one of claims 4 to 9 , characterized in that the temperature is 25 to 50 ° c. a process according to one of claims 4 to 10 , characterised in that the molar ratio of 1-@@ c ₃ to c ₁ ₂ alkyl@@ glucoside to the fatty acid ranges from 0.001 to 5 to 1 .
microparticles according to claim 26 , characterized in that the substance is chosen from gink@@ go@@ lides , and their derivatives .
summary of the safety profile in the safety profile in the clinical trials in the safety in in the in in of clinical trials in the in in in in clinical trials in in the in in clinical clinical in clinical clinical in clinical clinical in in clinical trials in the clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical clinical in
primary hypercholesterolaemia and mixed hypercholesterolaemia in the efficacy and safety of simvastatin in patients with hypercholesterolaemia , treatment with 10 mg , 20 mg , 40 mg and 80 mg simvastatin per day resulted in a 30 % , 38 % , 41 % and 47 % reductions in ld@@ l-cholesterol .
a compound of formula i as claimed in claim 1 wherein x is cr 7 = ch , wherein r 7 is hydrogen or alkyl of 1 to 3 carbon atoms .
consideration should be given to determination of serum lipids and blood glucose in the fasting patient .
dna according to one of claims 1 to 8 , characterized in that the regions coding for the complete repeats at position + 26 to + 92 , position + 98 to + 164 , position + 182 to + 249 and position + 258 to + 324 are superimposed in fig . 7 .
surgical instrument according to one of claims 10 or 11 , characterized in that the at least one axial stop ( 50 ) is located adjacent or in the region of the at least one first coupling member ( 52 ) .
therefore , the prac recommended the amendment of the marketing authorisations for the substances acting on the ras .
the method of claim 5 or claim 6 , wherein the modified cells are disrupted followed by collecting the plasma membrane fragments .
a method for screening compositions for identifying agonists , antagonists or modulators of acid-@@ sensitive ion channels , comprising contacting cells encoding acid controlled channels with the composition to be analyzed in the presence of phe-@@ met@@ arg-@@ phe-@@ amide ( f@@ mr@@ f@@ amide ) and a sufficient acidic extracellular ph to thereby amplify the acid controlled channel currents ; and determining whether the composition enhances or inhibits the opening of the acid susceptible ion channels of the deg / en@@ ac channel family .
a pharmaceutical composition comprising a compound according to any one of claims 1 to 7 to a pharmaceutically acceptable carrier compound .
the supportive endoluminal graft of any one of the preceding claims , wherein the trun@@ vering component ( 101 ) has a rupture liner ( 122 , 123 ) having a resilient wall of substantially inert , biocompatible material , wherein the rubber liner is mounted on the internal surface of the frusto-conical component and the compliant wall has a diameter size which is expanded with the constriction component .
it is recommended that all women of childbearing potential women of childbearing potential of childbearing potential of childbearing potential of childbearing potential of childbearing potential of childbearing potential of childbearing potential of childbearing potential of childbearing childbearing potential of childbearing childbearing childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential childbearing childbearing potential
there is no evidence of an improvement in the duration of observation .
process according to claim 1 , 2 or 3 , characterized in that it contains 5 to 15 % by weight of acetylsalicylic acid and / or benzyl alcohol . the stable solution of acetylsalicylic acid according to any one of claims 1 to 4 , characterized in that it contains 5 to 15 % by weight of acetylsalicylic acid , 10 - 40 % by weight of dimethyl isosorbide monoethyl ether and from 0.005 to 2 % by weight of saccharin and / or cyclooxygenase and / or from 1 to 40 % by weight of saccharin and /
a removable and sterilizable , or preferably disposable suction cannulas formed from transparent material , characterized in that they are suitable , in particular , in its insertion region to form an instrument according to any one of claims 1 to 3 .
the use of a gamma@@ -amino@@ butyric acid agonist , but not diazepam , for the manufacture of ophthalmic medicament intended for topical application for the treatment of ocular excess pressure , for example for the treatment of glaucoma .
multi-@@ punch balloon catheter for reducing damage to coated expandable medical implants
the apparatus of claim 4 , wherein a portion of the swe@@ dish switch ( 110 ) is also disposed on one of the first and second side surfaces of the control unit .
the recombinant vaccinia virus of claim 3 , wherein the immunodeficiency virus is monkey immunodeficiency virus .
the method of claim 7 , wherein the water-soluble polymer has a molecular weight greater than 5000 and less than 100,000 , in particular of about 18@@ 500 .
use according to any one of the preceding claims , characterized in that the medicament for the treatment of tumour diseases has an anti@@ mitotic effect in mammals .
a method according to claim 1 , in order to obtain specific gene sequences and their expression products in target cells present in cell environ@@ ments which differ or not .
4.2 posology and method of administration method and administration method method of administration method and administration method of administration method and of method of administration of method and of method of administration method of administration of administration method of of method of of method of of method of administration of method of of administration of method of administration of method of of method of administration
a compound of formula ( i ) of formula ( i ) ( i ) of formula ( i ) ( i ) ( i ) i ( i ) i i ( i ) i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
when zal@@ mox@@ is is used , this reaction may be treated with ganciclovir or val@@ ganciclovir .
because the number of patients with adreno@@ cortical carcinoma is low , the disease is considered ‘ rare ’ , and lyso@@ dren was given on 12 march 2007 .
the system of claim 2 , wherein the plurality of back@@ reflective markers ( 406 ) comprises : an elevated reflective surface ( 702 ) and a flat surface ( 704 ) disposed on the basis of the raised reflective surface .
store in the outer carton in order to protect from light .
the hybrid plasmid of claim 2 further comprising a transcription terminator of the alkaline protease of bacillus licheniformis atcc 5@@ 39@@ 26 operably linked to the mature region encoding the proteolytic enzyme of bacillus len@@ tus dsm 54@@ 83 of claim 2 .
the method of claim 11 or 12 comprising : ( a ) exposing the photo@@ polymerizable composition to a first reaction temperature of the first dose of actinic radiation for initiating the polymerization of the free radical functional group after a limited induction period t ; and ( b ) subjecting the photo@@ polymerizable composition to a second dose reaction temperature of a second dose of actinic radiation to initiate polymerization of the cationically active functional group after a limited induction period .
up to 1.@@ 58 g to 1.@@ 58 g to 1.@@ 58 g of ethanol g to 1.@@ 58 g 1.@@ 58 g 1.@@ 58 g 1.@@ 58 g 1.@@ 58 g 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58 58
the invention relates to a method for producing the peptides and to the pharmaceutical use thereof .
a cavit@@ y-@@ retaining tool for surgery according to claim 18 , wherein said connecting means ( 246 ) is adapted to be passed through a hole in said foil member ( 233 , 312 , 382 ) by a needle segment ( 241 ) which penetrates said film member ( 233 , 312 , 382 ) .
an implantable orthopaedic hip joint prosthesis according to claim 1 , wherein the projection of the insert is deformed when the insert is inserted into the tray and the protrusion in the un@@ deformed state returns when the projection is positioned in the roof of the shell .
select a flat , clean and well-@@ lit work surface .
the following pack sizes are available : outer cartons : outer cartons : outer cartons : outer cartons : outer cartons : outer cartons : outer cartons : outer outer cartons : outer outer cartons :
system according to claim 6 , characterized in that the care device ( 2 ) is designed so as to send a predetermined alarm division by means of wireless communication using the mobile station to the data processing system ( 14 - 20 ) after a second predetermined time is elapsed and in response to an indication of the detection means ( 10 ) , the at least one product ( 8 ) has not been removed .
loss of appetite , headache , constipation , headache , vomiting , headache , , , , , , , , , , , , , , , headache , , , , , headache , , , , , , , , , headache , , headache , headache , , , headache , , headache , headache , , constipation , headache , headache , , , , headache , , , , , , , , , , , , , , , , , , headache , , , headache , , , , , ,
agent according to one of claims 10 and 11 , characterized in that , with the amphiphilic non-ionic lipid ( lipids ) , at least one additive is associated to modify the permeability or surface charge of the vesicles and which is capable of modifying the permeability or the surface charge of the vesicles and which is selected from the group consisting of : long-chain alcohols and their salts , long-chain amino alcohol esters and their salts and quaternary ammonium derivatives , alkyl sulphates and ionic sterol derivatives .
a method according to claim 1 , wherein the therapeutic gene is the dystro@@ phin gene . method according to claim 1 , wherein , wherein , , , , , , , , , , , , , , the therapeutic gene is the dystro@@ phin gene .
a support structure as claimed in claim 1 , characterised in that each cam ( 190 ) is offset from the preceding and subsequent cam ( 190 ) such that the elements ( 30 ) , one after the other or a group after the other , are moved down downwards from the normal position and returned back to the normal position after a predetermined sequence .
use of pox@@ en@@ tants from combinations of multiple pox or para@@ pox virus strains for the preparation of medicaments for pre@@ finite tumor therapy to reduce pain and optimi@@ sation of the patient &apos;s well@@ ness .
a composition according to any one of claims 1 to 17 , wherein the ifn-β is maintained in a solution at a ph of 3.5 to 9.5 for a period of 24 hours at 4 ° c. the composition of claim 18 , wherein the ph is a neutral ph .
a spherical biocatalyst according to claim 1 or 2 , characterized in that the enzymatically active material contains an oxidoreductase or is an oxidoreductase .
a lifting means according to any one of the preceding claims , characterised in that the flow valve ( 12 ) is provided with a setting means , such that during the inflating and / or deflation of the inflatable seat , the relative pressures of the fluid have the relative pressures of the fluid in the compartments ( 14 ) of the inflatable seat to adjust the proportion of the fluid , which is supplied to each of the compartments ( 14 ) and / or extending them , depending on the pressure differences of the fluid in the
the pharmaceutical composition according to any one of claims 1 to 3 , wherein the heparin derivative has a molecular weight of between 2500 and 6@@ 500 daltons . the pharmaceutical composition according to any one of claims 1 to 3 , wherein the heparin derivative has a molecular weight of between 2500 to 6@@ 500 daltons .
the artificial sub@@ retinal implant device of claim 2 , wherein individual micro@@ photo@@ diodes ( 10 ) are embedded in said mes@@ h-@@ like mesh consisting of an inert substance .
however , many therapeutic principles in these arrhythmia are also based on empirical concep@@ ts and not confirmed in clinical studies .
expression of a fusion polypeptide transported without leader sequence from the cytoplasm
a method for producing locally limited x-ray radiation , the device being capable of being inserted into a body of a subject to be treated , the method comprising : providing a ge@@ tter having the steps of : providing a ge@@ tter , which method comprises : providing a ge@@ tter that comprises the steps of : providing a ge@@ tter that comprises the steps of : providing a ge@@ tter that is less than the activation temperature ; placing the cathode within a vacuum housing ; placing the cathode within a vacuum housing ; and increasing the temperature
co-administration of amprenavir and rifabutin resulted in an increase in rifabutin in a 193 % increase in rifabutin in a 193 % in a 193 % a a a 193 % a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
stelara concentrate for solution for infusion should be used for the intravenous induction dose only .
i need someone who gets this . ~ ~ ~ i need someone i need to know . ~ ~ ~ i need someone who &apos;s someone who &apos;s someone who &apos;s who who who &apos;s someone .
process for producing a disposable absorbent pad .
the magnet assembly of any preceding claim , wherein the first material is a metal alloy and the second material is the reinforced epoxy material . the magnet assembly of the preceding claim wherein the material is the material material the magnet assembly is the material .
pharmaceutical compositions comprising tumor necrosis factor and 2-methoxy@@ st@@ one@@ one@@ -3-@@ sulf@@ amate as estrone sulph@@ atase inhibitors
the method of claim 5 , wherein step ( vii ) comprises reducing the percentage by a predetermined amount prior to the repeat of steps ( v ) and ( vi ) .
the enhanced absorption pharmaceutical composition of claim 40 wherein the macrogol fatty acid ester is selected from the group selected from the group consisting of the ge@@ luci@@ re from the selected from the group consisting of the group consisting of the group consisting of the group consisting of consisting consisting of consisting consisting of consisting consisting of consisting consisting of consisting consisting of consisting consisting of consisting consisting of consisting consisting consisting of consisting consisting consisting of consisting consisting consisting of consisting consisting consisting of consisting consisting consisting consisting consisting consisting of consisting consisting consisting consisting consisting consisting consisting
plant according to one of claims 1-6 , characterized in that it is formed by a first pocket ( 61 ) with a flexible wall ( 63 ) , which includes a second dense pocket ( 2 ) with double wall ( 5 , 82 ) , and in that the first pocket ( 61 ) is formed with a double wall ( 5 , 82 ) , and in that the first pocket ( 61 ) is formed either the first chamber or the second chamber , while the second bag ( 2 ) determines the respective other chamber
peelable perforated blisters contain 14@@ x1 , 28@@ x1 , 30@@ x1 , x1 , 84@@ x1 , x1 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
rejection reduction dex 10 mg / m2 oral , days 6-@@ 7 , 13-@@ 16 ;
a cannula according to any preceding claim , wherein the at least one liquid inlet comprises a first fluid inlet immediately adjacent to the distal end and a second liquid inlet located proximate the first inlet .
the dna of claim 16 which encodes the amino acid sequence from the 57-@@ amino acid serine to the c-terminal of the amino acid sequence amino acid sequence amino acid sequence amino acid sequence sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid sequence acid
this is only a long term precursor .
reproductive studies in animal models indicated that recombinant interferon alfa-2b in rats was
an assembly as claimed in any one of the preceding claims , further comprising one or more blister packs with individually opening blisters that are only made of aluminum blisters , the order is such that the one or more blister blisters must be opened after the at least one blister .
the method of claim 1 , wherein at least a first of the species of oligonucleotide probes includes means for detecting the oligonucleotide probe .
a method for the production of the polypeptide of claim 1 of the polypeptide of claim 1 of ( a ) comprising a 1 of the polypeptide of claim 1 comprising claim 1 of claim 1 comprising ( a ) comprising a 1 comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising a comprising
the method of claim 71 , wherein said non-human animal is a transgenic mouse comprising a human antibody library a a is a a a a transgenic mouse .
a retroviral vector producing packaging cells for use in medicine as claimed in claim 8 , wherein the gene product is thymidine kinase and the chemical treatment is treatment with the is the the treatment in the treatment of is is the for use in the medicine in the medicine .
preparation according to claim 7 , characterized in that it comprises sorbic acid .
use according to claim 1 according to claim 1 of the compounds of general formula ( i ) as defined in claim 1 to claim 1 in claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim
a pharmaceutical composition according to any one of the preceding claims , comprising at least 25 mg of the non-steroidal anti-inflammatory drug . the pharmaceutical composition according to any of the preceding claims comprising at least 25 mg of said non-steroidal anti-inflammatory drug . the pharmaceutical composition according to any of the preceding claims comprising at least 25 mg of said anti-inflammatory drug . composition according to any one of the preceding claims comprising at least 25 mg of said anti-inflammatory drug .
the chmp decided that privi@@ gen ’ s benefits are greater than its risks and recommended that it be given marketing authorisation . • the chmp decided that privi@@ gen be given marketing authorisation . • the recommended marketing authorisation for marketing authorisation and marketing authorisation authorisation granted by the marketing authorisation authorisation . authorisation recommended the marketing authorisation . authorisation for marketing authorisation authorisation . authorisation marketing authorisation . authorisation marketing authorisation . authorisation authorisation authorisation . authorisation authorisation authorisation authorisation authorisation authorisation authorisation authorisation authorisation .
pectin@@ ase , pectins , low-molecular pectin and food and drink containing low-molecular pectin .
a host cell transformed with ( i ) dna sequence according to any one of claims 1 to 15 or ( ii ) a cloning or expression vector according to claim 16 .
the kit of claim 20 wherein the solid phase is coated with streptavidin and the probe is biotinylated .
a method according to claim 2 , wherein the at least three intensity values i &#91; ρ i , λ j &#93; comprise the values i &#91; ρ 1 , λ 1 &#93; , i &#91; ρ 1 , λ 1 &#93; , i &#91; ρ 1 , λ 2 &#93; , i &#91; ρ 1 , λ 2 &#93; ) and i &#91; ρ 2 , λ 2 &#93; ) and i &#91; ρ 2 , λ 2 &#93; ) and i &#91; ρ 2 , λ 2 &#93; ) and i &#91; ρ 2 , λ 2 &#93;
table 7 shows sv@@ r12 rates in treatment-naïve subjects with genotype 1 infection with ex@@ vi@@ era and ombitasvir / paritaprevir / ritonavir in combination with ribavirin for 12 weeks in study sap@@ phi@@ re-@@ i.
the intravascular multi@@ anchor stent ( 10 , 110 , 130 ) of claim 1 and 2 , wherein each spine ( 20 , 120 , 140 , 142 ) align@@ s after the common longitudinal axis ( a ) when the multi@@ anchor stent ( 10 , 110 , 130 ) is in an un@@ extended state .
use according to any one of the preceding claims , characterized in that no in the medicament is present in an amount of 1 - 100,000 nmol / min , use according to one of the preceding claims , characterised in that the concentration of the no in the range of 1 - 180 ppm , preferably 1 - 80 ppm , in particular 1 - 40 ppm , is present , the no in a carrier gas or gas mixture .
the method of any one of claims 1 to 10 , comprising storing the calibration factors in a memory associated with a field emitting coil coil .
a flow indicator according to claim 7 , wherein the spring ( 8 ) has a predetermined spring rate adapted to the optimal inhalation strength for a given user .
system according to claim 15 , characterized in that a locking circuit ( 80 ) is provided which alternately enables the high-frequency current supply to the electrode ( 16 ) and the position detection by means of the position sensor ( 42 , 62 ) via two direct electrical electrode leads ( 82 , 84 ) .
a pharmaceutical composition for parenteral injection , intravenous injection , subcutaneous injection , intra-@@ ocular administration , nasal administration , pulmonary administration and osmotic pump administration comprising a glycosylated leptin protein according to any one of claims 1 to 12 in a pharmaceutically acceptable carrier .
6 . agent according to one of claims 4 and 5 , characterized in that the thickener is xanthan gum , an algae or carrageenan derivative , an alginate , a cellulose derivative , a clay of mont@@ mo@@ ril@@ lon@@ ite type or an acrylic copolymer in the form of the sodium salt .
1 and no@@ te for guidance modified release oral and transdermal dosage forms &#91; recommendation for the oral and transdermal dosage forms &#93; , 1999 ema / cpmp / eec / 280 cor@@ r * ) conducted in the studies conducted in the studies ( 2009 to 2010 ) .
expression vector for fusion genes and method for producing immobilized enzyme
a method according to claim 3 , wherein the microorganism further comprises resistance to α-@@ amino-@@ β-hydroxy@@ valeric acid and l-@@ ion@@ ine ; and an auxo@@ troph@@ y which includes the permeable type for l-isoleucine and in the growth of l-leucine .
device for assisting the blood circuit ( 1 ) according to claim 15 , characterized in that the device comprises two opposing plates ( 25 , 26 ) which can be placed on both sides of the blood line ( 20 ) .
the method of claim 4 , wherein said tax@@ oid extraction agent is received from said first column , said first column being comprised of tax@@ oids and said tax@@ oid releases said tax@@ oids in critical or supercritical fluid / cosolvent mixtures , and said first tax@@ oid preparation is de@@ ases , said first tax@@ oid preparation being de@@ ases to produce tax@@ oids and a critical or supercritical fluid / cosolvent mixture .
more than 80 % of patients in the documented clinical trials were also treated with stimulants .
the method of claim 6 , including the step of flow cyto@@ metric cell sorting of apoptotic cells bound to the conjugated monoclonal antibody .
do not try to inject yourself to inject yourself to inject yourself to inject yourself .
a process according to claims 1 to 4 , wherein the denatured protein-containing aqueous composition is spray dried with a jet spray dri@@ er or nebulizer and optionally mixed before spray drying with a carbohydrate .
claims for the following contracting states : at , be , ch , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
a diagnostic garment according to any preceding claim , further comprising a thermistor ( 44 ) located on the glove or tube for measuring the skin temperature .
summary of the emea work programme 2007 emea / mb / 2007
2,5-@@ bis@@ diamine ¬ 1,4 benz@@ quinone derivatives for the treatment of alzheimer &apos;s disease , a method for the production thereof , and intermediates therefor
a process according to any one of claims 1 to 16 , wherein sequence b1 and sequence b2 are directly joined together or separated by a number of nucleobases or by a linker or a linker of a linker or a linker of a linker of a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
pharmaceutical compositions according to the preceding claims for the preparative treatment for surgical procedures on the colon and / or for the supportive treatment of mon@@ e@@ mias or hypera@@ mon@@ e@@ mias .
a method of producing a metal oxide cluster in a single step , said method comprising the steps of : reacting a metal alkoxide with a sub@@ stoichiometric amount of an acid in the presence of an oxide particle growth suppressor and a solubilizing agent and in the absence of water at a temperature and for a period of time sufficient to form a metal oxide cluster gel capable of forming a fine powder when all volatile materials are removed .
a dna according to claim 1 having the nucleotide sequence seq id no : 2 or homologous naturally occurring nucleotide sequence of another mammalian species hybridizable thereto and encodes a crf binding protein according to claim 1 .
preparation of pure stereoisomers of tri@@ cyclo- &#91; 5.@@ 2.@@ 1.0 ( 2.6 ) &#93; dec@@ -1@@ 9-@@ yl-@@ xantho@@ genate and their use as medicaments
composition according to claim 43 , in which the additional inorganic filters are nanopigments of amorphous or crystalline titanium oxide , in the form of ru@@ tile , in the form of ru@@ tile , in / or an@@ atase , iron oxide , zinc oxide , zirconium oxide , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
the active substance in nplate , romiplostim , stimulates platelet formation .
fenofibrate has a potential to decrease uric acid levels by approximately 25 % .
an emulsion according to any preceding claim wherein the emulsion further comprises at least one compound selected from the group consisting of on@@ biotic agents , osmotic pressure controlling agents , serum stres@@ fiers , and antioxidants .
following vaccination , pregnancy should be avoided for one month should be prevented from a month of vaccination . be avoided in order to avoid pregnancy be avoided for a period of 1 month should be avoided for a period of 1 month after vaccination . should be avoided . be avoided for avoided be avoided for avoided be avoided for avoided avoided avoided avoided avoided avoided avoided avoided avoided avoided avoided avoided
a device according to any preceding claim , characterised in that the balloon ( 24 ) has a length which is between about 3 and 4 cm in length .
container according to claim 12 , characterized in that the part ( 17 ) has an enlarged rear end region of the sheath ( 15 ) .
device for detecting an endoscope shape
the apparatus of claim 7 , wherein the slots ( 180 , 182 ) are substantially perpendicular to a plane formed by the first and second attachment rods ( 186 , 184 ) when the first and second plates ( 170 , 172 ) are in the closed position .
the peptide of claim 1 , wherein x is deleted and a1 is is is is is is is is is is aib and is is is x is is is is is is is is and the peptide is is is is is d-phe-@@ cys-@@ tyr-d-trp-lys-@@ leu-@@ pen@@ -@@ thr-nh 2 ( seq is no : 8 ) .
people over 65 years of age or with impaired kidney function
a composition comprising a compound a composition a a composition comprising a a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a a composition a
the incidence of hypoglycaemia was significantly lower in the sitagliptin arm group ( 4.9 % ) than the glipizide group ( 3@@ 2.0 % ( 3@@ 2.0 % ) ( ( 3@@ 2.0 % ( 3@@ 2.0 % ( 3@@ 2.0 % 3@@ 2.0 % 3@@ 2.0 % 3@@ 2.0 % 3@@ 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 % 2.0 %
the immunogenic fragment of claim 1 wherein said isolated polypeptide comprises the amino acid sequence of seq id no : 2 .
the method of claim 37 , further comprising the step of heating the construct .
powder containing low molecular weight dextran and process for producing the same
apparatus according to claim 1 , characterized in that the device ( 4 ) is a rotationally driven roller at a lower speed than that of the motor ( 5 ) which is the front part ( 3 ) .
composition according to either of claims 4 and 5 , characterized in that the acidic compound is tartaric acid , succinic acid , citric acid or one of its partial salts such as monosodium citrate .
the frequency terms listed are defined as follows : very common ( ≥ : very common : very common ( ≥ 1 ( ≥ 1 ( ≥ 1 / 1 ) , common ( ≥ 1 / 1 ( ≥ 1 / 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 ≥ 1 1 1 1 1 1 1 1 1 1 1 1 1 1
the use of homo- or copolymers based on quaternized 1-@@ vin@@ ylimid@@ imidazoles according to claim 1 or 2 , wherein the copolymer is composed of 1-@@ vinylpyrrolidone , 2-hydroxyethyl acrylate , 2-hydroxyethyl methacrylate , 2-hydroxy@@ propyl acrylate , 3-hydroxy@@ propyl acrylate or a mixture thereof as component b. the use of a homo- or copolymers as claimed in the claims 1 to 4 , wherein the polymer is composed of a component a alone or from 10 to 98 % by weight of component a in quaternized form and 2 to 90 weight percent of component b .
treatment should be carried out under the supervision of the supervision of a physician experienced in a physician a physician experienced a physician a physician a physician a physician a physician a physician a physician a physician a physician a physician a physician physician a physician a physician physician a physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician physician
genotype 2 / 3 : the recommended duration of treatment is 24 weeks of treatment . the recommended duration of treatment is of 24 weeks of treatment duration .
an air freshener according to claim 1 , characterised in that when the container ( 2 ) has been inserted with the wick ( 5 ) into the housing ( 1 ) , the cover cap ( 9 ) can be moved and removed over the wick ( 5 ) .
the inventive dental implant consists preferably of plastic , ceramic or hybrid materials .
do not attempt to inject yourself until you are sure that you are sure you have you and you are giving injection to you until you are sure you are not sure .
a device according to any preceding claim , wherein the electrode attachment comprises a plurality of active electrodes held in an electrode support .
an assay method , wherein atp is measured using luci@@ fer@@ in and luciferase for light generation , the amount of light being related to the amount of atp , characterized in that the luciferase is a protein according to any one of claims 1 to 10 .
cosmetic and / or dermatological and / or pharmaceutical composition for topical application comprising at least one compound which is an inhibitor of the enzyme 3-@@ beta-@@ h@@ sd
3 . a growth promo@@ tant according to claim 2 , wherein the gel matrix comprises k@@ -c@@ carrageenan , gelatin , alginates , cellulose , or the derivatives thereof , or gel forming synthetic polymers .
the european commission granted a marketing authorisation valid throughout the european union for the european union valid throughout the european union for the european union european european european union the european commission european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european union european
a taxane derivative according to claim 17 , wherein x 10 is t-@@ butoxy , r 9a is β-@@ hydroxy , r 10 is hydrogen , , , , , , , , , , , , , , , , , x is 10 , wherein r is 10 , wherein x 10 is x 10 , r 10 , 10 is 10 , 10 , 10 , 10 , 10 , 10 , 10 , 10 , 10 , 10 , 10 , 10 , 10 , 10 , 10 , 10 , 10 , 10 , 10
your doctor may prescribe a different dose .
use of an o-@@ glycan of an o-@@ glycan of an o-@@ an o-@@ an an o-@@ an an o-@@ an an o-@@ an an an o-@@ an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an an
a compound according to claim 14 or claim 15 wherein n is the integer 1 and alk 1 is an optionally substituted c 1-6 alkylene chain .
conditions or restrictions with regard to the safe and the safe the safe and the safe the safe the the safe the
the probe of claim 10 , wherein the at least one actuating member ( 82 , 142 or 176 ) comprises a plurality of electrodes spaced apart .
do you think i &apos;ll die ?
the compound according to claim 1 , wherein r is 2-amino-4-thiazolyl and r is carboxymethyl , 1-carboxy@@ -1-methylethyl , 1-carboxy@@ , 1-carboxy@@ 1-carboxy@@ , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
the prac considered the procedure of article 31 of directive 2001 / 83 / ec / ec / ec / ec / eec / 83 / 2001 / ec of / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec
in studies of the individual active substances , both alogliptin and metformin occurred in the milk of lactating rats .
the instrument according to claim 9 , characterized in that the at least one element ( 62 ) covers the at least one at least one one element ( 62 ) at the distal side and at least one at least one at least one of the at least one element ( 66 , 68 ) , the one element ( 66 ) , the at least one ( 62 ) one element ( one , one ) , the one element ( 62 ) , the one ( 62 ) one element ( 66 ) , the element (
a kit according to claim 17 for use in detecting a nucleotide variation in codon 12 of the k@@ ras gene , wherein the detection step primer comprises the sequence 5 &apos; -@@ act ggt ggt ag@@ g tg@@ g ag@@ c tg .
32 . a method according to claim 31 wherein the membrane has a pore size which is not above 0.45 µm .
composition according to any one of the one of the one the preceding claims , the characterized in that the the composition of the preceding claims , characterized in the the the preceding claims , the composition of the preceding claims the the the preceding claims the the the preceding claims , the the the the the preceding claims the preceding claims the the preceding claims the the preceding claims , the the the the preceding claims the preceding the the the the the the the the preceding claims the preceding claims the preceding claims the preceding claims preceding the
the method of claim 4 , further comprising the step of measuring the polarization degree associated with the hyperpolarized gas in the second vessel , prior to administration to a desired subject at the end use site .
a method of randomisation of polynucleotides at specific sites comprising the steps of : ( a ) providing polynucleotides that differ at one or more sites , said one or more site ( s ) defining the sites at which one or more sites ( s ) produced by means of an agent produced in step ( c ) from the polynucleotide hetero@@ duplex starting from the polynucleotide hetero@@ duplex starting at step ( c ) , filling one or more of the strand fracture ( s ) produced by the polynucleotide hetero@@ duplex starting in step ( c )
process according to claim 8 , characterized in that in step a ) the treatment is carried out by lowering the ph by means of acetic acid to the vicinity of 4 and that the precipitated ribosome are collected .
synergistic compositions of n-acyl homoserine lactones and 4-@@ quinolin@@ ones
a method for coating the surfaces of medical implants with living cells by means of a nutri@@ tive physiological liquid , wherein the implants are introduced and fixed in a receiving container , which is introduced into a receptacle and which is moved at least one axis , and , independently , the receptacle is moved at the same time , independently of each other , by two rotation axes extending perpendicular to each other .
penta@@ midine salts and their use for the treatment and prophylaxis of pneumocystis carinii pneumonia .
therefore , drinks containing plant extracts , containing herbal , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , drinks , , , , , , , , , , , drinks , drinks , , , , , , , , , , , , drinks , drinks , , , , , , , , , , , drinks , drinks , , , , , , , , ,
agent for dyeing keratin-containing fibres , in particular human hair , comprising as dye component a combination of aromatic aldehydes .
selection of resistance to lopinavir in patients after protease inhibitor therapy was characterised by studies of long-term isolates of 19 with protease inhibitors experienced in 2 phase ii and one phase iii study .
use of a biocompatible implant for the manufacture of a medicament for inducing an immune response in an immunologically immature animal according to claim 1 , wherein the immunologically immature animal is one day old animal .
the use according to any one of claims 1 to 5 , wherein the medicament further comprises a biologically compatible carrier , for example selected from dimethylsulfoxide , polyoxyethylene sorbitan monooleate , polyols , aqueous dextrose solution , ringer &apos;s solution , saline solution , or a combination thereof , and / or an adjuvant selected for example selected from anti-inflammatory agents , biological reaction modifiers , or a combination thereof .
u@@ li@@ pri@@ stal acetate is excreted in human milk .
method according to claim 29 , characterized in that the second insecticidal protein is selected from the group consisting of bt δ-@@ endotoxins , protease inhibitors , lectins , α-@@ amylases and peroxid@@ ases .
cosmetic and / or pharmaceutical preparations containing or and / or pharmaceutical preparations containing ( a ) fatty ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ) ) ) ( ( ( ( ( b1 ) ( ( ( ( ( ( ( b1 ) oligo@@ glycerols ; and / or ( b2 ) oligo@@ glycerol ( ( ( ( ( ( ( ( ( ( ( ( ( ) ) )
if the rate of infusion is not increased beyond the initial rate of 12 ml / h , the infusion of 12 ml / h should be re@@ initiated at the start of infusion at the start of infusion .
failure to respond poorly to erythropoietin should prompt to search for causative factors , but should not be used to monitor the response to erythropoietin to stimulate the response to erythropoietin , to search for response to response to erythropoietin to response to response to erythropoietin . to response to erythropoietin to response to erythropoietin , to prompt response to erythropoietin to to response to erythropoietin to erythropoietin .
a kit comprising in a therapeutically effective dose or multiple dose amount of glp-2 or an analogue thereof and at least one other peptide hormone selected from the group consisting of igf-1 , igf-@@ 2 , gh , egf , hgf and kgf .
allow the refrigerated solution to reach room temperature before the solution reach .
the blood-pressure measurement system of claim 10 , wherein the arrhythmia correction circuit ( 114 ) the amplitude ( 114 ) ( 114 ) ( 114 ) is ( the ) the amplitude of the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
dry eyes , swollen eyes , eye pain , restlessness , aqueous eyes , eye irritation .
drug groups may be affected with lansoprazol-@@ ct be influenced by may be influenced by be influenced by be influenced by be influenced by influenced by influenced by influenced by influenced by influenced by influenced by
a radially expandable support structure according to claim 1 according to to claim 1 , claim 1 to claim 1 to claim 1 , claim 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1
an endoscopic tool comprising : ( a ) a hollow tube ( 15 ) comprising a plurality of discrete units of hemostatic agent ( 18 ) , said hollow tube ( 15 ) having proximal and distal ends ( 38 , 39 ) having an opening in said distal end ( 38 ) of said hollow tube ( 15 ) , said valve allowing said blood killing means ( 18 ) to prevent said blood killing means ( 25 ) in said distal end ( 38 ) of said hollow tube ( 15 ) , but said valve allowing said
endoscopic probe according to claim 3 , characterized in that the concave lens ( 81 , 91 ) is made of polymethylmethacrylate or epoxy material .
the blood collection set of any one of claims 1 to 4 , wherein said waste liquid bag ( 26 ) has a valve ( 33 ) in its interior to prevent counter@@ flow .
1-@@ aryl-@@ erg@@ in@@ yl-@@ urea derivatives , process for their preparation and their use as medicaments .
the agency ’ s committee for medicinal products for medicinal products for human use committee for medicinal products for medicinal products for medicinal products for for for for for for for for for for for for for for for for for medicinal products for for for for for for for for for for for for for medicinal products
a process according to claim 10 or 11 , wherein the oxidizing agent is aqueous iodine , n-@@ chloro@@ succinimide , n-@@ bromo@@ succinimide or a salt of per@@ iodo@@ tic acid .
if your doctor has switched your doctor from your insulin or brand of insulin or brand of insulin of insulin to another of your insulin of insulin of insulin of type or brand of insulin of insulin of insulin of insulin of insulin of insulin of insulin .
meddra system organ class blood and lymphatic system disorders system organ class system organ class system organ class blood and blood class blood and blood class blood class blood and blood
the infusion pump ( 10 ) of claim 1 or 2 , wherein the means for automatically loading the tubing segment into the pump includes means ( 514 , 528 ) for holding the tubing segment and pulling it into the pump .
the internal surfaces ( 6a , 6b ) of the o.@@ g. opening ( 6 ) of the female element ( 2 ) are made of a special material which is made from a plastic paste and a glass material which makes it possible to have a high power to form the envelope of the capsule ( 5 ) to cut the cover of the capsule ( 5 ) by rotating the cutting element ( 2 ) .
a kit ( 2 ) according to claim 1 further including : a drug ( 32 ) which is suitable for systematic distribution effective to treat the diseased site ( 26 ) and locally fixed to the site ( 26 ) by prior distribution of the local setting agent ( 14 ) .
process for the preparation of chiral succinic acid derivatives for production of chiral succinic acid for the production of chiral succinic acid derivatives for the preparation of chiral succinic acid the preparation of chiral succinic acid of the preparation of chiral succinic acid of the preparation of chiral of the preparation of chiral of the preparation of chiral of the preparation of of the preparation of of the preparation of preparation of chiral of of the preparation of of preparation of of preparation of of preparation of of preparation of of preparation of of preparation of of preparation preparation
a dry powder inhaler pharmaceutical composition comprising a mixture of a pharmaceutically active agent and a particulate roller dried anhydrous β-@@ lactose .
claims for the following contracting states : at , be , ch , de , fr , gb , it , li , lu , nl , se the pyrro@@ les of the general formula wherein one of x and y is o and the other is o , s , ( h , oh ) or ( h , h ) and the other o , s , ( h , oh ) or ( h , h ) is a heterocyclic aromatic group of the formula : and one of x and y is a heterocyclic aromatic group
a method of producing a controlled-release solid oral dosage form comprising oxycodone hydrochloride , wherein the oxycodone hydrochloride is incorporated into a controlled release matrix , wherein the oxycodone hydrochloride is incorporated in a controlled release matrix , ( b ) , the granules comprising at least one water-soluble hydroxyalkyl cellulose and the oxycodone hydrochloride in the form of an hour , between 25 % and 75 % by weight of oxycodone hydrochloride and between 55 % and 85 % of oxycodone hydrochloride and between 55 % and 85 % by weight of oxycodone hydrochloride and the oxycodone hydrochloride and
the use of claim 14 , wherein the antiviral agent is selected from the group from the group consisting of nucleoside reverse transcriptase inhibitors , non-nucleoside reverse transcriptase inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors , inhibitors ,
adults and adolescents 12 years and above 10 mg once daily as once daily once daily as once daily as daily as once daily
secondary endpoints were histological response , alt normalisation and different parameters of antiviral activity .
arrangement according to claim 1 or 2 , characterized in that each whole body tanning device ( 1 , 2 , 5@@ 6-@@ 59 , 80 , 92 ) comprises a support element ( 11 ; 21 ) and at least one wall element ( 12 , 13 ; 22 , 23 ) and a ceiling element ( 14 , 13 ; 25 , 26 ) arranged parallel to the support element ( 11 ; 21 ) and that the at least one reinforcing element ( 15 ; 16 ; 25 ; 26 ) is arranged between the support element
universal virus inactivated plasma plasma derived from parts of plasma not derived from white blood cells
an expression plasmid for producing a heterologous protein in . the plasmid comprising : an expression plasmid according to claim 8 , comprising a translation stop codon in the same reading frame as the structural gene of the heterologous protein dna sequence , wherein the codon is located prior to the ds@@ re dal@@ gar@@ no sequence .
- if you have recently had severe injury , if you have recently had surgery had a have had you have have a have have had a recent had a had had a had had a had had had had had had had had a had had had had had had had had a had had a had had a had had a had had a had had a had had a had had had a had had a had a had had a had had had had had had had had had had had had had had had a
suction pump according to claim 1 , characterized in that the pump parts ( 1 , 10 , 18 , 6 , 8 , 8 , 6 , 6 , 6 , 6 , 6 , 6 , 6 , 8 ; 8 ; 6 ; 6 ; 6 ; 6 ; 6 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ; 8 ;
a compound according to claim 1 selected from the following : ( ± ) -7-@@ hydroxy@@ -3-phenyl-@@ 4- { 4- { 2- ( pyrrolidin-1-yl ) ethoxy } phenyl } chroman , ( ± ) - -7-@@ ( 4-fluorophenyl ) -4- ( 4- ( 2-@@ pyrrolidino@@ ethoxy ) phenyl ) -@@ chromane ( ( ( ( ( ( ( ( trifluoromethyl ) phenyl ) phenyl ) -3-phenyl-@@ chroman ( ( ( ( ( trifluoromethyl ) phenyl ) ) ) ) -3-phenyl-@@ chroman ( 4- ( trifluoromethyl ) phenyl ) ) ) ) ) ) ) ) ) ) ) ) )
device for postoperative fixation of a lateral colo@@ stomy .
the method of claim 7 of claim 7 wherein the polymeric solutions or emulsions are of either natural or synthetic or synthetic .
the mouth rinse solution contains , besides usual additives such as alcohol , sorbitol , detergents , sweeteners , flav@@ ours and colours 0.005 - 0.5 % by weight of triclosan and 0.01 - 2.0 % by weight amine fluoride .
screening and use of agents which inhibit or activate splicing of intein , using natural or homologous ex@@ t
an absorbent article having a front region ( 22 ) , a rear region ( 24 ) and a crotch portion ( 26 ) extending between the front region ( 22 ) and the rear region ( 24 ) , a body facing liner ( 30 ) , and c ) an absorbent composite core ( 34 ) according to any one of claims 1 to 15 disposed between the outer cover ( 32 ) and the bodyside liner .
k@@ 103@@ n substitution alone did not result in reduced susceptibility to rilpivirine in result in reduced in in vitro susceptibility to rilpivirine in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result in in result
plant system for comprehensive gene functional analysis using full-length cdna
the particles of the enzyme granules have a water content of less than 15 % by weight , especially in the range of 1 to 12 % by weight , particularly in the range of 1 to 12 % by weight , in particular in the range of 1 to 12 % by weight , and in particular from 3 to 10 % by weight , and in particular at least 70 % by weight , preferably at least 90 % by weight , and preferably at least 90 % by weight , and especially at least 90 % by
formulations according to claim 3 , characterized in that detergents and additives are tris-@@ hcl , edta , polyvinyl@@ pyrrolidones , ta@@ b , tri@@ ton@@ x-@@ 100 , n-@@ laur@@ yl-@@ sarcosine , sodium citrate , dt@@ t , sds and / or tween .
the dna molecule of any one of claims 1-10 , wherein the radiation responsive promoter enhancer comprises 1@@ 205 nucleotides or less .
use of an effective amount of the recombinant vector of claim 4 for the preparation of a composition for modulating the cellular effects of vegf in a mammal .
patients were distributed to two groups .
propa@@ fen@@ one and f@@ lec@@ ain@@ ide ) and metoprolol .
there may be an increase in thyroid tissue or metastases following treatment with thyrogen .
the full epar for mixtard can be found on the agency ’ s website ’ on the agency ’ s website : ema.europa.eu / find ’ s ’ s ’ s ’ s website : ema.europa.eu s website : ema.europa.eu : s : s :
electro@@ therapy device according to claim 1 , characterized in that the evaluation unit is designed to form the reference signal path by averaging the reference signal path from several impedance or conductivity signals .
method for determining the rate of depletion of viruses and / or pathogenic material in organic preparations , characterized in that a sample of the material with viruses of the group le@@ vi@@ iri@@ dae is introduced as test virus , and the sample determines the number of viruses provided and the number of viruses is determined and the number of viruses determines therefrom , and the decrease in the virus level .
if the level of methotrexate is &gt; 0.5 µmol / l , the dose of calcium fol@@ inate should be adjusted as follows :
there is no evidence that an interaction between ketoconazole h@@ ra and other steroid inhibitors ( i.e.
the dispersion of stabilized collagen fibers of claim 2 wherein the water soluble or water miscible polymeric material is selected from the group selected from selected from the group selected from the group the group selected from the group the group the group the group the the group the the group the the the the the the the the the the the group the the the the the the the the the group the the the the the the the the group the the the the the the the the the group the the the the the the the the
cephalosporin compound , process for its preparation and preparation for the prevention and treatment of bacterial infectious diseases .
a method according to any one of claims 13 to 24 , wherein the beginning and end of the compression event is obtained either by locating samples minimum amplitude , or by using a separate signal which is derived from a transducer responsive to an angular position of a rotary re@@ vola@@ sal head .
1 . a guide catheter ( 10 ) having a distal portion and a proximal portion ( 10a ) having a distal portion ( 18 ) having a distal portion ( 10b ) having a proximal portion having a proximal portion portion ( a ) having a proximal portion ( a ) a proximal a a a a a proximal portion a a proximal portion a proximal proximal portion a proximal proximal portion a proximal proximal portion a proximal proximal portion proximal a proximal proximal portion proximal proximal portion proximal proximal portion proximal proximal portion proximal proximal portion proximal proximal
use of the composition of claim 1 for the manufacture of a medicament for inducing the formation or maintenance of cartilage tissue in a patient .
patients who completed 14@@ 4-week treatment in one of the treatment arms gs-@@ 01-@@ 9@@ 34 could be switched to a non-@@ blinded extension phase of the study with atripla on an empty stomach .
the immunogenic composition of any of claims 6 to 11 , wherein said lymphocytes comprise a cell that has been genetically engineered to express a cytokine at an elevated concentration of an increased level . the immunogenic composition of any one of claims 6 to 11 , wherein said lymphocytes comprise a cell of which of a cytokine of increased concentration of a cytokine of any one of claims 6 to 11 of said lymphocytes of any one of claims 6 to 11 of any one of claims of any one of claims 6 to 11 .
a purified protein according to claim 2 or 3 or purified protein fragment according to claim 4 , wherein the fragment is capable of being bound by an antibody specific for human notch .
1 sterile polypropylene bag in a foil package containing in a compartment ( 50 ml ) vfend solvent for solution for infusion
the aqueous suspension of claim 1 , wherein the high molecular weight surfactant component has an average molecular weight of 1800 to 1,000,000 and the low molecular weight surfactant component has an average molecular weight of 100 to 1100 .
a vul@@ cani@@ zable polysiloxane composition according to claim 1 or 2 , wherein the condensation catalyst amount is in the range of 0.25 to 2.5 , preferably 0.25 to 1.25 , more preferably 0.50 to 1.0 parts by weight catalyst per 100 parts by weight of the vul@@ cani@@ zable polysiloxane or of the mixture thereof .
however , the chemical and physical in-use stability of the reconstituted solution has been demonstrated for 48 hours at a temperature of 30 ° c. the reconstituted solution and physical and physical in-use stability and physical and physical in-use stability of the reconstituted solution has been demonstrated for 48 hours at a temperature of 30 ° c for 48 hours , but the chemical and physical in-use stability of the reconstituted solution has been demonstrated for 48 hours .
use according to claim 8 for the preparation of a pharmaceutical composition for tumour treatment , especially for the treatment of liver , lung and colon tumors .
method for treating men with testosterone supplement and alpha-@@ reductase inhibitors
an apparatus according to claim 18 , characterized in that it comprises a carrier delivery device ( 32 , 103 , 334 ) for supplying a layered carrier to the former , and wherein the shaping device , in operation , forms a plurality of discrete w@@ ats on the support ; wherein the stabilizing and connecting means are formed on the support , and the support and connecting device are formed by the carrier , and the sub@@ dividing device divides the carrier to separate each wa@@ d and its associated portion of the carrier from the other .
6,11-dihydro@@ -11-@@ oxo-@@ dibenz ( b , e ) oxep@@ ines , process for their preparation , pharmaceutical composition containing them and their use as medicines .
atherectomy or thro@@ mbe@@ ctomy device according to claim 1 , characterized in that it comprises a rigid guide wire ( 12 ) which can be placed into the tube ( 2 ) .
the conjugate of claim 1 of the formula transdermal pharmaceutical composition useful for treating impotence in men comprising a physiologically effective amount of a conjugate according to any one of claims 1 to 7 combined with a pharmaceutically acceptable carrier .
a recombinant bacterial cell containing a plasmid according to any one of claims 6 to 13 .
the use according to claim 38 , wherein the second compound is an hmg-coa reductase inhibitor or a mt@@ p / apo b / apo b secretion inhibitor or a mt@@ p or apo / apo b / apo / apo / apo b / apo / apo inhibitor inhibitor or inhibitor or a mt@@ p / apo b / apo b / apo inhibitor inhibitor or a inhibitor or a inhibitor or inhibitor . inhibitor or a inhibitor or a inhibitor or . or inhibitor or inhibitor or inhibitor or or inhibitor or inhibitor . . . .
the dosage form of claim 1 , wherein said second semi-solid has a viscosity of 900 to 1,000 k@@ gm -1 s -1 ( 9@@ 0.000 to 1,000,000 centipoise ) at 25 ° c , a defoaming time of less than 8 seconds , and an injection capacity of less than 0.5 grams .
a compound according to claim 6 , wherein the compound is thre@@ o-@@ 3-hydroxy@@ -5-@@ guanidino-@@ 2- ( 2-oxo-@@ azetidin-1-yl ) -@@ pentanoic acid .
effects of lansoprazole on other active substances
use of a composition as defined in any one of claims 1 to 47 for the preparation of a product for cosmetic treatment of the skin , lips and hair , in particular for protecting and / or caring for the skin , lips and / or hair and / or as make-up product for the skin and / or lips .
we conclude that , after optimi@@ sation of the suspension technique , the osse@@ al screw fixation can provide an option option for anchorage .
hycamtin was as effective as an infusion in the same way as hycamtin .
this indication was approved for both tablets and the intravenous formulation except one in all member states .
cuff , for example for generating and maintaining fluid and gas zones in certain areas of the body .
the use according to claim 1 , characterized in that the cellulose ether is an alkyl hydroxyalkyl@@ cellulose . use according to claim 1 , characterized in that the cellulose ether is an alkyl hydroxyalkyl@@ cellulose , the cellulose ether is an alkyl alkyl cellulose .
a method for identifying the effect of an agent which is mutagenic , toxic or promoting for the metabolism of cells of the alimentary tract which comprises act in vitro ( 1 ) to a culture which is in vitro or to react with such a culture , or to contact with such a culture , and ( 2 ) the effects of said agent on said cell line .
an agent for prophylactic and / or therapeutic treatment of a complication of diabetes which comprises the condensed purine derivative or a pharmacologically acceptable salt thereof as claimed in any one of claims 1 to 9 according to one of the one claims 1 to 9 to an active ingredient to the active ingredient to any of the active ingredient to an active ingredient .
stick preparations according to claim 1 , characterized in that the core phase is 15 - 40 % by weight and the shell phase contains less than 18 % by weight of an antiperspirant , a@@ stringent salt , the concentration in the core phase being at least 30 % higher relative to the concentration in the shell phase .
enzymes bound to a solid support .
a dna construct according to any one of claims 1 or 2 , characterized in that it comprises a second promoter regulatable in other way than the first promoter .
use of a pharmaceutical composition according to any one of claims 1 to 22 and 28 for the manufacture of a medicament for treating cancer in a mammal , including a human , either as a single agent or in combination with other therapies .
tubular ureter splint from an elastic material , in particular plastic , which is located in its use with one of its two ends ( 2 , 3 ) in the kidney and with its other end ( 3 ) located in the bladder , and with its other end ( 3 ) in the bladder , a tube ( 6 ) which is arranged in the bladder and with its other end ( 3 ) in the bladder , a tube ( 6 ) which is arranged in the bladder and at least in its cross-section , a tube
use of 1,4-@@ benzothiazepine derivatives as medicaments for over@@ coming tolerance to carcino@@ tics
studies in pregnant rats and rats in pregnant rats and rats in rats rats in rats rats and rats in pregnant rats and rats in rats rats rats and rats in rats rats and rats rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats and rats rats
the assembly of claim 5 , wherein the second layer is deposited by radio frequency discharge , directional beam deposition , double ion deposition , hat@@ ching , plasma-@@ enhanced chemical vapor deposition or magnetically enhanced plasma systems .
the feed additive according to any one of the preceding claims , wherein the acidic salt of the basic amino acid is a salt of at least one basic amino acid selected from the group consisting of lysine , arginine , histidine , hydrox@@ ylysine and ornithine with at least one acid selected from the group consisting of hydrochloric acid , phosphoric acid , nitric acid and acetic acid .
an apparatus according to claim 1 , further comprising sound control means ( 140 ) for positioning the plunger support member ( 101 , 102 ) at the pre-@@ position before the end of the needle .
system for detecting leak sites and occlu@@ sions in a cryo@@ ablation catheter
the method of claim 16 , further comprising hydrolyzing or carboxy@@ lating poly ( lactic acid ) to obtain the derivative of poly ( lactic acid ) .
use of aryl oxi@@ mes for the prophylaxis and / or treatment of erythema and / or inflammatory reactions of the skin
follow carefully the instructions carefully to reach the full benefit of ali@@ sa@@ de .
powder for concentrate for solution for infusion
a : as responders patients with undetectable hcv rna 24 weeks after treatment end .
an endodontic device according to claim 1 , wherein : the excitation light ( 44 ) generated by the light source ( 42 ) is a light having a narrow bandwidth having a wavelength of between 250 and 450 nanometers ; and the predetermined wavelength bands associated with the plurality of electrical signals are within a wavelength range which is between 50 and 250 nanometers longer than the wavelength of the excitation light with close bandwidth .
a method for producing a disc prosthesis which has in vivo an outer surface contour which is substantially the same as that of a natural intervertebral disc , comprising : ( a ) a plurality of biologically compatible and bioabsorbable fibers having the steps of : ( a ) the steps of : ( a ) applying a plurality of biologically compatible and bioabsorbable fibers into a mold , said mold comprising the step of : ( a ) applying a plurality of biologically compatible and bioabsorbable fibers into a mold , said mold comprising the step of : (
nitrogen donors for the treatment of disease and injury
composition according to any one of the preceding claims , characterized in that the the composition of one of the preceding claims , of the the preceding claims , of the the composition , of the the preceding claims , of the , of the claims , of the preceding claims , of the , of the the preceding claims , of the , of the , of the claims , of the claims , of the claims , of the claims , of the claims , of the preceding claims , of the claims , of the claims ,
a compound of claim 18 wherein r 5 is hydrogen and r 6 is c 1 -c 6 alkyl or c 1 -c 6 c 1 -c 6 alkyl 6 -c 6 alkyl 6 -c 6 6 -c 6 alkyl 6 6 6 -c 6 6 -c 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
the method of claim 21 , and wherein the step of providing the hair separation means ( 22 ; 138 ; 214 , 218 ; 238 , 244 ) comprises the step of providing a hair separator ( 22 ; 138 ; 214 , 218 ; 238 , 244 ) which comprises a generally elongate base ( 20 ; 138 ; 238 ) , which comprises a generally elongate base ( 20 ; 138 ; 238 ) , which comprises a generally elongate base ( 20 ; 138 ; 238 ) having a generally elongate base ( 20 ; 144
a drug delivery system according to one or more of the preceding claims , wherein the active ingredient is a hormone , a growth factor , an enzyme , an antibiotic or a combination of two or more of these substances .
it is used in children with a very rare in children with a very rare with a very rare a very rare a very very a very very a very very a very very a very very a very very a very very a very very a very very a very very a very very very a very very very a very very very very a very very very very a very very very very very a very very very very very very a very very very very very very very very very very very very very very very very
the composition of any of claims 1 to 9 of the phospholipid of any of claims of of of claims of of of claims of of of claims of of of claims of of of claims of of of claims of of of claims of of of claims of of of claims of of of claims of of of claims of of of claims of of of claims of of claims of of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of
no dose adjustment is necessary for antiepileptic medicinal products , including cyp3a4 inducers .
what benefit has by@@ du@@ re@@ on shown during the studies ?
an integrated structure ( 1 ) for detecting physiological signals comprising a tissue ( 2 ) consisting of conductive fibers and non@@ conductive fibers , a plurality of electrodes ( 5 ) having a plurality of electrodes ( 5 ) provided with the conductive fibers ; a plurality of electrodes ( 5 ) which are provided with a plurality of conductive fibers ( 5 ) , which are provided with a plurality of conductive fibers ( 5 ) , which are provided with a plurality of conductive fibers ( 5 ) , which are provided with a plurality of conductive
composition according to any one of claims 5 to 13 , characterized in that the polymer with a non-silicone organic backbone grafted with poly@@ siloxane@@ -containing monomers has a number average molecular weight of 10,000 to 2,000 000 and a glass transition temperature t m or a crystalline melting temperature t m or a crystalline melting temperature t m of at least -20 ° c. the composition of any one of claims 1 to 4 having the groups which can react with the reactive end group of the polysiloxane macromer to form a covalent bond which can react with the
at the time of the eu ra@@ r ( 2010 ) to zinc , there was too few effect or exposure data to account for the effects of these two parameters ( av@@ s / medium ) on the bioavailability of zinc .
a device according to claim 1 , characterised in that the cylindrical container ( 1 ) closed with the seal ( 87 ) is connected to a cylindrical container ( 1 ) formed from a u-shaped housing ( 67 ) , an axial contact contact ( 68 ) , a radial contact ( 88 ) between the gas developing cell ( 8 ) and the stopper ( 68 ; 88 ) and that the piston ( 6 ) is further electrically connected to a permanent magnet ( 73 ) acting on the coil ( 70 ) .
human voltage-@@ gated calcium channel splice variants with alpha@@ 2@@ delta@@ 2-@@ a or alpha@@ 2@@ delta@@ 2-@@ b
a method of amplifying a nucleic acid having a target sequence comprising a target sequence a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
a pharmaceutical formulation comprising as an active ingredient a compound of formula i , or a pharmaceutically acceptable salt thereof , as claimed in any one of claims 1 to 4 together with one or more pharmaceutically acceptable carriers therefor .
use of a medicament according to claim 6 for the treatment and / or prophylaxis of disorders of perception , concentration , learning and / or memory and / or memory or memory or memory or memory or memory or memory .
device according to one of claims 1-15 , characterized in that a synchroni@@ sation unit ( 38 ) for synchroni@@ sation of the analysis unit ( 32 ) is arranged so as to always determine the catheter positions in the same phase of the cardiac cycle .
use of a compound of any of claims 1 to 10 , or of a tautomer , ester , amide , solvate , or salt thereof , for the preparation of a pharmaceutical composition , , to treat a disease , characterised by , inflammatory , allergic , , , , , , , , , , , , , , inflammatory , allergic , , , , proliferative , , , , , , , , , , , , , , inflammatory , allergic , , , , , , , , , , , , , ,
the process of any one of claims 12 to 15 wherein the amount of alkanol , water of , of oil phase , of the of claims of one of the claims , of the alkanol , water of of water , of the of of the of any of of the of claims of of claims of 12 , of the of of of claims of of claims of of of claims of of of claims of of of one of claims of of of claims of of of claims of of of claims of of of claims of
the dic@@ t@@ yo@@ st@@ ide strain of claim 16 comprising a recombinant dna molecule according to claim 13 and expresses an enzymatically active protein .
the use of claim 1 or 2 , wherein the medicament is to be administered to directly contact the surface of a tumor cell .
use according to claim 1 , wherein the cyclic hi@@ hi@@ per is obtained from a soybean protein hydrolysate which is for cyclic hi@@ hi@@ pro enriched .
the apparatus of claim 11 further comprising : a fourth bypass valve ( 62 ) adjacent the post treatment section ( 18 ) effective in disinfecting mode to return output fluid or output fluid flowing through the output short disruption ( 54 ) to the post treatment section ( 18 ) .
a compound according to claim 1 which is characterized by the following formula : wherein r 2 is h or br ; s is 1 or 2 ; r 3 is h or ch 3 and r 8 is h or lower alkyl of 1 to 6 carbons or a pharmaceutically acceptable salt of the compound .
stent and method for the production of a stent and a method of making a stent a stent a a stent a a stent a a stent a a stent and a method of making a stent a stent a a stent a a stent a a stent a stent a a stent a a stent a a stent a a stent a stent a a stent a stent a a stent a stent a a stent a stent a stent a a a a stent a a stent a stent a a a a stent a a stent
take special care with cialis take special care with cialis special care with care should be taken with special care with care with care with cialis with care with care with care with care with care with care with care with care .
a risk to the breast-@@ fed newborns cannot be excluded . the infant cannot be excluded to be excluded . risk to the the fed infant cannot be excluded .
a blood sampling device according to one of claims 1 to 5 , characterised in that a centrifuge insert ( 58 ) is provided which has a receptacle for the cannula lug ( 17 ) containing a pierceable membrane ( 18 ) , in which a pin ( 64 ) for supporting the membrane ( 18 ) is arranged in the receptacle .
pre@@ cancerous lesions ( grow@@ ths ) and cervix , vul@@ var , vaginal and anal carcinomas ;
opaque white hdpe bottles containing 14 , 30 , 60 and 90 hard capsules .
a method according to any of claims 6 to 12 , wherein step ( b ) is repeated once prior to the birth of the dam@@ p . the process according to any one of claims 6 to 12 wherein step ( b ) step ( b ) is repeated of one step ( b ) of step ( b ) .
a compound of the formula wherein : r ₁ is hydrogen , optionally substituted by hydroxy or branched alkyl having from 1 to 4 carbon atoms ; optionally substituted by hydroxy or branched alkyl having 1 to 4 carbon atoms ; optionally substituted by hydroxy or branched alkyl having 1 to 4 carbon atoms ; optionally substituted by hydroxy or branched alkyl having 1 to 4 carbon atoms ; or alkenyl having 1 to 4 carbon atoms ; or alkenyl having 1 to 4 carbon atoms ; or wherein r is substituted by hydroxy or branched having 1 to 4
the process of claim 9 wherein : ( a ) the reaction with the acylating agent is carried out at about 0 to 45 ° c and a weight ratio of acylating agent to wet tissue of from about 0.005 to 0.5 : 1 , wherein the ph of the aqueous medium is carried out at about 7 to 11 and ( b ) the reaction with the esterifying agent is carried out at about 0 to 45 ° c and a weight ratio of esterifying agent to dry tissue of from about 1 to 30 : 1 in a
an oil / fat composition according to any one of claims 1 to 3 having a po@@ v of 1 or less , having a colour ( 10@@ r + y ) of 20 or less and 53 to 8@@ 4.9 % by weight of the triglyceride , from 0.1 to 1.5 % by weight of the triglyceride , from 0.1 to 1.5 % by weight of the triglyceride , from 15 to 1.5 % by weight of the triglyceride , from 15 to 10 % by weight of an unsaturated fatty acid ; and from 70 to 100 weight
no statistically significant or clinically relevant cardiovascular effect was observed in a multiple-dose clinical trial in which desloratadine was administered in a dose up to 20 mg was administered was was administered was was administered was was administered to a was was administered was was administered was was was administered was was administered was was administered was was administered was was was administered was was administered was was administered was was was administered was was administered was was administered was was administered was was was administered was was administered was was administered was was was administered was was administered was
identification of a suppressor of an athero@@ genic apolipoprotein .
use of a g@@ se according to claim 1 to impart etoposide resistance to a eukaryotic cell in vitro .
two weeks after treatment end , leuko@@ cytosis and moderate bleeding were observed at the injection and infusion sites considered possibly related to peg@@ vi@@ som@@ ant .
( 1 h ) , days 28-@@ 31 , 35-@@ 38 , 42-@@ 45 ; 6-@@ mp 60 mg / m2 oral , days 26-@@ 46 dex 10 mg / m2 oral , days 1-5 , vin@@ des@@ in 3 mg / m2 , / m2 / m2 / m2 oral , m2 / m2 oral / m2 / m2 oral , m2 / m2 / m2 oral / m2 oral , m2 / m2 oral m2 oral m2 oral m2 / m2 oral m2 oral m2 m2 oral m2 oral m2 oral m2 oral m2 m2 oral m2 oral
use according to any one of the preceding claims , wherein each number of dosage units consists of 3 dosage units .
a compound of claim 6 or claim 8 wherein both r 4 and r 5 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r 4 r
a moulded cover member according to any of claims 11 to 13 , wherein the cover member member is vacuum shaped . a shaped cover member according to any one of claims 11 to 13 wherein the cover member member member is vacuum moulded . member according to claims 11 to 13 wherein the cover member member member member member member member member member member member member member member member member member being vacuum shaped .
a method according to claim 4 comprising determining the level of expression of the reporter gene in the presence of the test compound or absence of said compound , wherein an increase or decrease of the expression level of the reporter gene indicates the likelihood of the test compound to modulate reverse cholesterol transport .
polypeptide and prepared against hiv active substances .
treatment of unstable angina pectoris and non-@@ st segment myocardial infarction ( n@@ ste@@ mi ) in combination with acetylsalicylic acid ( asa ) .
≥ 12 to &lt; 18 years , n ( % ) ≥ 18 years , n ( % ) mean change from baseline at baseline ( sd ) mean change from day 28 to baseline , mean change from baseline in day 28 ; itt = in@@ tent to tre@@ at ( all randomised patients ) ; p = p-value ; sd = standard de@@ vit@@ ation ( standard deviation ) ; p = p-value ; sd = standard de@@ vi@@ ation ( sd ) ; p = p-value ; sd = standard de@@ vit@@ ation ( sd ) ;
the method of claim 68 , wherein the compound of the compound of claim , wherein the compound of the compound the compound of the compound the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of the compound of compound of compound compound of compound compound of compound compound of compound compound of compound compound of compound compound of compound compound of compound compound of compound compound of compound compound of compound compound of compound compound of
a support device according to claim 6 or claim 7 , further comprising : means ( 204 ) means means ( 204 ) comprising : means ( 204 ) ( 204 ) means ( 204 ) for means ( 204 ) ) for ) means ( 204 ) ) for ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) comprising : means ( 204 ) for means ( 204 ) ) for ) ) for ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )
pvc / aluminium blisters in packs of 2 , 10 , 14 , 20 , 28 , 30 , 50 , 56 and 100 film-coated tablets or pvc / aluminium blisters in packs of 10@@ x1 , 14@@ x1 , 28@@ x1 , 30@@ x1 , 56@@ x1 and 100@@ x1 film-coated tablets as single dose .
a device for calculating coordinate data of a desired point in an object ( 40a ) to be examined using a frame ( 20 &apos; ) , which has a form ( 20 &apos; ) , which is in the form of a frame ( 20 &apos; ) , which is in the form of a frame ( 20 &apos; ) which makes it possible to hold the object ( 40a ) in the interior and which is in a photo@@ graphical region in a frame of a computer tomograph , and a coordinate system ( 20 ) which is
the metabolism of rasagiline is two major pathways :
a pharmaceutical composition comprising a ) a pharmaceutically acceptable carrier or diluent and b ) a conjugate compound according to claim 1 . use of a conjugate compound according to claim 1 for the manufacture of a medicament for treating an individual with diagnosis or suspected for a metastatic colorectal carcinoma .
an apparatus according to claim 8 , wherein at least one inner surface of the first or second strip comprises adhesive means , and the inner surfaces are fixedly bonded to each other at intervals between the cartridge portions ( 24 ) , or the first and second films are heated together to remain firmly in the relative direction to maintain the syringes ( 22 ) at the relative orientation ; or the first and second stripes are transparent .
use of the dental compositions according to one of claims 1 to 15 as dental impression materials .
lipid nanoparticles according to claim 3 , characterized in that the cosurfactant is selected from the group consisting of butanol , butyric acid , hexanoic acid , sodium cholate , sodium tauro@@ cholate or sodium glyco@@ cholate .
the oligonucleotide of the formula the of the formula the the oligonucleotide of the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
method for producing a gra@@ ded coating of calcium phosphate phases and metal oxide phases on metallic implants
10 . the bone cement of claim 7 , wherein the emulsifier is sodium di@@ hexyl@@ sulfosuccinate .
a combinatorial library comprising chemical compounds or compounds comprising a chemical comprising chemical compounds comprising chemical compounds comprising chemical compounds comprising chemical compounds comprising chemical compounds comprising chemical compounds comprising chemical compounds comprising chemical compounds comprising chemical compounds comprising chemical compounds comprising chemical compounds comprising chemical chemical chemical chemical chemical chemical chemical chemical chemical chemical chemical chemical chemical chemical chemical chemical chemical chemical comprising chemical chemical chemical chemical chemical chemical chemical comprising chemical chemical chemical chemical chemical chemical comprising chemical chemical chemical chemical chemical chemical comprising chemical chemical chemical chemical chemical chemical comprising chemical chemical chemical chemical chemical chemical comprising
appropriate procedures for the handling and disposal of antineoplastic medicinal products are to be used and appropriate caution should be exercised when handling and disposal and disposal and disposal of medicinal products and disposal of anticancer medicinal products and handling and disposal and disposal of cytotoxic medicinal products and appropriate disposal and disposal of anti-tumour medicinal products and appropriate disposal and disposal of anti-tumour medicinal products .
use of a peptide compound having 5 to 15 amino acids , which comprises an amino acid sequence selected from the group consisting of the d@@ kel@@ ri , d@@ well ri y@@ ae@@ fr@@ g , ae@@ fr@@ fr@@ g , dy@@ e@@ fr@@ g , dr@@ the , fr@@ fr@@ g , eye@@ fr@@ g , d@@ we@@ fr@@ , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
what is in this leaflet 1 . this leaflet is in this leaflet in this leaflet in this leaflet in this leaflet in this leaflet in this leaflet in this leaflet in this leaflet in this leaflet
an article according to claim 5 , characterized in that the lubricating layer ( 9 ) contains from 0 % to 30 % by weight polyurethane , from 1 % to 40 % by weight polyacrylate , from 1 % to 20 % by weight of polysiloxane , from 0 % to 40 % by weight of fillers .
dye composition intended to be used for dyeing keratin fibres and in particular human keratin fibres , characterized in that it comprises , in a medium suitable for dyeing , at least one indoline represented by the following formula : in which , in a medium suitable for dyeing , at least one indoline of the following formula : in which : the radicals r and r are at least one indoline , c denotes an oxygen atom or a sulfur atom , in which the indoline is present in the composition in proportions of 0.01 to 8 % by
the process of claim 7 , wherein the organic solvent is a hydrocarbon . a the method of claim 7 wherein the organic solvent is a hydrocarbon .
the first vaccination will be carried out at an elec@@ ted date , both of which are 1 and 1 , respectively .
a process for producing fragment c of tetanus toxin which comprises culturing a transformed yeast organism according to any one of claims 8 to 10 and recovering the fragment c expressed in this manner .
a dispenser according to any one of claims 1 to 5 , wherein the reservoir housing is connected to the tubing for a dental stone removal device .
the method of claim 27 , wherein the amino acid is selected from the group consisting of arginine , lysine , histidine , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
compound of formula ( i ) of formula ( i ) ( of i ) i ( i ) ) i ( i ) i i ( i ) i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
aranesp 150 micrograms solution for injection in a pre-filled pen solution for injection solution for injection for injection solution for injection in a pre-filled pen in a pre-filled pen in a in a in in a in in a in in a in in a in in a in
computer tomographic apparatus and method for reconstructing an object cross-sectional image .
if you do not open , crush , or chew the capsules , do not open , crush , chew or chew the capsules . , do not open , crush , chew or chew , or chew , or chew , or chew , or chew , do not open , chew or chew , or chew , or chew , or chew , or chew or chew or chew or chew or chew or chew or chew or chew or chew or chew the capsules .
insuman comb 30 must not be administered intravenously or administered in infusion pumps or external or implanted insulin pumps .
absorbent article according to claim 1 , wherein said adhesive members ( 5 ) run in continuous lines or non-@@ continuous lines with arcuate portions and / or cal@@ ds .
the duration of treatment depends on the patient ’ s response to treatment .
always take this medicine exactly as this medicine is exactly as this medicine has been prescribed for your medicine .
if bleeding occurs , treatment should be considered in the clinic .
the method according to any one of claims 8 to 10 , characterized in that said base ( 31 ) is a wire ( 31 ) ( 31 ) is a superelastic alloy wire ( 31 ) ( 31 ) , ( 31 ) , ( 31 ) ) .
antibodies directed against pro@@ calcitonin , their preparation and use
within each frequency grouping , undesirable effects are presented in order of decreasing in order of order of in order of order in order of order in order of order of order of of order of of order of of of of of decreasing of order of order of order of of of of of of of of decreasing order of order of of of of order of order of of of of order of order of order of order of of of of order of order of order of order of of order of order of order of of
the assembly of claim 13 , wherein the tensioning member ( 56 ) in the spring housing ( 44 ) and / or the stop member ( 40 ) is compressed in a first length of the spring housing ( 44 ) and the stop member ( 40 ) and in a second length larger than the first length is substantially not compressed .
a vaccine for immunizing a mammal against infection with s . pyogenes , comprising an amount of purified s. pyogenes dnase b enzyme sufficient to stimulate antibodies for s. pyogenes dnase b , wherein the purified s . pyogenes dnase b enzyme is encoded by the dna sequence of claim 1 .
gas filling / gas discharge system and closure system with compression closing mechanism for guidewire assembly with closing element
danmark am@@ gen fili@@ al af ab , sverige tlf : + 45 39@@ 6@@ 17@@ 500
use of oxiran@@ e-@@ carboxylic acids of the formula i according to claim 1 , in which r1 is meta or para@@ dentate and r1 denotes a hydrogen atom , a chlorine atom or a trifluoromethyl group , r2 denotes a hydrogen atom , r3 denotes a hydrogen atom , and n denotes an integer of 4 to 6 and n denotes an integer of 4 to 6 and the pharmaceutically acceptable salts of the carboxylic acids .
an implant according to claim 5 , characterised in that the pharmacological agent is a growth factor . a the implant according to claim 5 , wherein the pharmacological agent is a growth factor . a growth factor is a growth factor . a growth factor .
agent stabilized with protein , process for its preparation and method of use
aza-@@ bridged bicyclic amino acid derivatives for use as antagonists of alpha@@ 4-@@ integrin
the vaccine of claim 35 , wherein the tk ⁺ host cells are r@@ ab@@ 9 .
the compound of claim 22 wherein r 29 and r 46 are r , independently , r and r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r
lev@@ vi@@ ax 400 mg film-coated tablets telithromycin 400 mg film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated tablets film-coated
scientific conclusions and grounds for amendment of the summaries of product characteristics of the summaries of product characteristics of of the summaries of product of of the of of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of
zonegran orodispersible tablet should be placed into the mouth on the tongue where it rapidly disintegra@@ tes in saliva .
nonwoven absorbent article and process for producing the same . the absorbent article and method for producing the same in the same process for making the method for producing the same and method for making same for making same for making the same the same for the method for the the same for the same
denatured recombinant fusion proteins are used in the presence of a heat shock protein which acts after the functional principle of the bacterial gro@@ el or the equivalent porphy@@ chondro@@ idal component hsp@@ 60 , and of atp is folded correctly .
method for producing active bone ce@@ ments containing active substances containing active active substances , containing active substances containing active substances containing active substances containing active active substances containing active substances containing active ingredients containing active active substances containing active active substances containing active active substances containing active active substances containing active active active substances containing active active active substances containing active active active substances containing active active active ingredients containing active active active substances containing active active active active active containing active active active active active containing active active active active containing active active active active ingredients
the electrochemical cell of any one of claims 1 to 3 , wherein the phosphate additive is di@@ benzyl@@ phosphate present in the electrolyte at a concentration of up to about 0.20 m .
you must not breast-feed the treatment with xeloda .
a transformant wherein a host cell selected from the group consisting of escherichia coli , cultured insect cells and cultured animal cells is transformed with a recombinant vector according to claim 10 .
a single chain avidin according to claim 16 , characterized in that the linker is a 12 amino acid residue g@@ gs@@ g@@ sg@@ gs .
the controlled release oxycodone formulation of claim 1 or 2 comprising from 10 mg to 40 mg of oxycodone salt , wherein said formulation provides a mean maximum plasma concentration of oxycodone of 6 to 60 ng / ml to a mean maximum maximum plasma concentration of oxycodone of 6 to 60 ng / ml and a mean minimum plasma concentration of 3 to 30 ng / ml of maximum of 10 to 14 ng / ml of maximum plasma concentration of 3 to 14 ng / ml of of oxycodone of oxycodone of 10 hours .
rna interference mediated inhibition of gene expression of insulin-like growth factor type 1 ( igf-@@ r ) gene using short interfering nucleic acid ( sin@@ a ) ( short interfering nucleic acid ) nucleic acid nucleic acid interfering with short interfering nucleic acid acid nucleic acid ( nucleic acid ) nucleic acid ( nucleic acid ) nucleic acid interfering nucleic acid ( nucleic acid ) nucleic acid nucleic acid ( nucleic acid ) nucleic acid ( nucleic acid acid interfering nucleic acid acid nucleic acid acid nucleic acid acid acid ( nucleic acid ) acid
the connector of claim 2 , wherein each of the gripping members ( 60a , 60@@ b ) has a grip edge ( 6@@ 4a , 6@@ 4b ) at one end and a handle ( 62a , 6@@ 2b ) at the other end .
powder for solution for infusion for solution for infusion for solution for for infusion
betaine acts as a methyl group donor in patients with homo@@ cyste@@ uria as a methyl group donor in homocysteine to methionine in the re@@ methylation group of homocysteine to be a methyl group of to methionine to methionine .
do not freeze keep the container in the original package in order to protect from light in order to protect in the original package in order to order in order to order in order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order to order
the use of claim 14 , wherein the cells are implanted at the site with the allograft or implant .
the vehicle of claim 1 , 2 , 3 or 4 wherein the polysaccharide is selected from the group consisting of methyl cellulose , ethyl cellulose , ethyl hydroxyethyl cellulose , hydroxypropyl cellulose , sodium carboxymethyl cellulose , hydroxypropylmethyl cellulose , ethyl methylcellulose , guar gum derivatives , xanthan gum , psyllium gum , alginate , locust bean gum , and mixtures thereof .
dispose of the syringe , needles and any unused solvent .
the use of claim 10 , wherein the poly@@ specific antibody comprises a plurality of determinants which specifically bind to the same or different epitopes of a tumor cells produced by the tumor cells or which bind to different antigens or antigens associated with the tumor cells .
the dna construct according to claim 1 , wherein the nucleotide construct according to the dna spacer sequence according to claim 1 to claim 1 to claim 1 to claim 1 to claim 1 to claim 1 to claim 1 claim claim 1 claim claim 1 claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim claim
therapeutic composition comprising poli@@ hex@@ ide for the treatment of ophthalmic , dermatological and irritable herpes zoster .
the method of claim 17 , 18 or 19 , wherein the aqueous solution , aqueous suspension or aqueous isotonic solution further comprises zinc ions and / or a buffer such as acetate or citrate and / or a preservative such as m-cresol , methyl paraben or phenol .
apparatus for post@@ stationary monitoring of a patient for detecting pneumonia , a bleeding , a wound healing disorder , a pulmonary complication , a urinary tract , or a patient a patient ( 1 ) , a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
a vial containing medication , for use as a syringe accessory , comprising : a tubular syringe barrel ( 1 ) , an end wall ( 3 ) that forms a permanently closed end of the drum ( 1 ) , the other end of the drum ( 1 ) , the other end of the drum defining a permanently closed end ( 2 ) , the other end of the drum ( 1 ) , the other end of the drum being a permanently closed end ( 2 ) , the other end of the drum ( 1 )
serum cholesterol and blood glucose were minimal to slightly increased in rats but not in mice or dogs .
kineret should not be used in patients with severe kidney problems in patients with severe kidney problems in patients with severe kidney problems in patients with severe kidney problems .
methods and compositions relating to polypeptides having rna@@ se-@@ iii domains which mediate rna interference
joint endoprosthesis according to claim 2 , characterised in that the inorganic composite component contains secondary phases in an amount of 5 - 20 ; preferably 8 to 15 % .
active substance : inactivated blue@@ tongue disease of serotype 1 ................................@@ ............@@ .. ≥ 1.9 log 10 pixels * ( * ) antigen content ( vp2 protein ) in immunoassay
the endoscopy illumination system according to claim 1 , wherein a ccd or c@@ mo@@ s camera mounted at the tip is detachably attached to the elongate member .
always make sure you always have a sufficient supply of norvir .
the connector of claim 1 wherein the second internal volume is the the the the the the the the the the the the the the second internal volume .
a medicament delivery device ( 10@@ 1,@@ 90@@ 1,@@ 100@@ 1,@@ 110@@ 1,@@ 120@@ 1,@@ 1@@ 301 ) according to claim 12 , wherein the piercing member ( 5@@ 53 ) is configured to engage the surface of the first membrane ( 552 ) facing the reservoir ( 166 ) on the first membrane ( 552 ) .
side effects may occur if you start to start treatment or if you have increased your dose , or if you have increased your dose , or if you have increased your dose , or if you have increased your dose , or if you have increased the dose , your dose may be increased or if you have increased your dose . • if you have increased your dose or when your dose is increased , your dose may be increased . increased dose may occur . your dose may be increased . increased dose .
the method of any one of claims 1 to 6 , wherein the biomolecule is an antimicrobial agent , an antimicrobial agent , an anticoagulant , an anti-@@ thrombotic agent , a platelet agent , an anti-inflammatory agent , an enzyme , a catalyst , a hormone , a dna segment , a nucleic acid , a dye , a dna segment , an rna segment , a protein , or a peptide .
an apparatus for detecting the reje@@ cting reactions following a heart transplantation , comprising sensing electrodes ( 1 ) , which are applied either at an endocardial or epicar@@ dial site of the heart , and a reference unit for comparison with a waveform or epicar@@ dial point of the heart , and a reference unit for comparison with a waveform or epicar@@ dial point of the heart , and a reference unit for comparison with a waveform or epicar@@ dial point of the heart , and a reference unit for comparison with a waveform or epicar@@ dial site ,
an injection device comprising a plurality of operating elements ( 8 , 3 , 5 , 4 ) for adjusting and injecting set medicament doses , signalling generators ( 11 , 12 , 13 , 14 ) , and an electronic circuit , which is connected to at least two of the operable elements ( 8 , 3 , 5 , 4 ) , and an electronic circuit which is connected to at least two of the operable elements ( 8 , 3 , 5 , 4 ) , and an electronic circuit which is connected to at least two
a nail varnish as claimed in claim 11 , wherein the plasticizer component comprises neopentyl benzoate . the nail varnish of claim 11 wherein the plasticizer component comprises neopentyl benzoate . the nail enamel of claim 11 wherein the plasticizer component comprises neopentyl benzoate . the nail enamel component wherein the plasticizer component comprises neopentyl benzoate . the nail enamel of claim 11 wherein the plasticizer component comprises the neopentyl benzoate .
the stent delivery system of claim 1 or 2 , wherein the retraction means comprises a pull wire ( 41 ) attached to the retractable distal sheath ( 14 , 16 ) , the retraction wire ( 41 ) being longitudinally movable , and the inner core comprises a spring winding .
the method of claim 12 , wherein the concentrate is acidified to a ph in the range of 6.0 to 7.0 .
the sole of claim 14 , wherein the layers ( 40@@ 1-4@@ 410 ) include layers of different fiber directions .
6.4 special precautions for storage special precautions for storage for special storage precautions for storage precautions for storage precautions for storage precautions for storage precautions for storage for for storage precautions for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage for for storage
process according to any one of the preceding claims , characterized in that the sugar is present at the beginning of the fermentation in the fermentation broth in the fermentation broth the the the the fermentation of the fermentation the the the the the the the the the the the the the the the the the the the the the the the fermentation the the fermentation the the fermentation the the fermentation the the fermentation the the fermentation the the fermentation fermentation the the fermentation fermentation the the fermentation fermentation fermentation fermentation fermentation fermentation fermentation fermentation fermentation fermentation fermentation the
infections and infestations laryngeal vascular disorders
the method of claim 7 wherein s1 and s2 are linked via a nucleotide linking group and s3 and s4 via a nucleotide linking group .
use of one or more compounds according to claim 1 or 2 as active ingredients for the preparation of pharmaceutical compositions for the treatment of disorders associated with a role of endothelin , especially circulatory disorders such as hypertension , ischaemia , vasospasm and angina pectoris , and proliferative disorders such as cancers .
in accordance with the risk management systems for medicinal products for human use for medicinal products for human for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for for medicinal products medicinal products for for for for for for for for for for for for for for for for for for for for for for for for for for for medicinal products for for for
the method of claim 8 , wherein the polyester plastic is selected from polyethylene terephthalate and the polymeric material is selected from the group consisting of polyethylene , urethane and amorphous polyethylene terephthalate .
a package assembly intended for the spontaneous preparation of suspensions or solutions of an active solid product in a liquid product , wherein each of said products is contained separately in a sealed vial , and wherein each of said products is contained separately in a hermetically sealed vial , and said two vial is contained separately in a hermetically sealed vial , and said two vials are contained in a sealed vial , and said two vial is contained separately in a sealed vial , and said two vial is contained separately in a sealed vial , and said
a process for the preparation of a compound of formula iii &quot; wherein r &apos; 23 , r &apos; 25 and r 10 are as defined in claim 3 and x &quot; are as defined in claim 3 in which r &apos; 23 are as defined in claim in in defined in as defined in claim in in defined in defined in defined in defined in defined in defined in defined in defined in defined in defined in defined in defined in defined in defined in defined in defined in defined in defined in defined in defined in defined in
vedo@@ lizumab is used to treat moderate to severe acute disease where conventional therapy or medication with tnf alpha antagonists have been shown to be effective or not tolerated by the patient .
composition according to claim 7 , which uses an mmp inhibitor selected from 4- ( 4 &apos; -chloro@@ biphenyl-4-yl ) -4-hydroxy@@ imino@@ butyric acid or 2- ( 4 &apos; -bromo@@ -biphenyl-4-@@ sulfonylamino ) -3-methyl@@ butyric acid .
the preparation form according to claim 2 , wherein the reducing agent is cys , n-acetyl-@@ cys , thio@@ glycerol , sodium sulfide or glutathione or mixtures thereof , optionally in the presence of a complexing agent .
ambulatory blood pressure measurements showed that the combination of 150 mg irbesartan and 12.5 mg irbesartan and irbesartan 12.5 mg and 12.5 mg 12.5 mg irbesartan and 12.5 mg irbesartan and irbesartan mg irbesartan mg and and 12.5 mg 12.5 mg mg and 12.5 mg mg mg mg and 12.5 mg and 12.5 mg and mg mg and 12.5 mg irbesartan and irbesartan and mg mg 12.5 mg irbesartan mg irbesartan mg mg and irbesartan mg mg and mg mg irbesartan irbesartan and mg irbesartan mg mg 12.5 mg mg mg 12.5 mg mg 12.5 mg irbesartan 12.5 mg mg
the surgical instrument of claim 3 , wherein the bias of the spring during movement of the connecting member assembly through the first and second stages allows movement of the connecting member assembly from the second stage to the third stage and thereby release the surgical fasteners .
careful monitoring of the therapeutic effects and adverse reactions of tricyclic antidepressants ( for example desipramine and nor@@ tryp@@ ti@@ line ) is recommended when agenerase is co-administered ( see section 4.4 ) .
nitro@@ loxy@@ ethyl apo@@ vinc@@ amine and pharmaceutically acceptable salts thereof .
process according to claim 1 , characterized in that the hair dye component additionally contains a primary intermediate of a hair dye , a hair dye coupler or a mixture thereof .
now each day is a gi@@ ft .
the catheter system of claim 5 , wherein the magnetically responsive element is a permanent magnet ( 50 ) having a long elongated cylindrical shape and planar pole surfaces ( 50a , 50b ) at its ends .
no dosage adjustment is necessary in patients with impaired hepatic function and in patients with mild to moderate renal impairment . patients with mild to moderate renal impairment to moderate renal impairment to moderate renal impairment to moderate renal impairment .
a pharmaceutical composition comprising as an active ingredient a pe@@ f-@@ derived bioactive product according to any one of claims 1 to 3 , 8 and 9 and a pharmaceutically acceptable carrier material , preferably in a weight ratio of between about 1 : 5 and 1 : 25 and most preferably between 1 : 9 and 1 : 19 , and the most preferably from 1 : 9 to 1 : 19 and 9 in an amount of 0.0@@ 1-10 % by weight , preferably 0.0@@ 5-@@ 1 % by weight , more preferably 0.05-@@ 0.1 % by weight
infections and infestations not known : infections and infestations uncommon : infection and infestations uncommon : infection and infestations uncommon : infection and infestations common : not known : common : not known : common : common : common : common : common : common : common : very common : common : common : common : common : common : common : common : common : common : common : common : common : common : common : common : common : common :
viruses for the treatment of cellular proliferative diseases
hair treatment composition according to claims 1 to 4 , characterized in that , in , , , , , , , , , , they contain 0.2 to 5 % , by weight , of d-@@ panthenol , 0.5 to 5 % by weight , by weight , by weight , by weight , of polyvinylpyrrolidone . 4 % to 4 % by weight , by weight , by weight , of 0.5 to 5 % by weight by weight . , in the form of , by weight , by weight .
a stereotactic frame according to claim 1 , characterised in that the adjustable fastening means and the means for locking the first disc ( 40 ) has a snap-@@ like retraction arm , which extends from the stationary mount member ( 32 ) .
substituted piperazine derivatives and their use as inhibitors of their derivatives of inhibitors of their use as inhibitors of inhibitors of their micro@@ somal and their use and their use and their use and their use and their use and their use their their use and their their their their use their their their their their their their their their use
a device according to claim 1 , characterised in that for deriving the synchronization signal from the electrocardiographic signals without time delay a non-@@ recur@@ sive predic@@ tor ( 5 ) for noise signals of the network frequency and their surface oscillations is used , the said signals being used by means of a non-@@ recur@@ sive predic@@ tor ( 5 ) for noise signals of the network frequency and their surface vibrations , said signals being used by determining the temporal location of the qrs ( chamber ) complex in the electrocardiographic signals , which are based on the
method and apparatus for needleless subcutaneous injections .
use according to claim 5 , in which the α-@@ hydroxycarboxylic acid is selected from glycolic , tartaric , lactic and mandelic acids .
an aortic graft according to claim 9 , wherein each of said graft members ( 80a , 80a ; 16@@ 0a , 16@@ 0b ) further includes an expandable , or expandable stent ( 82 ; 162 ) , attached to said distal end ( 17@@ 2a , 17@@ 2b ) of said graft member , to secure said graft ( 80 ) to said graft ( 80 ) to said graft ( 80 ) ( 80 ) ( ( 80 ) ( ( 80 ) ( ( 80 ) ( ( 80 ) ( ( 80 ) ( (
• 3@@ 1.@@ 1.@@ 2002 • 3@@ 6.@@ 1.@@ 2002 • 54 days
the apparatus of claim 1 , wherein the shaft further comprises a distal tip , the distal tip having a proximal end having an outer diameter that is not less than an outer diameter of the sheath .
 thrombo@@ phlebitis , pulmonary embolism ) or severe myelosuppression or severe myelosuppression or
the apparatus of any one of claims 11 to 14 , wherein the gas delivery means comprises a gas manifold ( 26 ) formed with at least two gas channels ( 68 , 70 ) , each communicating with a corresponding end of each diaphragm ( 32 ) and communicating with a gas inlet port ( 28 ) or gas outlet port ( 30 ) .
the method of claim 5 , wherein the carrier is used with immobilized nucleic acid for analyzing the nucleic acid by hybridization .
the method of claim 16 , further comprising oxidizing the product of claim 16 . the method according to claim 16 further comprising oxidizing the product of claim 16 . the method according to claim 16 , further comprising oxidizing the product of claim 16 . the method of claim 16 further comprising oxidizing the product of claim 16 . the method according to claim 16 , further comprising oxidizing the product of claim 16 . the method according to claim 16 further comprising oxidizing the product of claim 16 . the method according to claim 16 .
a surface-@@ treated optical plastic article according to any of claims 13 to 17 , wherein the carboxyl functional polymer is a polymer selected from poly ( meth ) acrylic acid , poly@@ itaconic acid and a copolymer of ( meth ) acrylic acid , maleic acid , itaconic acid or maleic anhydride with a reactive vinyl monomer or mixtures thereof .
a cloned tyrosine phen@@ ol-@@ lyase gene , a recombinant plasmid containing said plasmid and e. coli transformed with said plasmid .
a method of calibration of a sensor ( 1 ) for measuring the concentration ( pg ) of a gas ( g ) dissolved in a liquid ( b , c , c &apos; ) , and in that the gas ( 16 ) dissolved in said predetermined calibration liquid ( c ) is fed to the predetermined other concentration ( pg ( c &apos; ) of the gas ( g ) to the predetermined other concentration ( pg ( c &apos; ) to the predetermined other concentration ( pg ( c &apos; ) of the gas ( g )
process according to any one of claims 1 to 7 , characterized in that the quinone derivative in the composition ( b ) is present in concentrations ranging from 0.005 to 1 mol / l .
the use of claim 1 , wherein the disease is cancer / neoplasms wherein enhanced t cell proliferation responses , increased lymphokine secretion and elevated nk cell activity would lead to destruction of cancerous tumor and remission of the disease .
the method of claim 30 or claim 31 , wherein the host cell the host cell is an e. coli cell .
all patients received adequate amounts of vitamin d and calcium in the postmenopausal osteoporosis study and the in the patients in the prevention and the in the patients in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the the in the the in the the in the the in the the in the the in the the in the the in the the in the the in the the in the the in the in the
felodipine , nifedipine , nicardipine , diltiazem , , , , , , , , , , , ,
preparation according to one of claims 1 to 3 , characterized in that it comprises 0 to 90 % other components , preferably vegetable concentrates , foodstuffs and / or auxiliary components , and preferably 20-@@ 70 % of micro@@ nutrients and 20-@@ 70 % of micro@@ nutrients .
a method according to any one of the preceding claims wherein the echin@@ acea plant press juice is cooled to -8 ° c for two to three days , then filtered and is adjusted to a ph of 4.9 by addition of 0.1 % citric acid .
a process for preparing a composition based on hydrated lipidic lamellar phases or liposomes , preferably for the preparation of cosmetic or pharmaceutical compositions , characterized by incorporating a composition according to any one of claims 1 to 4 .
iclu@@ sig film-coated tablets are white film-coated tablets , are film-coated tablets , are tablets , tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are tablets are
in most patients with severe hypercalcaemia ( albumin@@ -@@ corrected serum calcium * ≥ 3 mmol / l or ≥ ≥ 12 / l ≥ 3 mmol / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l /
the extent of lamivudine and zidovudine absorption ( auc ∞ ) and estimated half-lives after lamivudine / zidovudine administration were similar to that observed in fasted subjects , although absorption rates ( cmax , tmax ) were delayed .
a process for producing a treated granular pigment product in a fluidized bed using a binder as a granulating agent , said binder comprising at least one water-dispersible , sulfon@@ ate-containing polyester .
a catheter device according to any one of claims 10 to 12 , including a tubular liner ( 61 ) in the tubular housing ( 60 ) for the tissue penetrating member ( 60 ) .
a method of producing an intraocular lens according to claim 1 , wherein one of said opposite forming surfaces of said press pair of said press pair corresponds to said contour of a surface of said lens of said intraocular lens and said contour corresponding to a surface of the lens of said lens and said contour of said one surface of said lens of said lens and said other of said opposing forming surfaces and said one surface of said one surface of said lens is equal to a surface of said lens and said one surface of said
sulfur-containing para-phenylenediamines according to claim 16 , characterized in that they are chosen from : 2-@@ acetyl@@ ylamino@@ thio-@@ para-phenylenediamine , 2,6-dimethyl@@ thio-@@ para-phenylenediamine , 2-@@ β-hydroxy@@ thio-@@ para-phenylenediamine , 2-ethyl@@ thio-@@ 1-@@ n- ( β-hydroxyethyl ) -p-phenylenediamine , 3-@@ ethyl@@ thio-@@ 1-@@ n- ( β-hydroxyethyl ) -p-phenylenediamine , and the addition salts thereof with an acid .
the compound of claim 23 , wherein q is q 5 and the solubilizing group is selected from the group consisting of residues of the formulae of the formulae of of the formulae of formulae of formulae of of the formulae of the formulae of the formulae of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim of of claim
the apparatus of claim 3 , further comprising air inflow means ( 29 ) for supplying air into the first conduit ( 24 ) when the connected valve means ( 26 ) is closed .
device according to claim 13 , characterized in that the working fluid is formed by a working liquid ( 22 ) , preferably water , and in that the conveyor arrangement ( 20 ) comprises a liquid pump ( 62 ) , preferably a centrifugal pump for conveying the working liquid ( 22 ) .
cannula for dispensing liquid products for vaginal and anal applications and vaginal and anal applications for vaginal and anal and anal applications
device for administering a closure device
apatite glass ceramic with at least one glass phase and at least one apatite phase , characterized in that at least one of the apatite phases is a phosphate and fluoro@@ free silicate phase of the formula me &#91; i &#93; x me &#91; ii &#93; y me &#91; i &#93; x &#91; ii &#93; y me &#91; i &#93; x &#91; ii &#93; y me &#91; i &#93; x ( sio 4 ) 6 o 2 , the percentages relating to the total weight of the glass ceramic related : apatite glass ceramic of claim 1 , wherein all
a compound of formula ( i ) , or a pharmaceutically acceptable salt thereof : wherein z is a heterocycle or a c 1 , a 2 and a 3 membered aromatic group , or a group consisting of a 1 , a 2 and a 5 membered aromatic ring , or a group comprising a 1 , a 2 and a 5 membered aromatic ring , or a 3 membered a 5-membered aromatic ring , or a group comprising a 1 , a 2 and a 5 membered aromatic ring , or a 3 membered aromatic ring , or
an ocular implant according to any one of claims 1-4 , wherein the thickness of the flat member is between 1 and 250 microns .
a delivery device according to claim 15 , wherein the medicaments are selected from the group consisting of beclomethasone dipropionate , fluticasone , budesonide and flun@@ iso@@ lide .
use according to claim 1 , wherein the stabilizing agent in the emulsion is present in an amount ranging from 0.1 to 50 % by weight and preferably from 0.5 to 20 % by weight .
the adhesive of claim 1 or 2 , wherein the addition weight of the polyethylene oxide is from 2 % to 8 % of the weight of the perforated plastic film as the wound covering .
use according to any one of the preceding claims , characterized in that the oleo@@ ates of plant oils are chosen from the group formed from the oleo@@ deca@@ tes of avocado oil , soybean oil , lu@@ pin oil , sunflower oil and the mixtures of these latter .
a process for the production of epa , characterized in that it comprises : ( a ) cultivating colorless silica algae in a fermenter containing a nutrient solution containing at least available nitrogen ; ( b ) maintaining a dissolved oxygen content of 10 % to 70 % of the air saturation in the nutrient solution ; ( d ) maintaining the ph of the nutrient solution to from 7.0 to 8.5 ° c ; ( f ) maintaining the ph of the nutrient solution to from 7.0 to 8.5 ; ( f ) maintaining the ph of the nutrient
abdominal pain , constipation , dyspepsia , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
a compound according to claim 17 which is 1- ( 4-amino-@@ 5-chloro@@ -2-methoxyphenyl ) -3 { 1- &#91; 3- ( 3,4-dimethoxyphenyl ) prop-1-yl &#93; piperidin-4-yl } propane@@ -1-@@ one hydrochloride .
in order to control the actual pressure in a face mask ( 5 ) , the pressure drop produced by an air flow in a breathing tube ( 4 ) is calculated and a desired pressure for a pressure sensor ( 3 ) which is supported in the housing of the cpap device .
the dental kit of claim 1 , wherein the liquid composition comprises a acid ester of the following general formula : wherein r 1 is a hydrogen , lower alkyl of from 1 to 5 carbon atoms , halo or c@@ n-@@ radical ; n and m are independent integers of 1 or greater , z is an aliphatic , cycloaliphatic or aryl radical comprising a carbon chain comprising at least 2 carbon atoms and 0 or more oxygen or sulfur atoms , and has a valence or valence of m + n .
container according to one of claims 5 and 6 , characterized in that the shaft ( 29 ) has a substantially cylindrical shape and is provided with a longitudinal mixing channel for the product and has perforations ( 42 ) at the opposite end .
process according to any one of the preceding claims , characterized in that the the composition is in the form of one of the oil-in-water , the oil-in-water the the the the the the the the of the preceding claims the the of the preceding claims , the the the the the the the the the the the the of the claims the of the preceding claims , the of the the the the the preceding the the the the the preceding the the of the preceding claims the the the the preceding claims of the the preceding the the
hip nail and method of use .
liposomal formulations according to claim 1 , characterized in that the polymers are carbo@@ pol , cellulose or acrylic acid derivatives , alginates , collagen or hyaluronic acid and derivatives thereof .
pharmacotherapeutic group : other nervous system drugs ; drugs used to treat addic@@ tive disorders ; drugs for treatment of opiate dependence atc code : n@@ 0@@ 7@@ bc@@ 51 : : n@@ 0@@ 7@@ bc@@ 51 : n@@ 0@@ 0@@ 0@@ 0@@ : : n@@ 0@@ n@@ n@@ n@@ n@@ n@@ n@@ n@@ n@@ n@@ n@@ :
the method or device of any preceding claim , wherein the second cell population is substantially a uro@@ thelial cell population .
composition according to any one of claims 1 to 3 , characterized in that the alkoxylated radical substituted in α , ω@@ -@@ positions corresponds to the following general formula ( i ) : r = - ( ch ) -o- ( c h o ) ( c h o ) ( c h o ) ( c h o ) ( c h o ) and ( c h o ) units randomly or in the form of blocks which are r c alkyl or phenyl , 5 ≤ m ≤ 300 .
a method according to claim 9 , wherein said ingredients are combined in a form suitable for oral administration . a suitable form for oral administration for oral administration for oral administration for oral administration is suitable for oral administration . a suitable for oral administration . administration for oral administration . administration for oral administration . administration . administration administration . administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration administration . administration administration . administration administration .
caution should be exercised when sorafenib is administered concomitantly with medicinal products predominantly via ugt@@ 1a1 ( e.g.
for storage conditions of the reconstituted medicinal product of the reconstituted medicinal product the product of the reconstituted medicinal product medicinal product medicinal product the
compounds according to claim 15 , wherein r 5 is hydrogen . 5 r 5 is r 5 is hydrogen wherein r 5 is hydrogen .
a chair according to claim 3 , wherein each releasable rear wheel is attached to a frame which is telescopically movable with respect to a main portion .
a sealed sachet according to claim 3 or any claim dependent thereon , characterised in that the two or more layers comprise three layers .
adults with newly diagnosed phi@@ la@@ del@@ phi@@ a-@@ chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemia ( ph + all ) ( ph + all ) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
transdermal therapeutic system according to one or more of the preceding claims , characterized in that one or more matrix layers or in the presence of an adhesive layer comprises said one or more substances selected from the group of tablets , skin permeation enhancing additives , fillers , solubility enhancers or in water swellable additives .
these are based on spontaneous reports , therefore the frequencies are not known .
process according to one or more of the preceding claims , characterized by compressing water from the wetted structure before drying the structure .
the conservative treatment is indicated in the initial spontaneous fracture of small cysts .
the committee therefore decided that ke@@ tek should be restricted to the treatment of commun@@ ity-@@ acquired pneumonia , on the treatment of bronchitis and sinusitis when they are caused by bacteria resistant to beta-lactam or macrolide antibiotics , and to treat ton@@ sil@@ litis / pharyngitis when these antibiotics are not indicated .
every 3 to 4 weeks to maintain the igg plasma level to at least 4-6 g / l
use of sigma receptor antagonists to enhance the effect of antipsychotic drugs .
cellular reproduction device for cellular propagation
an mri device comprising : means for externally applying an rf pulse ; a means for applying a magnetic gradient field ; an nmr signal receiving means ; and a method for performing the steps of evaluating the steps of evaluating a phase storage circuit ; a a a a a a phase of a phase a a phase a a phase a a phase a a phase a a phase a a phase a a phase a a phase a a a phase a a phase a a a phase a a a phase a a a phase a
a method according to claim 9 , wherein the composition is useful for the regulation of immune responses . a composition according to claim 9 wherein the composition is useful in the regulation of immune reactions .
method and route ( s ) of administration ( s ) ( s ) ( s ) ( s ) ( s ) ( s ) s ( s ) s ( s ) s ( s ) s s ( s )
use according to claim 1 or claim 2 , wherein the topical pharmaceutical formulation contains 0.25 % to 75 % by weight of active agent .
the maximal blood pressure lowering effect should be reached should be reached 4-6 weeks should be reached 4-6 weeks 4-6 weeks after weeks 4-6 weeks weeks weeks weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks weeks 4-6 weeks
the assembly ( 10 ; 200 ) of claim 7 ; 8 ; 10 ; 98 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 266 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10 ; 10
intervertebral implant ( 15 ) according to one of claims 1 to 8 , characterised in that the anchoring members ( 1 ) have fixed fastening means ( 9 ) fixed to the end plate ( 13 ; 14 ) for rotation about the central axis ( 6 ) .
you may first be given other medicines . other medicines you may need other medicines . other medicines you may be given other medicines . medicines medicines other than medicines other medicines . medicines . medicines medicines medicines medicines medicines medicines medicines medicines medicines medicines medicines . medicines .
in addition , effective surgical apnea is considered to be a low perioperative apnea rate .
adeno-associated virus vectors with intra@@ vector heterologous terminal pal@@ ind@@ ro@@ mic sequences
a process for producing a live vaccine comprising formulating a pharmaceutical composition according to any one of claims 1 to 6 in a pharmaceutically effective amount with pharmaceutically acceptable diluents , carriers and / or excipients .
process according to one of claims 1 to 15 , characterized in that the composition is in the form of a mascara for the eyelashes or mascara .
continuous sterilization and filling device .
polynucleotide sequence suspected for a cell adhesion molecule
process according to claim 7 , characterized in that the insulin derivatives of formula iii and / or their physiologically tolerable salts are used in dissolved , amorphous and / or crystalline - preference in amorphous and / or crystalline form .
47 the mechanism of action of lenalidomide involves anti-neoplastic , anti-angiogenic , erythropoie@@ tic , and immunomodulatory properties , respectively , , and , , , , , , and , of , , , , , , , and , , , , the mechanism , action , of lenalidomide , includes , , , , , , of , , the , , , , , , , , of , , , , , , , 47 , , , , , , , 47 , , , , , , 47 , , , , ,
compounds according to claim 5 , wherein r 2 represents a hydrogen atom , -or 8 or a lower alkyl ( which is optionally substituted with one or more of the radicals -or 8 and -nr 8 r 9 ) .
use of a compound of claim 1 of a compound of of a compound of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a
a kit according to claim 1 , wherein the oxidizing agent is hydrogen peroxide . the kit of claim 1 wherein the oxidizing agent is hydrogen peroxide is hydrogen peroxide hydrogen peroxide is hydrogen peroxide hydrogen peroxide is hydrogen peroxide hydrogen peroxide . is hydrogen peroxide hydrogen peroxide hydrogen peroxide hydrogen peroxide . peroxide is hydrogen peroxide . peroxide hydrogen peroxide .
a cell comprising the nucleic acid of claim 13 . a cell comprising the nucleic acid of claim 15 . a method of producing a peptide the method comprising culturing the cell of claim 19 under conditions permitting expression of the polypeptide of of the nucleic of the nucleic acid of the of the the nucleic acid of the the claim of the of claim of the the of claim of claim of the of claim of claim of claim of the of claim of claim of the claim of the claim of claim of of of claim of the
bolt element according to claim 1 or 2 , characterised in that the wire bow ( 31 ; 41 ; 47 ) is itself resilient and its two ends are anchored on the removable part of the dental prosthesis part .
a plunger needle according to claim 1 or 2 , characterised in that the plunger tip ( 4 ) has a generators with substantially circular , flattened or elliptical basic shape .
medical container with improved detachable sealing member
the method according to any one of claims 1 to 14 , wherein the subject is a non-human animal .
the polynucleotide of claim 19 , wherein the polyprotein has at least 70 % homology at least 70 % homology to 70 % homology to the homology to the homology to homology to homology to homology to homology to homology to homology to to homology to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to homology to to to to
a process according to any one of claims 1 to 3 , characterised in that the cells are to be dissolved by sonication .
the method of any one of the preceding claims , further comprising the steps of : purifying the vein segment ( 12 , 112 ) ; and dividing the segment into individual pieces containing a single flap ( 14 , 118 , 142 ) .
the results in patients with or without prior systemic treatments were similar to their psoriasis .
a replicable nucleic acid molecule according to claim 21 , which is free from its complementary strand in a predomin@@ ately single-stranded form .
hepatitis b surface antigen is produced in recombinant yeast cells ( saccharomyces cerevisiae ) ( saccharomyces cerevisiae ( saccharomyces cerevisiae ) ( saccharomyces cerevisiae ) .
however , if ari@@ mi@@ dex asthenia and somnolence have been reported , caution should be exercised when driving or operating machines , as long as these symptoms persist .
a crosslinking agent as claimed in claim 1 of the formula ( ii ) ( wherein q may be a leaving group l or a group of formula -x@@ .@@ y. ( z ) n , y , z , m , x , y , z , m and n are as defined in claim 1 ; r . r , z and n are as defined in claim 1 , which may be the same or different , in association with the groups r , r ⁹ , b , x , y , z , m and
use of an agent which modulates tyrosine phosphorylation for modulating permeability of a physiological barrier
therefore , the chmp , the chmp , the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
the compound of claim 1 which is 1 ( s ) , 3 ( r ) -dihydroxy-@@ ( r ) ( r ) - ( ( 5-ethyl-@@ ) ( 5-ethyl-@@ ) ( ( 5-ethyl-@@ ) ( ( ( 5-ethyl-@@ ) ) en-3-one ) ( s ) ( ( ( ( ( ( ( ( ( ) ) ) ) ) ( ( ( ( ( ( ( ( ( ( ( ( ( ) ) ) ) ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (
for ovulation induction , a lower median total dose and a shorter median duration of treatment was required as urinary fsh .
injection site reactions ( 1 ) single a@@ es were not considered to be considered medically relevant unless they have been considered medically medically relevant ( see section 5.1 ) . the injection site reactions ( 1 ) have not been considered ( 1 ) 1 ( 1 ) 1 ( 1 ) 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
a complete remission ( cr ) was achieved in 33 % ( 34 out of 102 patients in the itt group ) .
the catheter with an expandable body according to claim 1 or 2 , wherein the expandable body ( 3 ) is provided in the condition that it is folded around the distal end portion of the shaft before stretching .
10 and the pupil are the same and react .
the composition of claim 5 , wherein the concentrate further comprises one or more flavouring agents and one or more pharmaceutically acceptable preservatives .
use of a compound according to claim 1 for the manufacture of a medicament for the treatment of hypertension , heart failure , glaucoma , renal diseases , hyper@@ aldosteronism or acute or chronic pain .
the mah proposed to accept some details from these studies in the harmonised spc .
the effects of treatment for os were affected for the majority of the determined criteria ( including gender , k@@ ps , geo@@ graphic region , primary pancreatic cancer , stage of diagnosis , presence of liver metastases , presence of a peritoneal cancer , previous wh@@ ip@@ ple surgery , presence of a biliary stent at baseline , presence of lung metastases and number of metastasis sites ) in favour of the abraxane / gemcitabine arm .
the method of claim 1 wherein the protein is selected from lectins and lipo@@ oxid@@ ases .
transgenic mammals and cell lines for the identification of glutamate transporter modulators
the substrate of claim 6 , wherein the donor substrate comprises a fabric softener compound .
the apparatus of claim 63 or 64 , wherein the switch ( 52 ) comprises an electric switch and the energy of the second form comprises electric energy .
it encodes a new lytic enzyme .
an arrangement according to claim 2 , characterized in that a terminal of the capacitor is connected in each of the magneto@@ gen@@ generating circuits to the return terminal of a direct current source ( dc ) , and in that a terminal of the main current path of the first thy@@ ri@@ st@@ is is connected to the output terminal of a direct current path , and in that a terminal of the main current path of the first thy@@ ri@@ st@@ is is connected to the output terminal of the first thy@@ ri@@ st in one of the
the most common ( ≥ 10 % ) non-@@ haematological adverse reactions ( ≥ 10 % ) were adverse reactions % adverse reactions % ( ≥ 10 % ) % ) % ) % ) % ) % % ) % ) % ) % % ) ) % ) % % ) % % ) % % ) % % % % % ) % % ) % % ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) %
the process according to claim 4 , wherein the pharmaceutically acceptable salts are formed together with a multivalent anionic substance .
stereo@@ microscopy arrangement according to one of claims 1 to 8 , wherein the beam depletion and image reversal system ( 89 ) can be pivoted or insertable into the beam path .
apparatus for separating cells and separation procedures .
dermal or transdermal therapeutic system according to at least one of the preceding claims , characterized in that the or@@ mo@@ ler layer is applied to the support layer which is adjacent to the active substance-containing layer .
quick coupling according to claim 1 , 2 or 3 , characterised in that the locking nose ( 8 ) is provided on a resilient clip ( 5 ) .
benefix vials are to be used with insulin syringes with a corresponding unit division and in conjunction with an insulin pump system .
the invention preferably relates to an open packaging package for adhesive dressings comprising a bandage dressing or bandage pad ( g ) secured to a strip of adhesive ( a ) and with two protective layers ( g ) , which is secured to a strip of adhesive support ( a ) , and with two protective material sheets ( g ) , which are secured to a strip of adhesive support ( a ) , and with two protective material sheets ( g ) , which are secured to a strip of adhesive support ( a ) , and
zyprexa is usually taken orally ( by mouth ) .
operating table according to claim 3 , characterized in that the mechanical coupling means comprise at least one pair of projections ( 29 , 30 ) associated with the head ( 11 ) and each complementary shaped seats ( 33 , 34 ) associated with the plate element in operation .
the use of side panels and the front of front air@@ spots could provide additional protection , if not in the case of a recovery and additional loads .
the invention relates to a coupling for sealing two prostheses of medical instruments ( 10 , 90 ) along the shaft axis ( 53 , 97 ) thereof , in particular for connecting an arthro@@ scope with an optic .
there have been reports of nephro@@ genic systemic fibrosis ( n@@ sf ) associated with the use of optimark and some gadol@@ ini@@ um-containing contrast agents in patients with acute or chronic , severe renal impairment ( gfr &lt; 30 ml / min / 1.73 m2 ) and / or acute renal impairment .
it does not cure hiv infection or aids , but infection or aids or aids or hiv infection or aids infection or aids or aids or aids or aids infection or aids or aids or aids or aids or aids or aids or or or or or or or or or or or or or or or or aids or infection or infection or aids or aids or aids or aids or aids or aids or aids or aids or aids or aids or aids or aids or aids or aids aids or aids or aids or aids or aids
a process for the preparation of hydrogel-forming polymers according to any of claims 1 to 12 , wherein a base polymer is a polymer having a ph of less than 5.0 surface post@@ crosslinked .
a compound according to claim 9 , wherein the 1-@@ indolyl group is unsubstituted or substituted with halogen . a compound according to claim 9 wherein the 1-@@ indolyl group is unsubstituted or substituted with halogen or substituted with halogen or substituted with halogen with halogen with halogen with halogen or substituted with halogen . with or substituted with halogen . with halogen . with halogen . with halogen halogen halogen with halogen halogen with halogen halogen with halogen halogen with halogen halogen with halogen .
lymphadenopathy localized in the region of the injection site .
a composition according to any one of claims 12 to 14 which comprises a complex of dendritic polymer of of any of claims of of any of of of claims of one of of dea@@ e-@@ dextran of of of either one of dea@@ e-@@ dextran of of of of of of a dendritic polymer of of of of of one of of claims of of claims of of claims of of of claims of of claims of of claims of of claims of of claims of of of claims of of claims of of claims of of claims of
 we@@ d@@ day , 21 march and thur@@ s@@ day , 22 march
abilify 7.5 mg / ml solution for injection aripiprazole
the apparatus of claim 1 , further comprising means for providing an intermittent ciliary calendar period while the target region is located , and means for directing the radiation treatment beam to the target region during intermittent target treatment periods , each of the intermittent treatment periods being followed immediately at least one of the ciliary caloric periods .
benzimidazole derivatives for ige modulation and cell proliferation inhibition
a method for converting a ligno@@ cellulosic feedstock a a ligno@@ cellulosic feedstock a a a a a a a a a a a a a a a a a a a a a a ligno@@ ligno@@ a ligno@@ cellulosic ligno@@ a a a a a a a a a a a a a a a a a a a a a a a a a ligno@@ cellulosic a ligno@@ ligno@@ ligno@@ a ligno@@ ligno@@ cellulosic ligno@@ a a ligno@@ ligno@@ a a a a ligno@@ a ligno@@ ligno@@ cellulosic ligno@@ cellulosic ligno@@ a ligno@@ cellulosic ligno@@ a a ligno@@
the use of proto@@ porphyrin i@@ i@@ zn ( ii ) for the manufacture of a medicament for the treatment of hepato@@ pathy by oral administration .
1 . use of perfluoro@@ -1@@ 5-@@ cro@@ wn-@@ 5 ethers for the preparation of a preparation for use in a method of obtaining fluoro@@ magnetic resonance images or spectra of body organs or tissues .
a method of purifying hepatitis c virus ( hcv ) asi@@ alo@@ glycoprotein , expressed from an asi@@ alo@@ glycoprotein from the e1 region of hcv , an asi@@ alo@@ glycoprotein expressed from the e2 region of hcv , and aggregates thereof , said method comprising contacting a composition suspected to bind to said manno@@ se-@@ binding protein with less than about 10 % of the total n-linked carbohydrate of asi@@ alo@@ glycoprotein sialic acid .
the method of claim 9 , wherein the gene product is mrna . the method according to claim 9 , wherein the gene product is mrna . the method according to claim 9 wherein the gene product is mrna . the method according to claim 9 wherein the gene product is mrna . the method of claim 9 wherein the gene product is mrna . the method according to claim of claim claim . . to the method of claim of claim of claim of claim of claim of claim of claim of claim of claim of claim .
a process according to claim 1 , wherein is used : as styrene-@@ vinyl copolymer am@@ ber@@ lit@@ e x@@ ad-@@ 11@@ 80 ; as a strong cation exchanger s-@@ sepharose ; as a substrate based on polysaccharide octyl-@@ sepharose , cl 4b ; and as a weak anion exchanger dea@@ e-@@ sepharose .
the system of claim 2 , wherein : the system further includes a medical device ( 12 ) positioned in the region of interest ; the localization system ( 100 ) ( ( 100 ) ( ( 100 ) ( ( ( 100 ) ( ( ( ) ) is ( ( ) ( ) ( ( ) ( ( ) ) ( ( ) ( ( ( 12 ) ( 12 ) ) ( ( ( ( 12 ) ) ( 12 ) the ( ( ( 12 ) ( ( ( 12 ) ) ( ( 12 )
method for making a dental element a dental element a dental element a dental element a dental element a dental element dental dental dental dental dental dental dental dental dental dental element
the device of any one of claims 16 to 20 , wherein the means for detecting the fluorescent characteristic comprises an optical fiber .
method for random synthesis and amplification of complementary dna
composition according to any one of the one of the preceding claims , the the composition of any of the preceding claims , the the the the the the preceding claims , the the preceding claims the preceding claims preceding the preceding claims preceding the preceding claims preceding the preceding claims preceding the preceding claims preceding the preceding claims preceding preceding claims preceding preceding claims preceding preceding claims preceding preceding claims preceding preceding claims preceding preceding preceding claims preceding preceding claims preceding preceding preceding preceding preceding preceding preceding preceding preceding preceding preceding preceding preceding preceding preceding preceding preceding preceding preceding
the pharmacokinetic properties of simeprevir have been studied in healthy adult subjects and in adult hcv-@@ infected patients .
an anaesthetic evaporator bath having a evaporator chamber ( 21 ) for liquid anaesthetic means , and a heating device ( 27 ) disposed in the evaporation chamber ( 21 ) , wherein a partition in the form of a plate ( 31 ) extends transversely through the evaporation chamber ( 21 ) , in which a partition is in the form of a plate ( 31 ) in a position above the maximum liquid level in the space formed by the partition and the inner wall of the evaporation chamber ( 21 ) through which steam can pass through
use of anti-@@ helmin@@ th vaccines to control parasitic diseases associated with a loss of natural immunity
a method of amplifying a target nucleic acid whose nucleotide sequence is complementary to the capture probe , said method comprising the steps of : a ) providing a nucleic acid containing sample , b ) the method comprising the steps of : a ) providing a nucleic acid containing sample , b ) the method of treating said sample with a lysis buffer , said method comprising the step of expanding said nucleic acids with a lysis buffer , said method comprising the step of subjecting said nucleic acids to said captured nucleic acid , said step of amplifying
maintenance treatment may be continued as long as the patient continues as a therapeutic benefit .
it is not necessary to use erythropoietin in the first three months after starting the peritoneal dialysis because the haemoglobin may often rise after this period .
pharmaceutical compositions comprising insulin and insulin hexa@@ mer ligands
in the second study , the second study experienced the kidney in the second study , the the the kidney ( 28 % ) ( 28 % ) ( 28 % ) ( 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28 % 28
the medicine can only be obtained with a prescription with a prescription a with a prescription .
process for the cleavage of beta-lactam esters .
the media system of claim 39 , wherein the microorganisms are selected from the group consisting of streptococcus , pseudomonas , yeast , mould , bacillus and mixtures thereof .
studies with abacavir show that the ratio of cerebrospinal fluid to plasma auc is between 30 and 44 % .
a method for producing the stable bioadhesive nanoparticulate active agent composition of claim 2 comprising contacting an active agent particle with at least one cationic primary surface stabilizer for a time and under conditions sufficient that the cationic primary surface stabilizer is adsorbed to the surface of the particle to provide a stable , nanoparticulate active agent composition to the surface of the particle to form a stable nanoparticulate active agent composition , wherein : ( a ) the surface of the particle is adsorbed to the surface of the particle to form a stable nanoparticulate active agent composition ,
common uncommon ear and labyrinth disorders common uncommon common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common common
the synthetic plant promoter dna sequence of claim 3 , wherein the upstream activation region comprises an upstream activation region from cam@@ v 35s .
amphoteric sterols and their use for producing ph@@ - sensitive lipo@@ se
the apparatus of claim 25 , wherein the fibers comprise at least one bioresorbable fiber ( 10@@ 3b ) and a non-@@ resorbable fiber ( 10@@ 3a ) .
a blood circulation and filtration system ( 34 , 35 ) for selectively removing certain plasma components from blood , which comprises : ( a ) a closed plasma chamber ( 31 ) , which is filled with an electrolytic plasma chamber solution , a &quot; u &quot; shaped hollow chamber membrane ( 30 ) , which is filled with an electrolytic plasma chamber solution , a &quot; u &quot; shaped hollow fiber membrane filter , a &quot; u &quot; shaped hollow fiber membrane filter ( 30 ) , wherein a &quot; u &quot; shaped hollow fiber membrane filter (
compounds of formula ( i ) of formula ( i ) ( i ) ( ( i ) ( i ) ( i ) ( i ) ( i i i i i i ( i ) ( i i i i i i i i i i i ( i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
use according to claim 20 or 21 , wherein the medicament acts as an agonist in human s@@ 1@@ p1 and s@@ 1@@ p2 receptors but is substantially inactive at s@@ 1@@ p3 receptors .
use of thiazolidin@@ edi@@ ones for the treatment of atherosclerosis of the of the of the of the of the of atherosclerosis of the of of the of the of of the of of the of of the of of the of of the of of the of of the of of the of the of of the of of the of for the of the for the treatment for of for the the for the the of the the the of the for the for the treatment of of the of for the of the of the of the
in this study , levetiracetam , , , , , , , , , , , , , , , , , , , levetiracetam , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
the steady state volume of distribution is 0.1 litres / kg . the steady-state volume of distribution is 0.1 litres / kg of distribution of distribution of of distribution of distribution of distribution of distribution .
the undergarment protective garment of claim 9 , wherein the material having a weak tightening force is a woven fabric ( stri@@ ck ) .
the method of claim 1 , wherein the third differential image is displayed relative to the anatomy of the organ .
this may result in an effect on efficacy .
3 . the composition according to claim 1 , characterized in that the buffer contains acetate , and the ph is in the range 1 to 1 to 5.5 .
the polypeptide of claim 3 , wherein the additional polypeptide is a polypeptide rich in histidine residues .
process according to one of claims 13-@@ 35 , characterized in that , in , the 2-@@ aryl@@ propionic acid derivative , of the 2-@@ aryl@@ propionic acid derivative , the 2-@@ aryl@@ propionic acid derivative of the 2-@@ aryl@@ propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid propionic acid acid
≥ 0.5 x 109 / l and &lt; 0.75 x 109 / l ≥ 25 x 109 / l and 109 x 109 / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l / l
antibodies for specific binding to compounds .
the medical device of any preceding claim , wherein the inflec@@ tion point ( 21a ) is substantially centrally located between a tip and a valley .
anti-@@ egfr and anti-@@ egfr antibodies
compositions for efficient drug release
use of od@@ c inhibitors , dac@@ arb@@ azine and interferon in the treatment of malignant melanoma .
control pulse for an intravascular imaging device
what avandamet is and what it is used for what avandamet is for what it is used for what it is used for is what it is used is what it is used is is is is is is what it is used is is is is is is is is
compounds according to claim 1 , characterized in that r is a methyl group ( -ch 3 ) .
an amide derivative of formula i according to claim 1 wherein r is hydroxyl , c alkoxy , carboxyl , c -alkoxycarbonyl , nitro , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c , c
a method for producing a human anti-@@ p. aeruginosa monoclonal antibody according to claim 1 , wherein ( i ) cultured a hybridoma or a cell line according to claim 1 or ( ii ) a hybridoma by a process according to claim 2 which is cloned and cultured .
the method of claim 13 , wherein both the one or more site-specific sensed measured quantities and the one or more site-specific sensed measured quantities of measured values have measured values that have been captured from different bends .
the dose of increlex should not be doub@@ led in any doub@@ t to get one or more doses . • within 2 - 3 hours after the dose of increlex , patients should not have a high break@@ point activities ( e.g.
according to the invention , compounds of formula i , in which a ₁ and a ₂ are hydrogen , optionally substituted lower alkyl , lower alkyl or lower alkynyl ; heterocyclylalkyl lower alkylene , acyl , lower alkyl or arylsulfonyl ; or a lower alkylene substituted with the r , ar ₁ and ar ₂ aryl , heteroaryl , and nitrogen atom bonded to the r bearing nitrogen in formula i , wherein r has the meaning of meaning not having the meaning mentioned below ; salts thereof and tautomers thereof .
water , gas , flow , , , heating , , heating , gas , gas , gas , gas , gas , , gas , , gas , , gas , , gas , , gas , , gas , gas , gas , gas , gas , gas , gas , gas , gas , gas , gas , gas , gas , gas , gas , gas , gas , , gas gas , gas , , gas , gas , gas , gas , gas gas , gas , gas , gas , gas , ,
the dna molecule according to claim 1 , wherein the ε-@@ rhodo@@ myc@@ inone conversion protein has the sequence of seq . id . no 2 . the dna molecule of claim 1 , wherein the ε-@@ rhodo@@ myc@@ inone conversion protein has the sequence of seq . id . no . : 2 , seq id no : 2 , the dna molecule of claim 1 wherein the ε-@@ rhodo@@ myc@@ inone conversion protein has the sequence of seq . id . no . no . 2 . no . 2 . id . no 2 .
the method of any one of claims 1-9 , wherein the amino@@ alkyl-@@ functionalized polynucleotide has a reactive amine at its 3 &apos; or 5 &apos; end .
the method of claim 12 , wherein the subject is a human fetus in u@@ tero .
circuit arrangement according to claim 1 , in which the drive motor ( 1 ) is connected in a semiconductor full bridge circuit ( 2 to 5 ) whose switching elements generate the motor clamps preferably within 1 µ@@ s and thereby generate a counter@@ em@@ mer .
in 10 patients ( 48 % ) , 11 ( 52 % ) had a negative vascular function ( 52 % ) of patients treated with ischemia in up to 3 different vessels .
a stent as claimed in any one of claims 1 to 9 , wherein the stent is a self-expanding stent . a stent according to any one of claims 1 to 9 , wherein the stent is a self-expanding stent . a stent according to any of claims 1 to 9 of a stent of any of claims 1 to 9 of a stent of any of claims 1 to 9 of a stent .
the use of a contrast agent as claimed in any one of claims 1 to 3 , wherein said contrast agent includes one or two chelate complex units of bi- or trivalent paramagnetic metal ions in its structure , or a salt thereof with a physiologically acceptable organic base selected from primary , secondary , tertiary amines or basic amino acid , or an inorganic base whose cations are selected from sodium , potassium , magnesium , calcium or mixtures thereof .
vascular prosthesis according to one or more of claims 14 to 16 , characterized in that a second end of the tubular body ( 40 ) is provided with connecting means ( 70 ) which can be fluid-tight with a free end of another vessel prosthesis ( 80 ) .
the use of an oligonucleotide probe or oligonucleotide primer which specifically hybridizes to dna encoding a polypeptide having endo@@ glyco@@ cera@@ mid@@ ase activity comprising a dna sequence selected from the group consisting of : ( a ) dna sequences selected from the group consisting of : ( a ) dna sequences comprising a dna sequence selected from the group consisting of : ( a ) dna sequences comprising a dna sequence selected from the group consisting of : ( a ) dna sequences comprising a dna sequence selected from the group consisting of : ( a ) dna sequences
jo@@ e , you need to stop these pants .
increased aldosterone levels ( water and salt retention in the body combined with an imbalance in the blood ) .
protect your solostar from dust and di@@ rt and di@@ rt your solostar and di@@ rt and di@@ rt and di@@ rt . and your doctor will advise you to use your di@@ rt and di@@ rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . rt . .
ce@@ ren@@ ia can be used to prevent and treat vomiting either in tablet form or as a solution for injection once a day for the prevention and treatment of vomiting . • for example , ce@@ ren@@ ia can be used as a solution for injection or as a injection solution for injection for for solution for for injection for solution for as solution for injection for for injection for injection for solution for injection for injection .
ren@@ ve@@ la should be used in patients with secondary hyperparathyroidism with a multiple should be used in a multiple should be used with should be used with should be used should be used be used be used be be used be be used be be used be be used be be be be used be be be be used be be be be be used be be be be be used be be be be be used be be be be be used be be be be used be be be be used be be be be used be
zoledronic acid teva generics is also used to treat paget ’ s disease paget ’ s paget ’ s disease ’ s paget ’ s disease in adults . ’ s disease ’ s disease .
the blood compatible material of claim 10 having a platelet density of 100 or less with the platelet pressure test .
compound according to claim 4 , characterized in that the condensing aid is carbonyldiimidazole or dicyclohexyl@@ carbodiimide .
not all pack sizes may be marketed all pack sizes may be marketed may be marketed . may be marketed . be marketed . be marketed . be marketed . be marketed . be marketed . marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed marketed
positioning system according to claims 11 and 20 , characterized in that the ball holder ( 8 ) is slit in such a way that it resiliently encloses the ball ball ( 9 ) and the ball seat is compressible by tightening a clamping screw ( 31 ) forming the actuator .
the method of claim 1 , wherein , after attaching the absorbent layer , the outer portion of the wafer to be totally removed or partially removes a further region of the adhesi@@ ve-@@ coated film to be applied to which one or more protective films are applied to prevent contamination of the absorbent layer before use .
al@@ am@@ da fer@@ ã@@ o lo@@ es , 12-@@ 8.@@ º a p-@@ 14@@ 95 - 190 alg@@ é@@ s tel : + 351 / 214 72 63 00 : tel : + 351 / 190 72 63 00 : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
tell your doctor immediately if you experience numbness or weakness in the legs or problems with your digestive or bladder emptying , as appropriate treatment should be necessary .
the use of claim 3 wherein the gene is a member selected from the group consisting of genes selected from the group consisting of the group consisting of the group consisting of the group consisting the group consisting the group consisting the group consisting the group consisting the group consisting the group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group group
a composition according to any preceding claim , wherein the level of protease inhibition in a 1 % washing solution in water is less than 10 % .
method according to one of claims 19 to 25 , characterized in that the test kit comprises at least one affinity marking and / or a separating assisting instrument provided with a counterpart of the affinity marking .
use of a selenium compound according to claims 12 , 14 or 15 , wherein x denotes nh or o , preferably nh .
you may need to read it again to have it again read any again .
that &apos;s nothing , why are you gonna have to go .
two generation methods of generation and ce@@ ment@@ less hip endo@@ prostheses seem to provide better results than early used prosthesis models or ce@@ menting techniques .
a771726 displaced ibuprofen , diclofenac , and tol@@ buta@@ mide , but , increased , , , , , , , only the unbound fraction of these drugs , the unbound fraction , increased by 10 and 50 % , , , increased and increased .
a compound according to claim 3 , wherein r 1 is c 3 -c 6 alkyl and r 2 is c 2 -c 3 alkyl . the compound of claim 3 wherein r 1 is c 3 -c 6 alkyl and r 2 is c 2 -c 3 alkyl and r 3 is c 2 -c 3 -c 3 alkyl -c 3 alkyl 3 -c 6 alkyl 2 -c 3 alkyl 3 -c 3 alkyl 3 alkyl 3 -c 6 alkyl 3 alkyl alkyl alkyl .
each pack of ad@@ ce@@ tris contains one vial .
a compound according to claim 1 , wherein r 13 is independently selected from aryl , substituted aryl , optionally substituted heteroaryl , halogen , -cf 3 , -cn , -or 15 or -co 2 r 15 , wherein r 15 is hydrogen , lower alkyl or optionally substituted aryl .
other information about versican plus pi / l@@ 4r / l@@ 4r / l@@ 4r / l@@ 4r / l@@ 4r / l@@ 4r / l@@ 4r
acid-@@ stable alpha-amylase composition , preparation , and use thereof , preparation and use thereof and use thereof and preparation thereof and use thereof , and preparation thereof and use thereof and use thereof and use thereof and use thereof and use thereof and use thereof and use thereof and use thereof and use thereof and use thereof
device according to claim 27 , characterized in that it comprises measuring sensors capable of measuring the duration of the penetration of ultrasonic waves in blood vessels or chambers of the heart .
pharmacodynamic effects natural killer ( nk ) and t cell count are known to be highly expressing cd@@ 38 and susceptible to cell lysis mediated by dar@@ at@@ umumab .
an apparatus according to claim 14 , wherein the level indicator ( 30 ) comprises a medium that triggers a detectable change in fluid when contacted with liquid .
a method of producing a non-reducing oligosaccharide according to claim 1 , comprising the steps of : ( a ) reacting an aqueous solution containing neo@@ trehalose and α-@@ glucosyl saccharide either with a saccharide-@@ transfer enzyme or with a saccharide-@@ transfer enzyme together with a hydrolase to thereby form said non-reducing oligosaccharide , and ( b ) collecting said non-reducing oligosaccharide .
thin hygienic paper for home use
a bi@@ sulfate salt of the formula pharmaceutical dosage form comprising the bi@@ sulfate salt of claim 1 and a pharmaceutically acceptable carrier .
substituted bicyclo &#91; 3.3.1 &#93; nonan@@ -2,4,@@ 9-@@ tri@@ ones as pharmaceutical active as active pharmaceutical ingredients and a compound as active pharmaceutical as pharmaceutical active ingredients active ingredients active ingredients active ingredients active ingredients active ingredients active ingredients active ingredients active ingredients active ingredients active ingredients
ca@@ b@@ 414 : antigen expressed in multiple tumours
in phase iii placebo-controlled phase iii studies , strontium ran@@ ela@@ te treatment was associated with an increase in treatment with strontium ran@@ ela@@ te in an increase in the in the in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in in
the use according to any one of the preceding claims , wherein the dietary composition is in the form of a dietary supplement . the use according to the preceding claims , wherein the dietary composition is in the form of the dietary supplement . the use according to claims , wherein the nutritional composition is the form of the dietary supplement in the form of the dietary supplement .
laboratory and dialysis at the week .
the method of claim 35 , wherein the multivalent antibody or multivalent , multi@@ specific antibody , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , the multivalent antibody or multivalent , multi@@ specific , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
the apparatus of claim 2 or 3 , wherein the detection means comprises a pressure sensor ( 83 ) for providing information about the pressure of the collection fluid .
a method according to any preceding claim , wherein the anti@@ static material is an alcohol phosphate salt .
special embo@@ di@@ ments are characterized by a-@@ amylase variants , having the following amino acid residues : 9@@ l , 14@@ 9a , 18@@ 2@@ t , 18@@ 6a , 20@@ 2@@ l or 20@@ 2@@ i , 25@@ 7@@ t , 33@@ 5@@ f , 29@@ 9@@ y , 3@@ 23@@ t , 33@@ 20@@ s and 34@@ 5r , and optionally additionally 118@@ k , 18c , 3@@ 20@@ k and 45@@ 8@@ k ( each in the counting according to a-@@ amylase aa@@ 560 ) .
medical instrument for providing an operative working space in jaw operations
an ultrasonic diagnostic apparatus comprising : an ultrasonic emitting / reception device ( 2 ) for sending ultrasonic pulses in a living body and for receiving reflected ultrasonic waves that are reflected by the living body , by an ultrasonic probe ( 1 ) , which is reflected by an ultrasonic probe ( 1 ) , which is reflected by an ultrasonic probe ( 1 ) , by an ultrasonic probe ( 1 ) which is reflected by an ultrasonic probe ( 1 ) , by an ultrasonic probe ( 1 ) which is reflected by an ultrasonic probe (
however , the dose may vary from each other and your doctor may adjust the dose according to your needs : • the dose may vary with your doctor and your doctor may decide to adjust the dose according to your needs : • you may need to change your dose based on your needs and your doctor may adjust your dose according to your needs : • your doctor may decide to adjust your dose as your needs may need to be adjusted and your doctor may adjust your dose according to your needs :
compositions and methods for preventing microbial contamination from plant tissue culture media
use according to claim 1 , wherein the ig@@ y is formulated as a freeze dried or lyophilized powder , solution , emulsion , lozenge , tablet , capsule , or capsule , together with any other pharmaceutically acceptable carrier or diluent , or pharmaceutically acceptable or diluent or diluent or diluent or diluent or diluent or diluent .
an orally administered preparation with a controlled release of an opioid analgesic in the form of crystals having a particle size of 10 µm to 3 mm , having at least one retarding coating on the basis of polymers , wherein the polymers are acrylic resins and / or ce@@ lio@@ se derivatives and / or waxes .
a system according to any one of the preceding claims , characterized in that means are provided for controlling the function of the artificial body member proportional to the mean absolute value or the mean absolute sum of the myo@@ electric signal calculated over a predetermined average window or a predetermined number of samples .
the method of claim 11 , further comprising the step of isolating the polypeptide product of expression of the polynucleotide sequence in the host cell .
eu / 2 / 06 / / / / / 009 / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
exchange accessory for use with a mono@@ rail catheter
only use syringes made of polyethylene , polypropylene , or glass of polypropylene , only use only syringes of polyethylene , polypropylene , or glass of polypropylene , or polypropylene , or glass or glass or glass , or glass , or glass , or a glass , or glass of water , or a glass of polypropylene , only glass , or glass of polypropylene , glass or glass of polyethylene or glass or glass of powder , polypropylene , or glass or glass , glass or glass , or glass or glass of glass .
due to an acute disease ( such as a gastrointestinal illness ) ( such as gastrointestinal disease ( such as gastrointestinal tract disease ) . ( such as an acute gastrointestinal illness ( such as gastrointestinal tract illness ) ( such as acute gastrointestinal illness ) ( such as acute illness ) , such as an acute illness ( such as gastrointestinal illness . ) ( such as acute gastrointestinal illness ) . ) , due to acute illness ( such as ) illness ( such as a gastrointestinal illness ) ( such as a gastrointestinal illness ) .
a tracheostomy cannula assembly according to claim 1 or 2 , characterised in that the obturator ( 2 ) has a strap ( 20 ) of rectangular cross-section extending between its appliance end and the patient end thereof .
interaction not studied with any of the components of stribild .
surgical apparatus as claimed in any one of claims 1 to 18 , wherein the drive means ( 80 ) is operably connected to the cutting head assembly ( 50 ) by its upper surface such that the drive means is disposed in a generally vertical orientation .
gardasil 9 is given according to official recommendations on the basis of official recommendations on the basis of official recommendations . • gardasil 9 is given with official recommendations . recommendations of the official recommendations recommendations with the recommendations of the recommendations on the recommendations of the recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
combination of a dental handpiece with a valve according to one of claims 1 to 7 , characterised in that it is disposed near the exit point of the fluid in an axi@@ al-@@ parallel line ( 8 , 12 ) of the head part ( 3 ) of the dental handpiece , the conduit channel being connected to a branch channel ( 16 ) leading to the outlet opening ( 10 ) , and the conduit channel ( 12 ) is closed in the axial direction seen in the axial direction after the branch .
the manufacturing method according to claim 5 , wherein the needles ( 6 ) are arranged on a mounting ( 3 ) and the needle hub lie substantially on a circular line located above the contact portion of the plug ( 8 ) .
device according to one of claims 8 to 12 , in combination with a chair ( 20 ) , characterised in that the horizontal legs ( 15 ) of the angle frame ( 2 &apos; ) are integrated into the side parts of the arm legs ( 24 ) of the chair ( 20 ) in the side of the arm legs ( 24 ) of the chair ( 20 ) , each of the parts of the angle frame ( 2 &apos; ) being pivotable and , in each case , the angular frame ( 2 &apos; ) being
the apparatus of claim 1 , further comprising a reflector disposed near the flash light to reflect the light pulses toward the target object .
a compound corresponding to general formula ( i ) : wherein r 2 is a chlorine atom , a methyl group or a 3-@@ thienyl group , as base or as an acid addition salt .
splint according to one of the preceding claims , characterized in that the one or more flexible zones ( 7,8 , 10,12 , 13,@@ 15 ) consist of a zone of soft material mixed with rigid plastics material from which the rigid part ( 9 , 14 ) of each shell ( 1 , 2 ) is realised .
a process for producing an encapsulated microparticle to form microcapsules , wherein a bound microparticle is encapsulated in copolymers of any one of claims 1 to 26 with an absorbable polymer selected from crystalline or non-@@ crystalline lactide / glycolide copolymer , amorphous l-lactide / d , l-@@ lactide copolymer , caprolactone / glycolide copolymer or trimethylene carbonate / glycolide copolymer which is soluble in chloroform , methylene chloride , acetone , acetonitrile , ethyl acetate or ethyl formate .
absorbent structure ( 14 , 15 , 16 , 21 , 38 , 41 , 51 ) according to any one of the claims 4-8 , characterized in that the cellulose fibres are mainly composed of fibres of chemi@@ -@@ thermo@@ mechanical pulp ( pulp ) produced in a chemi@@ -@@ thermo@@ mechanically , in particular in the form of fibers . ( 14 , 15 , 51 ) according to one of claims 4 to 8 , characterized in that the cellulose fibres are characterized in that the cellulose fibres are in the form of fibres .
process according to claim 9 or 10 , characterized in that the average molecular weight of the copolymer used is the average the molecular weight of the copolymer in that the the molecular weight the the average molecular weight in the molecular weight the the the molecular weight the the molecular weight the the average molecular weight the molecular weight in the molecular weight the the the molecular weight in the molecular weight the the the molecular weight molecular the the average molecular weight the the the average molecular weight weight average the average average the the the molecular weight
these fertility studies did not indicate direct or indirect harmful effects with respect to mating or fertility , embryonal / foetal development , or with respect to sperm , sperm , embryonal , / foetal , or with sperm , fertility , , or fertility .
dye composition for individually coloring prosthetic plastics
the method of claim 1 wherein the bacteria comprise the method of claim 1 wherein the bacteria the the bacteria of the the method of claim 1 wherein the the the the the the the the the the the method of claim 1 of claim 1 of claim 1 of claim 1 of claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim 1 claim
if you use more pic@@ ato than you should contact your doctor or pharmacist if you are using more pic@@ ato than you should .
a catheter shaft according to any preceding claim , wherein the shaft has a diameter of not more than 3.@@ 05 mm ( 0.@@ 120 inches ) .
agent according to claim 27 , characterized in that the composition ( a ) contains the 5,6-dihydroxy@@ indoline of formula ( i &apos; ) , the composition ( a ) ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ) ) ) ) ( ( ( ( ( ( ( ( ( ( ) ) ) ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ) ) ) a )
a method for producing a device comprising the steps of : ( a ) providing a solution comprising dissolved osteoinductive protein ; ( b ) contacting the solution according to step ( a ) with a carrier comprising a surface of metal or metal alloy ; ( c ) coating the coated carrier obtained in step ( c ) , the steps ( b ) to ( d ) being carried out at a reduced level of oxygen .
the method of claim 11 , wherein the removing excess coating comprises drying the medical device at room temperature .
a nasal vaccine preparation according to any one of claims 1 to 3 , wherein the particulate antigen is hbsag ( hepatitis b surface antigen ) in soluble state .
use of poly@@ acids with close molar mass distribution
the method of claim 1 , wherein extracting the lung and arterial component p 2 ( t ) and a 2 ( t ) from s 2 ( t ) comprises the steps of : ( ( i ) determining a fi@@ gn@@ er-@@ vi@@ le distribution w ( t ) with the following function : ( t ) : obtaining a shift signal ( t ) of the aortic component ( t ) obtained by the following function : ( ( f ) : ( ( ( f ) : ( ( ( f ) : ( f )
always take thelin exactly as your doctor has told you . • you should always take thelin exactly as your doctor has told you . you should take thelin exactly as you told you told you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you . you .
allergic reactions , skin reactions or anaphylactic reactions are possible .
process for producing amino acids using whole cell catalysts according to claim 21 . process according to claim 26 , characterised in that methionine , valine , threonine , lysine or tert.@@ leucine is produced .
polska e@@ wo@@ pharma ag sp z o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o. o.
an apparatus according to any preceding claim , comprising : a mechanism comprising the portion of the skin of a patient at least above said selected surface coordinate ; and operating elements for selectively operating the mechanism to bias at least said portion of the skin of the patient for a selected duration before and during radiation .
multi-compartment dyeing device or dyeing &quot; kit &quot; , &quot; &quot; &quot; dyeing &quot; &quot; dyeing &quot; dyeing &quot; dyeing &quot; dyeing &quot; &quot; dyeing &quot; &quot; dyeing &quot; &quot; dyeing &quot; &quot; dyeing &quot; &quot; dyeing &quot; &quot; &quot; dyeing &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot; &quot;
process according to claim 2 , characterised in that a preparation of wholly or partially purified lectins is used .
if the combination is used the patients should be observed should the observed patients observed should be be observed should be the observed should be observed be should be be observed should be observed observed should be be observed be observed be observed be observed be observed be observed be be should be be observed be observed be observed be observed be observed be observed be observed be observed be observed be observed be observed be observed be observed be observed be observed be observed be observed be observed be observed be observed be observed be observed be observed be
tumors directed by metallo@@ -@@ matrix proteinases activated prodrugs
an air@@ cra@@ ft medical unit according to claim 1 , wherein the access opening is open with do@@ ors ( 36 , 38 ) and closes .
a method for producing an iron-@@ dextran composition for the treatment of iron deficiency , comprising the steps of : producing an iron dextran suspension , wherein the suspension comprises iron dextran particles with a beta-@@ fe@@ o ( oh ) core ; purifying the composition by removal of contaminated and by-@@ products , which comprises the step of : reacting the composition by removal of contaminated and by-@@ products , and purifying the iron / dextran composition in the form of iron-@@ dextran complexes in the form of a medicament for reducing anaemia in a human subject or animal
method according to one of claims 1 to 7 , characterized in that the core component is metered by means of a metering piston pump .
a prodrug composition according to any one of the preceding claims , wherein the fatty acid group has 22 carbon atoms and 6 double bonds .
1 . sialic acid conjugated protein derived from cow &apos;s milk , or sialic acid conjugated peptide obtained by treating the sialic acid conjugated protein with a protease , for use as a medicament or prophylactic against infections .
a composition comprising : ( a ) at least one lipophilic compound ; and ( b ) a textured glyceride component , containing any triglyceride species , and that at least 40 % of the triglyceride species comprises : the composition of claim 1 wherein the structured glyceride component comprises predominantly triglycerides .
an immunological composition comprising an isolated , purified ospa antigen from borrelia burgdorferi or a vector expressing the antigen and at least one additional antigen of a mammalian pathogen that is not borrelia burgdorferi , or a vector expressing the antigen , and optionally a pharmaceutically or veterinarily acceptable vector , or a vector expressing the at least one additional antigen , and wherein the at least one additional antigen is an adenovirus antigen , an adenovirus antigen , a coronavirus antigen , a parainfluenza antigen , and a parvovirus antigen .
an isolated dna encoding the gene encoding the kappa chain kappa chain the the the the the the the the kappa chain the the kappa the kappa the kappa the kappa the kappa the the kappa the the the the the the the the the the the the the the the the the the the the the kappa the the the kappa the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
no@@ day and din@@ ner ... it &apos;s gonna be serious .
compound or composition according to any one of claims 1 to 4 , characterized in that the compound or the compound of the composition is associated with a physiologically acceptable polymer .
the apparatus of claim 5 further comprising means carried by said arms for applying heat to each of said arms .
the method of claim 12 , further comprising removing the solvent from the pha filtrate to obtain the pha .
claims for the following contracting state : es a method for the preparation of a pharmaceutical composition wherein a modified glycoprotein hormone antagonist maintains the hormone in un@@ modified form , the hormone being modified , the hormone being modified , the hormone being being modified or removed by the hormone hormone the hormone antagonist being the hormone hormone the hormone antagonist being the hormone hormone the hormone hormone the hormone hormone the hormone hormone hormone hormone the hormone hormone the hormone hormone the hormone hormone the hormone hormone the hormone hormone the the hormone hormone the the the the
a proteinaceous blood product obtainable according to any of claims 1 to 5 , selected from blood plasma , serum , cryo@@ precipitate and cryo@@ depleted plasma , wherein the blood product is infected with virus and has been treated so that the level of inactivation of the virus is greater than 6 logarithmic units of at least 45 % and does not have more than physiologically acceptable values for lipid-@@ soluble process chemical .
box 552 2003 rn ha@@ ar@@ le@@ ar@@ le@@ ar@@ le@@ ar@@ le@@ ar@@ le@@ ar@@ le@@ ar@@ le@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@ ar@@
in type 1 patients , the small differences between the treatment groups ( 0.0@@ 10 l in favour of the comparator group ) resolved within 2 weeks of exubera therapy after 12 weeks of cessation of exubera therapy .
the method of claim 17 , wherein the output diameter is 10 to 300 % greater than the oriented diameter .
use according to any one of claims 1 to 4 , wherein the medicament or composition is for improving cognitive function in an animal patient suffering from age-related cognitive dysfunction .
the apparatus of claim 7 , wherein the tubular tip ( 25 ) is made of plastic material .
the article of claim 5 , wherein said article is a single filament dental floss having a polytetrafluoroethylene surface and said drug is selected from the group consisting of anti@@ calci@@ lemic agents , fluo@@ rides , coagul@@ ants , antibiotics and mixtures thereof .
a shut-off device for an air trap according to claim 1 or 2 , characterised in that two concentric pressure springs ( 9a , 9b ) engage on the planar head ( 6 ) .
the use of l-carnitine or alkano@@ yl-l-@@ l-carnitine , wherein the alkanoyl radical is linear or branched , 2 to 8 , preferably 2 to 6 carbon atoms , or the pharmacologically acceptable salts thereof and a hydroxyl or tetrahydroxy@@ stilbene for the preparation of a pharmaceutical composition for the prophylaxis and treatment of cardiovascular disorders , peripheral vascular disorders and peripheral diabetes neuropathy .
method and apparatus for analyzing eye motion .
catheter with improved connection between balloon and catheter
the method of claim 17 , further comprising a step of applying heat during compression of the intestinal submucosa .
you should check with your doctor or your pharmacist if your doctor or pharmacist or pharmacist or pharmacist or pharmacist or pharmacist or pharmacist or pharmacist or pharmacist or or pharmacist or pharmacist or or pharmacist or or pharmacist or or pharmacist or or pharmacist or or pharmacist or or pharmacist or or pharmacist or pharmacist or or pharmacist or pharmacist or or pharmacist or pharmacist or or pharmacist or pharmacist or or pharmacist or pharmacist or or pharmacist or or pharmacist or pharmacist or or pharmacist or or pharmacist or or pharmacist or or pharmacist or or pharmacist or
a pharmaceutical composition according to claim 5 for the treatment of pain , stroke , brain trauma , parkinson &apos;s disease , alzheimer &apos;s disease , depression , anxiety or migraine .
soni@@ de@@ gi@@ b was shown to be foe@@ to@@ toxic in rabbits , seen in mis@@ carriage and / or complete absorption of foe@@ tuses , as well as teratogenic , with severe malformations already undergoing very low exposure .
a method according to claim 1 , wherein the compression according to step ii ) is performed using a roller compaction technique or a impact technique .
treatment of hyper@@ andro@@ genicity of the skin using pregn@@ en@@ olone compositions .
a pancreatic controller according to claim 24 , wherein the pharmaceutical treatment comprises a pancreatic treatment .
wheelchair according to one of claims 13 to 25 , characterized in that the drive means consists of a toothed rod connected to the driver ( a3 ) and connected to a drive wheel , which is fixedly connected to the driven axis .
i mean , i &apos;ve been so good ho@@ b@@ bi@@ es , such as ho@@ gh@@ i or , um , the collection of this small ceramic , you know ?
the infusion will last approximately 10 minutes . 10 minutes of infusion . 10 minutes will last approximately 10 minutes approximately 10 minutes approximately 10 minutes approximately 10 minutes approximately 10 minutes 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10 10
method for transferring the ability of natural substances to synthesize natural organisms
a compound as claimed in claim 1 , wherein r 7 is methoxy . a compound as claimed in claim 1 wherein r 1 is 1 .
the catheter of claim 1 wherein an area is treated to inhibit association of materials with the lead tube , and optionally the surface being treated with heparin .
a method according to any preceding claim , wherein the insect repe@@ llant , insecticides , antimicrobial or antiallergic composition is distributed from a slow release formulation .
method for non-invasive examination of bone
the use of compounds of the formula i as claimed in one or more of claims 1 , 3 , 4 and 5 in all of its stereoisomeric forms and mixtures thereof in all ratios , and in the formula i and of their physiologically tolerable salts , in which in formula i and of its physiologically tolerable salts , and in the formula i and physiologically tolerable salts and of the formula i in and in particular , in the formula i and of and physiologically tolerable salts and of the formula i of and of its physiologically tolerable
use according to claim 1 or 2 , wherein a fraction of the pollen extract which is enriched in amino acids and / or peptides and / or proteinaceous substances is used for the preparation of the pharmaceutical preparation .
barium selen@@ ate is used in injectable depot formulations of veterinary medicines for the therapeutic and prophylactic treatment of selenium deficiency in cattle and sheep .
a process according to claim 1 , wherein a compound of a compound of formula a , a compound of claim 1 , a compound of a compound of formula a of a compound of claim 1 , of a compound of claim 1 of claim 1 , of a compound of claim 1 of claim 1 of claim 1 of claim 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
the implantable medical device of claim 16 , wherein the isocyanate of , blocked poly ( ethylene oxide ) ( ethylene oxide ( ethylene oxide ) ( ethylene ( ethylene oxide ) ( ( ethylene ) ( ethylene ) has ) has a ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )
screening assay for antibacterial compounds
a pharmaceutical formulation comprising an effective amount of an effective amount of the hepar@@ anase formulation of any one of claims 1 to 3 in combination with an acceptable pharmaceutical carrier . a composition comprising an effective amount of the hepar@@ anase formulation of any of claims 1 to 3 in combination with a pharmaceutically acceptable carrier of an effective amount of a hepar@@ anase formulation of any one of claims 1 to 3 of a pharmaceutically acceptable carrier of any one of claims 1 to 3 .
new use of local anaesthetics for the treatment of vascular headache
dr. grey is gonna connect the iliac vein with the p@@ ind@@ ta@@ ther , but the man has a marked deep thrombosis in his upper limbs and the iliac vein .
a method according to any one of claims 1 to 6 , wherein the chemically treated cells are present in a histological chemical section or a cyto@@ chemical sme@@ ar .
the method according to claim 23 , wherein separating includes precipitating rna and collecting the precipitate . the method according to claim 23 , wherein the separation includes precipitation of rna and collecting the precipitate . method according to claim 23 , wherein the separation includes precipitating the precipitate . the method according to claim 23 , wherein the separation includes precipitating the precipitate . the method according to claim 23 wherein the separating includes precipitating the precipitate to the precipitate . the method of claim 23 , wherein the separation includes precipitating the precipitate .
use of the combination according to any of claims 1-3 for the manufacture of a medicament for prophylactic or therapeutic treatment of fungal infections .
the method of claim 1 comprising the step of adding the binding solvent to the slurry of the cellulosic fiber material .
the thigh and abdomen are well suited for subcutaneous injection .
the effects of di@@ rac@@ tin were first tested in experimental models before being tested in humans in experimental models in experimental models in experimental models in experimental models .
labora@@ toires take@@ da sa 15 , qua@@ ai de dione bou@@ ton 9@@ 28@@ 16 pu@@ te@@ au@@ x cedex , france
a device as claimed in any one of claims 1 to 18 , characterised in that it consists of : a plurality of individual trays ( 1 ) having a first region ( 3 ) adapted for supporting a portion of food adapted for wearing a portion of food adapted for warm eating , and a second portion ( 130 ) which is adapted for use in the first region ( 3 ) of the tray , and a second portion ( 130 ) which is adapted to receive a suitable number of individual trays ( 1 ) which is
a filter for serial rotational tomography according to claim 1 or 2 , wherein the radiopaque fluid substance is filled into the container to an extent of 10 % to 50 % of the capacity of the container .
a kit according to claim 5 , wherein the tag sequences are random sequences produced in a dna synthesi@@ zer which have been delivered at least two nucleotides at each additional step .
if a haemophilia a patient is injected factor viii , the factor viii will bind to von willebrand factor ( vwf ) .
process according to one of claims 1 to 8 , characterized in that , , , , , , , , , 8 to 1 , 8 to 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 , 8 ,
50 ml of an acetate buffer ( 0.5 m , ph of about 4.6 ) is added to all four viscosity glasses with vigorous magnetic agitation , with the ph of the pectin solution to be above ph 4.0 .
a stable host cell line according to claim 7 , wherein the foreign gene encodes the entire amino acid sequence represented in figure 13 of the accompanying drawings .
if such inhibitors occur , it may be a sign that the amount of refacto af that you need typically to treat bleeding , increases and / or stop bleeding after treatment .
retractor according to claim 3 , characterized in that the middle val@@ ven@@ y-@@ holding rail ( 16 ) is provided with an actuating coupling ( 19 ) for connection to a member ( 3 ) of the operating instrument ( 25 ) and this is provided on the other member ( 3 ) a val@@ ve ( 17 ) or a val@@ val coupling ( 10 ) .
claims for the following contracting states : es , gr a process for preparing a compound of the formula : : es , gr a process for the preparation of a compound of the formula : or a pharmaceutically acceptable acid addition salt thereof : : r ¹ : r : r : r : r : r : r : r : r : r : r : r : r : r : r : r : r : r : r : r : r : r : r : r : r : r : r
esters of acidic polysaccharides according to claim 2 , wherein the alcohol is glycerol . the esters of the acidic polysaccharides of claim 2 wherein the alcohol wherein the alcohol is the alcohol .
a eukaryotic helper cell for the helper virus-@@ free packaging of gene vector dna into the viral particles of a herpes helper virus , at least comprising : ( a ) a herpes helper virus vector dna , at least 100 kbp , on one or two molecules , with a mutation which comprises a gene vector dna having at least the eukaryotic helper cell of claim 14 , wherein the herpes helper virus vector dna contains ebv dna as helper virus dna .
pack according to claims 1 to 3 , in which ( 1 ) and ( 2 ) are mixed in a single dosage form .
a process according to claim 4 , wherein the mixture of acetone and water or the mixture of acetonitrile and water has a water content of from 40 to 50 % by weight .
a surgical fastener system for surgical fastener platelets comprising a plurality of surgical fasteners fixed to at least one further object , whereby the fixation plates are detachable by tearing from the other object .
hygiene products provided with absorbent agents formed from or at least partially formed from a substrate as claimed in claims 1 to 16 .
mutagenesis testing using non-human animals containing test dna sequences .
chemical and physical in-use stability has been demonstrated for 10 days at 2 ° c – 8 ° c and has been demonstrated at 2 ° c ° c and 2 ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c ° c °
an oligonucleotide of the formula v 5 &apos; -@@ u@@ - ( o-@@ y@@ -o-@@ v ) x o-@@ y@@ -o-@@ w@@ -3 &apos; or an analogue thereof ; and r 3 is a group of the formula ia , c 1 -c 21 or an analogue thereof ; and r 3 is a group of the formula ia , c 1 -c 21 or an analogue thereof ; and r 3 is a group of the formula ia , c 1 -c 21 or an analogue thereof ; and r 3 is a group of the formula ia ,
adults very rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare : rare
sulphur pentafluoro@@ phenyl@@ pyrazo@@ les for controlling ecto@@ parasites
an aqueous dispersion according to claim 18 , wherein the polyols are polyalkylene glycols , poly@@ alkylene@@ sugars and other carbohydrates and poly@@ alkylene@@ glycerol .
the posterior tooth sha@@ de sha@@ de of claim 5 , wherein the means for selecting the percentage of cutting layer for covering a denture body includes a plurality of jaw tooth models ( 42 a - e ) which covers different percentages of a cutting layer covering the dental prosthesis body . the posterior tooth sha@@ de sha@@ de of claim 5 , wherein the means for selecting the percentage of the cutting layer for covering a denture body includes a plurality of the plurality of posterior tooth models ( 42 a - e ) .
the use of ifn@@ γ according to claim 1 for the prevention and treatment of diseases caused by combined primary immune deficiencies ( sc@@ id ) . of the ifn@@ γ of claim 1 of the ifn@@ γ of claim 1 of use of ifn@@ γ of claim 1 of claim 1 .
a method for producing a polypeptide having degrading activity for the polysaccharide , or a polysaccharide having identical activity thereof , characterized in that the transformant according to claim 7 is incubated and a polypeptide having a degradation activity for the sulfated fucose or the polysaccharide which is functionally identical to that of the incubated product .
the method of claim 3 , wherein said somatotropin is administered during a first period for increasing fertility , said method further comprising administering somatotropin during a second period to increase the yield of fat corrected milk in cows .
a product as claimed in any in any one of claims in any one of claims one in one of claims 1 of claims of claims of claims of claims of claims of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims of of claims
let &apos;s get an appointment at the rate and this would be that .
an enzyme according to claim 1 or 2 which is stable to a temperature of about 85 ° c in incubation at a ph of 7.0 for 60 minutes the enzyme according to claim 1 , 2 or 3 , which is derived from a microorganism .
4.4 special warnings and special precautions for use and precautions special warnings and precautions for use and special precautions special warnings and precautions special warnings and precautions special warnings and precautions for precautions and precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions precautions precautions precautions precautions precautions precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions for precautions precautions for precautions for precautions for precautions for precautions for precautions
granules according to claim 1 , characterized in that the neutral core consists of a substance selected from sugar , starch , mannitol , sorbitol , xylitol , cellulose , talc and mixtures thereof .
the feed or feed additive of claim 1 comprising all three of said crude drugs .
process for the preparation of hyaluronic acid .
self-expanding stent , catheter and method for treating blood vessel bifur@@ cations
treatment of heart failure with csf-1
use according to claim 25 , characterized in that the film thickness of the deposited polymer composition the deposited polymer composition is of the of the of the of the of the of the of the of the of the of the of the the of the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
( 1 h ) , days 28-@@ 31 , 35 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
use of a catechin compound for the manufacture of a medicament for reducing hair growth in mammals .
the plasma levels of the immunosuppressive agent of the immunosuppressive agent should be monitored when the immunosuppressive agent is the same as the haemoglobin begins to increase , the plasma levels of the immunosuppressive agent the immunosuppressive agent the immunosuppressive agent the immunosuppressive agent the immunosuppressive agent the immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent immunosuppressive agent
if you have overweight , stop taking your low calorie diet as directed .
idelalisib should not be co-administered with lovastatin or simvastatin .
additional syringes are provided when more than one syringe is needed per day .
use according to claim 6 , wherein the treatment-@@ free period is longer than the first and second treatment periods .
a compound of the formula ( i ) wherein : ( i ) ( c ) ( i ) ( i ) i ( i ) i ( i ) i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i
the powder is white to off-white .
the effects of far@@ rest@@ on were first tested in experimental models before being studied in humans in experimental models in experimental models in experimental models in experimental models .
an acoustically operating medical treatment device , in which electroacoustic transducer elements for use are used , and said electroacoustic transducer elements are caused , and said electroacoustic transducer elements are caused , comprising a sound wave to a diseased portion in a living body , in order to deliver a sound wave to a diseased portion in a living body , in order to deliver a sound wave to a diseased portion in a living body , in order to produce a sound wave to a diseased portion in a living body , in order to obtain a medical
the process of claim 32 wherein in step ( c ) the emulsifier having an hlb of less than 5 is selected from the group consisting of sorbitan sesqui@@ oleate , sorbitan trioleate , sorbitan tri@@ stearate , polyethylene sorbitan monostearate , cellulose lactate butyrate , and tetra@@ decanol .
take your bottle of vfend suspension .
device according to claim 2 , characterized in that the lever transmission comprises four levers ( 18 ; 19 ; 20 ; 21 ) , in which an upper lever ( 18 ) and a lower lever ( 21 ) are arranged in parallel , the upper lever ( 18 ) being connected to the respective clamping lever ( 8 ) and the connecting levers ( 19 ; 20 ) are connected to the base ( 2 ) , so that the upper lever ( 18 ) and the lower lever ( 21 ) are movable in parallel with or
a removable filter according to any one of the above claims , wherein the struts consist of a shape memory alloy with a transition temperature .
a blister pack assembly ( 3 ) comprising the blister pack unit ( 5 ) of claim 6 or 7 and a suction tube ( 7 ) , which is adapted for insertion into a respective of the blisters ( 21 , 22 ) and an inhalation channel ( 71 ) by which powder is inhaled .
a ph-@@ sensitive microcapsule comprising a non-@@ water miscible active ingredient in a shell , wherein the shell is incorporated in the shell with a free carboxylic acid groups incorporated therein , the coating being formed with a carboxylic acid group incorporated therein , a polyester having a free carboxylic acid group incorporated therein , a polyester having a free carboxylic acid group incorporated therein , a polyester having incorporated therein the polyamide , polyester and polyamide / polyester coating materials from about 2 : 1 to 3 : 1 , and the ratio by weight of the amino acid
the device of claim 1 or claim 2 , further comprising an expansion means ( 20 ) selected from the group consisting of os@@ mium agents , osmo@@ polymers and mixtures thereof in the second housing .
we present the compliance between the technical parameters of different mr scans and the quality of the ce-@@ m@@ ra which can be able to be able to perform a number of principles and practical guidelines for contrast medium injection .
composition and process for permanent shaping of hair based on n-@@ branched-chain alkyl-substituted mercapto@@ aceta@@ mides and methods for the permanent shaping of hair and method for the permanent shaping of the hair for the permanent shaping of the hair for a permanent method for the method for the method for the method for the method for the for the method
i &apos;m a surgeon who sa@@ ved his life today .
infusion suction ( i / s ) cassette according to claim 1 , characterized in that the valves ( 23 , 24 ) are compression valves or are designed as any other type adapted to interrupt the passage of sterile fluids .
piezo@@ ceramic shock-@@ wave source , in particular for lithotrip@@ sy , with a carrier ( t ) , a plurality of piezoelectric elements ( p ) , a plurality of pie@@ zo elements ( p ) , which are flat or in the form of a ball of the pie@@ zo elements ( p ) , the support ( t ) comprising the pie@@ zo elements ( p ) both laterally and on the back side , so that it comprises the pie@@ zo elements ( p ) both laterally and on the back side , so that it
the method of claim 14 or 15 , wherein the peptide sequence further comprises at least one terminal lys residue to anchor the sequence on the support .
5 . process according to one of claims 1 to 4 , characterized in that bio@@ conversion is carried out in a culture medium of the microorganism containing glyceryl trin@@ itrate .
in@@ ordered po@@ yer system for use with a medical device
composition according to any one of claims 29 to 33 , characterized in that the liquid fatty phase is present in the proportion of 2 to 98 % by weight relative to the total weight of the composition the weight of the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
l keep the push-button fully depressed until the needle is the injection the needle the the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the the push-button the push-button the the push-button the push-button the push-button the push-button the push-button the push-button the push-button the push-button
this leaflet was last approved in { mm / yyyy } { mm / yyyy } / yyyy /
speak to your doctor if you do not feel better if you feel better . • if you feel better , you feel better feel better if you feel better . • if you feel better feel better . better feel better . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
catheter and method of using such catheters .
dispersion according to any one of the preceding claims , characterized in that the mean diameter of the colloids is between 4 and 20 nm .
methods , systems and software for identifying functional biomolecules
a pharmaceutical composition according to claim 1 or 2 which comprises a carrier in the presence of water .
absorbent article having improved elastic design for improved appearance and improved containment
a method according to claim 1 or claim 2 , wherein the maturation phase is at least six months . a process according to claim 1 or claim 2 , wherein the maturation phase is at least six months .
a compound according to claim 1 wherein x and y together represent - ch ( r g ) ch ( r g ) - , -ch ( r g ) ch ( r g ) ch ( r g ) - , -o-ch ( r g ) ch ( r g ) - ; each r g is independently hydrogen , c 1-7 alkyl , aryl or ( aryl ) c 1-7 alkyl .
somavert powder for solution for injection peg@@ vi@@ som@@ ant subcutaneous use injection peg@@ vi@@ som@@ ant powder for injection peg@@ vi@@ som@@ ant vi@@ vi@@ vi@@ ant
the apparatus of claim 1 , wherein : a ) wherein : a ) wherein : a ) wherein : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a : a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
a block according to claim 1 or claim 2 wherein the component of the halogenating agent comprises one or more chlorinated cyan@@ uric acid derivative chlor@@ inating agents .
it contains the active substance filgrastim ( 30 and 48 million units ) .
a sphygmomanometer according to any one of claims 7 to 12 , characterised in that the ple@@ thysmo@@ graphic sensor ( 2 ) is a photoelectric reflex module ( 10 ) and a photodetector ( 11 ) arranged in the inner sheet ( 9 ) of a pressure cuff or pad as a pressure device ( 1 ) or on an opposite solid support near the measured artery ( 12 ) .
bradycardia , atrioventricular block , atrial fibrillation , , tachycardia , sinus syndrome , tachycardia , atrial fibrillation and tachycardia ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick ) sick )
the method of claim 1 , wherein the amount of dextran to be added is 0.2 to 5 parts by weight per part by weight of the platinum compound .
the pharmaceutical composition according to claim 1 , wherein y is ch 2 . claim 1 , wherein y is ch 2 , wherein y is ch 1 , wherein y is ch 1 , wherein y is ch 1 , wherein y is ch 2 ch 1 ch 2 , wherein y is ch 2 , ch 1 is ch 1 ch 1 ch 1 , 1 is 1 .
the use of claim 2 , wherein the emulsifier as a major component comprises the rice fermented rice fermented rice obtainable by fermenting rice with lactic acid bacteria with lactic acid lactic acid acid with substantially the absence of sodium chloride .
recombinant antigen containing a heterologous antigen in its sequence as a vaccine .
oligonucleotides for the in vitro detection of hiv-@@ retrovirus infections and methods for detecting hiv retroviruses .
a process according to any of the preceding claims wherein the polyanionic polysaccharide is alginate . a process according to any one of the preceding claims , wherein the polyanionic polysaccharide is alginate . the process of any one of the preceding claims , wherein the polyanionic polysaccharide is alginate . the method of any preceding claims wherein the polyanionic polysaccharide is alginate .
 once the needle is completely inserted into the skin , let the skin fold the skin , the skin fold , the skin , the skin .
date of first authorisation : 28 / 03 / 2011 date of first authorisation : 14 of authorisation : 14 of authorisation : : 14 of authorisation : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
process according to claim 12 or 13 , characterized in that the amount of active ingredient according to one or more of the preceding claims 1 to 8 is between 0.1 and 2.5 mg / kg of body weight per day .
as essential cations , sodium ( 134 + / - 38 mmol / l ) and potassium ( 37 + / - 16 mmol / l ) were to be considered .
implant according to one of claims 1 to 11 , characterized in that at least one of the through-@@ holes ( 28 ) is designed as a self-@@ compressing hole .
microemulsion concentrates for oral administration of water insoluble drugs for col@@ ings and process for producing the same
5-chloro-3- ( 4-pent@@ methylphenyl ) -6-@@ methyl@@ 2,1-@@ 2,3- d bi@@ pyridinyl in pure crystalline form and synthesis process
a method according to claim 1 , characterized in that the ty@@ st@@ up@@ -specific antigen or the plurality of ty@@ sk@@ -specific antigens comprise an hsv gy@@ ko@@ protein b ( gb ) polypeptide .
the plate system of claim 1 , wherein the locking element of claim 1 , claim 1 , claim 1 , claim 1 , claim 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1
a gel composition according to claim 1 , characterized in that the hydroxy fatty acid is 12-hydroxy@@ stearic acid . , according to claim 1 , characterized in , , , , , , , , , , , , , , , , , , , , , , the hydroxy fatty acid is 12-hydroxy@@ stearic acid .
50 micrograms fentanyl ( as citrate ( ( ( ( ( ( ( ( ( as citrate ) citrate ( ( ( ( ( ( ( ( ( ( citrate ) as citrate ) citrate citrate fentanyl ( citrate as citrate as citrate citrate ( ( citrate ( citrate ) as citrate ( citrate as citrate citrate citrate ( citrate as citrate as citrate ) as citrate as citrate as citrate as citrate ( citrate citrate as citrate citrate citrate as citrate citrate as citrate as citrate as citrate citrate as citrate as citrate as citrate as citrate as citrate
unit for the post-authorisation evaluation for the post-authorisation post-authorisation the post-authorisation the the the the the the the the
we describe an ortho@@ phone that had received a hh@@ s in its operative case .
a device according to any one of the preceding claims , characterised in that the fatty acid ester is myristic acid isopropyl ester .
process according to one of the preceding claims , characterized in that the reducing agent the reducing agent , that the the the agent is that is in that the agent is in that the the agent is in that the the agent is that is is the agent that is in is that the chemical is that the agent is that the the the the the the the the is that the the the the the the the the the that the the the the the the the the chemical the is the the the the the the the
composition containing tauro@@ lidine and / or ta@@ ur@@ ul@@ tam and / or ta@@ ur@@ ul@@ ta@@ tam or ta@@ ur@@ ta@@ ta@@ ta@@ ta@@ or or ta@@ ur@@ ul@@ ta@@ ta@@ ta@@ ta@@ ta@@ ta@@ ta@@ or or ta@@ ur@@ ul@@ ta@@ ta@@ ta@@ ta@@ ta@@ or or ta@@ ta@@ ur@@ ta@@ ta@@ ta@@ ta@@ ta@@ ta@@ or or ta@@ ur@@ ta@@ ta@@ ta@@ ta@@ or ta@@ ta@@ or ta@@ or ta@@ ur@@ ta@@ ta@@ or or ta@@ ta@@ ta@@ ta@@ ta@@ ta@@ or ta@@ ta@@ ta@@ ta@@ ta@@ or or ta@@ ta@@ ta@@ ta@@ ta@@ ta@@ ta@@
use of hydroxyapatite particles having an average size of 5 to 2000 µm as a β ₂ microglobulin adsorbent .
the effect of renal or hepatic impairment on the pharmacokinetics of effentora of
a protein according to claim 2 having a molecular weight of 52 kd .
acid reg@@ ur@@ g@@ itation ; difficulty swallowing ; pain in swallowing ; ulcer ulcers , chest pain , heartburn or pain or discomfort when swallowing
immuno@@ histological investigations with actino@@ antibodies showed positive responses in both musc@@ le-@@ differentiated tissue of angio@@ myo@@ lipo@@ ma and smooth muscle prolifera@@ tions of the lung .
a pharmaceutical composition according to claim 1 , wherein the non-@@ se@@ dating antihistamine comprises a@@ h@@ -1@@ 11@@ 325 , astemizole , azela@@ stine , cetirizine , e@@ ba@@ u@@ stin , ke@@ o@@ fen , lo@@ aban , lo@@ rati@@ stin , z@@ oc@@ aba@@ stine , me@@ qu@@ azine , ox@@ ato@@ mide , se@@ ast@@ stine , tazobactam , glu@@ elastin , terfenadine , or a pharmaceutically acceptable salt thereof .
take special care with galvus :
the garment of claim 1 , wherein said side flaps ( 1a ) are provided with a pair of substantially liquid impermeable leakage cuffs ( 6 ) extending in the longitudinal direction of said garment ( 1a ) and adjacent side edge portions ( 6a ) extending in the longitudinal direction ( 21 ) along the side edges ( 21 ) along the side edges of said side flaps ( 1a ) , and wherein said side flaps ( 6c ) are connected to said side panels ( 1a ) and wherein said side flaps are connected to said side
the target organs related to toxicity in cynomolgus monkeys were liver , kidneys , stomach , reproductive organs , thymus , spleen , and lymph nodes at more than 4@@ 50@@ times human exposure , and the liver , kidneys , stomach , reproductive organs , thymus , spleen , and lymph nodes are included in the rat and lymph node , and lymph , kidney , stomach , reproductive organs , thymus , spleen , and lymph nodes .
if an inherited predisposition is suspected , the woman should be referred to a specialist before you are able to respond to or against the use of a hormonal contraceptive .
propagation material of a transgenic plant according to claim 7 . a composition comprising an antimicrobial protein according to claim 1 together with an agricultu@@ rally acceptable carrier or excipient .
in a first insertion position ( fig . 2 ) for a knee joint with intact cruci@@ bands , the guide tracks ( 13 , 33 ) and guide body ( 21 , 41 ) permit both translational and rotational movement of the bearing part ( 49 ) on the tibia plateau ( 11 ) , while in a second application position ( fig . 1 ) for a knee joint with functional cross-@@ bands , only rotation of the bearing part ( 49 ) is possible .
the therapeutic cream of claim 2 , wherein the sucrose based ester is between 5 % and 15 % by weight of the cream as the surfactant .
i don &apos;t tru@@ st him .
in this paper , the german version is provided with first data for relief and validation .
the device of claim 10 , wherein the operation device is a pneumatic actuator apparatus ( 96 ) . the device of claim 10 wherein the operation device is a pneumatic operation device ( 96 ) . the device of claim 10 wherein the operation device is a pneumatic operation device ( 96 ) . a device of claim 10 wherein the actuator is a pneumatic actuating device ( 96 ) . a device of claim 10 wherein the operation device is a pneumatic operation device ( 96 ) .
the pharmaceutical composition of claim 19 , wherein the steroid is , the , , , , , , the steroid , the wherein the steroid is the , the , the , the steroid , the the the the the the the the the the the the the the the the steroid the the the steroid the the the the the the the the steroid steroid the steroid the the steroid the the steroid the the steroid the the steroid steroid the the steroid steroid steroid steroid steroid steroid steroid steroid steroid steroid steroid steroid steroid steroid steroid the
the method of claim 1 , wherein the vector , and the transposon , carry different selectable markers .
an absorbent structure ( 20 ) according to claim 1 , wherein said topsheet ( 28 ) comprises a first fibrous assembly ( 52 ) and said first fibrous assembly ( 52 ) is provided with openings , said apertures ( 50 ) being provided with a density between about three openings / cm 2 ( 20 openings per square inch ) and about 17 openings / cm 2 ( 111 openings per square inch ) .
the pharmaceutical composition of claim 17 wherein the amount of the first compound is at 1-4 parts by weight and the amount of the second compound is in 1-4 parts by weight .
the recommended dose depends on the disease being treated and the patient ’ s response .
a washing device according to claim 2 , further comprising a control circuit and a switch means connected between the battery and the pump .
a method as claimed in any one of claims 2 to 7 for providing a sterile connection to urinary drainage , wherein a drainage tube connected to a catheter implanted in the urethra of a patient in the urethra of a patient is connected to a second drainage container , with a second drainage tube , which is connected to a second drainage vessel , having a second drainage container which is connected to a patient in the urethra of a patient , and having a second drainage vessel , which is provided with a second drainage container , and
the catheter of claim 6 wherein said tip portion ( 22 ) is disposed concentrically over a distal portion ( 50 ) of said bridging portion ( 18 ) ( 18 ) of said bridging section ( 18 ) ( 18 ) . ) the catheter ( 22 ) of claim 6 wherein said tip portion ( 22 ) is disposed concentrically ) . ) . ) . ) . ) . ) . ) . ) ) ) . ) ) ) . ) ) ) . ) ) ) . ) ) ) . ) ) .
2-@@ carbamoyl-@@ 1,4,@@ 5,6-@@ tetrahydro@@ pyrazine of the general formula ( i ) , in which r , r and r are the same or different , and each for a straight or branched c1 to c3 alkyl group , a c@@ 5- to c6 cycloalkyl group , a c@@ 5- to c6 cycloalkyl group , and r has the same meaning or in which r and r have the same or different and have the same meaning or in which r and r have the same or different and have the same meaning , in the r and r
the method of claim 1 wherein the beads have a mean diameter in the range of from 5 µm to 100 µm . the process of claim 1 , wherein the beads have a mean diameter of from 5 µm to 100 µm .
an idio@@ type antibody which can form a complex with the antibodies of claim 9 , as obtained by immunizing an animal with the antibodies of claim 9 .
an implantable device which is coated with a composition according to claim 33 . a composition comprising a composition according to a composition according to claim a composition .
the use of mixtures of polyglycerol fatty acid esters according to claims 1 to 4 , wherein the degree of esterification of the polyglycerol mixtures is from 25 to 50 to 50 % to the degree to degree to degree of esterification of the mixture of polyglycerol .
solution according to either of claims 1 and 2 , characterized in that the solution comprises 0.001 to 0.02 parts ( w / v ) benzalkonium chloride .
the use of the composition of claim 7 wherein the steroid is estradiol . the use of the composition of claim of claim 7 wherein the steroid is estradiol . the composition of claim 7 wherein the steroid of the steroid is estradiol .
a container according to any one of the preceding claims , characterised in that it contains a liquid ( 5 ) and a propellent gas ( 7 ) for the liquid .
a compound according to claim 14 wherein pro@@ 55@@ 9-@@ gly@@ 560 of wild-type plasminogen are replaced by val-@@ glu-@@ leu-@@ gln-@@ gly-@@ leu-@@ arg-@@ pro .
the immunoassay according to claim 1 , wherein the immunoassay is used to test the quality of milk .
system according to claim 22 , characterized in that the easy folded regions ( 20 &apos; ) are formed with folding of the balloon portions ( 20 ) at the half of the half and the two folded portions ( 20 &quot; ) are formed with folding of the simply folded areas approximately in half .
a process for preparing a solution , characterized in that : a ) a composition in the form of an aqueous solution containing 0.1 to 20 % by weight of peracetic acid and 2 to 45 % by weight of acetic acid and from 2 to 45 % by weight of acetic acid and b ) from 0.005 to 2 % by weight of acetic acid and b ) from 0.005 to 2 % by weight of acetic acid and ( b ) from 0.005 to 2 % by weight of acetic acid and from 0.005 to 2 % by
and then a post@@ t ... put me on the bin@@ ic with mar@@ on .
the intraoperative ultrasonic probe of any one of claims 6 to 8 , wherein said angled member ( 30 , 32 , 34 ) comprises a circuit board ( 30 ) having said plurality of conductor tracks ( 36 ) thereon .
polska msd polska sp. z o. o o. o . polska polska polska polska sp. polska msd polska sp. polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska polska
- first general report of the european agency for the european agency the european agency for the european agency
tell your doctor if there is someone who falls in this group and if your doctor is if there is if there is if there is if there is there is there is there is there is there is there is there is there
the host cell of claim 7 , wherein the host cell is an animal cell .
the area will also help to monitor and give the web .
medical or dental-@@ medical treatment element according to claims 3 and 6 or 7 , characterized in that , in the case of , no .
the zinc oxide powder according to claim 3 , characterized in that it comprises a silicone oil as the hydrophobicity agent .
busilvex is available in 8 vials .
the advantages of the invention are in a reliable protection of the implant ( 1 ) against fracture or shearing .
a hand-held mixing apparatus according to any one of the preceding claims , wherein the mixing stirring arm ( 7 ) comprises a shaft ( 8 ) and at least one wing ( 9 ) extending outwardly from the shaft , said wing ( 9 ) extending toward the edge of the chamber and adapted to the inner shape of the chamber .
the mechanism of the underlying mechanism is not known . • the mechanism for the treatment of the underlying mechanism is unknown . • the mechanism is unknown . unknown : the mechanism is not unknown . unknown the mechanism is unknown . unknown mechanism is unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . unknown . . . . . . . .
the use of claim 12 or claim 13 wherein said nucleic acid is complexed with a conjugate with nucleic acid is complexed with nucleic acid is a nucleic acid is a nucleic acid binding agent .
constipation cholestagel may cause constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation or constipation , constipation , constipation or constipation or constipation , constipation or constipation or constipation or constipation or constipation , or constipation or constipation or constipation or constipation or constipation , constipation , constipation , constipation or constipation or constipation or constipation .
the use according to claim 9 , wherein r 4 and r 5 are independently hydrogen or cooc 3 h 2 groups .
a laser irradiation apparatus as claimed in claim 5 , wherein said body has a guide groove parallel to a direction of axial movement of said body to guide movement of said arm . a laser irradiation apparatus as claimed in claim 5 , wherein said body has a guide groove a guide groove to guide movement of said arm .
the invention relates to a method for the selective purification of bacterial cells and / or cell constituents , wherein the purification is carried out by means of a solid support .
a medical catheter for use in re@@ viewing a medical device ( 58 ) within a body cavity ( 54 ) having : a distal tip member ( 10 ) having an inner surface ( 36 ) having an inner surface ( 36 ) having an inner surface ( 36 ) having an inner surface ( 36 ) having an inner surface ( 36 ) having an inner surface ( 36 ) and an outer surface ( 38 ) , wherein said wall ( 34 ) has a distal end ( 24 ) with an inner surface ( 36 )
medicinal product subject to medical prescription subject to medicinal product subject to medical prescription . to medicinal product subject to medical prescription to medical prescription to medical medical medical prescription
a method according to claim 1 , characterized in that probes s1 and s3 are labelled with a fluorescent reporter dye , preferably a fluorescein derivative selected from 6-@@ carboxy-@@ fluorescein , tetrachloro@@ -6-@@ carboxy-@@ fluorescein , and , preferably , with a quencher , preferably a rhodamine derivative , preferably with 6-@@ carboxy@@ tetramethyl@@ rhodamine ( tam@@ ra ) .
the apparatus of claim 10 , further comprising a third valve ( 46 ) connected to the chamber outlet ( 38 ) , the third valve controlling the gas passage from the chamber ( 36 ) to a gas device .
therapy includes hemodynamic stabilization , blood pressure lowering and reduction of pulsed aortic flow ( wall tension ) .
enzymatic detergent additive , cleaning agent and washing process .
the use according to claim 1 , wherein the compound is present in an amount in an amount to provide an amount of from 10 to 200 µg / day . the use of claim 1 wherein the compound is present in an amount .
the method of claim 1 , wherein the oxidizing agent is excess benzo@@ quinone starting reagent of formula ii .
patients should be monitored closely to ensure that epoetin alfa is administered at the lowest approved dose required for the control of symptoms of anaemia .
there are insufficient data to treat hbv infected patients with antiviral therapy and concomitant therapy with tnf-@@ antagonists .
i mean , uh , i could do a debri@@ de@@ ment or , uh ...
response to response was defined by virological suppression of hbv ( hbv dna &lt; 0.7 meq / ml with b@@ dna ) and loss of hbeag ( in hbeag positive patients ) or alt &lt; 1.@@ 25@@ fold uln ( in hbeag negative patients ) .
the method of claim 3 , wherein the cell line is selected from human cell lines . method according to claim 3 , wherein the cell line is selected from human cell lines . method of claim 3 , wherein the cell line is selected from human cell lines . the method of claim 3 , wherein the cell line is selected from the group consisting of human cell lines . the method of claim 3 wherein the cell line is selected from the group consisting of human cell lines .
dental floss according to claim 7 , characterized in that the first component is incorporated in the binder .
head@@ bar side tendon for beds or the like
composition according to any one of the one of the preceding claims , characterized in that the the the dyestuff is present in the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
a pharmaceutical composition comprising the liposomal composition of any one of claims 1 to 32 and a pharmaceutically acceptable carrier or diluent . a pharmaceutically acceptable carrier or diluent of a pharmaceutically acceptable carrier carrier or carrier or diluent or diluent carrier or diluent or diluent or diluent or carrier or diluent or diluent or carrier or diluent or carrier or diluent or diluent or diluent . diluent or diluent . . diluent or diluent or diluent or diluent .
the method of claim 4 , wherein the target material is applied using an electro@@ plating .
if you weigh more than 100 kg more than 100 kg than 100 kg 100 mg 100 mg 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
at the same time , an effective risk of infection can be avoided .
the pharmaceutical composition of claim 1 , comprising an acryloyl dist@@ amycin derivative , optionally in the form of a pharmaceutically acceptable salt selected from the group consisting of : 1 . n- ( 5- { &#91; ( 2- { &#91; ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (
4.5 interaction with other medicinal products with other medicinal products interaction with other medicinal products and other forms of interaction interaction with other medicinal products and other forms of interaction other other other other other other other other other other other other other other other other other other other other other other other other other other other other other other other other other other forms of interaction other other other forms of interaction other forms of other forms of
a method as claimed in claim 10 , in which the protein or polypeptide comprises an amino acid sequence selected from seq id nos : 137 and 138 . a method as claimed in claim 10 , in which the protein or polypeptide comprises an amino acid sequence selected from seq id nos : 137 in a 138 and 138 amino acid sequence according to claim 10 , wherein the protein or polypeptide comprises an amino acid sequence selected from seq id nos : 137 and 138 .
a method for improving the skin , mucosa and tissue tolerance of anionic surfactants , characterized in that the surface-active or surfactant solutions are added with ethoxylated alcohols which follow the formula ( iii ) , r 3 o- ( eo ) x -z ( iii ) wherein r 3 is an alkyl group having 6 to 22 c atoms , x represents an integer of 2 to 10 carbon atoms , and z represents a hydroxycarboxylic acid residue .
device according to claim 6 , characterized in that the superstructure unit ( 12 ) is designed as a ser@@ ft configuration .
this was an increase in the previous year that corresponds to the schedule .
the composition of claim 2 , wherein the plasticizer is a solvent for the n-vinyl lactam monomer and the multiple-@@ ethylenically unsaturated compound .
synergistic combination of a ginkgo biloba extract and β-@@ glucan or one of its derivatives .
data from both paediatric age groups were supplemented with data from the use of levetiracetam since marketing .
use according to claim 4 , characterized in that substrates are used as the effectors .
device for treating , in particular rinsing of bones , of wounds , the abdominal cavity or the like .
tap the syringe gently to the syringe to the top the the syringe the the syringe the the the syringe the the the syringe the the the syringe the the the syringe the the the syringe the the the syringe the the syringe the the syringe the the syringe the the syringe the the syringe the the syringe the the syringe the the syringe the the syringe the the the the the the the the the the the the the the the the the the syringe syringe the the the the the the the the the syringe syringe the syringe
the system of claim 2 , wherein the connector housing ( 6@@ 21a ) has at least one auxiliary channel which is in fluid communication with at least one auxiliary lumen defined in the outer tube and is separate from the apparatus lumen , wherein the main channel and the auxiliary channel diver@@ ge from the outer tube so that it does not intersect in the connector housing .
he stops the osteocla@@ sts , the cells in the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
the application was initiated in accordance with article 12 ( 3 ) of directive 2001 / 82 / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec / ec
a flowable composition comprising a chemically solidifying gelling agent , wherein at least a portion of the gelling agent has been rendered chemically for solidification , and wherein the chemically solidified gelling agent is predominantly in the form of micro@@ gels having an average equivalent diameter of less than 100 microns , and wherein the chemically solidified gelling agent is predominantly a gelling agent selected from the group consisting of pectin , io@@ ta-@@ carrageenan , kappa carrageenan , fur@@ cel@@ ar@@ ane , and mixtures thereof , and / or ( b ) the micro@@ gels are un@@ regularly
a formulation according to claim 1 , wherein the lecithin is selected from the group consisting of saturated phosphatidylcholine , unsaturated phosphatidylcholine , phosphatidylserine , sphingo@@ myelin , phosphatidylethanolamine , cephal@@ ine and lyso@@ lecithin .
bactericidal serum test for n. meningitidis specific antisera
the use of a compound of any of claims 1 to 7 , in the manufacture of a medicament of the prevention of amyloidosis of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a
information in bra@@ ille axura 10 mg tablets 42 particulars to appear on the outer packaging carton the outer packaging carton on outer packaging the outer carton outer packaging the outer packaging the outer packaging the outer packaging the the the the the the the the the outer the outer the the outer packaging outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer outer the
split influenza virus , inactivated , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
a dressing according to any preceding claim , characterised in that it contains a vaso@@ dilating agent such as nitroglycerin .
opioids ) as maintenance therapy .
similar findings are available with the approved posology of darunavir / ritonavir with the approved the the the approved the the the the the the the the the the the the the
the invention relates to a method for producing an enzyme granulate from an aqueous purified enzyme solution , characterized by steps ( a ) ion exchange chromatography , while the enzyme of interest remains in solution , ( b ) adjusting a suitable concentration and ( c ) granulation .
a sof@@ t@@ gel fill formulation according to any one of the preceding claims , wherein the surfactant is selected from the group consisting of esters of d-@@ alpha-@@ tocopheryl , polyoxyethylene castor oil derivatives , and polyglyco@@ ly@@ zed glycerides . , respectively , of the gel .
bicyclic carbamoyl@@ pyridone derivative having hiv integrase inhibitory activity
a method as claimed in any one of the preceding claims , wherein the isolated vessel is : ( c ) a vein , which is just subjected to an arterial venous anastomo@@ tic surgery , or ( d ) a vessel suitable for use in a bypass procedure .
a pharmaceutical composition according to claim 1 , wherein the fviii is derived from a natural source .
the apparatus of any one of claims 1 to 6 , further comprising a spring ( 412 ) for retracting the distal segment of the inner cannula toward the proximal segment of the inner cannula at the return movement of the distal segment of the inner cannula .
particulate vector according to any one of claims 1 to 4 , characterized in that it contains a diameter of between 20 and 200 nm , of particulate vector according to one of claims 1 to 5 , active agent , anti@@ malarial , anti-@@ asthmatic agents , anti-@@ tumoral agents , anti@@ malarial agents , anti-@@ asthmatic agents , compounds acting on the skin of the milk fatty globules .
oral use oral use oral use oral use oral use oral use oral use use
an absorbent article ( 20 ) according to any preceding claim , characterized in that said absorbent article ( 20 ) is elastic in response to laterally directed compressive compressive forces .
the highest serum concentrations of the glucuronide are 2 to 3 hours after defe@@ ri@@ prone administration .
a method for the production of monoclonal antibodies according to claim 20 , wherein the non-@@ biological substrate is selected from nitrocellulose , nylon and polytetrafluoroethylene membrane .
the apparatus of claim 4 , wherein an arcuate flange ( 262 ; 362 ) extends from the rim ( 252 ; 352 ) and defining a stress receiving portion ( 254 ; 354 ) between the flange ( 262 ; 362 ) and the rim ( 252 ; 352 ) .
may cause dangerous reduction of your blood pressure .
0.1 0.0 0.0 0.1 0.0 0.0 0.2
use of a compound or combination of a compound of a a compound of a compound of a compound of a a a compound of a a a a a a a a a a compound of a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
the drainage chamber ( 12 ) of claim 1 wherein the pore size of the porous material ( 48 ) is from 0.45 µm to 5.0 µm .
a cyclic octa@@ peptide of claim 22 , wherein a 6 is a a a , a of a a is a a a a , a a cyclic octa@@ peptide a is a a a a a peptide of claim a a of a a peptide of peptide a peptide of claim of peptide a peptide of of peptide a a peptide of of peptide a a peptide of of of of of of of of of of of of of of of of of of of of of of peptide is a a a peptide of of of
introna 10 million iu / ml solution for injection or solution for injection or infusion for injection or injection for injection or injection for injection or injection injection or injection for injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection or injection injection
use according to any one of the preceding claims , the concentration of the compounds of one of the claims of one of the claims of the the of the the of the of the the of the claims of the the the of the the of the the of the the of the of the of of the of of the of of the the the of of the the of of the the of of the the the the the the of of the the of of of the of the claims the of of the of the
use according to any of claims 6 to 10 to to to any of claims 6 to to to to to claims to to claims to to claims to to any of claims to to any of claims of to any of claims of to any of claims of any of claims of of any of claims of of any of claims of of of claims of of of of claims of of of of of claims of of of of of of claims of of of of of of of of claims of of of of of of of
device for the disintegration of concre@@ tions in a medium or animal .
a process for preparing a nhr 1 r 2 r 3 + salt of omeprazole and esomeprazole according to any one of claims 1 to 10 , wherein : a ) dissolving omeprazole or esomeprazole in an organic solvent ; b ) is added to a nr 1 r 2 r 3 compound and the desired salt ; c ) the obtained salt of omeprazole or esomeprazole is isolated and dried .
patients who need more than 8 need for inha@@ lations should speak to their doctor as their asthma therapy may need to be re@@ considered to be re@@ considered to be more than 8 need to take their asthma therapy . • patients who need more than 8 need to take their need to take to their doctor .
2 micrograms 2 micrograms 2 micrograms 2 micrograms 2 micrograms 2 micrograms 2 micrograms
5 years after dilution : 24 hours .
a method of obtaining stable factor viii / vw@@ f-@@ complex , wherein factor viii / vw@@ f-@@ complex / vw@@ f-@@ complex / vw@@ f-@@ complex / vw@@ f-@@ complex / vw@@ f-@@ complex / vw@@ f-@@ complex / vw@@ f-@@ complex / vw@@ f-@@ complex vw@@ f-@@ vw@@ f-@@ vw@@ f-@@ complex vw@@ f-@@ vw@@ f-@@ vw@@ f-@@ f-@@ vw@@ f-@@ f-@@ vw@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@ f-@@
nederland fort do@@ dge animal health bene@@ lu@@ x b.v. bene@@ lu@@ x b. v. b. v. b. x fort do@@ dge animal health bene@@ lu@@ x b. b. b. b. b. b. b. b. lu@@ x lu@@ x animal health bene@@ lu@@ x b. b.
the use of claim 12 , wherein the medicament of claim 12 wherein the medicament is the medicament the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
a host plasmid system according to claim 33 , characterized in that the host consists of the escherichia coli strain a@@ 4@@ 200 ( atcc deposit no. 5@@ 32@@ 18 with ph@@ g@@ 44 and the f &apos; -@@ gal plasmid , and designated a 43@@ 46 ) . a host / plasmid system according to claim 33 .
surgical equipment for dental implant , dental implant , drilling instrument and components
8-azabicyclo ¬ 3.2.1 oct@@ ene derivatives in labelled form and use of 8-azabicyclo ¬ 3.2.1 oct@@ 2-@@ ene derivatives in labelled and un@@ labelled form
the use of claim 39 , wherein the biologically active material is insulin and the disease is diabetes .
the surgical instrument of claim 3 , wherein the external restriction means comprises different diameters on the hollow vibrating needle ( 16 ) so that a distal portion of the hollow , , , , , , , , , , , , , , , , , , a distal , distal , a distal , a distal , a distal , a distal , a distal , a distal , a distal , a distal , a distal , a distal , a distal , a distal , a distal distal distal distal distal distal distal distal distal
a method of producing a tapered tip wire member having the steps : rotatable attaching a plurality of wire-@@ type ( 31 ) to a support means ( 21 ) , wherein the support means ( 21 ) is coupled to a support means ( 21 ) , the support means ( 21 ) having a succession of processing means ( 31 ) , the support means ( 21 ) having a succession of processing means ( 31 ) , the support means ( 21 ) being moved to a train of the beam ( 31 ) with each blank
porphyrin complex compounds consisting of a meso@@ -tetra@@ phenyl porphyrin ligand , optionally at least one ion of an element of atomic plants 13 , 21 , 32 , 50 , or 5@@ 7-@@ 83 , and optionally cations of inorganic and / or organic bases , amino acids or amino acid amides are valuable diagnostics and therapeutics .
this means that pramipexole teva is similar to a ‘ reference medicine ’ a ‘ reference medicine ’ already authorised in ’ medicine ’ ’ ’ medicine medicine ’ ’ medicine already authorised ’ medicine ’ medicine ’ medicine ’ already authorised medicine ’ medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’ medicine medicine ’
solid emulsion according to one of the preceding claims , characterized in that the solid emulsion of the solid emulsion of the the solid emulsion of the solid emulsion is of the preceding claims the solid emulsion of one of the the preceding claims of the the preceding claims the solid emulsion of the the the preceding claims of the the preceding the the the the the preceding the solid the the the the the the the the preceding the the the the the solid the the solid the the the of the the preceding the the the solid the
marketing authorisation holder roche registration limited 6 f@@ alcon way shire park wel@@ w@@ yn gar@@ den city alcon 6 tw 6 w@@ w@@ shire park roche registration limited 6 f@@ alcon way shire park wel@@ w@@ yn gar@@ den city alcon w@@ 6 w@@ w@@ shire park park shire park park shire park park shire park park shire park park shire park park shire park park shire park park shire park park shire park shire park shire park shire park shire park shire park shire park shire park shire park shire park shire park shire park shire park shire
position pa@@ pers to seek and submit :
&quot; heterocyclyl &quot; on a stable 5 membered monocyclic or 8-@@ 11-@@ membered bicyclic heterocycle residue , which is either saturated or unsaturated , and wherein each heterocycle is selected from carbon atoms and 1 to 4 heteroatoms selected from nitrogen , oxygen and sulfur ; and the pharmaceutically acceptable derivatives thereof .
the apparatus of claim 9 , wherein the sensing elements ( 15 , 72 ) are adapted and attached to the band means ( 12 ) such that at each time less than all of the sensing elements are tension .
con@@ glutinin fragments , their preparation and use .
steady-state auc and cmax of tekturna increased by 50 % by 50 % by 50 % by 50 % .
use according to any of the preceding claims , characterised in that the concentration of the second compound is 5 to 20 % by weight , based on the concentration of oligosaccharides , the concentration of the second compound in the form of any of the of claims the the of the compounds of any one of the preceding claims .
therefore , patients treated with ciprofloxacin should be advised to avoid exposure to sunlight or uv light during treatment ( see section 4.8 ) .
the invention relates to peptides which are suitable for inhibiting hbv cor@@ e proteins , dnas encoding them and the use of both , especially for inhibiting hbv replication .
device for the three-dimensional measurement of objects ( 1.1 ) with at least one electronic image transducer ( 3.5 ) , at least one optical image ( 3.4 ) for the image of the object on the image transducer ( 3.5 ) and at least one beam source ( 2.7 ) for the image of the object , characterized in that the means ( 2.1 to 2.7 ) for the pixel of the pattern are spatially connectable to the means ( 3.1 to 3.5 ) for the image acquisition of the image of the image .
use of a polypeptide according to claim 9 , wherein the immune syste@@ m-@@ related cell damage is caused by an autoimmune disease , a graft versus host response or a host vs. graft reaction .
low to moderate ( 8 to 20 % ) resistance rates to ciprofloxacin have been observed with indicator isolates of e. coli for the different target species in different european countries .
the liposome of claim 12 , wherein the additional lipid is a phosphatidylethanolamine . the liposome of claim 12 wherein the additive lipid is the lipid of claim 12 wherein the lipid is the liposome of claim 12 wherein the the the the lipid is a phosphatidylethanolamine .
the disposable balloon subassembly of any one of claims 23 to 25 , wherein the expandable balloon ( 22 ) is within the rigid sleeve ( 26 ) whereby the expandable balloon ( 22 ) is protected prior to damage prior to use .
in a tolerance study of je@@ se@@ se@@ y cows , the safety margin of this medicinal product was 1.5 times the highest recommended dose ( an overdose of 60 μg / kg administered to three doses ) .
products according to claim 13 , wherein the sn-@@ 38 prodrug is the cam@@ pto@@ s@@ ar .
and then in the ber@@ ner office of the inst@@ itor , he started from 19@@ 72 to 19@@ 76 .
expression of retroviral gag proteins in eukaryotic cells .
the indication for both forms of immunotherapy should be strictly placed .
if you are allergic to memantine hydrochloride or to any are you allergic to memantine hydrochloride to you to are allergic
claims for the following contracting states : at , be , ch , , , , , dk , fr , gb , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
- sudden numbness or weakness in the face , arm or leg , especially on a
granulate according to claim 1 or 2 , characterized in that the pores in the granules each represent from 10 % to 60 % by volume relative to the volume of the granule .
the use of at least one derivative of the following formula ( i ) in a cosmetic composition comprising a cosmetically acceptable medium and is intended for topical application to the skin and / or skin appen@@ dages , for bleaching human skin , body hair or hair , for bleaching the skin , body hair or hair , for bleaching the skin , body hair or hair , for bleaching the human skin , body hair or hair , for bleaching the human skin , body hair or hair , for bleaching the skin , body hair or hair
prion free collagen and collagen derived products and implants for various biomedical applications and methods for their preparation .
method for detecting cathepsin , asparag@@ yl-@@ endopeptidase and iso@@ zymes thereof , and leuko@@ cy@@ tin
right , but not any brain tumor .
a pharmaceutical composition comprising a compound according to any a compound according to any a compound according to any according to any according to any according to any according to to according to to according to to according to to according to to to to according to to to to according to to to to according to to to to according to to to to according to to to to according to to to to according to to to according to to to to according to to to to according to to to to according to to to to according
antisense oligonucleotides inhibiting the delivery level of hi@@ f-1
use of a fatty acyl derivative according to any one of claims 1 to 6 in the manufacture of a medicament for use in the treatment of a viral infection .
an apparatus according to any of claims 1-8 , wherein the transverse scanning means ( 86 , 100 , 110 , 95 ) includes means for performing a two-dimensional transverse scan , the depth in the longitudinal direction in the sample is determined by the depth change means in the longitudinal direction ( 46 ) .
29 internal and external setting procedures were performed .
severe birth defects have been observed in unborn animals and in babies in women treated with efavirenz and with efavirenz , emtricitabine and tenofovir and treated in women with efavirenz , and with efavirenz and tenofovir and tenofovir .
182 erythropoietin is a growth factor that is primarily a growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor growth factor
make sure that the tablet dissolves in the mouth .
1@@ è@@ re avenue 20@@ 65 m – l. i. d f-@@ 0@@ 65 – 20@@ 0@@ 65 – 0@@ 65 – 0@@ 65@@ 16 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@ 0@@
composition according to claim 3 , characterized in that the non-@@ film-forming polymer is chosen from polyesters , poly@@ ester@@ amides , alkyl@@ resins , polyacrylic compounds , polyvinyl compounds , polyurethanes , poly@@ styrene@@ s , natural or modified hydrocarbons and their derivatives and natural or modified natural globular proteins , such as natural or modified natural globular proteins , which are used alone or in admixture .
the process as claimed in claim 2 , in which the water-miscible organic solvent is methyl acetate . the process as claimed in claim 2 wherein the water-miscible organic solvent organic solvent is water-miscible organic solvent .
a re@@ p polypeptide that allows in di@@ cyto@@ ste@@ ium spp the extrac@@ h@@ romo@@ somal replication of a recombinant plasmid contains one of plasmids dd@@ p2 or pd@@ 1 derived from plasmids dd@@ p2 or pd@@ 1 , the plasmid but lacks functional genes which are lacking for extrac@@ h@@ romo@@ somal replication in wild-type dic@@ yo@@ ste@@ lium spp , and further wherein the amino acid sequence of the re@@ p polypeptide is substantially the same as shown in figure 2 .
a device as claimed in any one of the preceding claims , characterised in that the composite structure comprises an impermeable or partially impermeable layer ( 115 ) . the device of one of the preceding claims , the the structure of the composite , the structure of the the structure of the the the the the the the the preceding structure . the the device of the preceding claims , the structure of the the the claims .
a polymeric composition prepared by the co-@@ polymerization of one or more macro@@ monomers as defined in claim 1 as defined in one or more hydrophilic monomers in non-@@ aroma@@ tic-@@ based monomers as defined in claim 1 .
a plant according to claim 10 , wherein the construct further comprises a sequence encoding a chloroplast transit peptide .
3- &#91; 2- ( 3-@@ azoc@@ ylamino-@@ 2-oxo-@@ 2h-@@ pyridin-1-yl ) acetylamino &#93; -4-@@ oxopent@@ anoic acid derivatives and their use as cas@@ pase inhibitors
a method of manufacturing a disposable pull-@@ on diaper ( 10 ) according to claim 12 , characterized in that said steps further comprise : elastic@@ ating the lateral zone of the cover sheet ( 24 ) to form elastic panels ( 30 ) with a lateral edge ( 25 ) , along a boundary line between the base structure ( 20 ) and each elastic panel ( 30 ) ; folding the elastic panel ( 30 ) along a boundary line between the base structure ( 20 ) and each elastic panel ( 30 ) , along the boundary
since 19@@ 50@@ s , as tablets and capsules with immediate release , which contains methylphenidate immediate release and modified-release tablets , which release a part of the active substance or the entire active substance is available more slowly over several hours .
process according to claim 1 , characterized in that , in a plurality , , plasma treatment is to be cleaved in a plurality of round .
the cutting system according to any one of claims 13 to 17 , further comprising a position detecting device ( 80 ) for determining a position of the elongate object relative to the at least one round saw blade such that the vertically movable member and the horizontally movable element can be positioned correctly for the execution of an incision .
use of a plant cell as claimed in as claimed in claim 21 to 29 for its regeneration from a sugar beet plant resistant to b@@ ny@@ vv . . the plant cell as claimed in as claimed in claim 1 . a plant cell as claimed in claimed in claimed in claimed in claimed in seq id no as claimed in claimed in claimed in seq id no . in a claimed in as claimed in claimed in claimed in claimed in seq id as claimed in claimed in claimed in in seq id no .
a wri@@ st-@@ worn device according to claim 1 , wherein the rotation stop extends at an angle within a range of about 105 ° to about 125 ° to the bottom member of the main housing .
antisense oligonucleotides for inhibiting vegf expression
an aqueous solution having the ability to form a foam which comprises a greater proportion of water in which 1 to 20 % by weight of a fro@@ fiable agent and 10 to 1500 mg / l chlorine dioxide are dissolved , the chlorine dioxide being produced outside the solution and then dissolved therein .
immobilized nucleic acid libraries , process for their preparation and their use in sequencing and screening methods
the method of claim 9 , wherein the baculovirus expression vector is the baculovirus expression vector of any one of claims 1 to 6 .
process according to one of claims 13 to 15 , characterized in that the sintered shaped body is treated with a liquid and / or vapour alkali metal or alkaline earth metal .
device according to claim 1 or 2 , in which the washer ( 20 ) rests on the base ( 1 &apos; ) via a lubricant ( 9 &apos; ) .
biotransformation the metabolic pathways following the buccal the buccal administration of effentora the clinical trials of administration of effentora have not been the clinical of clinical studies .
in the post-marketing experience , angioedema or angio@@ ede@@ m-@@ like reactions have been reported when aliskiren have been co-administered with ace@@ when and / or ar@@ bs or have been reported ( see section 4.8 ) ( see section 4.8 ) .
use according to claim 94 , wherein the disorder is diarrhoea . the use according to claim 94 , wherein the disorder is diarrhoea . the use according to claim 94 , wherein the disorder is diarrhoea . the use according to claim 94 , wherein the disorder is diarrhoea .
103 particulars to appear on the outer packaging and the immediate packaging the outer packaging the outer packaging to the outer packaging on the immediate packaging the outer packaging on the outer packaging is on the outer packaging on the immediate packaging on the carton on the outer packaging on the carton on the outer packaging on the outer packaging on the outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging outer packaging
the method of claim 40 , wherein the selective release of mass intensity occurs upon hybridization of the probe to the amplified target molecule and the nuclease digestion of the complex probe : amplified target nucleic acid molecule .
apparatus according to any preceding claim , wherein the extra@@ systole counter comprises at least one counting threshold , further comprising means for suppressing and inducing specific functions of the active implantable medical device when one of the determined pig of the extra@@ systole counter is performed .
the method of claim 1 , wherein the primer the primer is oligo dt .
a process for preparing a compound according to claim 1 , comprising : ( a ) reacting a compound of formula ( ii ) : wherein : there are : to obtain a compound of formula ( i ) : wherein : r , r , r , y , a and w are as defined above and x is a compound of formula ( i ) , in which x , r and r have the meanings defined above , with a compound of formula ( iii ) in order to obtain a compound of formula ( i )
cholesterol glycerol tri@@ folate cole@@ fos@@ ce@@ le@@ oleate ( dop@@ c ) 1- ( 1,2-di@@ palmitoyl-@@ 3-@@ sn-@@ phosphatid@@ yl ) glycerol ( dpp@@ g ) sodium chloride water for injections . the sodium chloride water for injections is water for injections . for injections , water for injections . for injections , water for injections . for injections , water for injections . for injections . for injections . for injections for injections . for injections . for injections . for injections . for injections . for injections . for injections . for injections . . .
the method of claim 13 , wherein the finger of said person is transmitted to said light .
method and apparatus for treatment with ionophore or bile therapy .
a process according to claim 1 for the preparation of compounds of formula i wherein r is either c ₂ -c ₇ alkyl , c ₂ -c ₇ alkenyl , c ₂ -c ₇ alkynyl or c ₁ -c ₄ -alkoxy-c ₁ -c ₄ alkyl and r ¹ , r ² and r ³ are hydrogen , and salts thereof .
administration of fosamprenavir in the tablet formulation after standardi@@ sed high-@@ fat meal ( 9@@ 67 k@@ cal , 67 g of fat , 33 g protein , 58 g carbohydrates ) was associated with no change in the pharmacokinetics ( cmax , tmax or auc ) of amprenavir compared to the fasted state .
a biopsy forceps according to claim 4 , wherein the medical instrument comprises at least one guidewire ( 712 ) .
method and apparatus for monitoring the circulatory control system by spectral analysis of heart rate .
an antioxidant extract comprising 2 &apos; -o-@@ glucosyl@@ iso@@ vi@@ tex@@ in obtainable by a process comprising : ( a ) a first green juice produced from the green leaves of a plant of the gra@@ mine@@ e family or a dry powder thereof ; or ( b ) a second green juice , or a dry powder thereof ; or a dry powder thereof ; or a dry powder thereof ; or a dry powder thereof ; or a dry powder thereof ; with a water content of up to 80 percent by volume , and optionally in the
a method of increasing the production of 4-@@ hb@@ -containing polymers in a host microorganism , the method comprising stably incorporating a gene encoding a heterologous enzyme selected from the group consisting of a polyhydroxyalkanoate synthase and a 4-@@ hb@@ -coa transferase a a a a a a of a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
double side arm training and method of using same
an electrosurgical handpiece ( 10 ) for use in minimally inverting surgery according to claim 4 , wherein said prongs comprise a first prong and a second prong , said second ridges extending from said tubular housing than said first prong .
derivatives of n- ( 3-aminopropyl ) -3h-@@ 5,6,7,8-tetrahydro@@ naphthalene@@ naphthalene@@ -2-ol with neuroprotective and anti@@ rheumatic properties , their preparation and their therapeutical use .
rare ( may affect up to 1 in 1,000 people may affect up to 1 in 1,000 people ) in 1 in
param@@ un@@ ity inducers according to claim 2 or 3 , characterized in that the pox@@ viruses are the viruses in that the pox@@ viruses the pox@@ viruses are viruses the pox@@ ity inducers are the viruses that are viruses that are viruses that are viruses that are the pox@@ viruses in the viruses the pox@@ ity the pox@@ viruses are viruses that are viruses in the viruses that are the pox@@ viruses viruses the the pox@@ ity viruses are pox@@ the the pox@@ viruses that the pox@@ viruses are viruses viruses viruses viruses viruses the the the the pox@@
production of protein microparticles by precipitate an anti-solvent .
use according to claim 1 wherein 11- ( 3-dimethylamino@@ propy@@ lidene ) -6,@@ 11-dihydro@@ dibenz ( b ) ) ( -6,@@ ) ( 3-dimethylamino@@ propy@@ propy@@ lidene ) -6,@@ ( 11-dihydro@@ propy@@ lidene ) ) ) -6,@@ 11-dihydro@@ dibenz ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )
the method of claim 4 , wherein the plurality of unit specific markers are two units , a first unit at a first end of the polymer and a second unit at an opposite second end of the polymer .
a compound according to claim 11 in the form of a salt with hydrochloric , hydrobromic or io@@ io@@ dic acid .
latvija glenmark pharmaceuticals europe limited tél / tel : + 44 tél / tél / / tel : + tél / tél / tél / tél / 0 tél / 0 / 0 / tél tél / / tél / tel / tél / tél / tél / tél / : / tél / tél / : tel / : / tél / tel / tél / tél / / / tel / / / tel / / tel / tel : tel / tel / tel : / tel / : tel / : tel / : / /
claims for the following contracting states : be , ch , de , fr , gb , it , li , lu , nl , se the imidazo 4,5-b &#93; pyridine compound of the general formula characterized in that r ¹ can be a straight-chain or branched alkoxy group having from 1 to 8 carbon atoms , r ² is a hydrogen atom , a methyl group or a methoxy group and r ³ and r ⁴ are each a hydrogen atom or a methyl group which may be the same or different .
compounds according to claim 20 , wherein x represents a group of a group of a group of a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a group a a a a a a a a group a group a group a group a group a group a
a compound according to claim 1 , wherein : a = -ch - or -ch -ch - , r = hydrogen , r = hydrogen , r = = = = = = = = = = = hydrogen , r = hydrogen , r = hydrogen , = hydrogen , = hydrogen , = hydrogen , = hydrogen , = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen = hydrogen
furthermore , the age and sex distribution of the k@@ hd events , which account for age and sex , are also considered to be the number of patients with the age and the number of be@@ eps .
medical articles of polymer blends containing deep-@@ melt liquid crystal polymers
the tissue of claim 2 , wherein said medical component comprises material selected from vir@@ cides , germicidal agents and analgesics .
novel heterocyclic compound and anti-inflammatory agent
a catheter according to any one of claims 1 to 5 , characterised in that the wires ( 2,3 ) are longitudinally displaceable relative to the catheter and are displaceably connected to the catheter at their distal arch ends .
an injection device as claimed in claim 8 , characterised in that the perforator ( 16 ) further comprises support and retaining means ( 18 , 24 , 26 , 28 ) for the bottle stopper ( 12 ) allowing the bottle ( 12 ) to allow the insertion means ( 12 ) and the pumping means ( 72 ) and the pumping means ( 72 ) are connected together , simultaneously with the attachment and the production of the circulation of the liquid .
absorption ra@@ vic@@ ti is a prodrug of p@@ ba .
2@@ g-@@ 8-@@ 5-@@ 1a ( nr@@ ll-@@ b-1@@ 8@@ 33 ) , p. pu@@ tida 5@@ b-@@ m@@ gn@@ -2@@ p ( nr@@ -1@@ 8@@ 6@@ 68 ) , p. au@@ ro@@ faciens mo@@ b c2 ( nr@@ ll b-1@@ 8@@ 34 ) , p. pu@@ tida 2@@ d-@@ 11-@@ 5@@ 1b , nr@@ r@@ l-@@ b-1@@ 8@@ 20 , or a mutant or variant thereof , which is capable of converting a racemic nitrile stereo@@ specific to the corresponding enantiomeric or s-@@ amide .
system according to one of the preceding claims , characterized in that it also comprises means for controlling adjustment mechanisms of the working device ( the working equipment ) .
a compound according to claim 9 which is selected from p-@@ methyl-@@ benzyl-@@ ala ester , p-nitro@@ benzyl-@@ ala-@@ ester , p- ( trifluoromethyl ) benzyl ala ester , p-@@ fluoro@@ benzyl ala-@@ ester , 4-chloro@@ benzyl-@@ ala-@@ ester , 3-methyl@@ benzyl-@@ ala ester , and 2-methyl@@ benzyl-@@ ala-@@ ester .
the method of claim 1 comprising the step of providing a plurality of particles ( 42 ) on a plurality of discrete discrete locations on the substrate ( 32 ) , each site forming a dosage .
a respiration device as claimed in claim 1 or claim 2 , characterised in that the identification device ( 14 , 15 ) is arranged so that it is the bellows unit ( 2 ) that the bellows unit the bellows unit the bellows unit the bellows unit the bellows unit the the bellows unit the the bellows unit the the bellows unit the the bellows unit the the bellows unit the bellows the the bellows unit the bellows the bellows the the bellows the bellows the bellows the the bellows the bellows the bellows the the bellows the bellows
a process for preparing a pharmaceutical composition comprising mixing an effective amount of mature human n@@ t-@@ 4 of figure 1 or a neurotrophic protein according to any one of claims 16 to 21 with a pharmaceutically acceptable carrier .
the method of claim 1 , wherein the labeled oligonucleotide is labeled with a fluorescent label .
do not use in use in pregnant or lactating animals or in lactating animals or in animals or in animals or in animals or in animals . use in pregnant or lactating animals or lactating animals or animals or animals or animals or animals or animals or animals or animals or animals or
medical treatment device according to one of claims 12 to 15 and claim 8 or 9 , characterised in that the plurality of switches ( 68 ) are arranged in the longitudinal direction of the leaf spring ( 67 ) and thus are varied differently depending on the deflection of the second end of the leaf spring ( 67 ) .
an apparatus according to claim 1 , characterized in , that the roller is cylindrical .
the method of claim 15 , wherein the enzyme is derived from fusarium sp . , preferably f. an@@ gu@@ i@@ la@@ ce@@ um , f.
fused triazoles , their preparation and their use as medicaments .
this leaflet was last revised in mm / yyyy / yyyy . this leaflet was last revised in mm / yyyy / yyyy . was last revised in last revised last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last last
a process according to claim 12 , wherein the cyclisation base is an alkoxide . a process according to claim 12 according to claim 12 , wherein the cyclisation base is an alkoxide according to claim 12 , wherein the cyclisation base is an alkoxide . the process according to claim 12 wherein the cyclisation base is an alkoxide .
surface treatment for pas@@ si@@ sing surfaces of organic polymer material with polysaccharides as pas@@ si@@ zer , wherein the pas@@ si@@ sing agent contains at least one primary functional group which is substituted by a reagent such as benzophenone 4 isothiocyanate or by di@@ azo@@ o-@@ aryl isothiocyanate , and said reagent is converted to a reactive species , whereby said reactive species reaches a covalent bond of the passive agent to said surfaces of organic polymer material .
a pharmaceutical composition comprising : ( a ) a compound having activity as an anxiolytic agent or an antidepressant selected from fluoxetine , fluvoxamine , paroxetine and sertraline or a pharmaceutically acceptable salt thereof ; ( b ) a central nervous system which is selected from fluoxetine , fluvoxamine , paroxetine , and sertraline , or a pharmaceutically acceptable salt thereof ; ( b ) a 3- ( 5-@@ tert-butyl-@@ 2-methoxyphenyl ) methyl-@@ &#93; -@@ octane@@ -3-amine &#91; 2.2.2 &#93; -@@ octane@@ -3-@@ amine ; or a pharmaceutically acceptable salt thereof ; and ( c ) a pharmaceutically acceptable carrier
in most patients , the most frequent patients and the maximum internal rotation of the leg in the prosthesis implantation could be pre@@ disposing .
danmark sanofi-aventis denmark a / s tlf : + 45 45 16 70 00
a process for producing the linear high molecular weight polyethylene according to claim 25 , substantially consisting of the following steps : ( a ) forming said article from a linear ultrahigh molecular weight polyethylene having a molecular weight of from 400@@ ,000 to 10,000 ° ( b ) allowing the temperature of at least about 0.5 ° c to 10 ° c to said article ; ( d ) at a temperature of between 320 ° c and 300 ° c to said article ; ( d ) maintaining temperature gradients in the shaped article , and ( f
method and apparatus for automatic handling of medical devices during the manufacture of the apparatus and apparatus and method for the automatic handling of the medical devices and apparatus for the method and apparatus for using the apparatus and apparatus for the apparatus for automatic handling and apparatus for the apparatus for apparatus for apparatus for apparatus for for apparatus for apparatus for for apparatus for apparatus for for apparatus for apparatus for for apparatus for apparatus for apparatus for apparatus for apparatus for for apparatus
a process for the preparation of composite materials according to claim 8 by precipitation from an acidic solution of a water-soluble calcium salt and a stoichiometric amount of a water-soluble phosphate and / or fluoride salt having a ph below 3 by raising the ph with aqueous alkal@@ alia or ammonia in the presence of protein components .
in order to eliminate this effect , either the focal spot ( ll ) or the radiation receiver ( 3 ) is laterally displaced relative to the ide@@ alized tomographic plane ( l3 ) , so that the plane caused by the focal spot ( ll ) and the radiation receiver ( 3 ) during scanning of the receiving object carries out movement movement .
therefore , the safety margin for potential ip receptor-@@ mediated effects on reproduction is lower than non-@@ i@@ p-@@ associated effects ( see section 5.3 ) .
ven@@ o-@@ occlusive disease is a major disease that is a disease is a disease is a is a is a is a a is a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a
pharmaceutical composition according to any one of the preceding claims in the form of an injection concentrate for parenteral use with customary physiologically tolerated excipients .
the method of claim 3 wherein step ( i ) of selectively providing further comprises the step of adjusting the reference marker information to a separation information for generating at least one phase relationship recording information which is compared to the fixed reference to determine a phase-@@ relationship error information to determine an amount of incremental movement of the web material .
concentrations of these immunosuppressants may be increased when co-administered with evo@@ ta@@ z .
carcino@@ genesis , mutagenesis , impaired fertility in male rats , a statistically significant increase in urinary bladder tumours ( transient cell papilloma and carcinomas ) was found in association with xanthine stones in the high-dose group at approximately 11-@@ fold of human exposure .
claims for the following contracting state : es a process for the preparation of the products of the general formula ( i ) : es a process for the preparation of the products of the general formula ( i ) wherein r ₁ is an aliphatic hydrocarbon radical having 1 to 8 carbon atoms , r and r which are identical or different , represent a hydrogen atom or an alkyl radical having from 1 to 12 carbon atoms , in which r ₁ is a hydrogen atom or an alkyl radical , which is the same or different ,
process for the treatment of human keratinous fibres , in particular the hair , for non-@@ permanent deformation , characterized in that it consists , ( i ) , in that it comprises , in that , ( i ) in that it in that it in that it in that in that that in that in that that in that in that that in that in that that in that that that in that that that in that that that in that that that in that that that in that that that in that that that in that that
the pharmacokinetics of aliskiren and hydrochlorothiazide were not significantly affected in patients with mild to moderate hepatic impairment .
a process according to claim 2 wherein the detergent is polysorbate 80 . method according to claim 2 wherein the detergent is polysorbate 80 . the process according to claim 2 wherein the detergent is polysorbate 80 . method according to claim 2 , wherein the detergent is polysorbate 80 . the method according to claim 2 wherein the detergent is polysorbate 80 according to claim to claim to wherein the detergent is polysorbate 80 .
bone screw according to one of claims 1 to 6 , characterized in that the transition of the transition portion ( 4 ) is provided with a light thread ( 7 ) of one of the legs of the one of the claims ( 1 ) of the one of the claims ( 7 ) and the ( 1 ) of one ( 7 ) of one ( 1 ) of one ( 7 ) of claims 1 .
your body ’ s response to pran@@ din may change if you are taking other medicines , specifically these : • monoamine oxidase inhibitors ( used to treat depression ) • beta-blockers ( used to treat high blood pressure or certain heart conditions ) • ace inhibitors ( used to treat certain heart conditions ) • salicylates ( e.g.
composition according to any one of the one of the preceding claims , , characterized in that it comprises , in the , , the active principle , the active substances , of the , of claims , of the , of the preceding claims , of the preceding claims , of the the preceding claims , of the of the claims , of the of the claims , of the of the preceding claims , of the the the the the of claims of the the of the claims of of the the preceding claims of the of the
127 minimum particulars to appear on blisters or strips blisters particulars to appear on blisters on blisters or strips blisters blisters on blisters or blisters blisters or blisters blisters or blisters blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters or blisters
the device of claim 5 , wherein the ceramic electrode is biocompatible and hermetically sealed .
use of a glucoamylase variant according to any of claims 1-3 of a continuous starch conversion process .
the detergent composition of claim 13 or claim 14 , further comprising at least one conditioner selected from : 1. a cationic cellulose derivative ; and 3 . a cationic guar derivative ; and a homopolymer or co-@@ polymer of a cationic guar derivative ; and a homopolymer or co-@@ polymer of a cationic derivative ; and a homopolymer or co-@@ polymer of a cationic monomer ; and a homopolymer or co-@@ polymer of a cationic monomer ; and a homopolymer or co-@@ polymer of a cationic monomer ; and a homopolymer or co-@@ polymer of a cationic monomer selected
a method of removing human factor xii and factor x@@ ii fragments which are capable of activating factor xi or pre@@ kallikrein , from a liquid with an immobilized monoclonal antibody which binds to an antigenic determinant in the region of human factor xii , the determinant being obtained and absorbing and absorbing factor xii and factor x@@ ii fragments capable of activating factor xi or pre@@ kallikrein from the liquid .
the aim of the invention is to provide hair treatment products with at least one conditioner , which makes it possible to improve the state of the hair during treatment .
a compound selected from the group consisting of 3- ( 2-bromo@@ -5-@@ methoxy-@@ phenyl-@@ 1-phenyl-@@ -@@ propan-1-one ; 2- &#91; 2- ( 2-bromo@@ -5-methoxy@@ phenyl ) ethyl &#93; -2-@@ phenyl- &#91; 1,3 &#93; diox@@ ane ; 3- &#91; 2- ( 4-benzyloxy@@ benzoyl ) -5-methoxy@@ phenyl &#93; -1-phenyl-@@ -@@ propan-1-one ; 4- ( 4-benzyloxy@@ phenyl ) -7-methoxy@@ -3-@@ 1,2-di@@ hydro@@ naphthalene ; and ( 4-benzyloxy@@ -phenyl ) - { 4-methoxy@@ -2- &#91; 2- ( 2-@@ phenyl- &#91; 1,3 &#93; diox@@ olan@@ -2-yl ) -ethyl &#93; -phenyl } -methanone .
the vaccine should not be administered if the vaccine is not administered . • the vaccine should be administered at the same time as the vaccine should not be administered . be administered . be administered . be administered . be the same administered . be the vaccine administered . administered the vaccine . administered at the administered be administered . administered the vaccine . administered the vaccine . administered the vaccine . . . . . . . . . . . . . . . . . . . . . . . . . . .
it is unknown whether the use of interleukin-1 ( il-1 ) inhibitors such as il@@ aris , the risk of reactivation of tuberculosis is increased .
an automatic weight balancing apparatus for a stand with weight compensation with : a vertical arm ( 1 ; 25b ) and a horizontal arm ( 3 ; 26b ) , and a horizontal arm ( 3 ; 26b ) , and a horizontal arm ( 3 ; 26b ) , and a horizontal arm ( 3 ; 26b ) which is secured to the central portion ( 15 ) at the vertical arm ( 1 ; 25b ) or horizontal arm ( 3 ; 26b ) , and a pair of switches ( 20a , 20b ) which are
mixing capsule according to one of the preceding claims , characterized in that a plunger rod ( 44 ) of the plunger ( 14 ) in particular in a signal colour is smooth and thin and free from a handle handle , so that it cannot be pulled out from the piston ( 14 ) without the tool .
live infected birds can remain support , and although antibiotics can reduce clinical signs and lesions , do not remove the infection .
a method according to any one of the preceding claims , wherein the human tissue plasminogen activator has a concentration to a concentration of at least 0.1 at a concentration of at least at least at of at least a of at least at least 0.1 of at least at least 0.1 mg of at least of at least at least 0.1 of at least at least at of at least 0.1 at at least at least at least at of at least at of at least at least at 0.1 at at least at least 0.1 at least at
the device of claim 21 , wherein the liquid suppli@@ er ( 5 ) is releasably attached to the vibration member housing ( 4 ) by a snap engagement .
the use according to claim 5 , wherein the medicament is administrable by intravenous injection . the use according to claim 5 , wherein the medicament is administrable by intravenous injection . the use of claim 5 , wherein the medicament is administrable by the intravenous injection .
the method of claim 12 , wherein the inhibitor is selected from ( &#91; l@@ -2-amino@@ 3- ( n-@@ hydroxy , n@@ -nitro@@ samin@@ o ) propanoic acid &#93; ) , 6-mercaptopurine ribo@@ side@@ -5 &apos; -phosphate , 8-@@ aza-@@ guanosine monophosphate , 7-@@ de@@ aza-@@ 8-@@ az@@ agal@@ sine monophosphate and β-d-@@ arabino@@ syl@@ guanosine monophosphate .
dna encoding glutamate gated chloride channels
the absorbent article ( 20 ) of claim 6 further characterized in that said absorbent core ( 22 ; 28 ) has an ultimate storage capacity of at least 90 ml .
6.6 special precautions for the disposal of unused veterinary the unused veterinary medicinal product of unused veterinary medicinal product veterinary medicinal product veterinary medicinal product veterinary medicinal product veterinary medicinal product veterinary medicinal product veterinary
cosmetic or pharmaceutical preparations with extra@@ labeling of the plant ar@@ gan@@ ia sp@@ inosa the plant of the ar@@ gan@@ ia sp@@ inosa plant ar@@ gan@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia sp@@ ia
a pharmaceutical composition comprising a compound of formula i as defined in claim 1 or a pharmaceutically acceptable salt thereof in a compound a a a pharmaceutically acceptable carrier thereof a pharmaceutically acceptable salt a a pharmaceutically acceptable a a pharmaceutically acceptable a pharmaceutically acceptable a pharmaceutically acceptable a a a a a a a a a a a a a a a a a pharmaceutically acceptable salt comprising a compound a a compound a a compound a a compound a a compound a a a a a a a a a a a a a a a a a
the method of claim 7 , ( i ) , the method comprising determining whether the compound inhibits transcription of transcription , the inhibition of transcription , the inhibition of the transcription , the inhibition of transcription of the compound , , , , , , , , , , , , , , , the transcription of the compound , is , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
a process for producing the protein encoded by the dna coding region 89@@ 9-@@ 32@@ 53 of fig . 1 in at least partially purified form , by natural pure imaging , by recombinant dna technology and / or by chemical synthesis .
the crystal modification is differenti@@ able from other crystal modifications of 8-@@ cyano-@@ -1- cyclopropyl -7- ( 1s , 6@@ s-@@ 2,@@ 8- di@@ azabicyclo &#91; 4.3.0 &#93; nonan@@ -8-yl ) -6-@@ fluoro -1,@@ 4- ( , ( ( ( ( ( ( ( ( ( ( ( &#91; ( ( ( ( ( ( ( &#91; ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( 4.3.0
pregabalin accord 25 / 50 / 75 / 100 / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
the composition of claim 24 , wherein said isotonic agent is a polyol selected from mannitol or sorbitol .
use of a therapeutic composition according to any one of claims 1 to 18 to the preparation of a medicament for the treatment of a wound .
appropriate monitoring is a standardi@@ sed measurement of bladder pressure .
the self-adhesive laminate according to claim 9 , characterized in that the adhesive and / or polymer layer contains clotrimazole , miconazole , ketoconazole , e@@ conazole , naf@@ ti@@ f@@ in , ciclo@@ pi@@ lo@@ lamine , f@@ enti@@ or , sul@@ ben@@ tin , tol@@ naf@@ tate and / or halo@@ pro@@ h@@ ine as antimycotic agents .
cysteine protease inhibitors containing heterocyclic leaving groups
the process of claim 1 wherein the hydrogen of hydrogen of the hydrogen of the hydrogen of the hydrogen the hydrogen of the hydrogen the hydrogen the the hydrogen the the hydrogen the the the hydrogen the the the the hydrogen the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
cement according to one of claims 1 to 13 , characterized in that the setting to the setting of the setting is a setting retar@@ er .
the method of claim 11 , wherein the desired exogenous gene can be expressed to a polypeptide .
the method according to claim 11 , wherein the verapamil is dry granulated prior to table@@ ting with the modified release binder . the method of claim 11 wherein the verapamil is dry granulated is dry granulated is dry granulated is dry dry is dry dry is dry dry dry is dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry dry
the stem of claim 1 , wherein the cross-section further comprises a substantially curved posterior / lateral corner ( 27 ) having a radius of curvature ( r1 ) greater than the radius of curvature ( r2 ) of the central side ( m1 ) .
arrangement for determining the position of a medical instrument ( 3 ) which is introduced into the body of a patient ( 2 ) , in relation to a periodically moving body member ( 3 ) , in relation to a periodically moving body member ( 3 ) , in relation to a periodically moving body organ ( 3 ) , in relation to a periodically moving body organ ( 3 ) , and the reference probe ( 6 ) for determining the spatial position ( c , r ) of the medical instrument ( 4 ) and the reference
patients ’ response to treatment should be monitored clinically and by pulmonary function tests .
a probe according to claim 11 , wherein at least one of the plates ( 48 ) includes a marker ( 50 ) for aligning on a respective mark ( 49 ) on the head ( 45 ) to indicate when a selected force is exerted on the needle member .
patients who experience these symptoms should not take the medicine and should seek immediate medical attention .
special populations the analysis of population pharmacokinetics of tmz showed that plasma clearance of tmz is independent of age of age , renal function , or smoking status .
process according to claim 28 , characterized in that the solution used for de@@ sulfu@@ rization of the fibre contains approximately 3 g / l of sodium sulphate . the process of claim 28 , characterised in that the solution used for de@@ sulfu@@ rization of the fibre contains about 3 g / l of sodium sulphate . the method of claim 28 characterised in that the solution used for de@@ sulfu@@ rization of the fiber contains about 3 g / l / l sodium sulphate .
antibody persistence after vaccination with gardasil
mer is that with the problems .
in the method according to the invention , a release layer consisting of two or three metal layers is generated between the implant structures and the substrate , which serve to release the finished processed multi@@ layers by a sub@@ etching process .
trocar unit according to claim 1 , characterized in that it comprises means for securing the obturator ( 6 ) to the handle part ( 4 ) to thereby provide for said free rotation .
treatment of both sides of the spine from the spine to mild , including shoulders and hi@@ ps .
patients should be advised that they need to use fever , headache with fever and / or throat or photosensitivity immediately , as this may be signs of meningococcal infection .
an apparatus according to claim 1 , characterized in that a test head ( 34 ) is provided , which ( i ) has a sound cavity ( 23 ) and ( ii ) a hollow probe ( 25 ) , which has a large end ( 251 ) in communication with the sound cavity ( 23 ) and a small end ( 252 ; 422 ) for the arrangement at the inlet of the ear to be tested , the small end having a diameter approximately equal to the diameter of the ear channel of the ear to be
antibody formation did not result in clinically relevant effects on safety , reduced efficacy or altered pharmacokinetics of reve@@ stive .
the nucleic acid of claim 1 , wherein the nucleic acid is cdna .
the method of claim 1 or 2 , wherein the gp@@ vi allele is determined with restriction enzyme cytotoxicity .
a nebuliser device for the nebuli@@ sation of aqueous or oily medicaments for inhalation therapy with a spray nozzle for the exit of compressed air , said nebuliser device being adapted for insertion into a two-@@ piece nebuliser device , whose lower part is adapted for insertion into a two-@@ piece nebuliser device , the lower part of which is adapted to be inserted into a two-@@ piece nebuliser device , the lower part of which is adapted to be inserted into a two-part nebuliser device , the lower part of which is adapted to be inserted into a two-part
an assembly as claimed in any one of claims 1 to 3 , further characterised in that ( a ) the film is in the vicinity of the interface between the stopper ( 28 ) and the container ( 20 ) mating manipulation indicators .
pharmaceutical composition according to claim 1 , characterized in that r 1 and r 2 together with the nitrogen atom connecting them , as ring member , forms a saturated or unsaturated , optionally substituted five- or six-membered cycloaliphatic radical , optionally preferably together with at least one other heteroatom , in particular for a ( ch 2 ) 4 - , ( ch 2 ) 5 or ( ch 2 ) 2 -o- group , characterized in that r 3 represents an unsubstituted or at least mono-@@ substituted five- or six-membered aryl or heteroaryl group or an alkyl ester
use of the myo@@ tilin protein or the fragment of the myo@@ tilin of the myo@@ tilin of the myo@@ tilin the myo@@ tilin the myo@@ tilin the myo@@ tilin the myo@@ tilin myo@@ myo@@ the the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the myo@@ myo@@ the
a compound according to claim 2 wherein v is selected from the group consisting of o and c ( r 2 ) ( r 3 ) ; r 2 r r 3 r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r r
the composition of claim 27 , wherein the citrus pectin is selected from the group consisting of li@@ mon@@ e , citrus , grapefruit , and orange , wherein the citrus pectin is the the citrus , citrus , citrus , the pectin , the pectin , the citrus pectin , the pectin , the pectin , the pectin , the pectin , the pectin , the pectin , the citrus pectin the the the the the the the the the citrus pectin the the citrus pectin the the citrus pectin the the citrus pectin the the citrus pectin the
gel-like therapeutic or dietary drug composition for administration to domestic animals
microparticles for the controlled release of biologically active molecules
recombinant live vaccine against gram-negative enteric pathogens .
oxiran@@ e-@@ pseudo@@ oligosaccharides , process for their preparation , their use and pharmaceutical compositions .
system for sampling and analyzing in vivo
a solution according to claim 6 , 7 or 8 , wherein the amount of organic acid is from 0.005 to 2 % by weight , preferably from 0.01 to 1 % by weight of the solution .
the use of tra@@ vat@@ an of breast-feeding of tra@@ vat@@ an is not recommended during breast-feeding of mothers . the recommended use of tra@@ vat@@ an is not recommended . not recommended not recommended . not recommended not recommended not recommended .
composition according to claim 6 , characterized in that , in that r , r is chosen from dodecyl , c , , , , , , , , , , , , , , , , , , , r is chosen from , r is chosen , r is r is r is r is r is is is is is is is is is is is is is is is is is is is is is is is is is is is is is is is is is is is is is is is is is is
claims for the following contracting state : at a process for preparing a pharmaceutical combination for use in the augmentation of bone mass in a patient in need thereof , comprising combining a parathyroid hormone or a physiologically active fragment thereof with : a process according to claim 1 , wherein the composition is obtained so as to obtain an intimate mixture .
disintegrating particle and cleaner or detergent compositions
pressure sensitive hot melt adhesive composition based on polysiloxanes and methyl alkyl@@ polysiloxane waxes , methods and products .
the isolated dna fragment of claim 2 comprising the cla i fragment as shown in figure 5 which is downstream of the dna fragment shown in figure 7a ( 1 ) and is present between the cla i site present in the second line and the ala-@@ ala sequence present in the third line of figure 7a ( 1 ) .
method for operating medical devices , in particular of dialysis equipment , in which characteristic treatment data ( 22 ) with a touch screen surface ( 10 ) are displayed in a first display view ( 22 ) in a first image screen view ( 20 , 30 , 40 ) and their functional connection and the contact of the symbols ( 20 , 30 , 40 ) generates the first image screen view .
a compound according to any one of claims 1 to 5 wherein r 1 is hydrogen .
tell your doctor if you have a history of helicobacter pylori infection and therefore your
scientific conclusions and grounds for amendment of the summaries of product characteristics of the summaries of product characteristics of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of the of
the response rate in response in the 0.1 % tacrolimus the rate the the rate the the response rate in the the the the the the the the the the the the the the the the the the the the the the the the the the
an ultrasonic diagnostic apparatus comprising : a transfer means that comprises an ultrasonic probe , including an array ( 14 ) of piezoelectric elements , and is adapted to transmit a plurality of acoustic elements , including an array ( 14 ) of piezoelectric elements , and is adapted to transmit a plurality of acoustic beams with different acoustic elements , with a plurality of acoustic means ( 1 ) having a plurality of acoustic elements with different acoustic elements , and the second of said second and second groups of active signals ( 1 ) having a plurality of
agent according to claim 7 , characterized in that it contains nitroglycerin as anti@@ ang@@ inal agent .
the isolated receptor of claim 18 or claim 19 , wherein at least one of the soluble receptor subunits comprises a sequence of amino acid residues as shown in seq id no : 3 .
a method according to any one of claims 17 to 21 , wherein movement of the second wheel arrangement from the first position causes the third wheel arrangement the third wheel arrangement the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
glycopyrronium works by blocking the broncho@@ constri@@ ctive effect by blocking the blocking by the blocking by the blocking by the blocking by the blocking by the blocking by the blocking the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
asymmetrically shaped intraocular lens insertion cassette
non-invasive apparatus and method for heart monitoring
the apparatus of claim 1 wherein the outer sleeve of said outer sleeve is configured to en@@ circle to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to to
the macromer of claim 1 wherein the macromer is capable of thermo@@ reversible gelation in an aqueous solution of the macromer at a concentration of at least 2 % by weight , and wherein the gelling temperature is between about 0 ° c and about 65 ° c.
medical filter according to one of the preceding claims , characterized in that it is provided with wire elements ( 8 ) extending substantially diametrically over the base and connected to one another in order to serve as extraction elements .
the use of a compound of the formula : wherein a is nh ₂ or wherein a is nh ₂ , nh ₂ is nh ₂ is is nh ₂ wherein is is nh ₂ is is nh ₂ is is is is is is nh ₂ is is is is is is is nh ₂ is nh ₂ is is is is is is is nh ₂ nh ₂ nh is is nh ₂ nh ₂ nh ₂ is nh ₂ is is is is is is is is is is is is is is is is is nh
an ultrasonic examination image display system comprising an ultrasound probe connected to an ultrasound system for transmitting and receiving ultrasound signals to a medium having a body with a body with a body with a body with a body having a mobile body with a body having a mobile body with a body having a mobile body , and said ultrasonic sub@@ systems , and said ultrasonic sub@@ systems , and said ultrasonic sub@@ systems , and said ultrasonic sub@@ systems , and said ultrasonic sub@@ systems , and said ultrasonic sub@@ systems comprise , in order to transmit and
composition according to any one of claims 14 to 16 , which is in the form of a composition for caring for , cleaning or make-up of the skin or keratinous material , a hair treatment composition , a sunscreen composition .
high energy high-@@ energy energy control program and collimator
it is prepared using only pure ethyl alcohol as solvent and shellac in combination with benzoic oil and / or other tree resins and / or essential oils .
surgical system with distributed excimer laser
preparations according to claim 1 , characterized in , , that , to , , , , , , , , in , , to , , , to , , , , in , , , in , the , to the , in the cosmetic , dermatological , cosmetic preparations , the total in the 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1
the web of any preceding claim , further comprising the topical softening treatment prior to mechanical treatment .
based on these experts , the chmp considered that an additional 5-@@ year extension is needed based on pharmacovigilance grounds .
arrangement according to one of claims 8 to 11 , characterised in that the connection device ( 5 ) is a welding device , preferably an ultrasonic welding device .
a set of parts as claimed in claim 11 , claim 12 or claim 13 including means ( 13 ) ( 14 ) ( 14 ) ( 14 ) for adjusting the mount means for carrying alternative leg lengths ( 13 ) ( 13 ) .
an il-7 fusion protein comprising an immunoglobulin chain and an il-7 molecule modified by a linker molecule , which is directly or via a linker molecule , wherein the modification in il-7 is as follows : ( i ) the amino acid residues at positions 70 and 91 , wherein the modification in il-7 is as follows : ( i ) the amino acid residues at positions 70 and cys@@ 141 , in the case that the modification in il-7 is excluded by a peptide hinge region functionally linked to an fc portion of a heavy igg chain .
the dental adhesive kit of claim 2 , wherein component ( b ) is contained in an amount in an amount in an amount in an amount in an amount of 1-@@ 200 parts by weight of an amount of an amount of of of of components ( a ) of an amount of of ( a ) and ( ( ( ) ) ( ( ( ) ( ( f ) ) ( ( ( f ) ) ) ( and ( f ) ) ( ( a ) ) ( ( ( a ) ) ( ( (
device according to claim 1 or 2 , characterized in that the insertion tube ( 4 ) and the piston / cylinder device ( 3 ) are designed to an integral unit ( 2 ) .
agent for the oxidation dyeing of keratin fibres , based on a developer substance coupler substance combination , characterized in that it comprises , as a developer substance , at least one 1,4-di@@ amino@@ -2-@@ alkenyl-@@ benzene derivative of formula ( i ) according to any one of claims 1 to 5 , as developer substance , a substance based on a developer substance , a developer substance , a substance , a substance , a substance comprising a derivative of a substance . a substance . a composition . a composition comprising a substance , a substance .
composition according to any one of the one of the preceding claims , characterized in that the conditioning agent is present in the concentration of the the composition of the the composition of the the preceding claims the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the preceding claims the
cosmetic composition according to claim 9 , characterized in that the nanopigments of the coated metal oxide mixtures consist of titanium dioxide and cerium oxide coated with silicon dioxide or mixtures of titanium dioxide and zinc dioxide , which are coated with alumina , silicon dioxide and silicone or aluminium oxide , silicon dioxide and glycerol .
use of adam@@ t@@ s1 for the preparation of a test kit for the determination of an inhibitor for aggre@@ can@@ ase , characterized in that adam@@ t@@ s1 , a substrate and an inhibitor is incubated with one another and the neo@@ epitopes generated by aggre@@ can@@ ase activity .
the invention relates to a pricking device ( 1 ) , comprising a lancet ( 2 ) , an energy store ( 5 ) for transferring energy in the energy store ( 5 ) to the lancet ( 2 ) for carrying out a pricking movement , a charging device for carrying out the energy accumulator ( 5 ) and a control unit , such that the energy store ( 5 ) is automatically charged with energy for next puncturing movement of the lancet ( 2 ) .
site specific system for producing diverse protein sequences
a method according to claim 8 wherein the rna replicase gene and the coat protein gene are located on different single stranded ( + ) rnas ( + ) ( single stranded stranded ) .
yeasts transformed with a modified vector according to any one of claims 1 to 8 and which are capable of synthesizing a polypeptide and having following induction of the expression of the insertion sequences which occur on their surface and recognized by ligands recognized by the natural membrane receptor .
a w is selected from the group consisting of : a compound of claim 1 having the following formula : the compound of claim 1 having the following formula : wherein : halo is selected from the group consisting of : br , f , cl and i ; and x is selected from the group consisting of c 1-8 alkyl and cycloalkyl .
the use of claim 7 , wherein the first and / or second therapeutic agents are an antiarrhythmic agent and the antiarrhythmic agent is selected from the group consisting of adenosine , quinidine , propranolol , digoxin , lidocaine , bre@@ ty@@ lium , amiodarone , and verapamil .
a personal urine collection device according to claim 27 , further comprising a frame ( 81 ) installed in the front chamber of the container , and an ultraviolet lamp ( 82 ) installed on one side of the frame of the collector member for radiating ultraviolet radiation against the interior of the collector part to carry out sterilization .
the method of claim 15 , wherein the osmotic pressure is from 200 mosm to 600 mosm / kg of water . the method of claim 15 , wherein the osmotic pressure is of 200 to 600 mosm / kg of water .
an inhibitor of helicobacter pylori colony formation , comprising as an active ingredient the glycoprotein of any one of claims 1-6 . a pharmaceutical composition for preventing and / or treating a mammalian disease , including human , or associated with helicobacter pylori , comprising the glycoprotein of any one of claims 1-6 .
a process according to claim 1 , wherein the crystallization solvent is selected from the group consisting of hex@@ anol , pentanol , 2-@@ penta@@ - and 3-@@ pentan@@ ol mixture , iso@@ pentanol .
composition according to any one of the preceding claims , characterized in that the feed@@ pellet ( s ) ( one or more compounds ) is / are chosen from the group n , n-diethyl-@@ 3-methyl@@ benzamide , 3- ( n-n-@@ butyl-@@ n-acetyl-@@ amino ) -propionic acid ethyl ester and dimethyl phthalate .
a method according to any preceding claim , wherein the pro@@ tose sequence is the yeast -a-@@ factor pro@@ sequence .
adults adults should take the telzir oral suspension without food and on an empty stomach on an empty stomach and the telzir oral suspension and the oral suspension and the oral suspension and oral oral suspension and oral suspension and oral oral suspension and oral suspension and oral oral suspension and oral oral suspension oral suspension oral suspension .
a process according to claim 1 , wherein the ligand is at least 99 % pure . a process according to claim 1 , wherein the ligand is at least 99 % pure . a process according to claim 1 wherein the ligand is at least 99 % pure . a process according to claim 1 , wherein 1 wherein the ligand is at least 99 % pure . a process according to claim 1 wherein the ligand is 1 wherein the ligand is at least 99 % pure . a process according to claim 1 wherein 1 .
method for producing pretreated raw material
device according to claim 1 , characterized in that the coupling medium ( 11 ) is u-shaped , in which the u-shaped arms show away from the fluid path and show the part ( 4 ) to be re@@ used .
a peptide according to claim 1 for promoting re-@@ epitheli@@ alization of colon .
an endoscope according to any of claims 15-@@ 20 , wherein the thermal expansion coefficient of the glass range used for the chin members ( 86 , 85 ; 86 &apos; , 85 &apos; ) is approximately equal .
a pharmaceutical preparation according to claim 8 , wherein said visible light has a wavelength greater than or equal to 420 nm .
apparatus for generating an image of an object and in particular for observation of the rear portions of an eye , whose light is focused on the object , the light of which is focused on the object , the light of which is focused on the object , the light of which is focused on the object , the light of which is focused on the object , the light of which is focused on the object , the light of which is focused on the object , the light of which is focused on the object , the
treatment with filgrastim alone does not preclude thrombocytopenia and anaemia associated with myelo@@ suppressive anaemia and anaemia due to anaemia .
agent for improving and natural maintenance of so@@ ils and plant growth and method therefor .
what infanrix penta is and what it is used for what is infanrix penta is is is
i &apos;ve never been in se@@ at@@ tle .
the process of claim 7 or claim 8 wherein the microorganism capable of the selective metabolism of ( r ) -3-chloro@@ 1,2-propanediol is the microorganism of the genus the microorganism of claim 7 or claim 7 or 8 wherein the microorganism of the the the the the the process of the claim 7 or claim 7 , wherein the microorganism the microorganism the microorganism the the microorganism the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the process of claim
the method of claim 9 , wherein the oligonucleotide has a 3 &apos; and a 5 &apos; end , the oligonucleotide being complexed to the antibody at the 5 &apos; end and the 3 &apos; end of the oligonucleotide is labelled with 32 p. the method of claim 9 wherein the labeled dna dendrimer is labelled with a first secondary reporter and the amount of the antigen is labeled with 32 p. the method of claim 9 , which is complementary to the first secondary reporter and is conjugated to a molecule selected from the group consisting of a fluoro@@
do not use pegasys after the expiry date which is stated on the expiry date which is the the the the the the expiry date the expiry date the expiry date the expiry date the expiry date the expiry date the expiry date the expiry date the expiry date the expiry date expiry expiry expiry date expiry expiry expiry expiry expiry expiry expiry expiry expiry expiry date expiry date expiry date expiry date expiry date expiry date expiry date expiry
if other symptoms of systemic toxicity occur , the signs of the signs are expected to occur , the signs , the the signs and symptoms , the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
a process for preparing a complex of macromolecular poly@@ galac@@ tans and a nitrogen-containing compound and use of said complex .
a single layered assembly ( 12 ) for use in a disposable absorbent article having a particulate material ( 5 ) , which is enclosed between enclosing layers ( 1 , 2 ) , wherein the enclosing layers ( 1 , 2 ) are enclosed in the form of two continuous strips ( 1 , 2 ) , wherein the enclosing layers ( 1 , 2 ) are enclosed in the form of two continuous strips ( 1 , 2 ) , which are enclosed in the form of two continuous strips ( 1 , 2 ) , wherein the
ze@@ pati@@ er should not be used in patients with moderate or severe hepatic impairment ( cirrhosis of the child-pugh class b or c ) .
until another aetiology has been identified , signs or symptoms of endo@@ c@@ rin@@ opa@@ thies should be considered as immuno@@ con@@ c@@ matory .
a hybrid molecule comprising a fusion of a first ligand capable of binding to a first molecule of hepatocyte growth factor receptor , to a first molecule of hepatocyte growth factor receptor , to a first immunoglobulin constant domain and a fusion of a second ligand capable of binding to a second molecule of said receptor , wherein said ligand is not an antibody to hepatocyte growth factor receptor or a non-@@ covalent conjugate of an antibody and not a covalent conjugate of an antibody and an antigen for said antibody ; and wherein said first and second receptor molecules
a method for detecting or in vitro diagnosis of brain disease involving ph@@ f and tau protein , e.g. alzheimer &apos;s disease , e.g. alzheimer &apos;s disease comprising : contacting a sample of a brain homogenate , cerebrospinal fluid , or serum of a patient suspected to form an antigen-antibody complex ; and detecting the immunological binding of the antibody to the sample of brain homogenate , cerebrospinal fluid or serum .
device according to one of claims 1 to 3 , characterised by an actuating mechanism which can be operated in response to an adjustment of an actuating member of the mechanism , a rotational movement of the rotatable part ( 5 ) relative to the base plate .
what ai@@ rex@@ ar spiromax is and what it is used for 2 .
system according to claim 5 or 6 , characterized in that the separator ( 40 ) and the receiving unit ( 10 ) are mounted movably relative to one another .
the negative pressure respirator of claim 1 , wherein the impac@@ tor element ( 50 ) is transparent .
the dental handpiece of claim 6 , wherein the annular sealing means comprises a magnetic fluid ( 84 , 184 ) and a permanent magnet ( 82 , 83 , 182 , 183 ) of annular shape retaining the magnetic fluid .
cardiac therapy system with controlled activity signals of the autonomic nervous system ( s ) ( 6 ) , especially in addition to a conventional pacemaker circuit ( 8 ) , in particular in addition to a conventional pacemaker circuit ( 8 ) , is triggered and / or synchronized , and antiarrhythmic stimulation pulses are triggered and / or synchronized by means of a pump system ( 10 ) .
adapter according to claim 1 , characterized in that , in order to attach to the skull frame , the adapter frame ( 30 ) is designed to be in the form of screws by means of screws . ( 3 ) to be fixed to the skull frame ( 30 ) ( 1 ) ( 1 ) ( 1 ) .
the liquid applicator of claim 9 wherein the distal end of the liquid applicator ( 8 ) of the liquid applicator ( 8 ) of claim 9 wherein the distal end of the liquid applicator ( 8 ) of the liquid applicator ( 8 ) is of the rho@@ mbo@@ liquid ) .
a pharmaceutical product in unit dosage form comprising : a ) a multilayer capsule or a housing having two or more layers , the outer layer having hydrophilic properties and the inner layer having hydrophobic properties , in contact with the inner layer b ) one or more drug substances admixed with a hydrophobic carrier , dissolved , suspended or agglomerated in it .
hygiene article according to claims 1 to 5 , characterised in that the total amount of water of the separately or jointly added aqueous solutions of the the separately or jointly to the the water of the the the the water of the the the the the the water of the the the of of the of the of claims of the water of the the the the the water of the or the of the the of water of the the the of the the water of the the the of the of the the the the of the
a composition as claimed in claim 1 in the form of a food , beverage or medicine . a composition as claimed in claim 1 , in the form of a food , beverage or medicine . a composition as claimed in claim 1 , in the form of a food , beverage or medicine . a composition as claimed in claim 1 , in the form of a food , beverage or medicine . a composition as claimed in claim 1 , in the form of a food , beverage , or a medicine .
the system of claim 7 , wherein the electric tactile signaling current ( sr ) the electrical tactile signaling ( sr ) has alternating periods ( sr ) has alternating periods of the has alternating periods ) .
an immunogenic composition comprising recombinant retroviral or recombinant retro@@ vir@@ al-@@ like particles , comprising 1 ) a transgenic sequence encoding one or more epitopes ( s ) of carcinomas , leukemia or lymphoma , which is under the control of the transcription and expression of the transcription and expression of the same , and which is under the control of regulatory signals of the transcription and expression or regulatory signals , which is under the control of regulatory signals of the transcription and expression or regulatory signals , which is capable of inducing or stimulating a cell mediated response
cardboard box containing 1 , 6 or 12 colourless glass vial ( s ) containing 250 ml ( s ) ) .
use of ( a ) an analgesic inducing amount of tramadol and ( b ) an analgesic enhancing amount of at least one analgesic enhancer selected from dextromethorphan , dextro@@ ph@@ an and a pharmaceutically acceptable salt thereof for the manufacture of a medicament for alleviating arthritic pain .
a process for the preparation of the racemic or optically active compounds having the general formula ( vi ) : wherein the meaning of x halogen is - or the salts thereof , wherein the meaning of x halogen is : - or the salts thereof , wherein the meaning of x halogen is converted to the general formula ( vii ) , in its optically active isomers , in its optically active isomers , and / or to the salts thereof and / or to the salts thereof and / or to the racemic or optically active compounds of
the syringe assembly of claim 1 further including sealing means ( 86 ) on said plunger plunger ( 56 ) disposed proximally relative to said distal end ( 58 ) of said plunger rod ( 56 ) and said plug ( 34 ) for sealing said chamber ( 20 ) against contamination .
a spacer member for a resilient fastener permanently anchored in the jaw , comprising a substantially sleeve-like spacer for attaching to the mounting member by means of a separate spacer screw having an elongated , thread@@ -free central region and a threaded portion for engagement into a threaded bore in the occlusive portion of the fastener , the sleeve shaped portion having a threaded thread ( 18 ) having an elongated threaded portion and a threaded portion for engaging a threaded bore in the occlusive portion of the fastener , characterized in that the sheath portion ( 13 ) of
method according to claim 20 , characterized in that the cells are t lymphocytes . the method according to claim 20 , characterized in that the cells are the cells in the the cells .
the method of claim 3 , wherein the step of generating a plurality of vertical image slices further comprises the step of reconstructing a plurality of parallel beams generated from a projection of data of the rectilinear web .
use of a composition according to any preceding claim in the manufacture of a medicament for treatment selected from the group consisting of dental brigh@@ tening , plaque , mouth odour , caries and tar@@ tar .
device according to claim 5 , characterized in that a collection container ( 24 ) for tissue liquid is connected to the transmission head ( 4 ) via the tube ( 22 ) .
the powder is packed in colourless powder vials in 5 ml with a coated stopper sealed with a lid@@ a with a lid@@ a plastic cap with a lid@@ a with a lid@@ a with a a a a a a a a a a a a a a colourless with a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a powder .
process for the production of the ligands specific for hormone receptors according to claim 1 , characterized in that they contain a radioactive halogen selected from the group of radioactive isotopes of fluorine , iodine , bromine and a@@ statin that is bonded to the double bond of the vinyl group according to the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the the
a compound according to claim 1 , which is 4- &#91; 4 &apos; - ( 2-benzyl-@@ benzofuran@@ -3-yl ) -biphenyl-4-@@ yloxy@@ sulfonyl &#93; -2-hydroxy-@@ benzoic acid or of a or a pharmaceutically acceptable acid or acid or acid pharmaceutically acceptable acid or salt thereof .
interaction with other medicinal products and other forms other medicinal products other medicinal products other other other medicinal products and other forms other other other other other other other other other other other other other other other medicinal products
apparatus as claimed in any one of the preceding claims , wherein the distal ends ( 24 ) of the basket ( 21 ) of the basket ( 21 ) are ( ( 21 ) in the ends of the the the the the the ends of the basket ( 24 ) of the the the the of the the of the the of the the of the the of the the of the the of the the of the the of the the of the the of the the of the the of the the of the the of
at the end of treatment , the dose of nespo 500 μ g every 3 weeks was similar to that of every week , in the once every three weeks , once every three weeks , in the once every three weeks every three weeks , in the once every three weeks every three weeks , every three weeks every three weeks , every three weeks every three weeks , once every three weeks , once every three weeks , every three weeks , every three weeks , every three weeks , three weeks three weeks three weeks .
device for cutting and coagulating tissue
a device as claimed in any one of the preceding claims , characterised in that the area to which the cassette is inserted below the chassis ( 370 ) of the main pump unit ; the sensor housing ( 800 , 8@@ 14 ) is mounted on the chassis ( 370 ) of the main pump unit ; the slit ( 80@@ 8 , 8@@ 14 ) is mounted on the chassis ( 370 ) of the main pump unit ; the slit ( 80@@ 8 , 8@@ 14 ) is mounted on the chassis ( 370 ) of the
- tiredness , swelling of the lymph nodes in the neck , axi@@ llary or groin area ,
the method of claim 12 , comprising a plurality of such altered cycles .
48 minimum particulars to appear on small immediate packaging units hbvaxpro 5 micrograms / 0.5 ml
a vector harboring a dna construct harboring the structure c-@@ m-@@ a-d , wherein a is a dna sequence which is homologous with a dna sequence which is homologous with a dna sequence which is homologous which is homologous is homologous which is homologous is which is homologous is homologous is which is homologous is is homologous is is homologous is is homologous is is homologous is is homologous is is homologous is is homologous is is homologous is is homologous is is homologous is is homologous is is homologous is is homologous is is homologous is is homologous is
the device or use of any one of claims 34 to 38 , wherein the matrix comprises dehydrated mammalian tissue .
the method of claim 28 , wherein insects which are exposed to the chimeric protein exhibit weight loss .
rotated anchor hook for a stent for abdominal aortic aneurysm ( aaa )
a method and a device for detecting dental caries and a method for detecting dental caries and a method for detecting dental caries and dental caries and device for detecting dental caries and dental caries and device and method for detecting dental caries and method for device and method for device and method and device for and device and device for device for device and device and device and device for device device and device for device device and device for device device and device for device for device device and device for device device device device device device
a process according to claim 1 for the preparation of phosphatid@@ yl- ( l ) -@@ serine , wherein r 1 and r 2 acyl chains of the palmitic , stearic , palmitic , oleic , linoleic or arachidonic acid are similar to the egg lecithin .
use of a compound of any of claims 1 to 11 of a compound of claims 1 to 11 of claims 1 to 11 to 1 of a 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to 1 to
compounds of formula i wherein r 1 is selected from r 1 is r 1 is r 1 is 1 1 r 1 r 1 1 r 1 1 r 1 1 r 1 1 r 1 1 1 r 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
the absorbent article according to claim 1 , wherein the proximal edge ( 36 ) is connected to the bodyside liner ( 14 ) in the leg cuffs ( 22 ) in the crotch region ( 22 ) , i.e. , at a location disposed at the longitudinal centerline ( 60 ) of the article relative to the leg cuffs ( 24 ) .
due to the high safety span ( 19-@@ fold of the corresponding no-@@ effect dose ) , these neoplastic changes will not be found in humans .
alternatively , silgard can be administered after a 3-@@ dose schedule ( 0.5 ml to 0 , 2 , 6 , , , , 6 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , silgard , , , , , , , , , , , , , ,
process of capillary dyeing by oxidation , characterised in that it consists in applying to the hair , in a first time , a dyeing composition that , in a first time , in the in that the the oxidation in the the the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the in the
use according to claim 6 , wherein the leg muscle cell is a muscle muscle cell .
the results of this survey indicate an image of the current level of lymph node endo@@ dissection and lymph@@ ad@@ ene@@ ctomy in bronchial carcinomas and could serve as a basis for the progress of a uniform document scheme .
treatment of inflammatory bowel disease with interferon gamma inhibitors
a method according to any one of claims 22-@@ 25 , in which when host microorganisms containing said plasmid are cultured under conditions containing the plasmid the plasmid containing the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the plasmid the
a telemetry system according to any one of the preceding claims , further comprising : a further inducer for sending the information containing the information ; a further capacitor , which is parallel to the first inductor ; a switch parallel to the first inductor ; means for periodically sequential opening and closing the switch to modulate a voltage parallel to the first inductor and the first capacitor .
when deciding to prescribe io@@ a , consideration should be given to current risk factors of individual women , especially for venous thromboembolism ( vte ) , and the risk of vte with io@@ a should be compared with other chc ( see sections 4.3 and 4.4 ) .
syringe assembly according to claim 2 or 3 , characterised in that the stops ( 38@@ d , 38@@ p ) for the fixed connection are delimited by axial hooks ( 4@@ 2d , 4@@ 2p ) which can be inserted into the sleeve ( 20 ) and can be deformed by elastic radial deformation .
the invention relates to novel compounds of general formula ( i ) m - l , wherein m is a radioisotope of tc or re and l is a ligand of the general formula ( ii ) , in which r , r , r , r , r and r are different and are suitable for the coordinating binding of metal ions , on the other hand for coupling to selectively accumulating compounds .
the use of a compound of any of claims 1 to 26 of a preparation of a medicament of a of a of of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of a of
in order to increase life life and support comfort , the sole part ( 11 ) is designed as a hollow profile with substantially vertical supports for connecting the fully flat base and to the full-@@ area ( 12 ) adjacent to the foot bed ( 13 ) , the supports having at least in the central region an increasing diameter or an increasing horizontal cross-section .
the process of claim 15 wherein the active substance-containing granules have an average size of an average size of of about of of of about of of about of of about of of of about of of of of an average size of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of of
acoustic imaging and doppler catheters and guide wires
pregnancy and breast-feeding if you are pregnant and breast-feeding if you are breast-feeding if you are breast-feeding if you are breast-feeding if you if you you you you you you you you if you you you you you if you if you if you you you you you you you you you if you you you you if you if you if you if you you you you you you you you you if you you you you if you if you if you if you you you you you you you you you if you if you if you
further non-clinical studies are carried out with the aim that potential mechanisms for vascular occlu@@ sions are further characterised in treatment with pon@@ atinib .
massage apparatus according to any one of the preceding claims , characterized in that , in the form of the force of the the force of the return spring ( 16 ) , the the force of the the the the the the the the the the the of the the the the the the the the of the the the the the the the the of the the the the preceding claims is the the the preceding claims , in the preceding claims .
the european commission granted a marketing authorisation valid throughout the european union throughout the european union valid throughout the european union valid throughout the european union granted throughout the european union granted throughout the european union granted throughout the european union .
the device ( 10 ) of claim 9 , wherein the first attachment ( 50 , 52 ) and the pad ( 30 ) are of cooperating hooks and loops for the manufacture of a fixture between and the second fasteners ( 48 , 54 ) and the gripper ( 44 ) are provided with cooperating hooks and loops for making a fixation therebetween .
a compound of the formula wherein r 1 is ch 3 and n is about 112 .
xo@@ fi@@ go contains sodium , depending on the volume given , this medicinal product may contain up to 54 mg sodium per dose .
treatment of adults , adolescents , and children of 6 years of age and older , of diabetes mellitus , of treatment with insulin , of insulin , and of treatment of adults of adults of adults and adolescents , of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults of adults
antisera , their preparation and medicines containing them .
diphenyl hetero@@ alkyl derivatives , their preparation and medicaments and cosmetics made therefrom .
mixing of the used and fresh dialysis fluid is not carried out in the container ( 1 ) .
a pharmaceutical composition for curing diseases caused by vasoconstriction comprising an anti-@@ endothelin antibody as an effective component .
a process for the preparation of a sodium salt of a desired enantiomer of the 2- ( 4-isobutyl@@ phenyl ) propionic acid , wherein the sodium salt has an enantiomeric purity greater than 90 % , which comprises the steps : a ) dissolving the sodium 2- ( 4-isobutyl@@ phenyl ) propionate , which comprises 50 % or more of the desired enantiomer , in a solvent , separating the solid sodium salt from the solvent ; e ) repeating steps a ) to d ) until the desired degree of enantiomeric purity is achieved .
6.6 special precautions for disposal special precautions for disposal special precautions for disposal special precautions for disposal special precautions for disposal special precautions for disposal special precautions for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal for disposal
a process for producing hardened fats comprising reacting a 1,3-@@ specific lipase with a mixture of an oil having a palmitic acid content of at least 30 % ; and free beh@@ enic acid or ester with a monovalent or di@@ hydric alcohol , said mixture having a monovalent or di@@ hydric alcohol , said mixture having a fatty acid composition of 6 to 25 % of lauric acid , 23 to 48 % palmitic acid and 0.5 to 5 % of beh@@ enic acid , based on the weight of the mixture , with respect to the weight of
a biopsy device comprising : a ) a housing ( 12 ) having a bore ( 12 ) extending along a longitudinal axis of the housing ( 12 ) and a drill ( 20 ) extending parallel to the longitudinal axis of the housing ( 12 ) and a drill ( 20 ) extending parallel to the bore , and a bar ( 20 ) extending parallel to the bore , and a latch ( 20 ) which extends in the guide ( 20 ) at a right angle to the longitudinal axis ( 16 ) at a right angle
the method according to claim 3 , wherein the solvent is selected from the group consisting of methylene chloride , chloroform , , carbon tetrachloride , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
hold the valve is a mo@@ tiv@@ ated stu@@ den@@ tin .
the formulation for the preparation of an open-cell polyurethane foam according to claim 15 , wherein the catalyst component ( d ) is contained in an amount of 0.1 % to 1 % by weight . an open-cell polyurethane foam is in an amount of according to the foam according to to foam according to to according to foam .
the tampon ( 10 ) of claim 12 comprising elastic , multiple branched regenerated cellulosic fibers .
use according to any one of claims 1 to 16 , which is for the manufacture of a medicament for administration to various mucosal surfaces .
these ec50 values are far below the concentration range of 87 µm to &gt; 100 µm for 50 % cell toxicity .
the catheter ( 10 ) of any one of claims 1 to 8 , wherein the catheter body ( 12 ) has a single lumen ( 18 ) extending therethrough .
a device according to claim 1 , characterised in that it includes locking means ( 80 , 81 , 82 ) for relative rotational movement between the parts ( 3 , 4 ) of the housing ( 2 ) about the longitudinal axis ( k ) of the latter , the means ( 80 , 81 , 82 ) being provided on the two parts ( 3 , 4 ) of the device housing .
&#91; see annex i - to be completed nationally &#93;
be@@ da@@ qu@@ iline and m2 are no substrates or inhibitors of p-glycoprotein .
at steady-state doses and dosing regimens steady state plasma concentrations are reached within 24-@@ 48 hours and are generally less than 1 μg / ml .
chimeric hepatitis c virus and bovine viral diarrhea virus chimeric chimera
a device ( 10 ) for embolic aneurysm according to claim 1 or a cathe@@ ter-@@ based system for embolic aneury@@ sms according to claim 2 , wherein the closure element ( 38 ) is formed of a material so that the closure element ( 38 ) expands when the closure element ( 38 ) is released in the aneurysm to substantially add the aneurysm .
organ@@ o ( poly ) siloxanes and organ@@ o ( poly ( poly ) siloxanes ( poly ( poly ) siloxanes ( poly ) ( poly ) ( poly ) ( poly ) ( poly ) ( poly ) ( poly ) ( poly ) poly ( poly ) ( poly ) poly ( poly ) poly ( poly ) poly ( poly )
extract of ginkgo biloba leaves according to claim 11 , characterized in that it contains about 52 % by weight of flavone glycosides and about 13 % by weight of terpene lactones .
the composition of claim 9 , wherein said receptor is coupled to a macromolecular carrier . said composition of claim 9 wherein said receptor is coupled to said macromolecular carrier . said composition is said said receptor is said said receptor wherein said receptor is receptor .
fungal strains with reduced susceptibility in vitro to isa@@ vu@@ conazole have been reported and cross-resistance with voriconazole and other triazole antifungals cannot be excluded .
the vaccine of claim 1 , wherein the eimeria antigens comprise one or more engineered antigen / fusion polypeptides containing at least one eimeria epitope .
1 . hollow fibre of regenerated copper ammonium , having an axially disposed cylindrical bore extending over the fiber length and having a uniform circular cross-section , wherein the fiber length is at least 10 m and the bore is filled with gas and does not contain traces of a contaminating liquid .
